

WEST Search History

DATE: Tuesday, October 05, 2004

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L33	L32 NOT Shimkets-Richard-A.IN.	231
<input type="checkbox"/>	L32	L31 NOT Rosen-Craig.IN.	242
<input type="checkbox"/>	L31	L30 NOT Rosen-Craig-A.IN.	242
<input type="checkbox"/>	L30	L29 AND epitope	427
<input type="checkbox"/>	L29	L28 AND T helper	510
<input type="checkbox"/>	L28	(amyloid)	8076
<input type="checkbox"/>	L27	L26 AND T helper	134
<input type="checkbox"/>	L26	L25 AND amyloid	897
<input type="checkbox"/>	L25	530/300,350.CCLS.	17056
<input type="checkbox"/>	L24	L23 AND T helper	34
<input type="checkbox"/>	L23	L22 AND amyloid	304
<input type="checkbox"/>	L22	514/1,2.CCLS.	7202
<input type="checkbox"/>	L21	Nielsen-K-G.IN.	7
<input type="checkbox"/>	L20	Nielsen-Klaus-G.IN.	0
<input type="checkbox"/>	L19	Nielsen-Klaus-Gregorius.IN.	8
<input type="checkbox"/>	L18	Rasmussen-P-B.IN.	27
<input type="checkbox"/>	L17	Rasmussen-Peter-B.IN.	0
<input type="checkbox"/>	L16	Rasmussen-Peter-Birk.IN.	13
<input type="checkbox"/>	L15	Jensen-M-R.IN.	9
<input type="checkbox"/>	L14	Jensen-Martin-R.IN.	0
<input type="checkbox"/>	L13	(Jensen-Martin-Roland.IN.)	9
<input type="checkbox"/>	L12	L11 AND T helper	45
<input type="checkbox"/>	L11	L10 AND amyloid	154
<input type="checkbox"/>	L10	424/178.1,184.1,185.1.CCLS.	4407
<input type="checkbox"/>	L9	Nielsen.IN.	8092
<input type="checkbox"/>	L8	Nielsen-K.IN.	62
<input type="checkbox"/>	L7	Nielsen-Klaus.IN.	5
<input type="checkbox"/>	L6	Rasmussen.IN.	5063
<input type="checkbox"/>	L5	Rasmussen-P.IN.	37
<input type="checkbox"/>	L4	Rasmussen-Peter.IN.	7
<input type="checkbox"/>	L3	Jensen.IN.	12980
<input type="checkbox"/>	L2	Jensen-M.IN.	61
<input type="checkbox"/>	L1	(Jensen-Martin.IN.)	4

END OF SEARCH HISTORY

h e b b cg b chh e h b f e ch e c ch

Hit List

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: US 6501428 B1

Using default format because multiple data bases are involved.

L1: Entry 1 of 4

File: USPT

Dec 31, 2002

US-PAT-NO: 6501428

DOCUMENT-IDENTIFIER: US 6501428 B1

TITLE: Antenna device for dual frequency bands

DATE-ISSUED: December 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Blom; Carl-Gustav	Lysekil			SE
<u>Jensen; Martin</u>	Kalmar			SE
Lindkvist; Henrik	Lund			SE

US-CL-CURRENT: 343/702; 343/895

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RWC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------

☐ 2. Document ID: US 5315084 A

L1: Entry 2 of 4

File: USPT

May 24, 1994

US-PAT-NO: 5315084

DOCUMENT-IDENTIFIER: US 5315084 A

TITLE: Baby bottle caterer with separate refrigeration and heating units

DATE-ISSUED: May 24, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Jensen; Martin</u>	Laguna Niguel	CA	92677	

US-CL-CURRENT: 219/689; 165/61, 219/710, 219/732

ABSTRACT:

A baby bottle caterer includes a manually transportable case with a refrigeration unit disposed in said case and sized for cooling a selected number of baby bottles in an upright orientation. A heating unit is provided and disposed in said case and sized for warming at most one baby bottle in an upright orientation, with the heating unit being in a spaced apart relationship with said refrigeration unit. In addition, a control system is included for running the heating unit for a sufficient time to

h e b b g e e e f e h b e f b e

warm said one bottle, and formula therein, to a selected temperature.

16 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 3. Document ID: WO 3030297 A1

L1: Entry 3 of 4

File: EPAB

Apr 10, 2003

PUB-NO: WO003030297A1

DOCUMENT-IDENTIFIER: WO 3030297 A1

TITLE: ELECTRIC APPARATUS

PUBN-DATE: April 10, 2003

INVENTOR-INFORMATION:

NAME

COUNTRY

SPIROPOULOS, VASILIOS

SE

JENSEN, MARTIN

SE

INT-CL (IPC): H01 Q 1/24; H04 M 1/02

EUR-CL (EPC): H01Q001/38; H01Q001/24

ABSTRACT:

CHG DATE=20030603 STATUS=N>An electric apparatus with wireless transmission comprises an apparatus casing and a circuit card disposed therein, an antenna (12) as well as a number of additional components (8-11, 13) such as a vibrator, a loudspeaker, an audio plug socket, a camera, a screen box, etc. The apparatus has a carrier device (2) of an electrically insulating and non-magnetic material. The antenna (12) and some of the additional components (8-11, 13) are disposed on or in the carrier device (2). The carrier device (2) has means (3, 4, 6) for mechanical securing on the circuit card (1). The antenna (12) has contact means (17) which extend to corresponding contact means (18) on the circuit card (1).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 4. Document ID: WO 9939403 A1

L1: Entry 4 of 4

File: EPAB

Aug 5, 1999

PUB-NO: WO009939403A1

DOCUMENT-IDENTIFIER: WO 9939403 A1

TITLE: ANTENNA DEVICE FOR DUAL FREQUENCY BANDS

PUBN-DATE: August 5, 1999

INVENTOR-INFORMATION:

NAME

COUNTRY

BLOM, CARL GUSTAF

SE

h e b b g e e e f e h b e f b e

JENSEN, MARTIN
LINDKVIST, HENRIK

SE
SE

INT-CL (IPC): H01 Q 1/36

EUR-CL (EPC): H01Q001/36; H01Q001/24, H01Q009/30 , H01Q011/08 , H01Q021/30

ABSTRACT:

CHG DATE=19990902 STATUS=O>An antenna device for a radio communications apparatus operates in at least two frequency bands. The antenna device has a helical antenna element (11) for the one frequency band and a rod-shaped antenna element (12) for the other frequency band. The helical antenna element (11) is galvanically connected to the circuits in the radio communications apparatus. The rod-shaped antenna element (12) is located outside the helical antenna element (11) and is provided with a supply portion (19) which wholly or partly surrounds the helical element (11) or its extension. A further rod-shaped antenna element is galvanically connected to the supply portion. The two rod-shaped antenna are located on opposite sides of the helical antenna element (11).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
(Jensen-Martin.IN.)	4

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 9 of 9 returned.

☐ 1. Document ID: CA 2453629 A1, US 6745878 B1

Using default format because multiple data bases are involved.

L15: Entry 1 of 9

File: DWPI

Jul 22, 2004

DERWENT-ACC-NO: 2004-417451

DERWENT-WEEK: 200454

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Transmission clutch interlock for tractor, has cable that couples interlock lever to clutch pedal so that interlock lever moves to release position when clutch pedal is moved to fully disengaged position

INVENTOR: JENSEN, M R

PRIORITY-DATA: 2003US-0350926 (January 22, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>CA 2453629 A1</u>	July 22, 2004	E	000	F16H063/36
<u>US 6745878 B1</u>	June 8, 2004		009	F16H059/56

INT-CL (IPC): B60 K 41/22; F16 H 59/56; F16 H 63/36

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw Desc
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	------------------------	---------------------	---------------------------

☐ 2. Document ID: BR 200212047 A, WO 2003015812 A2, US 20030157117 A1, EP 1420815 A2, AU 2002325199 A1

L15: Entry 2 of 9

File: DWPI

Aug 17, 2004

DERWENT-ACC-NO: 2003-312718

DERWENT-WEEK: 200457

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Novel analog of amyloid precursor protein or beta amyloid for treating Alzheimer's disease, has amyloid precursor protein/beta amyloid incorporating B-cell epitope of amyloid protein and foreign T-helper epitope

INVENTOR: DAL DEGAN, F; JENSEN, M R; KOEFOED, P; NIELSEN, K G; RASMUSSEN, P B; DEGAN, F D

PRIORITY-DATA: 2002US-373027P (April 16, 2002), 2001DK-0001231 (August 20, 2001), 2001US-337543P (October 22, 2001), 2002DK-0000558 (April 16, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
--------	----------	----------	-------	----------

BR 200212047 A	August 17, 2004		000	A61K039/00
WO 2003015812 A2	February 27, 2003	E	122	A61K039/00
US 20030157117 A1	August 21, 2003		000	A61K039/00
EP 1420815 A2	May 26, 2004	E	000	A61K039/00
AU 2002325199 A1	March 3, 2003		000	A61K039/00

INT-CL (IPC): A61 K 39/00; A61 K 39/385; A61 P 25/28; C07 K 14/47; C12 N 9/64

ABSTRACTED-PUB-NO: WO2003015812A
BASIC-ABSTRACT:

NOVELTY - An analog (I) of amyloid precursor protein (APP) or beta amyloid (A beta) which is derived from an animal APP or A beta , comprising APP or A beta incorporating at least one B-cell epitope of APP and/or A beta and at least one foreign T-helper epitope (TH epitope) so that immunization of the animal with the analog induces production of antibodies against the animal's autologous APP or A beta , is new.

DETAILED DESCRIPTION - An analog of amyloid precursor protein (APP) or beta amyloid (A beta) which is derived from an animal APP or A beta , comprises APP or A beta incorporating at least one B-cell epitope of APP and/or A beta and at least one foreign T-helper epitope (TH epitope) so that immunization of the animal with the analog induces production of antibodies against the animal's autologous APP or A beta , where the analog is:

- (a) a polyamino acid that consists of at least one copy of a subsequence of residues 672-714 in a 770 amino acid sequence (S1), given in the specification, where the foreign T-helper epitope (TH epitope) is incorporated by amino acid addition and/or insertion and/or deletion and/or substitution, where the subsequence is selected from residues 1-42, 1-40, 1-39, 1-35, 1-34, 1-28, 1-12, 1-5, 13-28, 13-35, 17-28, 25-35, 35-40, 36-42, and 35-42 of the amino acid sequence consisting of amino acid residues 673-714 of (S1);
- (b) a polyamino acid that contains the foreign TH epitopes and a disrupted APP or A beta sequence so that the analog does not include any subsequence of (S1) that binds productively to major histocompatibility complex (MHC) class II molecules initiating a T-cell response;
- (c) a polyamino acid that comprises the foreign TH epitope and APP or A beta derived amino acids, and comprises one single methionine residue located in the C-terminus of the analog, where other methionine residues in APP or A beta and in the foreign TH epitope have been substituted or deleted, and preferably have been substituted by leucine or isoleucine;
- (d) a conjugate comprising a polyhydroxypolymer backbone to which is separately coupled a polyamino acid as defined in (a), (b) and/or (c); and/or
- (e) a conjugate comprising a polyhydroxypolymer backbone to which is separately coupled the foreign TH epitope and a polyamino acid selected from the subsequence as defined in (a), a disrupted sequence of APP or A beta as defined in (b), and an APP or A beta derived amino acid sequence that comprises one single methionine residue located in the C-terminus, where other methionine residues in APP or A beta and in the foreign TH epitope have been substituted or deleted, and preferably have been substituted by leucine or isoleucine.

INDEPENDENT CLAIMS are also included for:

- (1) an immunogenic composition (C) comprising (I) and a carrier and/or vehicle and optionally an adjuvant;
- (2) a nucleic acid fragment (II) which encodes (I);

- (3) a vector (III) carrying (II), and is capable of autonomous replication;
- (4) a transformed cell carrying (III), and is capable of replicating (II);
- (5) a composition for inducing production of antibodies against amyloid, comprises (II) or (III), and a carrier, vehicle or adjuvant; and
- (6) a stable cell line which carries (III) and expresses (II), and optionally secretes or carries (I) on its surface.

ACTIVITY - Nootropic; Neuroprotective.

MECHANISM OF ACTION - Vaccine (claimed).

Mice transgenic for human APP (Alzheimer's precursor protein), called TgRND8+, expressed a mutated form of APP that results in high concentration of A beta -40 and A beta -42 in the mouse brains. The mice (8-10 mice/group) were immunized with either A beta -42 or hAB43+-34 variant, four times at two-week intervals. Doses were either 100 mg for A beta or 50 mg for hAB43+-34. Mice were bled at day 43 (after three injections) and after day 52 (after four injections) and the sera were used to determine the level of anti-A beta -42 specific titers using a direct A beta -42 enzyme linked immunosorbent assay (ELISA). The antibody titers obtained when immunizing with hAB43+-34 A beta variant were 4 times and 7.5 times higher after 3 and 4 immunizations, respectively, than the titers obtained when using the unaltered wild-type A beta -42 as an immunogen. The amount of variant used for immunization was only 50 % of the amount of wild-type sequence used for immunization.

USE - (I) is useful for in vivo down-regulation of APP or A beta in an animal, including a human being, and for treating and/or preventing and/or ameliorating Alzheimer's disease or other diseases and conditions characterized by amyloid deposits (claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 3. Document ID: AU 2002233166 A1, WO 200266056 A2, US 20020119162 A1, US 20020187157 A1, EP 1363664 A2

L15: Entry 3 of 9

File: DWPI

Sep 4, 2002

DERWENT-ACC-NO: 2002-706932

DERWENT-WEEK: 200427

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Novel immunogen useful for immunizing an animal, has an activated polyhydroxypolymer backbone to which is attached an antigenic determinant including a B cell epitope and another determinant including a T-helper epitope

INVENTOR: KOEFOED, P; NIELSEN, K G ; JENSEN, M R ; RASMUSSEN, P B

PRIORITY-DATA: 2001US-337543P (October 22, 2001), 2001WO-DK00113 (February 19, 2001), 2001US-0785215 (February 20, 2001), 2001DK-0001231 (August 20, 2001), 2000DK-0000265 (February 21, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2002233166 A1</u>	September 4, 2002		000	A61K039/385
<u>WO 200266056 A2</u>	August 29, 2002	E	052	A61K039/385
<u>US 20020119162 A1</u>	August 29, 2002		000	A61K039/00

US 20020187157 A1	December 12, 2002		000	A61K039/00
EP 1363664 A2	November 26, 2003	E	000	A61K039/385

INT-CL (IPC): A61 K 38/19; A61 K 38/20; A61 K 39/00; A61 K 39/385; A61 K 47/48

ABSTRACTED-PUB-NO: WO 200266056A
BASIC-ABSTRACT:

NOVELTY - An immunogen (I) comprising at least one first antigenic determinant that includes at least one B-cell epitope and/or at least one cytotoxic T lymphocyte (CTL) epitope, and at least one second antigenic determinant that includes a T helper cell epitope (TH epitope), where each of the first and second antigenic determinants are coupled to an activated polyhydroxypolymer carrier, is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for an immunogenic composition (II) for raising an immune response against an antigen in a mammal, including a human, comprising (I), and optionally an adjuvant.

ACTIVITY - None given.

MECHANISM OF ACTION - Vaccine.

Test details are described, but no results are given.

USE - (I) or (II) contained in a virtual lymph node (VLN) device is useful for immunizing an animal, including a human, against an antigen of choice, where the antigen shares the at least one first antigenic determinant with the immuogen (claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 4. Document ID: CZ 200202748 A3, WO 200162284 A2, AU 200133620 A, NO 200203961 A, EP 1259251 A2, BR 200108566 A, KR 2003001365 A, US 20030086938 A1, HU 200300067 A2, CN 1416350 A, JP 2003523402 W, NZ 521442 A, ZA 200204830 A, SK 200201178 A3

L15: Entry 4 of 9

File: DWPI

Mar 17, 2004

DERWENT-ACC-NO: 2001-589796
DERWENT-WEEK: 200430
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: In vivo down-regulation of amyloid protein for the treatment of Alzheimer's, comprises presenting an amyloidogenic polypeptide or its subsequence and/or at least one analogue of the amyloidogenic polypeptide to the immune system

INVENTOR: BIRK, P; JENSEN, M R ; NIELSEN, K G

PRIORITY-DATA: 2000US-186295P (March 1, 2000), 2000DK-0000265 (February 21, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>CZ 200202748 A3</u>	March 17, 2004		000	A61K038/17
<u>WO 200162284 A2</u>	August 30, 2001	E	120	A61K039/395
<u>AU 200133620 A</u>	September 3, 2001		000	A61K039/395
<u>NO 200203961 A</u>	August 20, 2002		000	A61K000/00
<u>EP 1259251 A2</u>	November 27, 2002	E	000	A61K038/17

BR 200108566 A	November 19, 2002	000	A61K039/395
KR 2003001365 A	January 6, 2003	000	A61K038/16
US 20030086938 A1	May 8, 2003	000	A61K039/00
HU 200300067 A2	May 28, 2003	000	A61K038/17
CN 1416350 A	May 7, 2003	000	A61K038/17
JP 2003523402 W	August 5, 2003	108	A61K039/00
NZ 521442 A	September 26, 2003	000	A61K039/395
ZA 200204830 A	November 26, 2003	141	A61K000/00
SK 200201178 A3	February 3, 2004	000	A61K039/395

INT-CL (IPC): A61 K 0/00; A61 K 35/12; A61 K 35/66; A61 K 35/76; A61 K 38/00; A61 K 38/16; A61 K 38/17; A61 K 39/00; A61 K 39/39; A61 K 39/395; A61 K 48/00; A61 P 25/28; C07 K 14/435; C07 K 14/47; C07 K 19/00; C12 N 1/15; C12 N 1/19; C12 N 1/21; C12 N 5/10; C12 N 15/09; C12 P 21/02; G01 N 33/53

ABSTRACTED-PUB-NO: WO 200162284A

BASIC-ABSTRACT:

NOVELTY - A method (M1) for in vivo down-regulation of amyloid protein in an animal, including a human, comprising presenting to the animal's immune system an immunogenically effective amount of at least one amyloidogenic polypeptide or its subsequence and/or at least one analogue of the amyloidogenic polypeptide, is new.

DETAILED DESCRIPTION - a method (M1) for in vivo down-regulation of amyloid protein in an animal, including a human, comprising presenting to the animal's immune system an immunogenically effective amount of at least one amyloidogenic polypeptide or its subsequence or at least one analogue of the amyloidogenic polypeptide, is new.

The amyloidogenic polypeptide or its subsequence has been formulated so that immunization of the animal with the amyloidogenic polypeptide or its subsequence induces production of antibodies against the amyloidogenic polypeptide. The analogue of the amyloidogenic polypeptide has at least one modification in the amino acid sequence. Immunization of the animal with the analogue induces production of antibodies against the amyloidogenic polypeptide.

INDEPENDENT CLAIMS are included for the following:

(1) a method (M2) for treating and/or preventing and/or ameliorating Alzheimer's disease or other diseases and conditions characterized by amyloid deposits, comprising down-regulating amyloid according to M1 to such an extent that the total amount of amyloid is decreased or that the rate of amyloid formation is reduced with clinical significance;

(2) an analogue (A1) of an amyloidogenic polypeptide which is derived from an animal amyloidogenic polypeptide where is introduced a modification which has as a result that immunization of the animal with the analogue induces production of antibodies against the amyloidogenic polypeptide;

(3) an immunogenic composition comprising:

(a) an immunogenically effective amount of an amyloidogenic polypeptide autologous in an animal, the amyloidogenic polypeptide being formulated together with an immunologically acceptable adjuvant so as to break the animal's autotolerance towards the amyloidogenic polypeptide, the composition further comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle; or

(b) an effective amount of A1 the composition further comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle and optionally an adjuvant;

(4) a nucleic acid fragment (N1) which encodes A1;

- (5) a vector carrying N1 and capable of automomous replication;
- (6) a transformed cell carrying the vector of (5), such that the transformed cell is capable of replicating N1;
- (7) a composition for inducing production of antibodies against an amyloidogenic polypeptide, comprising N1 or the vector of (5);
- (8) a stable cell line which carries the vector of (5) and which expresses N1, and which optionally secretes or carries A1 on its surface;
- (9) a method for the preparation of the cell of (6), comprising transforming a host cell with N1 or the vector of (6);
- (10) a method (M3) for the identification of a modified amyloidogenic polypeptide which is capable of inducing antibodies against unmodified amyloidogenic polypeptide in an animal species where the unmodified amyloidogenic polypeptide is a self-protein; and
- (11) a method (M4) for the preparation of an immunogenic composition comprising at least one modified amyloidogenic polypeptide which is capable of inducing antibodies against unmodified amyloidogenic polypeptide in an animal species where the unmodified amyloidogenic polypeptide is a self-protein.

ACTIVITY - Neuroprotective; Nootropic; Immunostimulant; Antidiabetic; Antiparkinsonian; Anticonvulsant.

MECHANISM OF ACTION - Amyloid-Protein-Antagonist; Vaccine; Gene-Therapy.

Mice transgenic for human APP (Alzheimer's precursor protein) were used for the study. These mice, called TgRND8+, express a mutated form of APP that results in high concentration of beta-amyloid-40 and beta-amyloid-42 in the mouse brains (Janus, C. et. al., Nature 408:979-982, (2000))

The mice (8-10 mice per group) were immunized with either beta-amyloid-42 (residues 673-714 of the 770 amino acid sequence defined in the specification, it is synthesized by standard Fmoc strategy) or the hAB43+-34 variant (produced recombinantly) four times at two week intervals. Doses were either 100 mg for beta-amyloid-42 or 50 mg for hAB43+34. Mice were bled at day 43 (after three injections) and after day 52 (after four injections) and the sera were used to determine the level of anti-beta-amyloid-42 specific titres using a direct beta-amyloid-42 ELISA.

The antibody titers obtained when immunizing with the hAB43+-34 beta-amyloid variant are approximately 4 times and 7.5 times higher after 3 and 4 immunizations, respectively, than the titers obtained when using the unaltered wild-type beta-amyloid-42 as an immunogen. This fact is put in perspective, when considering the fact that the amount of variant used for immunization was only 50% of the amount of wild-type sequence used for immunization.

USE - The amyloidogenic polypeptide or its subsequence, and its analogue is useful for the preparation of an immunogenic composition comprising an adjuvant for down-regulating amyloid in an animal. They are also useful in the treatment, prophylaxis or amelioration of Alzheimer's disease or other diseases characterized by amyloid deposits (claimed). They are also useful in the treatment of systemic amyloidosis, maturity onset diabetes, Parkinson's disease, Huntington's disease, fronto-temporal dementia, and prion-related transmissible spongiform encephalopathies.

They are also useful for inducing production of antibodies against an amyloidogenic polypeptide.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

□ 5. Document ID: TW 510921 A, WO 9846642 A1, AU 9870303 A, ZA 9803148 A, NO 9905002 A, EP 975668 A1, CN 1252809 A, SK 9901409 A3, BR 9811462 A, NZ 337955 A, HU 200001930 A2, MX 9909394 A1, KR 2001006416 A, CZ 9903657 A3, JP 2001521386 W, AU 743400 B

L15: Entry 5 of 9

File: DWPI

Nov 21, 2002

DERWENT-ACC-NO: 1998-594561

DERWENT-WEEK: 200353

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Modified human tumour necrosis factor-alpha - comprises immunodominant T cell epitope, useful in vaccines to treat or prevent TNF-associated diseases, e.g. cancer

INVENTOR: DALUM, I; ELSNER, H ; JENSEN, M R ; MOURITSEN, S

PRIORITY-DATA: 1997US-044187P (April 24, 1997), 1997DK-0000418 (April 15, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>TW 510921 A</u>	November 21, 2002		000	A61K031/505
<u>WO 9846642 A1</u>	October 22, 1998	E	134	C07K014/525
<u>AU 9870303 A</u>	November 11, 1998		000	
<u>ZA 9803148 A</u>	December 29, 1999		124	A61K000/00
<u>NO 9905002 A</u>	December 15, 1999		000	C07K000/00
<u>EP 975668 A1</u>	February 2, 2000	E	000	
<u>CN 1252809 A</u>	May 10, 2000		000	C07K014/525
<u>SK 9901409 A3</u>	June 12, 2000		000	C07K014/525
<u>BR 9811462 A</u>	September 12, 2000		000	C07K014/525
<u>NZ 337955 A</u>	September 29, 2000		000	C07K019/00
<u>HU 200001930 A2</u>	September 28, 2000		000	C07K014/525
<u>MX 9909394 A1</u>	April 1, 2000		000	C07K014/525
<u>KR 2001006416 A</u>	January 26, 2001		000	C07K014/525
<u>CZ 9903657 A3</u>	September 12, 2001		000	C07K014/525
<u>JP 2001521386 W</u>	November 6, 2001		138	C12N015/09
<u>AU 743400 B</u>	January 24, 2002		000	C07K014/525

B INT-CL (IPC): A61 K 0/00; A61 K 31/505; A61 K 38/19; A61 K 38/22; A61 K 39/00; A61 P 1/04; A61 P 3/10; A61 P 11/06; A61 P 17/06; A61 P 19/02; A61 P 19/10; A61 P 25/02; A61 P 29/00; A61 P 35/00; C07 K 0/00; C07 K 9/00; C07 K 14/525; C07 K 16/24; C07 K 19/00; C12 N 1/15; C12 N 1/19; C12 N 1/21; C12 N 5/10; C12 N 15/09; C12 N 15/11; C12 P 21/02; G01 N 33/53

ABSTRACTED-PUB-NO: WO 9846642A

BASIC-ABSTRACT:

New modified human tumour necrosis factor alpha , TNF alpha , (I) , able to generate, in humans, neutralising antibodies (Ab) to wild-type human TNF alpha (Ia): (a) has at least 1 fragment of TNF substituted by a peptide containing an immunodominant T-cell epitope, or (b) is a truncated form of (a) containing an immunodominant epitope and one or both flanking regions of TNF, including at least 1 TNF alpha B-cell epitope. The substitution causes a significant change in the amino acid (aa) sequence of any one of the strands in the front beta -sheet (fbS), any of the connecting loops and/or any of the B', I or D strands in the back beta -sheet (bbS). Also new are: (1)

dimers, oligomers and multimers of (I); (2) isolated DNA (II) that encodes (I); (3) (expression) vectors containing (II); (4) hosts transformed with the expression vector, and (5) fusion proteins (FP) of (I) with an immunological adjuvant.

USE - Cells of (4) are used to produce recombinant (I) which are used as vaccines for treatment or prevention of diseases associated with excessive release or activity of (Ia), e.g. rheumatoid arthritis, Crohn's disease, ulcerative colitis, cancer of any sort, disseminated sclerosis, diabetes, psoriasis, osteoporosis and asthma. Ab are also useful as diagnostic immunoassay reagents, while (II) is a source of primers and probes, and used for expressing (I) in vivo (DNA vaccines).

ADVANTAGE - (I) have no residual TNF activity, are immunogenic in a large proportion of the human population (by using promiscuous epitopes) and are optimised for production of neutralising Ab.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 6. Document ID: WO 9721647 A1, EP 809615 A1, AU 9714668 A

L15: Entry 6 of 9

File: DWPI

Jun 19, 1997

DERWENT-ACC-NO: 1997-332699

DERWENT-WEEK: 199802

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Stabilising odours in animal manure - by maintaining water content of manure, adjusting pH to levels that will minimise release of odorous compounds including ammonia and hydrogen sulphide and maintaining adjusted pH level at constant value

INVENTOR: GREENE, G L; JENSEN, M R; JORGENSON, M D ; ZIMMERMAN, L G ; ZIMMERMAN, L

PRIORITY-DATA: 1995US-0573043 (December 15, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9721647 A1	June 19, 1997	E	021	C05F003/00
EP 809615 A1	December 3, 1997	E	000	C05F003/00
AU 9714668 A	July 3, 1997		000	C05F003/00

INT-CL (IPC): C05 F 3/00

ABSTRACTED-PUB-NO: WO 9721647A

BASIC-ABSTRACT:

A method of stabilising odours in animal manure comprises: (i) obtaining a quantity of animal manure comprising water and solids and containing sources of odorous compounds including ammonia and hydrogen sulphide: (ii) maintaining the water content of the manure; and (iii) adjusting the pH of the manure to a level that will minimise the release of odorous compounds including ammonia and hydrogen sulphide to the surrounding air from the manure by mixing it with an admixture material to obtain a homogeneous mixture. The adjusted pH level is maintained at constant value to stabilise the release of the odorous compounds from the manure. Also claimed is a method of stabilising odours in animal manure comprising obtaining a quantity of animal manure comprising water and solids and containing sources of odorous compounds including ammonia and hydrogen sulphide, maintaining the water content of the manure, adjusting the pH of the manure to a level that will minimise the release of odorous compounds including ammonia and hydrogen sulphide to the surrounding air from the manure by mixing it with an admixture material in an amount of 0.25-0.5 parts to one part manure on dry weight basis solids to obtain a homogeneous mixture. The adjusted

pH level is maintained at constant value to stabilise the release of the odorous compounds from the manure.

ADVANTAGE - The manure can be treated in a variety of collection devices. The method is effective for treating manures of differing composition. The fertiliser potential of the manure is preserved and the method is cost-effective and economical. The method is also environmentally acceptable.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 7. Document ID: US 20030082514 A1, WO 9638553 A1, AU 9658933 A, EP 832207 A1, AU 699568 B, JP 11505724 W, KR 99022157 A, EP 832207 B1, EP 1041143 A2, DE 69610310 E, ES 2151167 T3, US 20010053523 A1

L15: Entry 7 of 9

File: DWPI

May 1, 2003

DERWENT-ACC-NO: 1997-042713

DERWENT-WEEK: 200331

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Identifying biologically active peptide(s) and nucleic acids - by transducing vectors contg. random DNA sequences into cells and screening for altered phenotypic trait

INVENTOR: DALUM, I; DUCH, M ; HINDERSSON, P ; JENSEN, M R ; LUND, A H ; MOURITSEN, S ; PEDERSEN, F S ; SORENSEN, M S ; MOURITZEN, S ; SOERENSEN, M S

PRIORITY-DATA: 1995DK-0000629 (June 2, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20030082514 A1	May 1, 2003		000	C12Q001/00
WO 9638553 A1	December 5, 1996	E	027	C12N015/10
AU 9658933 A	December 18, 1996		000	C12N015/10
EP 832207 A1	April 1, 1998	E	000	C12N015/10
AU 699568 B	December 10, 1998		000	C12N015/10
JP 11505724 W	May 25, 1999		031	C12Q001/68
KR 99022157 A	March 25, 1999		000	C12N015/10
EP 832207 B1	September 13, 2000	E	000	C12N015/10
EP 1041143 A2	October 4, 2000	E	000	C12N015/10
DE 69610310 E	October 19, 2000		000	C12N015/10
ES 2151167 T3	December 16, 2000		000	C12N015/10
US 20010053523 A1	December 20, 2001		000	C12Q001/68

INT-CL (IPC): C12 N 5/10; C12 N 15/09; C12 N 15/10; C12 N 15/85; C12 N 15/86; C12 P 19/34; C12 P 21/02; C12 Q 1/00; C12 Q 1/68; G01 N 33/50; G01 N 33/60; G01 N 33/68

ABSTRACTED-PUB-NO: EP 832207B

BASIC-ABSTRACT:

A method for identification of biologically active peptides and nucleic acids comprises:

(a) producing a pool of appropriate vectors, each contg. totally or partially random DNA sequences;

(b) transducing of the vectors into a number of identical eukaryotic cells in such a way that a single ribonucleic acid and possibly peptide is expressed or a limited number of different random ribonucleic acids and peptides are expressed by each cell;

(c) screening of the transduced cells to see whether some of them have changed a certain phenotypic trait;

(d) selecting and cloning of the changed cells;

(e) isolating and sequencing of the vector DNA in the pheno-typically changed cells, and

(f) deducing the ribonucleic acid and peptide sequence from the DNA sequence.

USE - The method can be used for the identification of T cell epitopes. It helps to identify biologically active peptides which regulate cell surface expression. The peptides and nucleic acids identified can be used therapeutically or as lead cpds. for drug development (all claimed).

ABSTRACTED-PUB-NO:

US20010053523A EQUIVALENT-ABSTRACTS:

A method for identification of biologically active peptides and nucleic acids comprises:

(a) producing a pool of appropriate vectors, each contg. totally or partially random DNA sequences;

(b) transducing of the vectors into a number of identical eukaryotic cells in such a way that a single ribonucleic acid and possibly peptide is expressed or a limited number of different random ribonucleic acids and peptides are expressed by each cell;

(c) screening of the transduced cells to see whether some of them have changed a certain phenotypic trait;

(d) selecting and cloning of the changed cells;

(e) isolating and sequencing of the vector DNA in the pheno-typically changed cells, and

(f) deducing the ribonucleic acid and peptide sequence from the DNA sequence.

USE - The method can be used for the identification of T cell epitopes. It helps to identify biologically active peptides which regulate cell surface expression. The peptides and nucleic acids identified can be used therapeutically or as lead cpds. for drug development (all claimed).

A method for identification of biologically active peptides and nucleic acids comprises:

(a) producing a pool of appropriate vectors, each contg. totally or partially random DNA sequences;

(b) transducing of the vectors into a number of identical eukaryotic cells in such a way that a single ribonucleic acid and possibly peptide is expressed or a limited number of different random ribonucleic acids and peptides are expressed by each cell;

(c) screening of the transduced cells to see whether some of them have changed a certain phenotypic trait;

(d) selecting and cloning of the changed cells;

(e) isolating and sequencing of the vector DNA in the pheno-typically changed cells, and

(f) deducing the ribonucleic acid and peptide sequence from the DNA sequence.

USE - The method can be used for the identification of T cell epitopes. It helps to identify biologically active peptides which regulate cell surface expression. The peptides and nucleic acids identified can be used therapeutically or as lead cpds. for drug development (all claimed).

WO 9638553A

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	KWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	----------

☐ 8. Document ID: CA 2105018 A, PH 30284 A, US 5322703 A, ZA 9308759 A, WO 9514390 A1, AU 9456794 A, EP 730410 A1, TW 283628 A, CN 1103256 A, JP 09505478 W, CA 2105018 C

L15: Entry 8 of 9

File: DWPI

Mar 11, 1994

DERWENT-ACC-NO: 1994-167986

DERWENT-WEEK: 199953

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: High yield roasted coffee blend mfr. - by combining dried roasted coffee beans with non-dried roasted coffee beans to give a blend with balanced strength, flavour and acidity

INVENTOR: JENSEN, M R ; KIRKPATRICK, S J ; LEPPLA, J K ; JENSEN, M

PRIORITY-DATA: 1992US-0943079 (September 10, 1992), 1993US-0162818 (December 6, 1993), 1993ZA-0008759 (November 23, 1993), 1993WO-US11476 (November 24, 1993), 1994AU-0056794 (November 24, 1993), 1994EP-0902412 (November 24, 1993), 1993CN-0121446 (November 29, 1993), 1995JP-0515024 (November 24, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
CA 2105018 A	March 11, 1994		029	A23F005/04
PH 30284 A	February 20, 1997		000	A23F005/48
US 5322703 A	June 21, 1994		012	A23F005/04
ZA 9308759 A	September 28, 1994		029	A23F000/00
WO 9514390 A1	June 1, 1995	E	026	A23F005/04
AU 9456794 A	June 13, 1995		000	A23F005/04
EP 730410 A1	September 11, 1996	E	000	A23F005/04
TW 283628 A	August 21, 1996		000	A23F005/04
CN 1103256 A	June 7, 1995		000	A23F005/10
JP 09505478 W	June 3, 1997		028	A23F005/04
CA 2105018 C	June 23, 1998		000	A23F005/04

INT-CL (IPC): A23F 0/00; A23F 5/02; A23F 5/04; A23F 5/10; A23F 5/12; A23F 5/48

ABSTRACTED-PUB-NO: CA 2105018A

BASIC-ABSTRACT:

Mfr. comprises (a) drying green coffee beans prior to roasting to a moisture content of 0.5-7 wt.% at 21-163 deg.C. for 1 minute-24hrs.; (b) roasting the dried beans at 177-649 deg.C. for 10s-5.5 minutes to a Hunter L-colour of 10-16; and (c) blending the dried roasted beans with non-dried beans roasted to a Hunter L-colour of 17024 and having a moisture content before roasting of greater than 7 wt.%. The blend comprises (i) 1-50 wt.% dried roasted beans; and (ii) 50-99 wt.% of non-dried roasted beans.

A roasted coffee prod. produced is also claimed.

USE/ADVANTAGE - The prod. can be combined with soluble coffees or admixed with non-coffee materials. It can be caffeinated or decaffeinated. It can be added to filter packs or used to mfr. soluble coffee. The blend has a high yield with a balance of strength, flavour and acidity. The prod. yields 30-63% more brewed coffee than other low density, fast roasted coffee. The chemistry of the prod. is unique when of conventional and/or dark roasted coffee.

ABSTRACTED-PUB-NO:

US 5322703A EQUIVALENT-ABSTRACTS:

High-yield roasted coffee with balanced flavour is made, by (a) drying green coffee beans at 21-163 deg.C for 1-1440 mins., to moisture content of 0.5-7 wt.%; (b) roasting at 177-649 deg.C for 10-330 secs. to Hunter L-colour of 10-16; and (c) blending prod. with non-dried coffee beans roasted to Hunter L-colour of 17-24 and moisture content more than 7 wt.%.

Blend comprises 1-20 wt.% dried roasted beans and 80-99 wt.% of non-dried roasted bean.

ADVANTAGE - Has improved brew yield of 30-100%.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 9. Document ID: US 4823815 A

L15: Entry 9 of 9

File: DWPI

Apr 25, 1989

DERWENT-ACC-NO: 1989-144328

DERWENT-WEEK: 198919

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Tissue expanding system base - has top layer joined to periphery whose thickness is equal to combined thickness of base and layer

INVENTOR: CONDON, D E; JENSEN, M R ; WATSON, D A

PRIORITY-DATA: 1986US-0909223 (September 19, 1986), 1988US-0228841 (August 3, 1988)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 4823815 A	April 25, 1989		007	

INT-CL (IPC): A61B 19/00

ABSTRACTED-PUB-NO: US 4823815A

BASIC-ABSTRACT:

The skin expanding device has a non-extensible base and a top expansion layer joined to the periphery of the base to define an expansion chamber when fluid is introduced

between the base and the expansion layer. The expansion layer is joined to the base such that the layer is in contact throughout its entire area with the base when the device is in a non-expanded state to form a flat skin expander.

When the skin expander is in a non-expanded state, the thickness of the expander is substantially equal to the combined thicknesses of the base and the expansion layer. The expansion layer has a thick non-expanding portion and a thin expanding portion such that when the expander is being filled with fluid.

USE - In surgical procedures where implanting of skin is required, e.g. breast prostheses.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Jensen-M-R.IN.	9

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 9 of 9 returned.

☐ 1. Document ID: US 20030157117 A1

Using default format because multiple data bases are involved.

L13: Entry 1 of 9

File: PGPB

Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030157117

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030157117 A1

TITLE: Novel method for down-regulation of amyloid

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rasmussen, Peter Birk	Horsholm		DK	
<u>Jensen, Martin Roland</u>	Horsholm		DK	
Nielsen, Klaus Gregorius	Horsholm		DK	
Koefoed, Peter	Horsholm		DK	
Degan, Florence Dal	Horsholm		DK	

US-CL-CURRENT: 424/185.1; 435/226

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 2. Document ID: US 20030086938 A1

L13: Entry 2 of 9

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030086938

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030086938 A1

TITLE: Novel methods for down-regulation of amyloid

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
<u>Jensen, Martin Roland</u>	Horsholm		DK	
Birk, Peter	Horsholm		DK	
Nielsen, Klaus Gregorius	Horsholm		DK	

US-CL-CURRENT: 424/185.1

ABSTRACT:

Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloidogenic proteins (proteins contributing to formation of amyloid) such as beta amyloid (A.beta.). Immunization is preferably effected by administration of analogues of autologous amyloidogenic polypeptides, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A.beta. which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the majority of A.beta.'s B-cell epitopes. Also disclosed are nucleic acid vaccination against amyloidogenic polypeptides and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic analogues of the amyloidogenic proteins, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20030082514 A1

L13: Entry 3 of 9

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030082514

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030082514 A1

TITLE: Method for identification of biologically active peptides and nucleic acids

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jensen, Martin Roland	Holte		DK	
Pedersen, Finn Skou	Aarhus		DK	
Mouritsen, Soren	Birkerod		DK	
Hindersson, Peter	Copenhagen		DK	
Duch, Mogens	Risskov		DK	
Sorensen, Michael Schandorf	Aarhus		DK	
Dalum, Iben	Horsholm		DK	
Lund, Anders Henrik	Aarhus		DK	

US-CL-CURRENT: 435/4; 435/320.1, 435/455, 435/6, 435/91.2

ABSTRACT:

Biologically active peptides and nucleic acids are identified by a method comprising the following steps: (a) production of a pool of appropriate vectors each containing totally or partly random DNA sequences, (b) efficient transduction of said vectors into a number of identical eukaryotic cells in such a way that a single ribonucleic acid and possibly peptide is expressed or a limited number of different random ribonucleic acids and peptides are expressed by each cell, (c) screening of said transduced cells to see whether some of them have changed a certain phenotypic trait, (d) selection and cloning of said changed cells, (e) isolation and sequencing of the vector DNA in said phenotypically changed cells, and (f) deducing the ribonucleic

acid and peptide sequences from the DNA sequence. The peptide sequences may be introduced into or fused to a larger protein, preferably an antibody molecule or a fragment thereof. This may be obtained by introducing the random DNA sequences into or fusing them to a DNA sequence encoding such larger protein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 4. Document ID: US 20020187157 A1

L13: Entry 4 of 9

File: PGPB

Dec 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020187157

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020187157 A1

TITLE: Novel method for down-regulation of amyloid

PUBLICATION-DATE: December 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
<u>Jensen, Martin Roland</u>	Holte		DK	
Rasmussen, Peter Birk	Frederiksberg		DK	
Nielsen, Klaus Gregorius	Soborg		DK	

US-CL-CURRENT: 424/185.1; 424/85.1, 424/85.2

ABSTRACT:

A method for in vivo down-regulation of amyloid protein in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunogenically effective amount of at least one amyloidogenic polypeptide or subsequence thereof which has been formulated so that immunization of the animal with the amyloidogenic polypeptide or subsequence thereof induces production of antibodies against the amyloidogenic polypeptide, and/or at least one analogue of the amyloidogenic polypeptide wherein is introduced at least one modification in the amino acid sequence of the amyloidogenic polypeptide which has as a result the immunization of the animal with the analogue induces production of antibodies against the amyloidogenic polypeptide.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 5. Document ID: US 20010053523 A1

L13: Entry 5 of 9

File: PGPB

Dec 20, 2001

PGPUB-DOCUMENT-NUMBER: 20010053523

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010053523 A1

TITLE: Method for identification of biologically active peptides and nucleic acids

PUBLICATION-DATE: December 20, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jensen, Martin Roland	Holte		DK	
Pedersen, Finn Skou	Aarhus		DK	
Mouritsen, Soren	Birkerod		DK	
Hindersson, Peter	Copenhagen		DK	
Duch, Mogens	Risskov		DK	
Sorensen, Michael Schandorf	Aarhus		DK	
Dalum, Iben	Horsholm		DK	
Lund, Anders Henrik	Aarhus		DK	

US-CL-CURRENT: 435/6; 435/320.1, 435/455

ABSTRACT:

A library is composed of viral vectors in which each of the vectors (a) involves a peptide expression cassette containing a random nucleotide sequence, (b) transduces a eukaryotic cell to allow expression of the random nucleotide sequence, and (c) is produced by (i) conventional random oligonucleotide synthesis or (ii) random codon synthesis where codons encode an even distribution of random amino acids.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 6. Document ID: WO 3015812 A2

L13: Entry 6 of 9

File: EPAB

Feb 27, 2003

PUB-NO: WO003015812A2

DOCUMENT-IDENTIFIER: WO 3015812 A2

TITLE: NOVEL METHOD FOR DOWN-REGULATION OF AMYLOID

PUBN-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME	COUNTRY
RASMUSSEN, PETER BIRK	DK
JENSEN, MARTIN ROLAND	DK
NIELSEN, KLAUS GREGORIUS	DK
KOEFOED, PETER	DK
DEGAN, FLORENCE DAL	DZ

INT-CL (IPC): A61 K 39/00; A61 K 39/385; C07 K 14/47; A61 P 25/28

EUR-CL (EPC): A61K039/00

ABSTRACT:

CHG DATE=20030403 STATUS=O>Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protein (APP) or beta amyloid (A beta). Immunization is preferably effected by administration of analogues of autologous APP or A beta , said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A beta which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid

vaccination against APP or A beta and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 7. Document ID: EP 1041143 A2

L13: Entry 7 of 9

File: EPAB

Oct 4, 2000

PUB-NO: EP001041143A2

DOCUMENT-IDENTIFIER: EP 1041143 A2

TITLE: A method for identification of biologically active peptides and nucleic acids

PUBN-DATE: October 4, 2000

INVENTOR-INFORMATION:

NAME	COUNTRY
JENSEN, MARTIN ROLAND	DK
PEDERSEN, FINN SKOU	DK
MOURITZEN, SOEREN	DK
HINDERSSON, PETER	DK
DUCH, MOGENS	DK
SOERENSEN, MICHAEL SCHANDORF	DK
DALUM, IBEN	DK
LUND, ANDERS HENRIK	NL

INT-CL (IPC): C12 N 15/10; C12 Q 1/68; G01 N 33/50; G01 N 33/68

EUR-CL (EPC): C12N015/10; G01N033/50, G01N033/68

ABSTRACT:

CHG DATE=20001116 STATUS=O> Biologically active peptides and nucleic acids are identified by a method comprising the following steps: (a) production of a pool of appropriate vectors each containing totally or partly random DNA sequences, (b) efficient transduction of said vectors into a number of identical eukaryotic cells in such a way that a single ribonucleic acid and possibly peptide is expressed or a limited number of different random ribonucleic acids and peptides are expressed by each cell, (c) screening of said transduced cells to see whether some of them have changed a certain phenotypic trait, (d) selection and cloning of said changed cells, (e) isolation and sequencing of the vector DNA in said phenotypically changed cells, and (f) deducing the ribonucleic acid and peptide sequences from the DNA sequence. The peptide sequences may be introduced into or fused to a larger protein preferably an antibody molecule or a fragment thereof. This may be obtained by introducing the random DNA sequences into or fusing them to a DNA sequence encoding such larger protein.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 8. Document ID: WO 9846642 A1

L13: Entry 8 of 9

File: EPAB

Oct 22, 1998

PUB-NO: WO009846642A1

DOCUMENT-IDENTIFIER: WO 9846642 A1

TITLE: MODIFIED TNF alpha MOLECULES, DNA ENCODING SUCH MODIFIED TNF alpha MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNF alpha MOLECULES AND DNA

PUBN-DATE: October 22, 1998

INVENTOR-INFORMATION:

NAME	COUNTRY
JENSEN, MARTIN ROLAND	DK
MOURITSEN, SOEREN	DK
ELSNER, HENRIK	DK
DALUM, IBEN	DK

INT-CL (IPC): C07 K 14/525; C07 K 19/00

EUR-CL (EPC): C07K014/33; C07K014/525

ABSTRACT:

CHG DATE=19990905 STATUS=O>A modified human TNF alpha molecule capable of raising neutralizing antibodies towards wild-type human TNF alpha following administration of said modified TNF alpha molecule to a human host, wherein at least one peptide fragment of the human TNF alpha molecule has been substituted by at least one peptide known to contain an immunodominant T cell epitope or a truncated form of said molecule containing an immunodominant epitope and one or both flanking regions of the human TNF alpha molecule comprising at least one TNF alpha B cell epitope, wherein the substitution introduces a substantial change in the amino acid sequence of the front beta -sheet, in any one of the connecting loops and/or in any one of the B', I or D strands of the back beta -sheet. The modified human TNF alpha molecules or DNA encoding them may be formulated as vaccines against TNF alpha optionally with pharmaceutically acceptable adjuvants, for the prevention or treatment of chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases, cancer, disseminated sclerosis, diabetes, psoriasis, osteoporosis or asthma. Human body fluids may be tested for the presence of TNF alpha by contact with a composition containing the modified TNF alpha .

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 9. Document ID: WO 9638553 A1

L13: Entry 9 of 9

File: EPAB

Dec 5, 1996

PUB-NO: WO009638553A1

DOCUMENT-IDENTIFIER: WO 9638553 A1

TITLE: A METHOD FOR IDENTIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES AND NUCLEIC ACIDS

PUBN-DATE: December 5, 1996

INVENTOR-INFORMATION:

NAME	COUNTRY
JENSEN, MARTIN ROLAND	DK

PEDERSEN, FINN SKOU	DK
MOURITSEN, SOEREN	DK
HINDERSSON, PETER	DK
DUCH, MOGENS	DK
SOERENSEN, MICHAEL SCHANDORF	DK
DALUM, IBEN	DK
LUND, ANDERS HENRIK	DK

INT-CL (IPC): C12 N 15/10; C12 N 15/86; C12 Q 1/68; G01 N 33/68
 EUR-CL (EPC): C12N015/10; C12Q001/68, G01N033/50 , G01N033/68

ABSTRACT:

CHG DATE=19990617 STATUS=O>Biologically active peptides and nucleic acids are identified by a method comprising the following steps: (a) production of a pool of appropriate vectors each containing totally or partly random DNA sequences, (b) efficient transduction of said vectors into a number of identical eukaryotic cells in such a way that a single ribonucleic acid and possibly peptide is expressed or a limited number of different random ribonucleic acids and peptides are expressed by each cell, (c) screening of said transduced cells to see whether some of them have changed a certain phenotypic trait, (d) selection and cloning of said changed cells, (e) isolation and sequencing of the vector DNA in said phenotypically changed cells, and (f) deducing the ribonucleic acid and peptide sequences from the DNA sequence. The peptide sequences may be introduced into or fused to a larger protein preferably an antibody molecule or a fragment thereof. This may be obtained by introducing the random DNA sequences into or fusing them to a DNA sequence encoding such larger protein.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
(Jensen-Martin-Roland.IN.)	9

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 61 of 61 returned.

☐ 1. Document ID: US 20040135703 A1

Using default format because multiple data bases are involved.

L2: Entry 1 of 61

File: DWPI

Jul 15, 2004

DERWENT-ACC-NO: 2004-579164

DERWENT-WEEK: 200456

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Sensor for monitoring vehicles on roadway, includes antenna for transmitting/receiving modulated signal and reflections of modulated signal to/from vehicle

INVENTOR: ARNOLD, D V; DOUGALL, J B ; HARRIS, L ; JENSEN, M ; KARLINSEY, T W ; SMITH, R ; WAITE, J L

PRIORITY-DATA: 2001US-0964668 (September 27, 2001), 2003US-0744686 (December 23, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20040135703 A1	July 15, 2004		019	G08G001/01

INT-CL (IPC): G08 G 1/01

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Drawn Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------

☐ 2. Document ID: DE 10261223 A1, WO 2004056873 A1

L2: Entry 2 of 61

File: DWPI

Jul 8, 2004

DERWENT-ACC-NO: 2004-508406

DERWENT-WEEK: 200449

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New agent comprising two linked binding components, useful for treating and preventing immunological disorders, where the components are specific for natural killer cells and T lymphocytes

INVENTOR: BERTHOLD, F; JENSEN, M ; SEDLACEK, H

PRIORITY-DATA: 2002DE-1061223 (December 20, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 10261223 A1	July 8, 2004		008	A61K045/06
WO 2004056873 A1	July 8, 2004	G	000	C07K016/28

INT-CL (IPC): A61 K 38/17; A61 K 39/395; A61 K 45/06; A61 P 37/00; C07 K 14/11; C07 K 14/115; C07 K 14/705; C07 K 14/74 ; C07 K 16/28

ABSTRACTED-PUB-NO: DE 10261223A

BASIC-ABSTRACT:

NOVELTY - Active agent (I) comprising two molecular components (C1, C2) that bind to molecules (M1, M2), respectively, and are covalently linked together, are new. M1 is NCAM, KIR2DL/S, KIR3DL, CD94/CD159, CD57, CD85, CD16, NKp30, p44 or p46, NKG2D or CD244, and M2 is CD2, CD4, CD44, CD69 or T-cell receptor.

ACTIVITY - Immunostimulant; Cytostatic; Antiinflammatory; Antibacterial.

No biological data given.

MECHANISM OF ACTION - (I) stimulates the immune system, particularly by inhibiting function of natural killer (NK) cells by binding to them, especially to an inhibitory or activating receptor, adhesion molecule of cytokine/chemokine receptor. Particularly (I) binds to an activating receptor without causing activation, or causing inactivation. Alternatively, (I) induced formation of an antibody that inhibits NK function. Inhibition of NK results in a greater antigen-specific immune response.

USE - (I) are used for treatment or prevention of immunological diseases, especially tumors; conditions associated with defective or inadequate activation of T cells (e.g. the consequences of cancer therapy, chronic inflammation or infections); diseases that involve benign or malignant natural killer (NK) cell replication, and autoimmune diseases (e.g. myasthenia gravis) associated with excessive NK cell activation. (I) may also be used to inhibit NK cells in preparations of blood cells, leucocytes and lymphocytes.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 3. Document ID: US 6702138 B1, US 20040040962 A1

L2: Entry 3 of 61

File: DWPI

Mar 9, 2004

DERWENT-ACC-NO: 2004-213991

DERWENT-WEEK: 200420

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Valve assembly for beverage container e.g. coffee tumbler, mug, has gear assembly, arranged below valve member, attached to valve member and arrangeable between closed position and open position

INVENTOR: BIELECKI, A; FURLONG, B ; JENSEN, M ; NOWACK, T

PRIORITY-DATA: 2002US-0235992 (September 4, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 6702138 B1</u>	March 9, 2004		000	B65D051/18
<u>US 20040040962 A1</u>	March 4, 2004		012	A47G019/22

INT-CL (IPC): A47 G 19/22; B65 D 51/18

ABSTRACTED-PUB-NO: US20040040962A

BASIC-ABSTRACT:

NOVELTY - A gear assembly (220), arranged below an upwardly-biased valve member (240), is attached to the valve member and arrangeable between a closed position and an open position. The upwardly-biased valve member engages with a valve seat when the gear assembly is in closed position. The upwardly-biased valve member is arranged away from the valve seat when the gear assembly is in open position.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a beverage container.

USE - For opening or closing flow path in beverage container e.g. coffee tumbler, mug.

ADVANTAGE - Enables easy determination whether valve is opened or closed.

DESCRIPTION OF DRAWING(S) - The figure shows the exploded cross-sectional view of a beverage container.

Tumbler 110

Handle 120

Collar 122

Gear assembly 220

Upwardly-biased valve member 240

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 4. Document ID: DE 10233167 B3

L2: Entry 4 of 61

File: DWPI

Jan 15, 2004

DERWENT-ACC-NO: 2004-073082

DERWENT-WEEK: 200408

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Offshore wind-powered energy plant detects approaching ship for bringing horizontal rotor to a standstill and rotating gondola supporting rotor to opposite side of vertical mast secured to seabed

INVENTOR: JENSEN, M ; RICHERT, F

PRIORITY-DATA: 2002DE-1033167 (July 22, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 10233167 B3</u>	January 15, 2004		004	F03D007/00

INT-CL (IPC): F03 D 7/00; F03 D 11/04

ABSTRACTED-PUB-NO: DE 10233167B

BASIC-ABSTRACT:

NOVELTY - The energy plant uses a rotor with a horizontal axis supported by a gondola, mounted on a mast (10) for rotation about a vertical axis, with a foundation (14) securing the mast to the seabed (12). The approach of a ship (16) is detected for bringing the rotor to a standstill and rotating the gondola to the opposite side of the mast to the approaching ship. The foundation may be secured via suction feet (18) vented for movement of the entire structure of the energy plant to prevent

impact with a ship.

USE - The offshore energy plant is used for converting wind energy into electrical energy.

ADVANTAGE - Prevents danger to shipping approaching energy plant.

DESCRIPTION OF DRAWING(S) - The figure shows a schematic representation of an offshore wind-powered energy plant.

Mast 10

Seabed 12

Foundation 14

Ship 16

Suction feet for foundation 18

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 5. Document ID: US 20030215427 A1

L2: Entry 5 of 61

File: DWPI

Nov 20, 2003

DERWENT-ACC-NO: 2003-902016

DERWENT-WEEK: 200382

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New genetically engineered CE7-specific redirected immune cells expressing and bearing CE7-specific chimeric receptor on cell surface membrane, useful in cell immunotherapy for treating CE7+ malignancies, e.g. neuroblastoma

INVENTOR: JENSEN, M

PRIORITY-DATA: 2001US-282859P (April 11, 2001), 2002US-0120198 (April 11, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20030215427 A1</u>	November 20, 2003		045	A61K048/00

INT-CL (IPC): A61 K 48/00; C07 H 21/04; C12 N 5/08; C12 N 15/85

ABSTRACTED-PUB-NO: US20030215427A

BASIC-ABSTRACT:

NOVELTY - New genetically engineered CE7-specific redirected immune cells which express and bear on the cell surface membrane a CE7-specific chimeric receptor comprising at least one intracellular signaling domain, at least one transmembrane domain, and at least one extracellular domain comprising a CE7-specific receptor.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a CE7-specific chimeric T cell receptor comprising an intracellular signaling domain, a transmembrane domain, and an extracellular domain comprising a CET-specific receptor;

(2) a DNA construct encoding a CE7-specific chimeric T cell receptor;

(3) a plasmid expression vector containing a DNA construct in proper orientation for expression;

(4) a method of treating a CE7+ malignancy in a mammal;

(5) a method of making and expanding the CE7-specific redirected T cells; and

(6) a method of stably transfecting and redirecting T cells by electroporating T cells in the presence of naked DNA.

ACTIVITY - Cytostatic.

MECHANISM OF ACTION - Cell Immunotherapy.

USE - The genetically engineered CE7-specific redirected T cells are useful for treating CE7+ malignancies, e.g. neuroblastoma.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Summary	Claims	KWIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	----------	---------	--------	------	-----------

☐ 6. Document ID: DE 10319764 A1, DE 20210407 U1

L2: Entry 6 of 61

File: DWPI

Jan 22, 2004

DERWENT-ACC-NO: 2003-879379

DERWENT-WEEK: 200415

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Vehicle for supplying offshore wind energy systems is pressure-tight underwater vehicle with device for pressure-tight coupling to entrance provided on wind energy system

INVENTOR: JENSEN, M

PRIORITY-DATA: 2002DE-2010407 (July 5, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 10319764 A1</u>	January 22, 2004		000	B63G008/00
<u>DE 20210407 U1</u>	November 13, 2003		008	B63G008/00

INT-CL (IPC): B63 G 8/00; F03 D 9/00; F03 D 11/00

ABSTRACTED-PUB-NO: DE 20210407U

BASIC-ABSTRACT:

NOVELTY - The vehicle (10) is in the form of a pressure-tight underwater vehicle and is provided with a device for pressure-tight coupling to an entrance (14) provided on the wind energy system (12). The vehicle can be in the form of a submarine with immersion cells. The vehicle can travel on the sea bed. It can be a half-track vehicle or a full-track vehicle and is provided with an emergency exit.

DETAILED DESCRIPTION - AN INDEPENDENT CLAIM is also included for the following:

(a) an offshore wind energy system with a coupling to an inventive vehicle.

USE - For supplying offshore wind energy systems.

ADVANTAGE - Enables offshore wind energy systems to carry out servicing work even in

bad weather, high sea states and similar.

DESCRIPTION OF DRAWING(S) - The drawing shows a schematic representation of a foundation part of a wind energy system and an inventive vehicle

vehicle 10

entrance 14

wind energy system 12

Full	Title	Citation	Front	Review	Classification	Date	Reference		Abstract	Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	----------	--------	------	----------

☐ 7. Document ID: SE 520652 C2, SE 200103330 A

L2: Entry 7 of 61

File: DWPI

Aug 5, 2003

DERWENT-ACC-NO: 2004-569177

DERWENT-WEEK: 200455

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Installation arrangement for helical antenna, e.g. in mobile phone, has holder made of electrically insulating and non-magnetic material

INVENTOR: JENSEN, M ; SPIROPOULOS, V

PRIORITY-DATA: 2001SE-0003330 (October 4, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>SE 520652 C2</u>	August 5, 2003		000	H01Q001/24
<u>SE 200103330 A</u>	April 5, 2003		001	H01Q001/24

INT-CL (IPC): H01 Q 1/24

ABSTRACTED-PUB-NO: SE 200103330A

BASIC-ABSTRACT:

NOVELTY - The holder has an engagement component (6) for fixing the position of the helix and fixtures (9) for attachment to a circuit board or an apparatus casing. The engagement component comprises somewhat elastic material and limits an undercut accommodation space (7) dimensioned to accommodate the helix at least partly. The helix can snap-engage into the accommodation space.

USE - For mounting a helical antenna, especially on the circuit board of a mobile phone.

ADVANTAGE - The holder provides reliable fixing of the antenna and allows easy replacement.

DESCRIPTION OF DRAWING(S) - The figure displays perspectively and separately the helical antenna and the holder.

antenna 4

engagement component 6

accommodation space 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 8. Document ID: WO 2003030297 A1

L2: Entry 8 of 61

File: DWPI

Apr 10, 2003

DERWENT-ACC-NO: 2003-313926

DERWENT-WEEK: 200330

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Wireless device e.g. cellular mobile telephone with antenna enclosed in preformed insulating carrier which can be snap connected to circuit card of telephone

INVENTOR: JENSEN, M ; SPIROPOULOS, V

PRIORITY-DATA: 2001SE-0003331 (October 4, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 2003030297 A1</u>	April 10, 2003	E	014	H01Q001/24

INT-CL (IPC): H01 Q 1/24; H04 M 1/02

ABSTRACTED-PUB-NO: WO2003030297A

BASIC-ABSTRACT:

NOVELTY - Includes a circuit card, an antenna (12) and a number of additional components (8-11, 13) e.g. a vibrator, a loudspeaker, an audio plug socket, a camera, a screen box, etc. A carrier device (2) made from an electrically insulating and non-magnetic material is fixed by snap connections to the circuit card. The antenna and some of the additional components are positioned on or in the carrier device.

USE - As e.g. cellular mobile telephone.

ADVANTAGE - Enables manufacturer of antenna to have increased control over the environment in which the antenna is to operate.

DESCRIPTION OF DRAWING(S) - The drawing shows an exploded perspective diagram of the device.

Carrier device 2

Additional components 8-11, 13

Antenna 12

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 9. Document ID: US 20030058133 A1, WO 2003027986 A1, US 6693557 B2, EP 1438702 A1

L2: Entry 9 of 61

File: DWPI

Mar 27, 2003

DERWENT-ACC-NO: 2003-512396

DERWENT-WEEK: 200456

file://C:\TEMP\2HYNRDXQ.htm

10/5/04

TITLE: Vehicular traffic monitoring sensor, comprises signal processing and multi-layer radio frequency circuit boards oriented parallel to each other, with multi-layer board comprising planar antenna

INVENTOR: ARNOLD, D V; DOUGALL, J B ; HARRIS, L ; JENSEN, M ; KARLINSEY, T W ; SMITH, R ; WAITE, J L ; HARRIS, L C ; JENSEN, M A ; SMITH, R L

PRIORITY-DATA: 2001US-0964668 (September 27, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20030058133 A1	March 27, 2003		020	G08G001/01
WO 2003027986 A1	April 3, 2003	E	000	G08G001/01
US 6693557 B2	February 17, 2004		000	G08G001/01
EP 1438702 A1	July 21, 2004	E	000	G08G001/01

INT-CL (IPC): G08 G 1/01; H01 Q 1/42

ABSTRACTED-PUB-NO: US20030058133A

BASIC-ABSTRACT:

NOVELTY - The sensor (500) comprises signal processing circuit board oriented parallel to multi-layer frequency (RF) circuit board having RF components and planar antenna on either sides. The planar antenna transmits and receives radiating signal to and from vehicular target. Signal processing circuit board includes signal processing components and electrically conductive ground layer on either sides.

USE - Used for detecting the presence, location, speed, direction of travel, volume, and occupancy of vehicular traffic on roadway.

ADVANTAGE - The sensor employs a planar design and hence has a reduced profile. Sensor provides controlled manufacturing processes for forming controlled interconnects and structures on replicable circuit boards.

DESCRIPTION OF DRAWING(S) - The drawing shows an integrated above-ground traffic sensor.

Sensor 500

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 10. Document ID: US 20030028269 A1

L2: Entry 10 of 61

File: DWPI

Feb 6, 2003

DERWENT-ACC-NO: 2003-456362

DERWENT-WEEK: 200343

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Industrial plant asset management system, creates template from assets displayed in graphical user interface, where template is exported to another management system for subsequently configuring other management system

INVENTOR: ANDERSON, M; CEGLIA, K ; FROGGET, D ; HAYASHIDA, B ; JENSEN, M ; PEDEN, M ; RICHETTA, P ; ROBY, S ; SEYMOUR, D ; SPRIGGS, B

PRIORITY-DATA: 2002US-0196007 (July 15, 2002), 2000US-0515529 (February 29, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20030028269 A1	February 6, 2003		051	G05B015/00

INT-CL (IPC): G05 B 15/00

ABSTRACTED-PUB-NO: US20030028269A

BASIC-ABSTRACT:

NOVELTY - The system has a selection device for navigating and making selection from the graphical user interface (102) which hierarchically displays the assets on a window of display device. A template is created from the displayed assets by using the configurations corresponding to the assets. The created template is exported to another management system, for subsequently configuring the other management system.

USE - For managing protecting industrial plant assets including multifarious grouping of machinery and processes, by using a unified display environment and common database structure.

ADVANTAGE - Provides a unique system that integrates a host of condition-monitoring devices, technologies into a single system that address all machinery types and modes of data acquisition with a unique display application and common open database. Reduces installation, integration capital and maintenance costs. As number of computers and operating systems required are reduced. Also eliminates need for configuration of save device or point in the multiple applications, thereby proving quick, easy, less cost system configuration. The system also has extensive external communication capabilities and provides access to information such as drawings, records, reports.

DESCRIPTION OF DRAWING(S) - The figure shows the industrial plant asset management system with unified graphical interface common database structure.

graphical user interface 102

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 11. Document ID: AU 2002345802 A1, WO 2002103037 A1, US 20030003523 A1

L2: Entry 11 of 61

File: DWPI

Jan 2, 2003

DERWENT-ACC-NO: 2003-210101

DERWENT-WEEK: 200452

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Detecting a detected substance, by using amplifying oxidative chemistry for depositing conductive transition metal layer on bound conductive aggregates in the path between conductors and monitoring current flow

INVENTOR: JENSEN, M

PRIORITY-DATA: 2001US-299278P (June 19, 2001), 2002US-0174869 (June 18, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 2002345802 A1	January 2, 2003		000	C12Q001/28
WO 2002103037 A1	December 27, 2002	E	017	C12Q001/28

INT-CL (IPC): C12 M 1/34; C12 Q 1/26; C12 Q 1/28; C12 Q 1/68; C25 D 3/46; G01 N 27/04

ABSTRACTED-PUB-NO: WO2002103037A

BASIC-ABSTRACT:

NOVELTY - Detecting (M) a detected substance in sample, comprising providing aggregates of complex having detected substance, capture substance and oxidative enzyme linked to complexes on a base along a path defined by pair of electrical conductors, exposing aggregates to substrate and transition metal ions to form metal layer on aggregates, and monitoring current flow of an electric circuit that includes the path, is new/

DETAILED DESCRIPTION - Detecting (M) a detected substance in sample, comprising:

(a) providing, in a path between spaced-apart electrical conductors on a substantially non-conductive base, aggregates of a complex between the detected substance, a capture substance specifically bound to it and an oxidative enzyme;

(b) exposing the aggregates in the path to substrate capable of being oxidized by the oxidative enzyme and to transition metal ions so that the substrate is oxidized and the metal ions are reduced to zero-valence metal atoms that precipitate on the aggregates to form a transition metal layer; and

(c) measuring electrical resistance of an electrical circuit comprising the conductors, the transition metal layer and an electrical energy source, where a change in resistance relative to a control lacking the detected substance indicates the detected substance in the sample.

USE - (M) is useful for detecting a detected substance e.g. nucleic acid or a polypeptide in a sample (claimed).

ADVANTAGE - (M) is more sensitive than conventional methods, because (M) exponentially amplifies each complex formed on the path between the capture substance and the detected substance into a large number of deposited transition metal atoms that can be quantified. (M) is quantitative because the conductivity (and thickness) of the transition metal layer formed is directly proportional to the amount of oxidative enzyme in the aggregates and, therefore to the amount of the detected substance in the sample. (M) is more cost effective than the colloidal gold conjugates, because the oxidative enzymes such as horseradish peroxidase (HRP) are less expensive than colloidal gold.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	WORD	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 12. Document ID: AU 2002256390 A1, WO 200288334 A1, US 20030171546 A1, EP 1392818 A1

L2: Entry 12 of 61

File: DWPI

Nov 11, 2002

DERWENT-ACC-NO: 2003-167116

DERWENT-WEEK: 200433

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New zetakine chimeric immunoreceptors, useful for treating human brain tumors or other cancers, particularly via the autocrine/paracrine cytokine systems utilized by human malignancy

INVENTOR: JENSEN, M

file://C:\TEMP\2HYNRDXQ.htm

10/5/04

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2002256390 A1</u>	November 11, 2002		000	C12N005/06
<u>WO 200288334 A1</u>	November 7, 2002	E	058	C12N005/06
<u>US 20030171546 A1</u>	September 11, 2003		000	C07K014/705
<u>EP 1392818 A1</u>	March 3, 2004	E	000	C12N005/06

INT-CL (IPC): A01 N 65/00; C07 H 21/04; C07 K 14/52; C07 K 14/705; C12 N 5/00; C12 N 5/06; C12 N 5/08; C12 N 15/00; C12 P 21/02

ABSTRACTED-PUB-NO: WO 200288334A

BASIC-ABSTRACT:

NOVELTY - A new chimeric immunoreceptor, termed zetakine, comprises the following linked elements:

- (a) an extracellular domain comprising a soluble receptor ligand;
- (b) a support region capable of tethering the extracellular domain to a cell surface;
- (c) a transmembrane region; and
- (d) an intracellular signaling domain.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method for treating human cancer by administering to a human suffering from cancer several cells expressing the chimeric immunoreceptor cited above, where the soluble receptor ligand of the immunoreceptor is specific for a cancer-specific cell surface receptor.

ACTIVITY - Cytostatic.

Test details are described but no results given.

MECHANISM OF ACTION - Cytokine Agonist.

USE - The zetakine chimeric immunoreceptors are useful for treating human brain tumors or other cancers, particularly via the autocrine/paracrine cytokine systems utilized by human malignancy.

ADVANTAGE - The soluble receptor ligands of the zetakine chimeric immunoreceptors are more likely to be stable in the extracellular environment, non-antigenic, and more selective, as compared to the antibody fragments or cell adhesion molecules of prior art.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	K00C	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 13. Document ID: US 20020062146 A1

L2: Entry 13 of 61

File: DWPI

May 23, 2002

DERWENT-ACC-NO: 2002-616998

DERWENT-WEEK: 200458

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Transmyocardial coronary revascularization for treating myocardial ischemia, involves creating transmyocardial blood flow passageway between chamber of heart and

coronary vein

INVENTOR: FLAHERTY, J C; JENSEN, M; LAMSON, T C; MACHOLD, T R; MAKOWER, J; TUMAS, M W; WHITT, J B

PRIORITY-DATA: 1998US-0059531 (April 13, 1998), 1996US-0730327 (October 11, 1996), 1996US-0730496 (October 11, 1996), 1997US-0837295 (April 11, 1997), 2000US-0710332 (November 9, 2000), 2001US-0994222 (November 26, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020062146 A1	May 23, 2002		038	A61F002/06

INT-CL (IPC): A61 F 2/06; A61 F 2/24; A61 F 9/00

ABSTRACTED-PUB-NO: US20020062146A

BASIC-ABSTRACT:

NOVELTY - A transmyocardial coronary revascularization (TMCR) is performed by creating a transmyocardial blood flow passageway (10) between a chamber of the heart and a coronary vein.

DETAILED DESCRIPTION - A transmyocardial direct coronary revascularization (TMDCR) is performed by creating a transmyocardial blood flow passageway between a chamber of the heart and a coronary vein, permitting blood to flow from hard chamber into the coronary blood vessel. The transmyocardial passageway remains devoid of any stent positioned in the place.

INDEPENDENT CLAIMS are included for the following:

- (1) an intraluminal and intracardiac valving apparatus;
- (2) a system comprising two of the valving apparatus;
- (3) a protrusive stent apparatus;
- (4) a method for performing an intraluminal medical procedure within the lumen of an obstructed coronary artery.

USE - For revascularization of coronary artery for treating myocardial ischemia (claimed).

ADVANTAGE - The method enables to perform transmyocardial direct coronary revascularization without any need of stenting of transmyocardial passageway and/or implantation of valving apparatus. The method also enables the user to perform revascularization in patients suffering from total coronary artery occlusions, without the need for advancing a catheter through the occlusions. The method does not require precise measurement or cutting-to-length of valving apparatus.

DESCRIPTION OF DRAWING(S) - The figure shows partial cut-away sectional view of human heart having transmyocardial passageway created between left ventricle and coronary vein.

Fluid passageway 10

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 14. Document ID: AU 2002256962 A1, SE 200102113 A, SE 517273 C2, WO 2002101402 A1, TW 508710 A

DERWENT-ACC-NO: 2002-711375
DERWENT-WEEK: 200452
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Laser chips evaluation by bringing to a measurement position consists of T.V. imaging and near infra red viewing for image and signal analysis

INVENTOR: JENSEN, M; WEST, R

PRIORITY-DATA: 2001SE-0002113 (June 12, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2002256962 A1</u>	December 23, 2002		000	G01R031/26
<u>SE 200102113 A</u>	May 21, 2002		008	H01S005/026
<u>SE 517273 C2</u>	May 21, 2002		000	H01S005/026
<u>WO 2002101402 A1</u>	December 19, 2002	E	000	G01R031/26
<u>TW 508710 A</u>	November 1, 2002		000	H01L021/66

INT-CL (IPC): G01 R 31/26; H01 L 21/66;

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 27 of 27 returned.

☐ 1. Document ID: WO 2004066802 A2

Using default format because multiple data bases are involved.

L18: Entry 1 of 27

File: DWPI

Aug 12, 2004

DERWENT-ACC-NO: 2004-580829

DERWENT-WEEK: 200456

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Capillary carrier for e.g. administration of medications to patients, has seals which are arranged at least near inlet portion and outlet portion of capillary tube and by which capillary tube is sealingly fixed to channel

INVENTOR: ARNDT, H; RASMUSSEN, P B

PRIORITY-DATA: 2003DK-0000111 (January 28, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 2004066802 A2</u>	August 12, 2004	E	010	A61B000/00

INT-CL (IPC): A61 B 0/00

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 2. Document ID: AU 2003208314 A1, WO 2003075951 A2

L18: Entry 2 of 27

File: DWPI

Sep 22, 2003

DERWENT-ACC-NO: 2003-748335

DERWENT-WEEK: 200431

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Reducing pain or increasing the threshold for nociception in an individual comprises administering an agent capable of inducing an active immune response that targets the individual's autologous tumor necrosis factor alpha

INVENTOR: EBERT, B; PEDERSEN, H R ; PEDERSEN, L H ; RASMUSSEN, P B

PRIORITY-DATA: 2002US-363128P (March 11, 2002), 2002DK-0000368 (March 11, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2003208314 A1</u>	September 22, 2003		000	A61K039/00
<u>WO 2003075951 A2</u>	September 18, 2003	E	120	A61K039/00

INT-CL (IPC): A61 K 39/00

ABSTRACTED-PUB-NO: WO2003075951A
BASIC-ABSTRACT:

NOVELTY - Reducing pain or increasing the threshold for nociception in an individual comprising administering an agent capable of inducing an active immune response that targets the individual's autologous tumor necrosis factor alpha (TNF alpha), is new.

ACTIVITY - Analgesic.

No biological data given.

MECHANISM OF ACTION - Vaccine against autologous tumor necrosis factor alpha (TNF alpha).

USE - The method is useful in reducing pain or increasing the threshold for nociception in an individual. The method is especially intended for reducing neuropathic pain (all claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 3. Document ID: DK 200200385 A

L18: Entry 3 of 27

File: DWPI

Sep 13, 2003

DERWENT-ACC-NO: 2003-805785

DERWENT-WEEK: 200376

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Wind-driven decoy system rotates around vertical shaft mounted rotatably on frame inserted into ground - NoAbstract

INVENTOR: RASMUSSEN, P B

PRIORITY-DATA: 2002DK-0000385 (March 12, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DK 200200385 A</u>	September 13, 2003		001	A01M031/06

INT-CL (IPC): A01 M 31/06

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 4. Document ID: AU 2003206678 A1, WO 2003068295 A1

L18: Entry 4 of 27

File: DWPI

Sep 4, 2003

DERWENT-ACC-NO: 2003-679581

DERWENT-WEEK: 200428

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Infusion system for infusion of medication to patient comprises wet part having medication and infusion mechanism, control part, and personal digital device having mechanism for radio communication with control part and infusion device

INVENTOR: ARNDT, H; RASMUSSEN, P B

PRIORITY-DATA: 2002DK-0000241 (February 18, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2003206678 A1</u>	September 4, 2003		000	A61M005/14
<u>WO 2003068295 A1</u>	August 21, 2003	E	016	A61M005/14

INT-CL (IPC): A61 M 5/14; G06 F 17/00; G06 F 17/000

ABSTRACTED-PUB-NO: WO2003068295A

BASIC-ABSTRACT:

NOVELTY - An infusion system comprises wet part having medication infusion mechanism; control part actuator, electronic control logic, and radio communication mechanism (25, 26); and personal digital device (3) having radio communication with control part and infusion device (2). The wet and control parts form infusion device, carried by a person (1) with infusion mechanism implanted.

USE - For infusion of medication to patient (claimed).

ADVANTAGE - The invention enables the person to interfere with the rate of infusion of medication the infusion device discharge, thus it is possible for the patient to give a bolus rate of infusion without anyone noticing that the person suffers from sickness. It is possible to record information's about the status of the system, unfused rate of medication, and to document the results. The patient is able to control the rate of infusion any time and any place, without the need for additional equipment.

DESCRIPTION OF DRAWING(S) - The figure is a system for infusion of medication to a person, based on radio communication between the elements of the system.

Person 1

Infusion device 2

Personal digital device 3

Radio communication mechanism 25, 26

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 5. Document ID: AU 2003208305 A1, WO 2003068294 A2

L18: Entry 5 of 27

File: DWPI

Sep 4, 2003

DERWENT-ACC-NO: 2003-679580

DERWENT-WEEK: 200428

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Device used for administering medication in fluid form comprises outlet, compartment for storage of fluid, two individual communications having flow restricting mechanism and holding mechanism, and valve

INVENTOR: DIRAC, H; GRAVESEN, P ; RASMUSSEN, P B

PRIORITY-DATA: 2002DK-0000970 (June 25, 2002), 2002DK-0000240 (February 18, 2002)

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.19&ref=18&dbname=PGPB,USPT,U...> 10/5/04

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 2003208305 A1	September 4, 2003		000	A61M005/00
WO 2003068294 A2	August 21, 2003	E	027	A61M005/00

INT-CL (IPC): A61 M 5/00

ABSTRACTED-PUB-NO: WO2003068294A
BASIC-ABSTRACT:

NOVELTY - Device comprises an outlet (3), a compartment (1) for storage of fluid, two individual communications in fluid communication with the compartment and outlet and a valve downstream of the compartment and upstream at at least one flow restricting mechanism. The communication has a flow restricting mechanism, and holding device intermediate the compartment and valve.

USE - Used for administering medication in fluid form (claimed), e.g. infusion of insulin to a diabetic patient.

ADVANTAGE - The device is unable to harm a patient during a fault situation, and monitors flow of the medication.

DESCRIPTION OF DRAWING(S) - The drawing shows a medication container separate from the infusion control system.

Compartment 1

Elastomer pressure jacket 2

Outlet 3

Container 28

First position 29

Second position 30

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	KWC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	-----	------------

☐ 6. Document ID: AU 2002358467 A1, WO 2003055916 A2, US 20030176328 A1

L18: Entry 6 of 27

File: DWPI

Jul 15, 2003

DERWENT-ACC-NO: 2003-598262

DERWENT-WEEK: 200421

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New conjugate comprising an adiponectin polypeptide and a first non-polypeptide moiety, useful for preparing a composition for treating a mammal having e.g., diabetes, atherosclerosis or cardiovascular disease

INVENTOR: ANDERSEN, K V; BOGSNES, A ; HALKIER, T ; PEDERSEN, A H ; RASMUSSEN, P B ; SCHAMBYE, H T

PRIORITY-DATA: 2002US-412169P (September 20, 2002), 2001DK-0001952 (December 21, 2001), 2001US-343482P (December 21, 2001), 2002DK-0000627 (April 25, 2002), 2002US-375492P (April 25, 2002), 2002DK-0001036 (July 3, 2002), 2002US-394117P (July 3, 2002), 2002DK-0001385 (September 20, 2002), 2002US-0325717 (December 20, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 2002358467 A1	July 15, 2003		000	C07K017/00
WO 2003055916 A2	July 10, 2003	E	184	C07K017/00
US 20030176328 A1	September 18, 2003		000	A61K038/17

INT-CL (IPC): A61 K 38/17; C07 H 21/04; C07 K 14/47; C07 K 17/00

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 7. Document ID: BR 200212047 A, WO 2003015812 A2, US 20030157117 A1, EP 1420815 A2, AU 2002325199 A1

L18: Entry 7 of 27

File: DWPI

Aug 17, 2004

DERWENT-ACC-NO: 2003-312718

DERWENT-WEEK: 200457

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Novel analog of amyloid precursor protein or beta amyloid for treating Alzheimer's disease, has amyloid precursor protein/beta amyloid incorporating B-cell epitope of amyloid protein and foreign T-helper epitope

INVENTOR: DAL DEGAN, F; JENSEN, M R ; KOEFOED, P ; NIELSEN, K G ; RASMUSSEN, P B ; DEGAN, F D

PRIORITY-DATA: 2002US-373027P (April 16, 2002), 2001DK-0001231 (August 20, 2001), 2001US-337543P (October 22, 2001), 2002DK-0000558 (April 16, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
BR 200212047 A	August 17, 2004		000	A61K039/00
WO 2003015812 A2	February 27, 2003	E	122	A61K039/00
US 20030157117 A1	August 21, 2003		000	A61K039/00
EP 1420815 A2	May 26, 2004	E	000	A61K039/00
AU 2002325199 A1	March 3, 2003		000	A61K039/00

INT-CL (IPC): A61 K 39/00; A61 K 39/385; A61 P 25/28; C07 K 14/47; C12 N 9/64

ABSTRACTED-PUB-NO: WO2003015812A

BASIC-ABSTRACT:

NOVELTY - An analog (I) of amyloid precursor protein (APP) or beta amyloid (A beta) which is derived from an animal APP or A beta , comprising APP or A beta incorporating at least one B-cell epitope of APP and/or A beta and at least one foreign T-helper epitope (TH epitope) so that immunization of the animal with the analog induces production of antibodies against the animal's autologous APP or A beta , is new.

DETAILED DESCRIPTION - An analog of amyloid precursor protein (APP) or beta amyloid (A beta) which is derived from an animal APP or A beta , comprises APP or A beta incorporating at least one B-cell epitope of APP and/or A beta and at least one foreign T-helper epitope (TH epitope) so that immunization of the animal with the analog induces production of antibodies against the animal's autologous APP or A beta , where the analog is:

(a) a polyamino acid that consists of at least one copy of a subsequence of residues 672-714 in a 770 amino acid sequence (S1), given in the specification, where the foreign T-helper epitope (TH epitope) is incorporated by amino acid addition and/or insertion and/or deletion and/or substitution, where the subsequence is selected from residues 1-42, 1-40, 1-39, 1-35, 1-34, 1-28, 1-12, 1-5, 13-28, 13-35, 17-28, 25-35, 35-40, 36-42, and 35-42 of the amino acid sequence consisting of amino acid residues 673-714 of (S1);

(b) a polyamino acid that contains the foreign TH epitopes and a disrupted APP or A beta sequence so that the analog does not include any subsequence of (S1) that binds productively to major histocompatibility complex (MHC) class II molecules initiating a T-cell response;

(c) a polyamino acid that comprises the foreign TH epitope and APP or A beta derived amino acids, and comprises one single methionine residue located in the C-terminus of the analog, where other methionine residues in APP or A beta and in the foreign TH epitope have been substituted or deleted, and preferably have been substituted by leucine or isoleucine;

(d) a conjugate comprising a polyhydroxypolymer backbone to which is separately coupled a polyamino acid as defined in (a), (b) and/or (c); and/or

(e) a conjugate comprising a polyhydroxypolymer backbone to which is separately coupled the foreign TH epitope and a polyamino acid selected from the subsequence as defined in (a), a disrupted sequence of APP or A beta as defined in (b), and an APP or A beta derived amino acid sequence that comprises one single methionine residue located in the C-terminus, where other methionine residues in APP or A beta and in the foreign TH epitope have been substituted or deleted, and preferably have been substituted by leucine or isoleucine.

INDEPENDENT CLAIMS are also included for:

(1) an immunogenic composition (C) comprising (I) and a carrier and/or vehicle and optionally an adjuvant;

(2) a nucleic acid fragment (II) which encodes (I);

(3) a vector (III) carrying (II), and is capable of autonomous replication;

(4) a transformed cell carrying (III), and is capable of replicating (II);

(5) a composition for inducing production of antibodies against amyloid, comprises (II) or (III), and a carrier, vehicle or adjuvant; and

(6) a stable cell line which carries (III) and expresses (II), and optionally secretes or carries (I) on its surface.

ACTIVITY - Nootropic; Neuroprotective.

MECHANISM OF ACTION - Vaccine (claimed).

Mice transgenic for human APP (Alzheimer's precursor protein), called TgRND8+, expressed a mutated form of APP that results in high concentration of A beta -40 and A beta -42 in the mouse brains. The mice (8-10 mice/group) were immunized with either A beta -42 or hAβ43+-34 variant, four times at two-week intervals. Doses were either 100 mg for A beta or 50 mg for hAβ43+-34. Mice were bled at day 43 (after three injections) and after day 52 (after four injections) and the sera were used to determine the level of anti-A beta -42 specific titers using a direct A beta -42 enzyme linked immunosorbent assay (ELISA). The antibody titers obtained when immunizing with hAβ43+-34 A beta variant were 4 times and 7.5 times higher after 3 and 4 immunizations, respectively, than the titers obtained when using the unaltered wild-type A beta -42 as an immunogen. The amount of variant used for immunization was only 50 % of the amount of wild-type sequence used for immunization.

USE - (I) is useful for in vivo down-regulation of APP or A beta in an animal, including a human being, and for treating and/or preventing and/or ameliorating Alzheimer's disease or other diseases and conditions characterized by amyloid deposits (claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 8. Document ID: ZA 200303964 A, WO 200274806 A2, US 20030170206 A1, NO 200303781 A, EP 1366075 A2, CZ 200302526 A3, US 20040013644 A1, HU 200303251 A2, SK 200301188 A3, BR 200207576 A, AU 2002235727 A1

L18: Entry 8 of 27

File: DWPI

Apr 28, 2004

DERWENT-ACC-NO: 2002-750536

DERWENT-WEEK: 200432

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New glycosylated variant of interferon-beta polypeptide, useful for treating multiple sclerosis, cancer or viral infections, comprises an increased glycosylation activity compared to the parent polypeptide

INVENTOR: DRUSTRUP, J; PEDERSEN, A H ; RASMUSSEN, G ; RASMUSSEN, P B ; DURSTRUP, J ; ANDERSEN, K V ; BORNAES, C ; SCHAMBYE, H T

PRIORITY-DATA: 2002DK-0000257 (February 19, 2002), 2001DK-0000323 (February 27, 2001), 2001DK-0000333 (March 1, 2001), 2001DK-0001040 (June 29, 2001), 2001DK-0001277 (August 30, 2001), 2001DK-0001954 (December 21, 2001), 1999DK-0001197 (August 27, 1999), 1999DK-0001691 (November 26, 1999), 2000DK-0000194 (February 7, 2000), 2000DK-0000363 (March 7, 2000), 2000DK-0000642 (April 14, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
ZA 200303964 A	April 28, 2004		107	C07K000/00
<u>WO 200274806 A2</u>	September 26, 2002	E	100	C07K014/565
<u>US 20030170206 A1</u>	September 11, 2003		000	A61K038/21
<u>NO 200303781 A</u>	August 26, 2003		000	C07K014/565
<u>EP 1366075 A2</u>	December 3, 2003	E	000	C07K014/565
<u>CZ 200302526 A3</u>	December 17, 2003		000	C07K014/565
<u>US 20040013644 A1</u>	January 22, 2004		000	A61K038/21
<u>HU 200303251 A2</u>	December 29, 2003		000	C07K014/565
<u>SK 200301188 A3</u>	March 2, 2004		000	C07K014/565
<u>BR 200207576 A</u>	April 27, 2004		000	C07K014/565
<u>AU 2002235727 A1</u>	October 3, 2002		000	C07K014/565

INT-CL (IPC): A61 K 38/21; A61 P 25/28; A61 P 31/12; A61 P 35/00; C07 K 0/00; C07 K 14/565; C07 K 17/00; C12 N 15/22

ABSTRACTED-PUB-NO: WO 200274806A

BASIC-ABSTRACT:

NOVELTY - A glycosylated variant of a parent interferon beta (IFNB) polypeptide comprising at least one in vivo glycosylation site, where an amino acid residue of the parent polypeptide located close to the glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) increasing in vivo glycosylation of the parent IFNB molecule, comprising:
 - (a) substituting an amino acid residue occupying a first position located closed to the in vivo glycosylation site of the parent IFNB molecule with a second amino acid residue to produce a variant IFNB molecule;
 - (b) measuring the degree of glycosylation of the variant relative to that of the parent IFNB molecule as obtained from expression in a glycosylating host cell under comparable conditions;
 - (c) repeating step (a) if necessary, to substitute the second amino acid residue with a third amino acid residue and/or to substitute an amino acid residue located in a second position close to the glycosylation site with a second amino acid residue, and repeating step (b) of either the parent molecule or the variant molecule resulting from step (a), where steps (a)-(c) being repeated until an increased in vivo glycosylation is obtained;
- (2) a nucleotide sequence encoding the variant;
- (3) an expression vector comprising the nucleotide sequence;
- (4) a glycosylating host cell comprising the nucleotide sequence or the expression vector;
- (5) producing a glycosylated IFNB molecule, comprising:
 - (a) cultivating a transformed glycosylating host cell under conditions conducive for producing a glycosylated molecule; and
 - (b) isolating the resulting glycosylated molecule;
- (6) preparing a conjugated variant, where the IFNB polypeptide variant is reacted with the molecule to which it is to be conjugated under conditions conducive for the conjugation to take place, and the conjugate is recovered;
- (7) a pharmaceutical composition comprising the conjugate and a diluent, carrier or adjuvant; and
- (8) treating a mammal with multiple sclerosis, comprising administering an amount of the conjugate or the composition cited above.

ACTIVITY - Neuroprotective; Cytostatic; Virucide. No biological data is given.

MECHANISM OF ACTION - Gene therapy.

USE - The variant, conjugate or composition, is useful in the treatment of, or in the manufacture of a treatment of diseases, in particular multiple sclerosis (claimed). The variant may also be used in treating cancer (e.g. breast or bladder cancer) or viral infections (e.g. herpes zoster, viral hepatitis).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 9. Document ID: AU 2002233166 A1, WO 200266056 A2, US 20020119162 A1, US 20020187157 A1, EP 1363664 A2

L18: Entry 9 of 27

File: DWPI

Sep 4, 2002

DERWENT-ACC-NO: 2002-706932

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.19&ref=18&dbname=PGPB,USPT,U...> 10/5/04

TITLE: Novel immunogen useful for immunizing an animal, has an activated polyhydroxypolymer backbone to which is attached an antigenic determinant including a B cell epitope and another determinant including a T-helper epitope

INVENTOR: KOEFOED, P; NIELSEN, K G ; JENSEN, M R ; RASMUSSEN, P B

PRIORITY-DATA: 2001US-337543P (October 22, 2001), 2001WO-DK00113 (February 19, 2001), 2001US-0785215 (February 20, 2001), 2001DK-0001231 (August 20, 2001), 2000DK-0000265 (February 21, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2002233166 A1</u>	September 4, 2002		000	A61K039/385
<u>WO 200266056 A2</u>	August 29, 2002	E	052	A61K039/385
<u>US 20020119162 A1</u>	August 29, 2002		000	A61K039/00
<u>US 20020187157 A1</u>	December 12, 2002		000	A61K039/00
<u>EP 1363664 A2</u>	November 26, 2003	E	000	A61K039/385

INT-CL (IPC): A61 K 38/19; A61 K 38/20; A61 K 39/00; A61 K 39/385; A61 K 47/48

ABSTRACTED-PUB-NO: WO 200266056A
BASIC-ABSTRACT:

NOVELTY - An immunogen (I) comprising at least one first antigenic determinant that includes at least one B-cell epitope and/or at least one cytotoxic T lymphocyte (CTL) epitope, and at least one second antigenic determinant that includes a T helper cell epitope (TH epitope), where each of the first and second antigenic determinants are coupled to an activated polyhydroxypolymer carrier, is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for an immunogenic composition (II) for raising an immune response against an antigen in a mammal, including a human, comprising (I), and optionally an adjuvant.

ACTIVITY - None given.

MECHANISM OF ACTION - Vaccine.

Test details are described, but no results are given.

USE - (I) or (II) contained in a virtual lymph node (VLN) device is useful for immunizing an animal, including a human, against an antigen of choice, where the antigen shares the at least one first antigenic determinant with the immuogen (claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	----------

☐ 10. Document ID: WO 200250313 A2, AU 200221587 A

L18: Entry 10 of 27

File: DWPI

Jun 27, 2002

DERWENT-ACC-NO: 2002-519890
DERWENT-WEEK: 200270
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Tanning of hides or skins e.g. cattle hides, involves utilizing tanning agents

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.19&ref=18&dbname=PGPB,USPT,U...> 10/5/04

and laccase derived from a specified genus

INVENTOR: RASMUSSEN, L; RASMUSSEN, P B; SORENSEN, N H

PRIORITY-DATA: 2001US-261937P (January 16, 2001), 2000DK-0001921 (December 21, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 200250313 A2</u>	June 27, 2002	E	012	C14C000/00
<u>AU 200221587 A</u>	July 1, 2002		000	C14C000/00

INT-CL (IPC): C14 C 0/00

ABSTRACTED-PUB-NO: WO 200250313A

BASIC-ABSTRACT:

NOVELTY - A hide or skin is tanned by using tanning agents in a tanning bath. The bath comprises a laccase derived from the genus Myceliophthora, and an aromatic compound (as tanning agent) and possibly other compounds which are able to react with the hides or skins and/or the aromatic compound. An oxidation agent is introduced into the equilibrated tanning bath.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a tanning bath comprising a tanning agent and a laccase derived from the genus Myceliophthora.

USE - For tanning hides and skins, e.g., cattle hides.

ADVANTAGE - It is possible to obtain at least some degree of fixation in comparison to the prior art methods, if the tanning is supported by a laccase derived from the genus Myceliophthora in the tanning bath, and if specific primary and secondary substrates for this enzymes are added sequentially. The use of toxic co-agents (like formaldehyde) used to crosslink organic tanning agents is avoided. The invention is environmentally friendly, as cheap synthetic tanning agents can be used instead of the conventionally used tanning agents produced by extraction of wood from tropic forests.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 11. Document ID: EP 1334128 A2, WO 200236628 A2, AU 200212107 A, US 20020169290 A1

L18: Entry 11 of 27

File: DWPI

Aug 13, 2003

DERWENT-ACC-NO: 2002-557420

DERWENT-WEEK: 200355

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Single chain multimeric interferon (IFN) beta polypeptide for treating e.g. viral infections, comprises two linked monomers, where one monomer is IFN beta monomer with an introduced glycosylation site

INVENTOR: ANDERSEN, K V; BORNAES, C ; PEDERSEN, A H ; RASMUSSEN, P B

PRIORITY-DATA: 2000DK-0001646 (November 2, 2000), 2001US-0004201 (November 1, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
--------	----------	----------	-------	----------

EP 1334128 A2	August 13, 2003	E	000	C07K014/565
WO 200236628 A2	May 10, 2002	E	093	C07K014/565
AU 200212107 A	May 15, 2002		000	C07K014/565
US 20020169290 A1	November 14, 2002		000	C07K014/565

INT-CL (IPC): A61 K 38/21; C07 K 14/565

ABSTRACTED-PUB-NO: WO 200236628A

BASIC-ABSTRACT:

NOVELTY - A single chain multimeric interferon beta polypeptide (I) comprising two monomers linked through a peptide bond or a peptide linker, where one of the monomers is an interferon beta monomer having an amino acid sequence that differs from that of wild-type human interferon beta in an introduced glycosylation site, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a conjugate (II) of (I) comprising:

(a) a multimeric polypeptide comprising two monomers linked via a peptide bond or a peptide linker, where one of the monomers is an interferon beta monomer comprising an amino acid sequence that differs from that of wild-type human interferon beta in an introduced glycosylation site; and

(b) a non-polypeptide group covalently attached to the multimeric polypeptide;

(2) a nucleotide sequence (III) encoding (I) or (II);

(3) an expression vector (IV) comprising (III);

(4) a host cell (V) comprising (III) or (IV); and

(5) preparing (II), where the multimeric polypeptide is reacted with the polymer molecule under conditions conducive for the conjugation to take place, and the conjugate is recovered; and

(6) a pharmaceutical composition (VI) comprising the multimeric polypeptide (I) or (II) and a diluent or carrier.

ACTIVITY - Virucide; Cytostatic; Antitumour; Antiinflammatory; Antiulcer; Neuroprotective; Hepatotrophic. No biological data is given.

MECHANISM OF ACTION - Gene therapy; Immune response modulator.

USE - (I), a conjugate (II) comprising (I) or a composition (VI) comprising (I) or (II) is useful for treating viral infections, cancers, tumors or tumor angiogenesis, Crohn's disease, ulcerative colitis, Guillain-Barre syndrome, glioma, idiopathic pulmonary fibrosis, abnormal cell growth, or immunomodulation in any suitable animal. (II) and (VI) are also useful for manufacturing a medicament for treating the conditions, or for immunomodulation in any suitable animal, preferably humans. (I), (II) or (VI) is also useful for treating multiple sclerosis, hepatitis or herpes infection. The medicament prepared using (II) or (VI) is also useful for treating multiple sclerosis, relapsing remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis, monosymptomatic multiple sclerosis, hepatitis, or a herpes infection. Most preferably, (II) or (VI) is useful for treating a mammal with multiple sclerosis e.g., benign multiple sclerosis, primary progressive multiple sclerosis, or any of the above mentioned conditions (e.g., viral infections, cancers, tumors or tumor angiogenesis, Crohn's disease, ulcerative colitis, etc.), where the mammal has circulating antibodies against interferon 1a or 1b (all claimed). Nucleic acid (III) encoding (I) is useful for gene therapy applications for treating the above mentioned conditions.

ADVANTAGE - (I) and a conjugate (II) comprising (I) have a number of improved properties as compared to human interferon beta , including increased functional in vivo half-life, increased serum half-life, reduced immunogenicity and/or increased bioavailability. Thus use of (I) or (II) provides longer duration between injections, fewer side effects, and/or increased efficiency due to reduction in antibodies.

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	RWC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	-----	------------

☐ 12. Document ID: MX 2002001969 A1, WO 200115736 A2, AU 200066870 A, BR 200013638 A, CZ 200200521 A3, NO 200200929 A, SK 200200294 A3, KR 2002034181 A, ZA 200200337 A, US 6531122 B1, EP 1328295 A2, JP 2003527090 W, US 20030175240 A1, US 20030175241 A1, US 20030170206 A1, HU 200302674 A2, US 20040013644 A1

L18: Entry 12 of 27

File: DWPI

Jul 1, 2003

DERWENT-ACC-NO: 2001-218488

DERWENT-WEEK: 200420

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: A conjugate exhibiting interferon beta activity useful for treating multiple sclerosis comprises a non-polypeptide group covalently attached to an interferon beta polypeptide

INVENTOR: ANDERSEN, K V; BORNAES, C ; PEDERSEN, A H ; RASMUSSEN, P B ; SCHAMBYE, H T ; BORNES, C ; ANDERSEN, K ; PEDERSEN, A ; SCHAMBYE, H ; DRUSTRUP, J ; RASMUSSEN, G ; BOMAES, C

PRIORITY-DATA: 2000DK-0000642 (April 14, 2000), 1999DK-0001197 (August 27, 1999), 1999US-160782P (October 21, 1999), 1999DK-0001691 (November 26, 1999), 2000DK-0000194 (February 7, 2000), 2000DK-0000363 (March 7, 2000), 2001DK-0000333 (March 1, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>MX 2002001969 A1</u>	July 1, 2003		000	A61K047/48
<u>WO 200115736 A2</u>	March 8, 2001	E	108	A61K047/48
<u>AU 200066870 A</u>	March 26, 2001		000	
<u>BR 200013638 A</u>	May 14, 2002		000	A61K047/48
<u>CZ 200200521 A3</u>	May 15, 2002		000	A61K047/48
<u>NO 200200929 A</u>	April 25, 2002		000	A61K000/00
<u>SK 200200294 A3</u>	August 6, 2002		000	A61K047/48
<u>KR 2002034181 A</u>	May 8, 2002		000	C07K014/565
<u>ZA 200200337 A</u>	December 24, 2002		152	A61K000/00
<u>US 6531122 B1</u>	March 11, 2003		000	A61K038/21
<u>EP 1328295 A2</u>	July 23, 2003	E	000	A61K047/48
<u>JP 2003527090 W</u>	September 16, 2003		152	C12N015/09
<u>US 20030175240 A1</u>	September 18, 2003		000	A61K038/21
<u>US 20030175241 A1</u>	September 18, 2003		000	A61K038/21
<u>US 20030170206 A1</u>	September 11, 2003		000	A61K038/21
<u>HU 200302674 A2</u>	November 28, 2003		000	A61K047/48
<u>US 20040013644 A1</u>	January 22, 2004		000	A61K038/21

, US 20030170206 A1 , HU 200302674 A2 , US 20040013644 A1 INT-CL (IPC): A61 K 0/00; A61 K 38/21; A61 K 47/48; A61 P 25/00; C07 K 14/565; C07 K 17/00; C07 K 17/02; C12 N 1/15; C12 N 1/19; C12 N 1/21; C12 N 5/10; C12 N 15/09

NOVELTY - A conjugate (I) exhibiting interferon beta activity comprises at least one first non-polypeptide group covalently attached to an interferon beta polypeptide, the amino acid sequence of which differs from wild-type human interferon beta in at least one introduced and at least one removed amino acid residue comprising an attachment group for the first non-polypeptide group.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a nucleotide sequence (II) encoding the interferon beta polypeptide part of (I);
- (2) an expression vector (III) comprising (II);
- (3) a host cell (IV) comprising (III);
- (4) reducing (M1) the immunogenicity and/or increasing functional in vivo half-life and/or serum half-life of an interferon beta polypeptide comprising introducing an amino acid residue constituting an attachment group for a first non-polypeptide group into a position exposed at the surface of the protein that does not contain such a group and removing an amino acid residue constituting an attachment group for a first non-polypeptide group and subjecting the modified peptide to conjugation with the non-polypeptide group;
- (5) preparing (M2) (I);
- (6) a pharmaceutical composition (V) comprising (I) and a carrier, diluent or adjuvant; and
- (7) a cell culture comprising (IV) and medium comprising the polypeptide produced by expression of the nucleotide sequence in the host cell, where the amount of polypeptide is at least 800 000 IU/ml of medium, preferably 800 000-3 500 000 IU/ml of medium.

ACTIVITY - Neuroprotective; antiviral; cytostatic; immunomodulatory; antiulcer; antiinflammatory.

No supporting biological data given.

MECHANISM OF ACTION - Gene therapy.

USE - (I) and (V) are useful in the treatment of disease, especially multiple sclerosis, and for treating mammals having circulating antibodies against interferon beta 1a or 1b (claimed). (II) may be used for gene therapy. (I) and (II) can also be used to treat viral infections, cancer, inflammation, Crohns disease and ulcerative colitis and for immunomodulation.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 13. Document ID: ZA 200109304 A, WO 200066627 A1, AU 200042861 A, EP 1179017 A1, NO 200105181 A, CN 1357007 A, KR 2002034073 A, NZ 515762 A, JP 2002542813 W

L18: Entry 13 of 27

File: DWPI

Jan 29, 2003

DERWENT-ACC-NO: 2001-015973
DERWENT-WEEK: 200314
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Producing mammalian heparin-binding proteins to mediate detachment and

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.19&ref=18&dbname=PGPB,USPT,U...> 10/5/04

contraction of endothelial cells and fibroblasts, involves introducing genes encoding heparin-binding proteins into mammalian cells and culturing

INVENTOR: BJORN, S; FLODGAARD, H J ; RASMUSSEN, P B ; SVENDSEN, I ; BJORN, S M G ; SVENDSEN, I T

PRIORITY-DATA: 1999DK-0000612 (May 6, 1999), 1999US-131574P (April 29, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>ZA 200109304 A</u>	January 29, 2003		050	C07K000/00
<u>WO 200066627 A1</u>	November 9, 2000	E	044	C07K014/47
<u>AU 200042861 A</u>	November 17, 2000		000	C07K014/47
<u>EP 1179017 A1</u>	February 13, 2002	E	000	C07K014/47
<u>NO 200105181 A</u>	December 20, 2001		000	C07K000/00
<u>CN 1357007 A</u>	July 3, 2002		000	C07K014/47
<u>KR 2002034073 A</u>	May 8, 2002		000	C07K014/47
<u>NZ 515762 A</u>	November 22, 2002		000	C07K014/47
<u>JP 2002542813 W</u>	December 17, 2002		051	C12N015/09

INT-CL (IPC): C07 K 0/00; C07 K 14/47; C12 N 5/10; C12 N 5/22; C12 N 5:22; C12 N 15/09; C12 P 21/02

ABSTRACTED-PUB-NO: WO 200066627A

BASIC-ABSTRACT:

NOVELTY - Producing a mammalian heparin-binding protein (HBP) in a mammalian cell that can be cultured under anaerobic conditions, comprises introducing a nucleic acid (I) encoding HBP into a mammalian cell, culturing the cell under conditions conducive to expression of HBP, and recovering HBP from the culture medium.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a mammalian host cell (II) that can be cultured under anaerobic condition, comprising (I).

USE - The method is useful for producing HBP in recombinant mammalian cells. HBP is used to mediate detachment and contraction of endothelial cells and fibroblasts when added to cells grown in monolayer cultures. HBP is also used to stimulate monocyte survival and thrombospondin secretion.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWMC	Draw. Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 14. Document ID: US 20040115211 A1, WO 200021983 A2, AU 9960784 A, EP 1117683 A2, US 20030165525 A1, AU 766093 B

L18: Entry 14 of 27

File: DWPI

Jun 17, 2004

DERWENT-ACC-NO: 2000-317931

DERWENT-WEEK: 200440

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Novel polypeptide of somatic protein extract useful as vaccine against virulent Mycobacterium infection, isolated from cell wall, cell membrane and cytosol

INVENTOR: ANDERSEN, P; FLORIO, W ; OKKELS, L M M ; ROSENKRANDS, I ; SKJOET, R L V ; VEGGERBY, C ; WELDINGH, K ; HANSEN, C V ; RASMUSSEN, P B ; SKJOT, R L V ; OETTINGER, T ; SKIOT, R

PRIORITY-DATA: 1999US-116673P (January 21, 1999), 1998DK-0001281 (October 8, 1998), 1997DK-0000376 (April 2, 1997), 1997DK-0001277 (November 10, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20040115211 A1</u>	June 17, 2004		000	A61K039/00
<u>WO 200021983 A2</u>	April 20, 2000	E	271	C07K014/00
<u>AU 9960784 A</u>	May 1, 2000		000	
<u>EP 1117683 A2</u>	July 25, 2001	E	000	C07K014/35
<u>US 20030165525 A1</u>	September 4, 2003		000	A61K039/02
<u>AU 766093 B</u>	October 9, 2003		000	C07K014/00

INT-CL (IPC): A61 K 39/00; A61 K 39/02; A61 K 39/04; A61 K 39/38; C07 K 14/00; C07 K 14/35; G01 N 33/569

ABSTRACTED-PUB-NO: WO 200021983A

BASIC-ABSTRACT:

NOVELTY - A pure polypeptide (PP) of somatic proteins extract (I) having at least 80% identity to a 297, 90, 115, 136, 146, 165, 164, 185, 216, 257, 297, 347, 495, 600, 105, 144, 146, 318, 466, 115, 187 or 388 residue amino acid sequence (S1), fully defined in the specification, or a subsequence of them, of at least 6 amino acids, is new.

DETAILED DESCRIPTION - (I) or their subsequence has at least one of the following properties:

(a) the PP induces an in vitro recall response, or an in vitro response, during primary infection with virulent Mycobacterium, determined by a release of interferon (IFN)- gamma of at least 1,500 pg/ml from reactivated memory T-lymphocytes withdrawn from a mouse within 4 days or 28 days, respectively, after the mouse has been rechallenged with 1 multiply 106 or 5 multiply 104 cells, respectively, of virulent Mycobacterium, the induction being performed by the addition of the PP to the suspension, comprising about 2 multiply 105 cells, isolated from the spleen of the mouse, the addition of PP resulting (a1) in a concentration not more than 20 mu g/ml suspension, the release of IFN- gamma is assessed (a2) by determining IFN- gamma in supernatant harvested 3 days after the addition of PP;

(b) PP induces a protective immunity, determined by vaccinating an animal with PP and an adjuvant, three times at two weeks intervals, starting at 6-8 weeks of age, 6 weeks after last vaccination challenging with 5 multiply 106 cells of virulent Mycobacterium/ml, by aerosol, and determining a significant decrease in the number of bacteria recoverable from the spleen compared to an animal given placebo treatment;

(c) PP induces an in vitro response, or in vitro recall response, determined by release of IFN- gamma of at least 1000 pg/ml or 500 pg/ml, respectively, from Peripheral Blood Mononuclear Cells (PBMC) withdrawn from TB patients, or PPD positive individuals, 6 months after diagnosis, the induction being performed by addition of PP to a suspension having 1-2.1 multiply 105 PBMC, the addition of PP resulting in (a1) and (a2) in supernatant harvested 5 days after the addition of PP to the suspension, and in the recall response this does not induce an IFN- gamma release in an individual not infected with, or who has cleared infection with, a virulent Mycobacterium;

(d) PP induces a specific antibody response in a TB patient, as determined by enzyme linked immunosorbent assay (ELISA) technique or a western blot, when the whole blood is diluted 1:20 in phosphate buffered saline (PBS), and stimulated with PP in a concentration not more than 20 mu g/ml; and

(e) PP induces a positive delayed type hypersensitivity (DTH) response, determined by intradermal injection of at most 100 mu g of the PP to an individual who is

clinically or subclinically infected with avirulent Mycobacterium, a positive response having a diameter of at least 10 mm 72 hours after the injection, and does not induce a positive response in an individual not infected or who has cleared infection.

INDEPENDENT CLAIMS are also included for the following:

- (1) a pure PP (II) which comprises (S1);
- (2) composition comprising:
 - (a) (I) or (II) and at least one other PP derived from virulent Mycobacterium; or
 - (b) a microorganism in which at least one copy of a DNA sequence encoding (I) or (II) has been incorporated into the genome;
- (3) a diagnostic reagent comprising (I) or (II) for diagnosing an infection with a virulent Mycobacterium, and optionally in a carrier, or vehicle;
- (4) an extract of PP obtainable by:
 - (a) killing a sample of virulent Mycobacterium and centrifuging the sample at 2000g for 40 minutes;
 - (b) resuspending the pellet in PBS and 0.5% Tween 20 and sonicating with 20 rounds of 90 seconds;
 - (c) centrifuging again at 5000g for 30 minutes;
 - (d) extracting soluble coatings with 10% SDS (sodium dodecyl sulfate);
 - (e) centrifuging again at 20000 g for 30 minutes; and
 - (f) precipitating the supernatant with an adjuvant;
- (5) screening for inhibition of the infectivity of a virulent Mycobacterium belonging to the tuberculosis complex, comprising inhibiting the expression of one or more of PP and observing the effect, if any, on the infectivity of the bacteria;
- (6) a method of using (I) with a significant effect on the infectivity of a virulent Mycobacterium, tested by the method of (5), for designing a prophylactic or therapeutic agent;
- (7) a nucleotide sequence (III) having a 273, 348, 411, 441, 498, 495, 558, 651, 774, 894, 1044, 1488, 1803, 318, 435, 441, 894, 957, 1401, 348, 564 or 1167 base pair sequence, all fully defined in the specification, or an analog of them which hybridizes with any of the sequences in (S2), their complementary nucleotide sequences, or a part or subsequence, under stringent conditions; and
- (8) a monoclonal or polyclonal antibody which specifically reacts with (I) or (II) in an immunoassay, or a specific binding fragment of the antibody.

ACTIVITY - Tuberculostatic.

MECHANISM OF ACTION - Vaccine. Five groups of 6-8 weeks old, female C57B1/6J mice were immunized subcutaneously at the base of the tail with vaccines (0.2 ml) of BCG (1), heat killed Mycobacterium tuberculosis/DDA (2), 50 mu g ST-CF/DDA (3), 50 mu g SPE/DDA (4) and control: DDA in NaCl (5). Group (2), (3) and (4) were given booster dose. After 4 weeks, mice were sacrificed and immune response in spleen cells was monitored. ST-CF and SPE induced immune response, while only a very low IFN- gamma release was observed with BCG and ST-CF.

USE - (I) and (II) are useful in preparing a prophylactic or therapeutic medicine as

a vaccine for induction of a protective or generation of an immune response in a mammal against infection with a virulent Mycobacterium (claimed). (I) and (II) are also useful as diagnostic reagent for the diagnosis of a virulent Mycobacterium infection.

ADVANTAGE - The vaccine of the invention induces efficient immunological memory, providing long term protection against TB.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

□ 15. Document ID: DE 69918146 E, WO 200020027 A2, AU 9958510 A, NO 200101586 A, EP 1117421 A2, CN 1323217 A, KR 2001085894 A, HU 200103976 A2, JP 2002526419 W, CZ 200101049 A3, AU 751709 B, ZA 200102603 A, SK 200100427 A3, NZ 511055 A, EP 1117421 B1, US 20040141958 A1

L18: Entry 15 of 27

File: DWPI

Jul 22, 2004

DERWENT-ACC-NO: 2000-349917

DERWENT-WEEK: 200450

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Inducing immune responses to weakly immunogenic, tumor associated peptide antigens for the treatment of breast and prostate cancer

INVENTOR: DALUM, I; GAUTAM, A ; HAANING, J ; KARLSSON, G ; LEACH, D ; MOURITSEN, S ; NIELSEN, K G ; RASMUSSEN, P B ; STEINAA, L ; RASMUSSEN BIRK, P ; BIRK, P

PRIORITY-DATA: 1998US-105011P (October 20, 1998), 1998DK-0001261 (October 5, 1998), 1998DK-0000012 (October 5, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 69918146 E</u>	July 22, 2004		000	A61K038/17
<u>WO 200020027 A2</u>	April 13, 2000	E	219	A61K039/00
<u>AU 9958510 A</u>	April 26, 2000		000	
<u>NO 200101586 A</u>	May 31, 2001		000	A61K000/00
<u>EP 1117421 A2</u>	July 25, 2001	E	000	A61K038/17
<u>CN 1323217 A</u>	November 21, 2001		000	A61K038/17
<u>KR 2001085894 A</u>	September 7, 2001		000	A61K039/00
<u>HU 200103976 A2</u>	February 28, 2002		000	A61K039/00
<u>JP 2002526419 W</u>	August 20, 2002		200	A61K039/00
<u>CZ 200101049 A3</u>	August 14, 2002		000	A61K039/00
<u>AU 751709 B</u>	August 22, 2002		000	A61K039/00
<u>ZA 200102603 A</u>	December 24, 2002		275	A61K000/00
<u>SK 200100427 A3</u>	February 4, 2003		000	A61K038/17
<u>NZ 511055 A</u>	October 31, 2003		000	A61K039/00
<u>EP 1117421 B1</u>	June 16, 2004	E	000	A61K038/17
<u>US 20040141958 A1</u>	July 22, 2004		000	A61K048/00

, US 20040141958 A1 INT-CL (IPC): A61 K 0/00; A61 K 38/17; A61 K 38/18; A61 K 39/00; A61 K 39/39; A61 K 48/00; A61 P 15/00; A61 P 35/00; C07 K 14/47; C07 K 14/50; C07 K 14/705; C07 K 14/71; C07 K 16/18; C12 N 5/16; C12 N 15/09; C12 N 15/12; C12 N 15/63

ABSTRACTED-PUB-NO: WO 200020027A

BASIC-ABSTRACT:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.19&ref=18&dbname=PGPB,USPT,U...> 10/5/04

NOVELTY - A method (I) for inducing immune responses against weakly immunogenic cell-associated peptide antigens (PA) such as those associated with cancers (i.e. self-proteins) (e.g. human PSM (undefined), Her2 and/or fibroblast growth factor (FGF) 8b), is new.

DETAILED DESCRIPTION - A method (I) for inducing an immune responses against weakly immunogenic or non-immunogenic polypeptide antigens (PAs) in animals (including humans), comprising effecting simultaneous presentation by antigen producing cells (APCs) of the animals immune system of:

- (1) at least 1 CTL (cytotoxic T-lymphocyte) group derived from the PA and/or at least 1 B-cell group derived from the cell-associated PA; and
- (2) at least 1 first T helper cell group (TH1 group) which is foreign to the animal.

INDEPENDENT CLAIMS are also included for the following:

(1) a method (II) for the selection of an immunogenic analog of a cell-associated PA that is weakly immunogenic or non-immunogenic which is capable of inducing an immune response in an animal against cell displaying MHC (major histocompatibility complex) Class I (MHC-I) molecules bound to group derived from the cell-associated PA, comprising:

(A) identifying a subsequence of the amino acid sequence of the cell-associated PA which does not contain known or predicted CTL groups;

(B) preparing at least 1 punitively immunogenic analogs of the PA by introducing at least 1 TH group foreign to the animal in a position within the subsequence identified in step (A); and

(C) selecting those analogs from step (B) which are verifiably capable of inducing a CTL response in the animal

(2) a method (III) for the preparation of a cell that produces analogs of cell-associated PAs, comprising introducing a nucleic acid encoding the analog into a vector and transforming a suitable host cell (III) with the vector;

(3) a method (IV) for preparing analogs of cell-associated PAs comprising culturing the transformed host cell (III) under conditions suitable for expression of the protein and recovering the PA analog from the culture;

(4) an analog (V) of human PSM (undefined) that is immunogenic in humans and comprises at least part of all known and predicted CTL and B-cell groups of PSM and includes at least 1 foreign TH group;

(5) an analog (VI) of Her2 that is immunogenic in humans and comprises at least part of all known and predicted CTL and B-cell groups of Her2 and includes at least 1 foreign TH group;

(6) an analog (VII) of human/murine FGF (fibroblast growth factor) 8b that is immunogenic in humans and comprises at least part of all known and predicted CTL and B-cell groups of FGF 8b and includes at least 1 foreign TH group;

(7) compositions comprising (V), (VI) and/or (VII) and an adjuvant;

(8) nucleic acids ((VIII)-(X)) encoding (V), (VI) and/or (VII);

(9) vectors ((XI)-(XIII)) comprising (VIII)-(X) (respectively);

(10) a transformed cell (XIV) comprising (XI)-(XIII);

(11) compositions for inducing production of antibodies against PSM, Her2 and FGF 8b, comprising (VIII)-(X) and/or (XI)-(XIII) and an adjuvant; and

(12) a method for the preparation of the cell (XIV), comprising transforming a host cell with (VIII)-(X) or (XI)-(XIII).

USE - (I) is used to stimulate immune responses to weakly, or non-immunogenic peptide antigens especially self proteins for the treatment of diseases associated with expression of those antigens. If the PA is human PSM (undefined), (I) is used for the treatment of prostate cancer. If the PA is human fibroblast growth factor (FGF) 8b, (I) is used for the treatment of prostate cancer or breast cancer. If the PA is Her2, (I) is used for the treatment of breast cancer (claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	-----	------------

☐ 16. Document ID: US 20030092899 A1, WO 9904005 A1, AU 9881238 A, EP 1003870 A1, US 6436409 B1

L18: Entry 16 of 27

File: DWPI

May 15, 2003

DERWENT-ACC-NO: 1999-132249

DERWENT-WEEK: 200335

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New nucleic acid containing regulator and LHP gene of Mycobacterium tuberculosis - useful in vaccines, for diagnosis, and for expression of heterologous proteins

INVENTOR: ANDERSEN, P; BERTHET, F ; GICQUEL, B ; RASMUSSEN, P B ; ANDERSON, P

PRIORITY-DATA: 1997US-052631P (July 16, 1997), 1998US-0116492 (July 16, 1998), 2002US-0140045 (May 8, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20030092899 A1	May 15, 2003		000	C07H021/02
WO 9904005 A1	January 28, 1999	E	088	C12N015/31
AU 9881238 A	February 10, 1999		000	C12N015/31
EP 1003870 A1	May 31, 2000	E	000	C12N015/31
US 6436409 B1	August 20, 2002		000	A61K039/04

INT-CL (IPC): A61 K 39/00; A61 K 39/04; A61 K 39/38; C07 H 21/02; C07 H 21/04; C07 K 14/35; C07 K 16/12; C07 K 19/00; C12 N 1/12; C12 N 1/21; C12 N 15/31; C12 N 15/62; C12 N 15/74; C12 P 19/34; C12 Q 1/68; C12 R 1:42; G01 N 33/53; C12 N 1/21; C12 R 1:19; C12 R 1:32; C12 R 1:34; C12 R 1:38; C12 N 1/21; C12 R 1:19; C12 R 1:32; C12 R 1:34; C12 R 1:38; C12 R 1:42

ABSTRACTED-PUB-NO: US 6436409B

BASIC-ABSTRACT:

New polynucleotide (I) is: (a) a sequence of approximately 1.3 kb (S1); (b) is the 1-524 (S2), 1-481 (S3) or 525-826 (S4) bp fragment of (S1), also a biologically active derivative of (S2) or (S3); (c) contains at least 12 consecutive nucleotides (nt) from (S2)-(S4); (d) is the complement of (S2)-(S4); or (e) hybridises under stringent conditions to (S2)-(S4).

Also new are: (A) polynucleotides (Ia) comprising (S2), (S3) or their active derivatives fused to a sequence (II) encoding a polypeptide (III); (B) recombinant

vectors containing (I) or (Ia); (C) recombinant host cells containing (I), (Ia) or the vector of (B); (D) polypeptide (IIIa) expressed by these host cells, their oligomers or antigenic fragments; (E) mono- or poly-clonal antibodies (Ab) specific for (IIIa) or their oligomers; and (F) the (1)-derived probes or primers (P14), (P15), and (P16), which can be used in pairs P14/P15, or P14/P16. 5'-CTGCAGCAGGTGACGTCGTTG (P14), 5'-CCGGGTGGCCGGGAAGTCTGTGT (P15), 5'-ACTACTTTCTCTTTCTACCTTCC (P16).

USE - (IIIa) and their oligomers are used: (a) as immunogens and vaccines, to protect against bacteria of the Mycobacterium tuberculosis (M.t.) complex in humans or animals (the vaccines may include other immunogenic proteins of M.t. or their fragments, specifically ESAT-6); and (b) for diagnosing M.t. infection by detection of specific antibodies (claimed).

Also the cells of (C) can be used as vaccines. Ab are used diagnostically to detect M.t., particularly in serum, and (I) or its fragments can be used to detect the M.t. complex or M.bovis by standard hybridisation or amplification assays (claimed).

Also the regulatory region present in (S1) may be used to express almost any heterologous protein in mycobacteria, particularly as a fusion with polyhistidine.

ADVANTAGE - The two proteins encoded in (S1), LHP and ESAT-6, are expected to provide a synergistic increase in ability to induce a protective immune response.

ABSTRACTED-PUB-NO:

WO 9904005A EQUIVALENT-ABSTRACTS:

New polynucleotide (I) is: (a) a sequence of approximately 1.3 kb (S1); (b) is the 1-524 (S2), 1-481 (S3) or 525-826 (S4) bp fragment of (S1), also a biologically active derivative of (S2) or (S3); (c) contains at least 12 consecutive nucleotides (nt) from (S2)-(S4); (d) is the complement of (S2)-(S4); or (e) hybridises under stringent conditions to (S2)-(S4).

Also new are: (A) polynucleotides (Ia) comprising (S2), (S3) or their active derivatives fused to a sequence (II) encoding a polypeptide (III); (B) recombinant vectors containing (I) or (Ia); (C) recombinant host cells containing (I), (Ia) or the vector of (B); (D) polypeptide (IIIa) expressed by these host cells, their oligomers or antigenic fragments; (E) mono- or poly-clonal antibodies (Ab) specific for (IIIa) or their oligomers; and (F) the (1)-derived probes or primers (P14), (P15), and (P16), which can be used in pairs P14/P15, or P14/P16. 5'-CTGCAGCAGGTGACGTCGTTG (P14), 5'-CCGGGTGGCCGGGAAGTCTGTGT (P15), 5'-ACTACTTTCTCTTTCTACCTTCC (P16).

USE - (IIIa) and their oligomers are used: (a) as immunogens and vaccines, to protect against bacteria of the Mycobacterium tuberculosis (M.t.) complex in humans or animals (the vaccines may include other immunogenic proteins of M.t. or their fragments, specifically ESAT-6); and (b) for diagnosing M.t. infection by detection of specific antibodies (claimed).

Also the cells of (C) can be used as vaccines. Ab are used diagnostically to detect M.t., particularly in serum, and (I) or its fragments can be used to detect the M.t. complex or M.bovis by standard hybridisation or amplification assays (claimed).

Also the regulatory region present in (S1) may be used to express almost any heterologous protein in mycobacteria, particularly as a fusion with polyhistidine.

ADVANTAGE - The two proteins encoded in (S1), LHP and ESAT-6, are expected to provide a synergistic increase in ability to induce a protective immune response.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 17. Document ID: WO 9903338 A1, AU 9883345 A

L18: Entry 17 of 27

File: DWPI

Jan 28, 1999

DERWENT-ACC-NO: 1999-131742
DERWENT-WEEK: 199925
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Method of baiting and hauling up fishing hooks secured to snoods on a long line fishing system - has long line, with attached snoods and hooks, pulled forward by a driving wheel through a station having a hook turning arrangement, hook storage and bait hopper, for baiting

INVENTOR: RASMUSSEN, P B

PRIORITY-DATA: 1998DK-0000741 (May 29, 1998), 1997DK-0000854 (July 14, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 9903338 A1</u>	January 28, 1999	E	031	A01K091/18
<u>AU 9883345 A</u>	February 10, 1999		000	A01K091/18

INT-CL (IPC): A01 K 91/18

ABSTRACTED-PUB-NO: WO 9903338A
BASIC-ABSTRACT:

Provides automatic baiting of hooks on a long fishing line (1), with attached snoods (2) and hooks (3), pulled forward by a driving wheel through a hook turning arrangement and a hook storage (5) with a bait hopper. The hook, round the back bone (23) of the fish or piece of fish cut by a rotating knife (17), is secured without risk of being pulled loose or from predators.

USE - Commercial long line baited hook fishing.

ADVANTAGE - Automated baiting of hooks makes long line fishing more economically competitive with fishing with nets, more efficient baiting and hauling up, increases efficiency of the associated work processes by removing bottlenecks and gives

giving no risk of being pulled loose by the passage of the hooks through the water or from predators seeking to take the bait from the hooks.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 18. Document ID: WO 9900417 A1, AU 9880124 A

L18: Entry 18 of 27

File: DWPI

Jan 7, 1999

DERWENT-ACC-NO: 1999-095680
DERWENT-WEEK: 199908
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Recombinant eukaryotic cells expressing mammalian heparin binding protein in a mature form - useful as an antimicrobial, a regulator of macrophage or monocyte function, and as a stimulant for monocyte survival

INVENTOR: BJORN, S E; FLODGAARD, H J ; RASMUSSEN, P B ; SVENDSEN, I ; WIBERG, F C

PRIORITY-DATA: 1997DK-0000963 (August 22, 1997), 1997US-082413P (June 25, 1997),
1997DK-0000773 (June 30, 1997), 1997US-055192P (August 11, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 9900417 A1</u>	January 7, 1999	E	059	C07K014/47
<u>AU 9880124 A</u>	January 19, 1999		000	C07K014/47

INT-CL (IPC): C07 K 14/47; C12 N 5/10

ABSTRACTED-PUB-NO: WO 9900417A

BASIC-ABSTRACT:

New recombinant eukaryotic cell (A) expressing an acidic proteoglycan (I) also includes nucleic acid (II) encoding a mammalian heparin-binding protein (III) which, in glycosylated form: (i) has a molecular weight about 28 kDa (by sodium dodecylsulphate polyacrylamide gel electrophoresis under reducing conditions); (ii) is produced by azurophil granules of polymorphonuclear leucocytes; and (iii) is a chemoattractant for monocytes. Also claimed are recombinant hybrid mammalian myeloma cells (B) fused to a cell expressing (I) and containing (II).

USE - (A) and (B) are used to produce (III) which has antimicrobial activity; regulates monocyte/macrophage function (chemotaxis, survival and differentiation); mediates detachment and contraction of endothelial cells and fibroblasts in monolayer cultures; and stimulates monocyte survival and thrombospondin secretion.

ADVANTAGE - (A) and (B) produce (III) in a mature form, eliminating the need for cleavage of pro and/or signal peptides, providing efficient and high yield production.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 19. Document ID: WO 9900416 A1, AU 9880123 A

L18: Entry 19 of 27

File: DWPI

Jan 7, 1999

DERWENT-ACC-NO: 1999-095679

DERWENT-WEEK: 199908

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Inhibiting pathogen entry into mononuclear cells using heparin-binding protein - useful to treat diseases caused by intracellular pathogens e.g. Leishmania, Listeria, Mycobacterium tuberculosis or human immunodeficiency virus

INVENTOR: FLODGAARD, H J; RASMUSSEN, P B

PRIORITY-DATA: 1997DK-0000962 (August 22, 1997), 1997US-050787P (June 25, 1997),
1997DK-0000772 (June 30, 1997), 1997US-055191P (August 11, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 9900416 A1</u>	January 7, 1999	E	057	C07K014/47
<u>AU 9880123 A</u>	January 19, 1999		000	C07K014/47

INT-CL (IPC): A61 K 38/17; C07 K 14/47

ABSTRACTED-PUB-NO: WO 9900416A

BASIC-ABSTRACT:

A novel method for inhibiting entry of a pathogen into mononuclear cells of a patient comprises administering a pharmaceutical composition comprising a carrier or diluent and a mammalian heparin-binding protein (HBP) which, in glycosylated form: (i) has molecular weight approximately 28 kDa as determined by SDS-PAGE under reducing conditions; (ii) is produced in the azurophil granules of polymorphonuclear leukocytes; and (iii) is a chemoattractant for monocytes.

USE - The method is useful to inhibit the entry of pathogens such as protozoa (especially Leishmania), bacteria (especially Listeria or Mycobacterium e.g. M. tuberculosis) and viruses (especially human immunodeficiency virus) into mononuclear cells (claimed), especially monocytes or macrophages (claimed) in humans or pigs. It may be used to treat diseases caused by intracellular pathogens such as those above (claimed); pathogens may infect patients by several mechanisms, one of which is by infecting and subsequently parasitizing mononuclear cells, and the method is more effective at preventing entry of these pathogens than current treatment with cytokines.

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	-----	----------

☐ 20. Document ID: EP 1449922 A2, WO 9844119 A1, AU 9868204 A, EP 972045 A1, NZ 504951 A, JP 2001515359 W, AU 740545 B, US 20020094336 A1, US 20020176867 A1, US 20030147897 A1, US 20030165525 A1, US 6641814 B1, US 20040013685 A1, US 20040115211 A1

L18: Entry 20 of 27

File: DWPI

Aug 25, 2004

DERWENT-ACC-NO: 1998-542705

DERWENT-WEEK: 200456

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New isolated mycobacteria polypeptides and nucleic acids - used for developing products for the diagnosis of or vaccination against mycobacterial infections, particularly tuberculosis

INVENTOR: ANDERSEN, P; FLORIO, W ; NIELSEN, R ; OETTINGER, T ; RASMUSSEN, P B ; ROSENKRANDS, I ; WELDINGH, K ; SKJOET, R L V ; SKJOT, R ; OLSEN, A W ; SKJOT, R L V ; HANSEN, C V ; OKKELS, L M M ; BROCK, I ; SKIOT, R

PRIORITY-DATA: 1998US-070488P (January 5, 1998), 1997DK-0000376 (April 2, 1997), 1997US-044624P (April 18, 1997), 1997DK-0001277 (November 10, 1997), 1993DK-0000798 (July 2, 1993), 1998DK-0001281 (October 8, 1998), 1999DK-0001020 (July 13, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>EP 1449922 A2</u>	August 25, 2004	E	000	C12N015/31
<u>WO 9844119 A1</u>	October 8, 1998	E	163	C12N015/31
<u>AU 9868204 A</u>	October 22, 1998		000	
<u>EP 972045 A1</u>	January 19, 2000	E	000	
<u>NZ 504951 A</u>	June 29, 2001		000	
<u>JP 2001515359 W</u>	September 18, 2001		280	C12N015/09
<u>AU 740545 B</u>	November 8, 2001		000	
<u>US 20020094336 A1</u>	July 18, 2002		000	A61K039/02
<u>US 20020176867 A1</u>	November 28, 2002		000	A61K039/04
<u>US 20030147897 A1</u>	August 7, 2003		000	A61K039/02

US 20030165525 A1	September 4, 2003	000	A61K039/02
US 6641814 B1	November 4, 2003	000	A61K039/02
US 20040013685 A1	January 22, 2004	000	A61K039/02
US 20040115211 A1	June 17, 2004	000	A61K039/00

INT-CL (IPC): A61 K 31/711; A61 K 38/00; A61 K 38/16; A61 K 39/00; A61 K 39/02; A61 K 39/04; A61 K 39/104; A61 K 39/112 ; A61 K 39/38; A61 K 39/40; A61 K 48/00; A61 P 31/04; A61 P 43/00; C07 H 21/04; C07 K 14/30; C07 K 14/35; C07 K 16/12; C07 K 19/00; C12 M 1/34; C12 N 1/12; C12 N 1/21; C12 N 5/10; C12 N 9/00; C12 N 15/09; C12 N 15/31; C12 N 15/62; C12 N 15/74; C12 P 21/02; C12 P 21/04; C12 P 21/08; C12 Q 1/68; G01 N 33/569

ABSTRACTED-PUB-NO: US20020094336A

BASIC-ABSTRACT:

A pure polypeptide fragment (I) is new, which comprises: (a) an amino acid sequence selected from one of the sequences shown; (b) a subsequence of (I) which has a length of at least 6 amino acid residues, being immunologically equivalent to (I) with respect to the ability of evoking a protective immune response against infections with mycobacteria belonging to the tuberculosis complex (TC) or with respect to the ability of eliciting a diagnostically significant immune response indicating previous or ongoing sensitisation with antigens derived from mycobacteria belonging to the TC; or (c) an amino acid sequence having a sequence identity with (a) or the subsequence as in (b) of at least 70% and at the same time being immunologically equivalent to (I) with respect to the ability of evoking a protective immune response against infections with mycobacteria belonging to the TC or with respect to the ability of eliciting a diagnostically significant immune response indicating previous or ongoing sensitisation with antigens derived from mycobacteria belonging to the TC; provided that: (i) the polypeptide fragment is in pure form when consisting of the amino acid sequence 1-92 of Seq ID 2; or when consisting of the amino acid sequence 87-108 of Seq ID 4 fused to beta-galactosidase; (ii) the degree of sequence identity in (c) is at least 95% when the polypeptide comprises a homologue of a polypeptide which has the amino acid sequence of Seq ID 12 or a subsequence as in (b); and (iii) the polypeptide fragment contains a threonine residue corresponding to position 213 in Seq ID 42 when comprising an amino acid sequence of at least 6 amino acids in Seq ID 42. Also claimed are: (1) a fusion polypeptide fragment which comprises: (a) a first amino acid sequence including at least one stretch of amino acids constituting a T-cell epitope derived from Mycobacterium tuberculosis (MT) protein ESAT-6, and a second amino acid sequence including at least one T-cell epitope derived from a MT protein different from ESAT-6 and/or including a stretch of amino acids which protects the first amino acid sequence from in vivo degradation or post-translational processing; or (b) a first amino acid sequence including at least one stretch of amino acids constituting a T-cell epitope derived from the MT protein MPT59, and a second amino acid sequence including at least one T-cell epitope derived from a MT protein different from MPT59 and/or including a stretch of amino acids which protects the first amino acid sequence from in vivo degradation or post-translational processing; (2) a nucleic acid fragment in isolated form which: (a) comprises a nucleic acid sequence which encodes (I) or a polypeptide as in (1) or comprises a complementary nucleic acid sequence; (b) has a length of at least 10 nucleotides and hybridises readily under stringent hybridisation conditions with a nucleic acid fragment which has a nucleotide sequence (NS) selected from sequences 1, 3, 5, 7, 9, 11, 13, 15, 41, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 87, 89, 91, 93, 140, 142, 144, 146, 148, 150, and 152; or a complementary sequence, provided that when the nucleic acid fragment comprises a subsequence of Seq ID 41, then the nucleic acid fragment contains an A corresponding to position 781 in Seq ID 41, and when the nucleic acid fragment comprises a subsequence of a NS complementary to Seq ID 41, then the nucleic acid fragment comprises a T corresponding to position 781 in Seq ID 41; (3) a replicable expression vector which comprises a nucleic acid fragment as in (2); (4) a transformed cell harbouring at least one vector as in (3); (5) a monoclonal or polyclonal antibody which is specifically reactive with a (I) or a polypeptide as in (1).

USE The products can be used in the detection of and prevention of mycobacterial infections. In particular, the polypeptides and nucleic acids can be used for the diagnosis of or vaccination against tuberculosis caused by MT, M africanum or M. bovis.

ABSTRACTED-PUB-NO:

WO 9844119A EQUIVALENT-ABSTRACTS:

A pure polypeptide fragment (I) is new, which comprises: (a) an amino acid sequence selected from one of the sequences shown; (b) a subsequence of (I) which has a length of at least 6 amino acid residues, being immunologically equivalent to (I) with respect to the ability of evoking a protective immune response against infections with mycobacteria belonging to the tuberculosis complex (TC) or with respect to the ability of eliciting a diagnostically significant immune response indicating previous or ongoing sensitisation with antigens derived from mycobacteria belonging to the TC; or (c) an amino acid sequence having a sequence identity with (a) or the subsequence as in (b) of at least 70% and at the same time being immunologically equivalent to (I) with respect to the ability of evoking a protective immune response against infections with mycobacteria belonging to the TC or with respect to the ability of eliciting a diagnostically significant immune response indicating previous or ongoing sensitisation with antigens derived from mycobacteria belonging to the TC; provided that: (i) the polypeptide fragment is in pure form when consisting of the amino acid sequence 1-92 of Seq ID 2; or when consisting of the amino acid sequence 87-108 of Seq ID 4 fused to beta-galactosidase; (ii) the degree of sequence identity in (c) is at least 95% when the polypeptide comprises a homologue of a polypeptide which has the amino acid sequence of Seq ID 12 or a subsequence as in (b); and (iii) the polypeptide fragment contains a threonine residue corresponding to position 213 in Seq ID 42 when comprising an amino acid sequence of at least 6 amino acids in Seq ID 42. Also claimed are: (1) a fusion polypeptide fragment which comprises: (a) a first amino acid sequence including at least one stretch of amino acids constituting a T-cell epitope derived from Mycobacterium tuberculosis (MT) protein ESAT-6, and a second amino acid sequence including at least one T-cell epitope derived from a MT protein different from ESAT-6 and/or including a stretch of amino acids which protects the first amino acid sequence from in vivo degradation or post-translational processing; or (b) a first amino acid sequence including at least one stretch of amino acids constituting a T-cell epitope derived from the MT protein MPT59, and a second amino acid sequence including at least one T-cell epitope derived from a MT protein different from MPT59 and/or including a stretch of amino acids which protects the first amino acid sequence from in vivo degradation or post-translational processing; (2) a nucleic acid fragment in isolated form which: (a) comprises a nucleic acid sequence which encodes (I) or a polypeptide as in (1) or comprises a complementary nucleic acid sequence; (b) has a length of at least 10 nucleotides and hybridises readily under stringent hybridisation conditions with a nucleic acid fragment which has a nucleotide sequence (NS) selected from sequences 1, 3, 5, 7, 9, 11, 13, 15, 41, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 87, 89, 91, 93, 140, 142, 144, 146, 148, 150, and 152; or a complementary sequence, provided that when the nucleic acid fragment comprises a subsequence of Seq ID 41, then the nucleic acid fragment contains an A corresponding to position 781 in Seq ID 41, and when the nucleic acid fragment comprises a subsequence of a NS complementary to Seq ID 41, then the nucleic acid fragment comprises a T corresponding to position 781 in Seq ID 41; (3) a replicable expression vector which comprises a nucleic acid fragment as in (2); (4) a transformed cell harbouring at least one vector as in (3); (5) a monoclonal or polyclonal antibody which is specifically reactive with a (I) or a polypeptide as in (1).

USE The products can be used in the detection of and prevention of mycobacterial infections. In particular, the polypeptides and nucleic acids can be used for the diagnosis of or vaccination against tuberculosis caused by MT, M africanum or M. bovis.

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 13 of 13 returned.

☐ 1. Document ID: US 20040115211 A1

Using default format because multiple data bases are involved.

L16: Entry 1 of 13

File: PGPB

Jun 17, 2004

PGPUB-DOCUMENT-NUMBER: 20040115211

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040115211 A1

TITLE: TB diagnostic based on antigens from M. tuberculosis

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Andersen, Peter	Bronshoj		DK	
Skiot, Rikke	Hedehusene		DK	
Oettinger, Thomas	Hellerup		DK	
Rasmussen, Peter Birk	Frederiksberg		DK	
Rosenkrands, Ida	Vorlose		DK	
Weldingh, Karin	Vorlose		DK	
Florio, Walter	Carrara		IT	

US-CL-CURRENT: 424/184.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Cl	RMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	----	------	------------

☐ 2. Document ID: US 20030165525 A1

L16: Entry 2 of 13

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030165525

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030165525 A1

TITLE: TB diagnostic based on antigens from M. tuberculosis

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Andersen, Peter	Bronshoj		DK	
Weldingh, Karin	Vaerlose		DK	
Hansen, Christina Veggerby	Manchester		GB	
Florio, Walter	Carrara		IT	

Okkels, Li Mei Meng	Bagsvaerd	DK
Skjot, Rikke Louise Vinther	Hedehusene	DK
Rasmussen, Peter Birk	Copenhagen	DK

US-CL-CURRENT: 424/190.1

ABSTRACT:

The present invention is based on the identification and characterization of a number of novel M. tuberculosis derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as diagnostic reagents containing the polypeptides.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Cl	FWMC	Drawl Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	----	------	-----------

☐ 3. Document ID: US 20030157117 A1

L16: Entry 3 of 13

File: PGPB

Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030157117

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030157117 A1

TITLE: Novel method for down-regulation of amyloid

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rasmussen, Peter Birk	Horsholm		DK	
Jensen, Martin Roland	Horsholm		DK	
Nielsen, Klaus Gregorius	Horsholm		DK	
Koefoed, Peter	Horsholm		DK	
Degan, Florence Dal	Horsholm		DK	

US-CL-CURRENT: 424/185.1; 435/226

ABSTRACT:

Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protein (APP) or beta amyloid (A.beta.). Immunization is preferably effected by administration of analogues of autologous APP or A.beta., said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A.beta. which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against APP or A.beta. and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

☐ 4. Document ID: US 20030092899 A1

L16: Entry 4 of 13

File: PGPB

May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030092899

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030092899 A1

TITLE: Polynucleotide functionally coding for the LHP protein from Mycobacterium tuberculosis, its biologically active derivative fragments, as well as methods using the same

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gicquel, Brigitte	Paris		FR	
Berthet, Francois-Xavier	Paris		FR	
Anderson, Peter	Bronshoj		DK	
Rasmussen, Peter Birk	Bergsgade		DK	

US-CL-CURRENT: 536/23.1; 424/184.1

ABSTRACT:

The present invention is directed to a polynucleotide carrying an open reading frame coding for an antigenic polypeptide from Mycobacterium tuberculosis, named lhp, which is placed under the control of its own regulation signals which are functional in mycobacteria, specially in mycobacteria belonging to the Mycobacterium tuberculosis complex and also in fast growing mycobacteria such as Mycobacterium smegmatis. The invention is also directed to the polypeptide LHP encoded by lhp and most preferably to suitable antigenic portions of LHP as well as to oligomeric polypeptides containing more than one unit of LHP or an antigenic portion of LHP. The invention concerns also immunogenic and vaccine compositions containing a polypeptide or an oligomeric polypeptide such as defined above, as well as antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. In another embodiment, the present invention is directed to a polynucleotide carrying the natural regulation signals of lhp which is useful in order to express heterologous proteins in mycobacteria. Finally, the present invention is directed to oligonucleotides comprising at least 12 consecutive nucleotides from the regulation sequence of lhp which are useful as reagents for detecting the presence of Mycobacterium tuberculosis in a biological sample.

☐ 5. Document ID: US 20020187157 A1

L16: Entry 5 of 13

File: PGPB

Dec 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020187157

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020187157 A1

TITLE: Novel method for down-regulation of amyloid

PUBLICATION-DATE: December 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jensen, Martin Roland	Holte		DK	
<u>Rasmussen, Peter Birk</u>	Frederiksberg		DK	
Nielsen, Klaus Gregorius	Soborg		DK	

US-CL-CURRENT: 424/185.1; 424/85.1, 424/85.2

ABSTRACT:

A method for in vivo down-regulation of amyloid protein in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunogenically effective amount of at least one amyloidogenic polypeptide or subsequence thereof which has been formulated so that immunization of the animal with the amyloidogenic polypeptide or subsequence thereof induces production of antibodies against the amyloidogenic polypeptide, and/or at least one analogue of the amyloidogenic polypeptide wherein is introduced at least one modification in the amino acid sequence of the amyloidogenic polypeptide which has as a result the immunization of the animal with the analogue induces production of antibodies against the amyloidogenic polypeptide.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Cl	KWIC	Draw	Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	----	------	------	-----

☐ 6. Document ID: US 20020176867 A1

L16: Entry 6 of 13

File: PGPB

Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020176867

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020176867 A1

TITLE: Hybrids of M. tuberculosis antigens

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Andersen, Peter	Bronshoj		DK	
Olsen, Anja Weinreich	Soborg		DK	
Skjot, Rikke Louise Vinther	Hedehusene		DK	
<u>Rasmussen, Peter Birk</u>	Frederiksberg		DK	

US-CL-CURRENT: 424/190.1; 530/359

ABSTRACT:

The present invention discloses fusion proteins of the immunodominant antigens ESAT-6 and Ag85B from Mycobacterium tuberculosis or homologues thereof, and a tuberculosis vaccine based on the fusion proteins, which vaccine induces efficient immunological memory.

☐ 7. Document ID: US 20020094336 A1

L16: Entry 7 of 13

File: PGPB

Jul 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020094336

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020094336 A1

TITLE: Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis

PUBLICATION-DATE: July 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Andersen, Peter	Bronshøj		DK	
Nielsen, Rikke	Frederiksberg C		DK	
Oettinger, Thomas	Hellerup		DK	
<u>Rasmussen, Peter Birk</u>	Kobenhaven O		DK	
Rosenkrands, Ida	Kobenhaven O		DK	
Weldingh, Karin	Kobenhaven N		DK	
Florio, Walter	Frederiksberg C		DK	

US-CL-CURRENT: 424/190.1; 435/183

ABSTRACT:

The present invention is based on the identification and characterization of a number of M. tuberculosis derived novel proteins and protein fragments (SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 17-23, 42, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72-86, 88, 90, 92, 94, 141, 143, 145, 147, 149, 151, 153, and 168-171). The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides. Another part of the invention is based on the surprising discovery that fusions between ESAT-6 and MPT59 are superior immunogens compared to each of the unfused proteins, respectively.

☐ 8. Document ID: US 6641814 B1

L16: Entry 8 of 13

File: USPT

Nov 4, 2003

US-PAT-NO: 6641814

DOCUMENT-IDENTIFIER: US 6641814 B1

**** See image for Certificate of Correction ****

TITLE: Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis

DATE-ISSUED: November 4, 2003

NAME	CITY	STATE	ZIP CODE	COUNTRY
Andersen; Peter	Br.o slashed.nsh.o slashed.j			DK
Nielsen; Rikke	Frederiksberg			DK
Oettinger; Thomas	Hellerup			DK
<u>Rasmussen; Peter Birk</u>	K.o slashed.benhaven			DK
Rosenkrands; Ida	K.o slashed.benhaven			DK
Weldingh; Karin	K.o slashed.benhaven			DK
Florio; Walter	Frederiksberg			DK

Full	Title	Citation	Front	Review	Classification	Date	Reference	Remarks	Remarks	Class	KMNC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	---------	---------	-------	------	----------

The present invention is directed to a polynucleotide carrying an open reading frame coding for an antigenic polypeptide from *Mycobacterium tuberculosis*, named *lhp*, which is placed under the control of its own regulation signals which are functional in mycobacteria, specially in mycobacteria belonging to the *Mycobacterium tuberculosis* complex and also in fast growing mycobacteria such as *Mycobacterium smegmatis*. The invention is also directed to the polypeptide LHP encoded by *lhp* and most preferably to suitable antigenic portions of LHP as well as to oligomeric polypeptides containing more than one unit of LHP or an antigenic portion of LHP. The invention concerns also immunogenic and vaccine compositions containing a polypeptide or an oligomeric polypeptide such as defined above, as well as antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. In another embodiment, the present invention is directed to a polynucleotide carrying the natural regulation signals of *lhp* which is useful in order to express heterologous proteins in mycobacteria. Finally, the present invention is directed to oligonucleotides comprising at least 12 consecutive nucleotides from the regulation sequence of *lhp* which are useful as reagents for detecting the presence of *Mycobacterium tuberculosis* in a biological sample.

Number of Drawing Sheets: 17

Full	Title	Citation	Front	Review	Classification	Date	Reference	Project	Document	Cl	KMIC	Drawl Des
------	-------	----------	-------	--------	----------------	------	-----------	---------	----------	----	------	-----------

Sep 18, 2003

TITLE: NOVEL APPLICATION OF VACCINATION AGAINST TNF-ALPHA

PUBN-DATE: September 18, 2003

DK

EUR-CL (EPC): A61K038/19; A61K039/00, C07K016/24

CHG DATE=20040110 STATUS=O>The present invention relates to novel medical applications of down-regulation of tumour necrosis factor alpha (TNF-alpha) activity, especially novel applications of active immunization against TNF-alpha in order to reduce or alleviate pain. In particular, the present invention discloses novel methods for treating or ameliorating neuropathic pain.

Full	Title	Citation	Front	Review	Classification	Date	Reference				Cl	KOMC	Draw	Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	----	------	------	-----

☐ 11. Document ID: WO 3015812 A2

L16: Entry 11 of 13

File: EPAB

Feb 27, 2003

PUB-NO: WO003015812A2

DOCUMENT-IDENTIFIER: WO 3015812 A2

TITLE: NOVEL METHOD FOR DOWN-REGULATION OF AMYLOID

PUBN-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME	COUNTRY
RASMUSSEN, PETER BIRK	DK
JENSEN, MARTIN ROLAND	DK
NIELSEN, KLAUS GREGORIUS	DK
KOEFOED, PETER	DK
DEGAN, FLORENCE DAL	DZ

INT-CL (IPC): A61 K 39/00; A61 K 39/385; C07 K 14/47; A61 P 25/28

EUR-CL (EPC): A61K039/00

ABSTRACT:

CHG DATE=20030403 STATUS=O>Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protein (APP) or beta amyloid (A beta). Immunization is preferably effected by administration of analogues of autologous APP or A beta , said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A beta which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against APP or A beta and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

Full	Title	Citation	Front	Review	Classification	Date	Reference				Cl	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	----	-----	----------

☐ 12. Document ID: WO 9904005 A1

L16: Entry 12 of 13

File: EPAB

Jan 28, 1999

PUB-NO: WO009904005A1

DOCUMENT-IDENTIFIER: WO 9904005 A1

TITLE: A POLYNUCLEOTIDE FUNCTIONALLY CODING FOR THE LHP PROTEIN FROM MYCOBACTERIUM TUBERCULOSIS, ITS BIOLOGICALLY ACTIVE DERIVATIVE FRAGMENTS, AS WELL AS METHODS USING THE SAME

PUBN-DATE: January 28, 1999

INVENTOR-INFORMATION:

NAME	COUNTRY
------	---------

GICQUEL, BRIGITTE
BERTHET, FRANCOIS-XAVIER
ANDERSEN, PETER
RASMUSSEN, PETER BIRK

FR
FR
DK
DK

INT-CL (IPC): C12 N 15/31; C07 K 14/35; C12 N 15/62; C07 K 19/00; C12 N 15/74; G01 N 33/53; C12 N 1/21; C07 K 16/12; A61 K 39/04; C12 Q 1/68
EUR-CL (EPC): C07K014/35; C12N015/74, C12R001/19

ABSTRACT:

CHG DATE=19990905 STATUS=O>The present invention is directed to a polynucleotide carrying a n open reading frame coding for an antigenic polypeptide from Mycobacterium tuberculosis, named lhp, which is placed under the control of its own regulation signals which are functional in mycobacteria, specially in mycobacteria belonging to the Mycobacterium tuberculosis complex and also in fast growing mycobacteria such as Mycobacterium smegmatis. The invention is also directed to the polypeptide LHP encoded by lhp and most preferably to suitable antigenic portions of LHP as well as to oligomeric polypeptides containing more than one unit of LHP or an antigenic portion of LHP. The invention concerns also immunogenic and vaccine compositions containing a polypeptide or an oligomeric polypeptide such as defined above, as well as antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. In another embodiment, the present invention is directed to a polynucleotide carrying the natural regulation signals of lhp which is useful in order to express heterologous proteins in mycobacteria. Finally, the present invention is directed to oligonucleotides comprising at least 12 consecutive nucleotides from the regulation sequence of lhp which are useful as reagents for detecting the presence of Mycobacterium tuberculosis in a biological sample.

Full	Title	Citation	Front	Review	Classification	Date	Reference				Cl	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	----	------	------------

☐ 13. Document ID: WO 9844119 A1

L16: Entry 13 of 13

File: EPAB

Oct 8, 1998

PUB-NO: WO009844119A1

DOCUMENT-IDENTIFIER: WO 9844119 A1

TITLE: NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM M. TUBERCULOSIS

PUBN-DATE: October 8, 1998

INVENTOR-INFORMATION:

NAME	COUNTRY
ANDERSEN, PETER	DK
NIELSEN, RIKKE	DK
ROSENKRANDS, IDA	DK
WELDINGH, KARIN	DK
RASMUSSEN, PETER BIRK	DK
OETTINGER, THOMAS	DK
FLORIO, WALTER	DK

INT-CL (IPC): C12 N 15/31; A61 K 39/04; C07 K 14/35; C12 N 15/62; A61 K 38/16; G01 N 33/569; C12 Q 1/68; C07 K 16/12
EUR-CL (EPC): C07K014/35

ABSTRACT:

CHG DATE=20031129 STATUS=O>The present invention is based on the identification and characterization of a number of M. tuberculosis derived novel proteins and protein fragments (SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 17-23, 42, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72-86, 88, 90, 92, 94, 141, 143, 145, 147, 149, 151, 153, and 168-171). The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides. Another part of the invention is based on the surprising discovery that fusions between ESAT-6 and MPT59 are superior immunogens compared to each of the unfused proteins, respectively.

Full	Title	Citation	Front	Review	Classification	Date	Reference				Cl	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	----	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Rasmussen-Peter-Birk.IN.	13

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 37 of 37 returned.

☐ 1. Document ID: DK 200201771 A, EP 1420501 A2

Using default format because multiple data bases are involved.

L5: Entry 1 of 37

File: DWPI

May 16, 2004

DERWENT-ACC-NO: 2004-413298

DERWENT-WEEK: 200439

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Permanent magnet rotor for motor, generator, has ventilation holes in area between poles formed of permanent magnets

INVENTOR: RASMUSSEN, P ; STIESDAL, H

PRIORITY-DATA: 2002DK-0001771 (November 15, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DK 200201771 A</u>	May 16, 2004		000	H02K001/27
<u>EP 1420501 A2</u>	May 19, 2004	E	004	H02K001/27

INT-CL (IPC): H02 K 1/27

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 2. Document ID: US 20040071853 A1

L5: Entry 2 of 37

File: DWPI

Apr 15, 2004

DERWENT-ACC-NO: 2004-328553

DERWENT-WEEK: 200444

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Novel polypeptide having lipase activity, is triacylglycerol hydrolyzing enzyme capable of hydrolyzing glycolipids and galactosyl diglycerides that are normally present in flour to corresponding galactosyl monoglycerides

INVENTOR: MADRID, S M; POULSEN, C H ; RASMUSSEN, P ; SOE, J B ; ZARGAHI, M R

PRIORITY-DATA: 1998WO-DK00136 (April 3, 1998), 1997DK-0000400 (April 9, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20040071853 A1</u>	April 15, 2004		038	A21D010/00

INT-CL (IPC): A21 D 10/00

NOVELTY - A polypeptide (I) having lipase activity, where the polypeptide is a triacylglycerol hydrolyzing enzyme, and where (I) is capable of hydrolyzing glycolipids that are normally present in a flour to the corresponding galactosyl monoglycerides, and hydrolyzing at least 10% of galactosyl diglycerides normally present in a flour dough to monoglycerides, is new.

DETAILED DESCRIPTION - A polypeptide (I) having lipase activity, where the polypeptide is a triacylglycerol hydrolyzing enzyme, and where (I) is capable of hydrolyzing glycolipids that are normally present in a flour to the corresponding galactosyl monoglycerides, where (I) is capable of hydrolyzing at least 10% of galactosyl diglycerides normally present in a flour dough to monoglycerides, where (I) retains at least 82.5% activity after 4 days at room temperature and at a pH of 3.5-8, and where the polypeptide is capable of hydrolyzing glycolipids that are normally present in a flour to the corresponding galactosyl monoglycerides, where (I) is capable of hydrolyzing glycolipids, monogalactosyl diglyceride and digalactosyl diglyceride, that are normally present in a flour to monogalactosyl monoglyceride and digalactosyl monoglyceride, where (I) retains at least 82.56 activity after 4 days at room temperature and at a pH of 3.5-8 and where the polypeptide is capable of hydrolyzing glycolipids, monogalactosyl diglyceride and digalactosyl diglyceride, that are normally present in a flour, to the corresponding galactosyl monoglycerides, where (I) retains at least 82.5% activity after 4 days at 20 deg. C and at a pH 3.5-8, and is capable of modifying by hydrolysis the glycolipids, monogalactosyl diglyceride (MGDG) and digalactosyl diglyceride (DGDG), to the more polar components monogalactosyl monoglyceride (MGMG) and digalactosyl monoglyceride (DGMG). INDEPENDENT CLAIMS are also included for the following:

- (1) a polypeptide (II) comprising at least one amino acid sequence Ser-Val-Ser-Thr-Ser-Thr-Leu-Asp-Glu-Leu-Gln-Leu-Phe-Ala-Gln-Trp-Ser- Ala-Ala-Ala-Tyr-Xaa-Ser-Asn-Asn (S1), Val-His-Thr-Gly-Phe-Trp-Lys (S2), and Ala-Trp-Glu-Ser-Ala-Ala-Asp-Glu-Leu-Thr-Ser-Lys-Ile- Lys (S3);
- (2) a recombinant DNA molecule (III) comprising a nucleotide sequence coding for (I);
- (3) a cell comprising (IV) and capable of expressing (I);
- (4) preparing (I);
- (5) a dough improving composition (V) comprising (I) and at least one further conventional dough additive component; and
- (6) a recombinant DNA molecule comprising a nucleotide sequence coding for a polypeptide exhibiting lipase activity and which polypeptide comprises (S1)-(S3), or a nucleotide sequence coding for a polypeptide exhibiting lipase activity having a fully defined amino acid sequence (S4) of 297 amino acids as given in the specification, or ttccaraanccngtrtgnac, caryntttgcncartgg, gcvgchswytccavgc, a fully defined sequence of 317, 1045 base pairs as given in the specification, or variant, homologue, fragment or sequence complementary to it.

USE - (I) is useful for preparing a baked product having improved pore homogeneity and reduced average pore diameter. The dough does not contain added lipids. The polypeptide is added to the dough in an amount that is in the range of 5000-30000 lipase units (LUS) per kg flour. The emulsifier is added to the dough. (I) is useful for improving the stability of a gluten network in a dough, imparting improved pore homogeneity, reducing pore diameter of a baked product made from the dough or its combination that involves adding (I) to the dough, the gluten index being determined by Glutomatic 2200 apparatus (all claimed).

ADVANTAGE - (I) is added to a bread dough in an amount of 5000 LUS per kg flour as it reduces the average pore diameter of the crumb of the bread made from the dough by at

least 10%, relative to a bread that is made from a bread dough without addition of the polypeptide. When (I) is added to a bread dough in an amount of 5000 LUS per kg flour, it increases the gluten index in the dough by at least 5%, relative to a dough without addition of the polypeptide, the gluten index being determined by means of a Glutomatic 2200 apparatus (claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 3. Document ID: WO 2004024757 A2

L5: Entry 3 of 37

File: DWPI

Mar 25, 2004

DERWENT-ACC-NO: 2004-329446

DERWENT-WEEK: 200430

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Novel modified peptide nucleic acid monomer, useful for treating bacterial, viral, and fungal infections, cancer and cardiovascular disease

INVENTOR: FRANDSEN, N M; HAMZAVI, R ; KJAERULFF, S ; NIELSEN, P E ; NYBORG, M ; RASMUSSEN, F W ; RASMUSSEN, P

PRIORITY-DATA: 2003DK-0000600 (April 16, 2003), 2002DK-0001334 (September 11, 2002), 2002DK-0001786 (November 19, 2002), 2002DK-0001956 (December 20, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 2004024757 A2</u>	March 25, 2004	E	112	C07K014/00

INT-CL (IPC): C07 K 14/00

ABSTRACTED-PUB-NO: WO2004024757A

BASIC-ABSTRACT:

NOVELTY - A modified peptide nucleic acid (PNA) monomer (P1), is new.

DETAILED DESCRIPTION - A modified peptide nucleic acid (PNA) monomer (P1) having the formula (I).

B = naturally-occurring nucleobase preferably A, T, G or C, or a non-naturally occurring nucleobase;

Pr = hydrogen or protection group;

R1, R2, R3 = hydrogen, an amino acid side chain, or an 2-6C alkyl, aryl, aralkyl, heteroaryl, hydroxy, 1-6C alkoxy, 1-6C alkylthio, hydroxy- or alkoxy- or alkylthio-substituted 1-6C-alkyl, NR4R5 or Z1-Z2;

R4, R5 = hydrogen, 1-6C alkyl, hydroxy- or alkoxy-, alkylthio-substituted 1-6C-alkyl or Z1-Z2;

Z1 = bond or one of the radicals of formula (IIa)-(IIf); and

Z2 = alpha or beta forms of monosaccharide, disaccharide, polysaccharide, or one of the radicals of formula (III).

n = 0-8.

INDEPENDENT CLAIMS are also included for the following:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.6&ref=5&dbname=PGPB,USPT,USO...> 10/5/04

(1) a peptide nucleic acid oligomer (P2) with 4-50 monomers chosen from aeg-PNA monomers and a monomer of (P1);

(2) peptide nucleic acid molecule (P3) having the formula (1) or (2), or chosen from (GalNAc(OH)3)2-Lys-Gly-CATCACTGGCAGACCCTG-NH2, (GalNAc(OH)3)3-Lys2Gly-GTGGATGATACCTGGATC-NH2, and (GalNAc(OH)3)4-Lys3Gly-GTGGATGATACCTGGATC-NH2;

(3) peptide nucleic acid molecule, comprising:

(a) (P2) and a conjugates bound to the PNA either directly or through a linking moiety, where conjugate is reporter enzyme, reporter molecule, steroid, carbohydrate, terpene, peptide, protein, aromatic lipophilic molecule, non-aromatic lipophilic molecule, phospholipid, an intercalator, cell receptor binding molecule, crosslinking agent, water soluble vitamin, lipid soluble vitamin, RNA/DNA cleaving complex, metal chelator, porphyrin, alkylator, or polymeric compound chosen from polymeric amines, polymeric glycols and polyethers;

(b) PNA oligomer with 4-50 aeg-PNA monomers and one or more ligands; or

(c) PNA oligomer with 4-50 aeg-PNA monomers and one or more conjugates bound to the peptide nucleic acid either directly or through one or more linking moieties, where the conjugate is an amino acid side chain, or 2-6C-alkyl, aryl, aralkyl, heteroaryl, hydroxy, 1-6C alkoxy, 1-6C alkylthio, hydroxy- or alkoxy- or alkylthio- substituted 1-6C-alkyl, -NR4R5, R4 and R5 are as described above, Z1 is a bond, peptide of 1-10 amino acids or one of the radicals of formula (III) and Z2 is as described above;

(4) a pharmaceutical composition (PC) comprising (P1), (P2), (P3) or its salt as an active ingredient together with a carrier or diluent; and

(5) a compound chosen from GalNAc(OBz)3-O-(CH2)4-COOH, GalNAc(OBz)3-O-(CH2)4-CONH-Lys (GalNAc(OBz)3-O-(CH2)4-CONH)-Gly-OH, GalNAc(OBz)3-O-(CH2)4-CONH-Lys (GalNAc(OBz)3-O-(CH2)4-CONH)-Lys (GalNAc(OBz)3-O-(CH2)4-CONH)-Gly-OH, or GalNAc(OBz)3-O-(CH2)4-CONH-Lys- (GalNAc(OBz)3-O-(CH2)4-CONH- Lys (GalNAc(OBz)3-O-(CH2)4-CONH-Lys (GalNAc(OBz)3-O-(CH2)4-CONH)))-Gly-OH

ACTIVITY - Antibacterial; Virucide; Protozoacide; Fungicide; Cytostatic; Immunosuppressive.

No biological data is given.

MECHANISM OF ACTION - None given.

USE - (P1), (P2) or (P3) is useful in the manufacture of a medicament or composition for the treatment or prevention of bacterial, viral, protozoal and fungal infections, cancer, metabolic diseases, cardiovascular diseases, autoimmune and immunological disorders, or for disinfecting non-living objects, such as surgery tools, hospital inventory, dental tools, slaughterhouse inventory and tool, dairy inventory and tools, barbers and beauticians tools, etc. (P1)-(P3) and PC are useful for treating the above disease, which involves administering (P1), (P2), (P3), PC or its salt to the patient and need of treatment. (All claimed.)

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 4. Document ID: AU 2003221472 A1, WO 2003092735 A2

L5: Entry 4 of 37

File: DWPI

Nov 17, 2003

DERWENT-ACC-NO: 2004-011825

DERWENT-WEEK: 200442

COPYRIGHT 2004 DERWENT INFORMATION LTD

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.6&ref=5&dbname=PGPB,USPT,USO...> 10/5/04

TITLE: New peptide nucleic acid conjugates useful for the treatment of e.g. bacterial and viral infections, cancer, and metabolic diseases

INVENTOR: RASMUSSEN, J H; RASMUSSEN, P

PRIORITY-DATA: 2002DK-0000660 (May 1, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2003221472 A1</u>	November 17, 2003		000	A61K047/48
<u>WO 2003092735 A2</u>	November 13, 2003	E	021	A61K047/48

INT-CL (IPC): A61 K 47/48

ABSTRACTED-PUB-NO: WO2003092735A

BASIC-ABSTRACT:

NOVELTY - Peptide nucleic acid conjugate is new.

DETAILED DESCRIPTION - Peptide nucleic acid (PNA) conjugate of formula M-L-PNA (I) is new.

M = mimetic;

L = bond or linker; and

PNA = peptide nucleic acid conjugate oligomer of 4 - 25 monomers.

INDEPENDENT CLAIMS are included for the following:

- (1) a cell penetrating compound (M) comprising backbone modified peptides;
- (2) use of modified PNA molecule in the manufacture of a medicament useful for treating infectious diseases; and
- (3) a composition (C1) comprising a modified PNA molecule.

ACTIVITY - Antibacterial; Virucide; Cytostatic; Immunosuppressive.

MECHANISM OF ACTION - None given.

USE - For the down regulation of the expression of specific genes by targeting the genes at the mRNA or DNA level; treating bacterial and viral infections, cancer, metabolic diseases or immunological disorders (all claimed); and in disinfecting non-living objects e.g. surgery and dental tools, hospital and slaughterhouse inventory, dairy inventory and tools, barbers and beauticians tools.

ADVANTAGE - The modification of PNA by linking a peptide or peptide like sequence enhances the activity of PNA.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 5. Document ID: US 20020103906 A1

L5: Entry 5 of 37

File: DWPI

Aug 1, 2002

DERWENT-ACC-NO: 2002-666558

DERWENT-WEEK: 200271

COPYRIGHT 2004 DERWENT INFORMATION LTD

<http://westbrs.9000/bin/gate.exe?f=TOC&state=7kphob.6&ref=5&dbname=PGPB,USPT,USO...> 10/5/04

TITLE: Web browser intranet-based TCP/IP network for servicing remote clients in financial institution, has web server linked to TCP/IP network server and financial institution legacy system, to service client requests

INVENTOR: AHRENS, M Y; BIDDLECOMBE, S S; BRADEN, S L; CHILTON, C L; DEVAULT, R; DILLON, K O; KNIGHT, T A; LIEURANCE, K; MADDEN, T D; MOLAY, B; NELSON, C; PHILLIPS, R E; RASMUSSEN, P; SELZER, J; SHAFT, M M; VASQUEZ, J E; VERWERS, J E; WRIGHT, K S; YOUNG, D

PRIORITY-DATA: 2000US-217882P (July 10, 2000), 2001US-0901418 (July 9, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020103906 A1	August 1, 2002		018	G06F015/16

INT-CL (IPC): G06 F 15/16; G06 F 15/173

ABSTRACTED-PUB-NO: US20020103906A
BASIC-ABSTRACT:

NOVELTY - A remote client computer has a web browser application for inputting data into an active server pages (ASP) function. A web server is linked to the client computer to provide and service the ASP. The web server accesses the TCP/IP network servers and mainframe financial institution legacy system for servicing client requests through the dynamic HTML (DHTML) ASP.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

- (1) Client computer networking method;
- (2) Computer-readable medium having instructions for servicing web browser-based client requests;
- (3) ASP generated DHTML document provision method;
- (4) Client computer and mainframe legacy system communication method; and
- (5) Centralized server farm.

USE - For servicing clients in a remote site and for providing quality services to the customer from financial institutions such as bank.

ADVANTAGE - By providing web browser intranet-based TCP/IP network, high speed communication is achieved between financial institution and client computer, thereby the efficiency of sales and service is improved.

DESCRIPTION OF DRAWING(S) - The figure shows the flow diagram representing the typical communication flow through the business component dynamic link library (DLL).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 6. Document ID: US 6315240 B1

L5: Entry 6 of 37

File: DWPI

Nov 13, 2001

DERWENT-ACC-NO: 2002-214791

DERWENT-WEEK: 200227

COPYRIGHT 2004 DERWENT INFORMATION LTD

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.6&ref=5&dbname=PGPB,USPT,USO...> 10/5/04

TITLE: Improved tail fin assembly and control surface for attachment to high performance tactical missiles

INVENTOR: BROGMUS, E; RASMUSSEN, P; STUBBS, S

PRIORITY-DATA: 2000US-0516846 (March 2, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 6315240 B1</u>	November 13, 2001		008	F42B010/04

INT-CL (IPC): F42 B 10/04; F42 B 10/06

ABSTRACTED-PUB-NO: US 6315240B

BASIC-ABSTRACT:

NOVELTY - The improved controllable tail fin assembly(10) of aerodynamic configuration fits onto a high performance tactical missile. The fin has a pair of outer walls extending from a thin outer edge(12) to a wider inner fin platform containing ballast plates(30). An output control shaft projects radially outwards from the missile tail into the tail fin assembly(10). The fin platform has a central cavity containing two inwardly inclined sidewalls to ensure fin rotation in conjunction with the control shaft. A curved bottom portion of the cavity contacts with the rounded end of the control shaft when mounted onto the missile.

USE - As an improved tail fin assembly and control surface for attachment to high performance tactical missiles.

ADVANTAGE - The improved fin can be easily attached to a missile body within design tolerances without requiring special tools.

DESCRIPTION OF DRAWING(S) - The drawing shows a schematic of the tail fin assembly.

Tail fin 10

Outer edge 12

Ballast plates 30

Fin web 31

Ballast plate screws 32

Plate front edges 33

Mould lines 34

Screw aperture 36

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 7. Document ID: SE 522434 C2, SE 200000377 A

L5: Entry 7 of 37

File: DWPI

Feb 10, 2004

DERWENT-ACC-NO: 2002-129102

DERWENT-WEEK: 200413

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Preparation of sugar from sugar beet or sugarcane, by treating molasses with carbon dioxide at high pressure and separating gas hydrate crystals

INVENTOR: ANDERSEN, T B; GUDMUNDSON, C ; JOERGENSEN, L B ; KOCKUM, H ; RASMUSSEN, P ; THOMSEN, K ; ANDERSE, T B

PRIORITY-DATA: 2000SE-0000377 (February 8, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>SE 522434 C2</u>	February 10, 2004		000	C13D003/16
<u>SE 200000377 A</u>	August 9, 2001		018	C13D003/00

INT-CL (IPC): C13 D 3/00; C13 D 3/16; C13 F 1/00

ABSTRACTED-PUB-NO: SE 200000377A

BASIC-ABSTRACT:

NOVELTY - Purification and concentration of the molasses is carried out by treatment with carbon dioxide at high pressure to form gas hydrate crystals, which are separated to give a purified sugar solution.

DETAILED DESCRIPTION - A method for preparing sugar from sugar beet or sugarcane comprises extracting the sugar with water to form a sugar-containing molasses which is then purified and concentrated in order to recover the sugar by crystallisation. Purification and concentration of the molasses is carried out by treating it with liquid or gaseous carbon dioxide at -10 to +12 deg.C and 1-10 MPa to form gas hydrate crystals. These crystals are separated from the molasses, forming a purified sugar solution with an increased sugar content, which is further treated to recover the sugar crystals.

USE - Preparation of sugar from sugar beet or sugarcane.

ADVANTAGE - Energy consumption is reduced by more than 50 % compared with a conventional sugar beet or sugarcane extraction process. Lime and coke consumption can be significantly reduced or even eliminated.

DESCRIPTION OF DRAWING(S) - Figure 2 shows a flow diagram for the sugar production process.

Sugar beet delivery 1

Sugar beet receiving station 2

Sugar beet slices 3

Extraction apparatus 4

Sugar solution 5

Pressurized reactor 6

Carbon dioxide 7

Carbon dioxide hydrate or ice seed crystals 8

Carbon dioxide hydrate crystals 9

Concentrated sugar solution 10

Pressurized reactor 11

Carbohydrate crystals 12

Sugar crystals 13

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 8. Document ID: ES 2193993 T3, DE 20022300 U1, WO 200147616 A1, DE 19963421 A1, BR 200016750 A, EP 1242159 A1, CZ 200202237 A3, EP 1242159 B1, JP 2003518432 W, DE 50002227 G, US 20030116508 A1, CN 1414875 A

L5: Entry 8 of 37

File: DWPI

Nov 16, 2003

DERWENT-ACC-NO: 2001-399569

DERWENT-WEEK: 200381

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Filter aid feed system comprises containers fitted with screw conveyors which dispense measured amounts into tank where it is converted to suspension

INVENTOR: BALLREICH, G; LASSAK, R ; RASMUSSEN, P

PRIORITY-DATA: 1999DE-1063421 (December 28, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>ES 2193993 T3</u>	November 16, 2003		000	B01D037/04
<u>DE 20022300 U1</u>	June 28, 2001		021	B01D037/03
<u>WO 200147616 A1</u>	July 5, 2001	G	000	B01D037/04
<u>DE 19963421 A1</u>	July 12, 2001		000	B01D037/03
<u>BR 200016750 A</u>	September 3, 2002		000	B01D037/04
<u>EP 1242159 A1</u>	September 25, 2002	G	000	B01D037/04
<u>CZ 200202237 A3</u>	March 12, 2003		000	B01D037/04
<u>EP 1242159 B1</u>	May 14, 2003	G	000	B01D037/04
<u>JP 2003518432 W</u>	June 10, 2003		021	B01D037/02
<u>DE 50002227 G</u>	June 18, 2003		000	B01D037/04
<u>US 20030116508 A1</u>	June 26, 2003		000	B01D035/143
<u>CN 1414875 A</u>	April 30, 2003		000	B01D037/04

INT-CL (IPC): B01 D 35/143; B01 D 36/00; B01 D 37/02; B01 D 37/03; B01 D 37/04; B01 F 3/12; B01 F 15/02; B01 F 15/04; C12 H 1/02

ABSTRACTED-PUB-NO: DE 20022300U

BASIC-ABSTRACT:

NOVELTY - Feed system for filter aid comprises bags (5, 6, 7) for the filter aid and screw conveyors (25 - 27) fitted to each bag which dispense measured amounts via pipes (52) into a tank (28) where it is converted to a suspension. A valve (42) and pump (44) dispense measured amounts of suspension. Sensors (48, 49) produce filtration data which is fed to a unit which controls the screw conveyors, valve and pump.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a system as above where the tank is replaced by a mixer for the dry materials.

USE - In the drinks, e.g. beer, industry.

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.6&ref=5&dbname=PGPB,USPT,USO...> 10/5/04

DESCRIPTION OF DRAWING(S) - The drawing shows the feed system.

Containers for filter aid 5 - 7

Screw conveyors 25 - 27

Tank 28

Valve 42

Pump 44

Sensors 48, 49

Pipes 52

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 9. Document ID: US 6221457 B1

L5: Entry 9 of 37

File: DWPI

Apr 24, 2001

DERWENT-ACC-NO: 2001-290011

DERWENT-WEEK: 200130

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Display system for curved surfaces

INVENTOR: RASMUSSEN, P

PRIORITY-DATA: 1995US-0443058 (May 17, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 6221457 B1</u>	April 24, 2001		007	G09B027/08

INT-CL (IPC): G09 B 27/08

ABSTRACTED-PUB-NO: US 6221457B

BASIC-ABSTRACT:

NOVELTY - A flexible sheet can be stored or patterned while in a flat configuration, and subsequently readily adapted to overlay a curved surface, for example a hemisphere of a sphere. Radial incisions made to the sheet provide a hub and triangular gores that adapt the sheet to conform to the curved surface. A patternable transparent cover, adapted to be removably and/or pivotally secured to the hemisphere, closely overlays the sheet to form a covering assembly. Covering assemblies may be placed over one or both hemispheres of a sphere and fixedly or removably joined together.

USE - Display system for curved surfaces.

DESCRIPTION OF DRAWING(S) - An exploded perspective view of a covering assembly for a curved surface.

sheet 12

hemisphere. 14

□ 10. Document ID: US 6781276 B1, WO 200060719 A1, DK 9901655 A, AU 200035512 A, DK 173641 B, EP 1173915 A1

L5: Entry 10 of 37

File: DWPI

Aug 24, 2004

DERWENT-ACC-NO: 2000-665036

DERWENT-WEEK: 200457

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Electricity generator for windmill, has stator fabricated with at least two fully enclosed modules which can be mounted and dismantled independently of each other.

INVENTOR: RASMUSSEN, P ; STIESDAL, H

PRIORITY-DATA: 1999DK-0001655 (November 17, 1999), 1999DK-0000451 (March 31, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6781276 B1	August 24, 2004		000	H02K001/12
WO 200060719 A1	October 12, 2000	E	023	H02K001/12
DK 9901655 A	October 1, 2000		000	H02K001/12
AU 200035512 A	October 23, 2000		000	H02K001/12
DK 173641 B	May 14, 2001		000	H02K001/12
EP 1173915 A1	January 23, 2002	E	000	H02K001/12

INT-CL (IPC): H02 K 1/12; H02 K 15/02

ABSTRACTED-PUB-NO: WO 200060719A

BASIC-ABSTRACT:

NOVELTY - The electricity generator has stator fabricated with at least two fully enclosed modules which can be mounted and dismantled independently of each other. Each module is individually contained in an enclosure, with a tightness corresponding to the enclosing and tightness desired in the finished generator.

DETAILED DESCRIPTION - The individual stator modules are installed to form a closed ring of stator modules, with a diameter that does not exceed the diameter of the air gap of the generator. Each module may be displaced radially on the stator structure to adjust the air gap. INDEPENDENT CLAIMS are included for a stator module, and for use of a generator in a windmill.

USE - For electricity generation by windmill, especially operating a generator that is directly driven by the windmill rotor without a gearbox between the rotor and the generator.

ADVANTAGE - The stator modules can be installed, repaired and dismantled independently. The stator can be transported in separate parts.

DESCRIPTION OF DRAWING(S) - The figure shows a detailed illustration of the generator.

Stator module 33

Stator housing 34

Manholes 35

Torque supports 36

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 11. Document ID: WO 200048297 A1, AU 200024305 A, NO 200103869 A, EP 1159780 A1, KR 2001102036 A, CN 1340238 A, ES 2168235 T1, JP 2002537750 W

L5: Entry 11 of 37

File: DWPI

Aug 17, 2000

DERWENT-ACC-NO: 2000-565314

DERWENT-WEEK: 200458

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Synchronous electrical generator for wind turbine, has one or more current windings or coils wound around pole legs or cores providing magnetic flux paths

INVENTOR: DAM LARSEN, K; DAM LARSEN, U ; RASMUSSEN, P ; LARSEN, K D ; LARSEN, U D

PRIORITY-DATA: 1999DK-0000177 (February 10, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 200048297 A1</u>	August 17, 2000	E	060	H02K021/24
<u>AU 200024305 A</u>	August 29, 2000		000	H02K021/24
<u>NO 200103869 A</u>	October 4, 2001		000	H02K000/00
<u>EP 1159780 A1</u>	December 5, 2001	E	000	H02K021/24
<u>KR 2001102036 A</u>	November 15, 2001		000	H02K021/24
<u>CN 1340238 A</u>	March 13, 2002		000	H02K021/24
<u>ES 2168235 T1</u>	June 16, 2002		000	H02K021/24
<u>JP 2002537750 W</u>	November 5, 2002		049	H02K021/14

INT-CL (IPC): H02 K 0/00; H02 K 1/27; H02 K 21/14; H02 K 21/24; H02 K 21/26

ABSTRACTED-PUB-NO: WO 200048297A

BASIC-ABSTRACT:

NOVELTY - Magnets are provided surrounding rotors (124). Air gaps are formed between rotors and stators. One or more current windings or coils are wound on pole legs or pole cores providing magnetic flux paths. The pole legs or cores are arranged in stator.

USE - For wind turbine.

ADVANTAGE - High density of magnetic flux is allowed to pass through pole leg or core, when pole leg is surrounded by corresponding coil, thereby reducing consumption of material for pole legs or cores.

DESCRIPTION OF DRAWING(S) - The figure shows the perspective view of synchronous electrical generator.

Rotors 124

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

□ 12. Document ID: RU 2225118 C2, WO 9950399 A2, AU 9929530 A, BR 9909280 A, EP 1068302 A2, ZA 200004817 A, CN 1303427 A, KR 2001042255 A, JP 2002509720 W, MX 2000009629 A1, AU 763250 B, NZ 506892 A, US 6667065 B1, US 20040043109 A1

L5: Entry 12 of 37

File: DWPI

Mar 10, 2004

DERWENT-ACC-NO: 1999-601334

DERWENT-WEEK: 200428

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Use of a non-maltogenic exoamylase for producing starch products, particularly baked farinaceous bread products, with reduced staling

INVENTOR: DUEDAHL-OLESEN, L; KRAGH, K M ; LARSEN, B ; RASMUSSEN, P ; ZIMMERMANN, W ; RASSMUSSEN, P

PRIORITY-DATA: 1998DK-0000457 (April 1, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
RU 2225118 C2	March 10, 2004		000	A21D008/02
<u>WO 9950399 A2</u>	October 7, 1999	E	034	C12N009/24
AU 9929530 A	October 18, 1999		000	
BR 9909280 A	November 21, 2000		000	C12N009/24
<u>EP 1068302 A2</u>	January 17, 2001	E	000	C12N009/24
<u>ZA 200004817 A</u>	May 31, 2001		083	A21D000/00
<u>CN 1303427 A</u>	July 11, 2001		000	C12N009/24
<u>KR 2001042255 A</u>	May 25, 2001		000	C12N009/24
<u>JP 2002509720 W</u>	April 2, 2002		081	C12P019/04
<u>MX 2000009629 A1</u>	December 1, 2001		000	A21D002/26
<u>AU 763250 B</u>	July 17, 2003		000	C12N009/24
<u>NZ 506892 A</u>	November 28, 2003		000	C12N009/24
<u>US 6667065 B1</u>	December 23, 2003		000	A21D008/04
<u>US 20040043109 A1</u>	March 4, 2004		000	A23L001/10

INT-CL (IPC): A21 D 0/00; A21 D 2/26; A21 D 8/02; A21 D 8/04; A23 L 1/10; C12 N 9/24; C12 N 9/28; C12 P 19/04; C12 P 19/04; C12 P 19/04; C12 R 1/07; C12 R 1/38

ABSTRACTED-PUB-NO: WO 9950399A

BASIC-ABSTRACT:

NOVELTY - Use of a non-maltogenic exoamylase (NME) for retarding retrogradation of starch in starch products is new.

DETAILED DESCRIPTION - (A) A novel process for making a starch product comprises adding to a starch medium a NME that is capable of hydrolyzing starch by cleaving off one or more linear maltooligosaccharides (MOSs), predominantly consisting of 4 to 8 D-glucopyranosyl units, from the non-reducing ends of the side chains of amylopectin.

INDEPENDENT CLAIMS are also included for the following:

(1) a NME obtainable from *Bacillus clausii*, or a functional equivalent, where the enzyme has a molecular weight of 101 kDa (as estimated by SDS-PAGE) and/or the enzyme has an optimum of activity of pH 9.5 and 55°C, and

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.6&ref=5&dbname=PGPB,USPT,USO...> 10/5/04

(2) use of an NME in a starch product to retard staling of the starch product.

USE - The process can be used for obtaining hydrolysis products such as maltotetraose, maltopentaose, maltohexaose, maltoheptaose or maltooctaose (claimed). The starch product may be a dough e.g. a baked farinaceous bread product (claimed).

ADVANTAGE - The starch products have retarded detrimental retrogradation properties, e.g. for retarding the staling of baked products.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 13. Document ID: DE 69825263 E, WO 9845453 A1, AU 9868207 A, EP 977869 A1, ES 2168236 T1, EP 1433852 A1, EP 977869 B1

L5: Entry 13 of 37

File: DWPI

Sep 2, 2004

DERWENT-ACC-NO: 1998-568355

DERWENT-WEEK: 200457

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New *Aspergillus tubigensis* lipase - used as dough additive to reduce pore size in the crumb, increase pore homogeneity and increase gluten index

INVENTOR: MADRID, S M; POULSEN, C H ; RASMUSSEN, P ; SOE, J B ; ZARGAHI, M R

PRIORITY-DATA: 1997DK-0000400 (April 9, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 69825263 E	September 2, 2004		000	C12N009/20
<u>WO 9845453 A1</u>	October 15, 1998	E	095	C12N015/55
<u>AU 9868207 A</u>	October 30, 1998		000	
<u>EP 977869 A1</u>	February 9, 2000	E	000	
<u>ES 2168236 T1</u>	June 16, 2002		000	C12N015/55
<u>EP 1433852 A1</u>	June 30, 2004	E	000	C12N015/55
<u>EP 977869 B1</u>	July 28, 2004	E	000	C12N009/20

INT-CL (IPC): A21 D 8/04; C07 K 19/00; C12 N 1/15; C12 N 9/20; C12 N 15/55; C12 N 15/80

ABSTRACTED-PUB-NO: WO 9845453A

BASIC-ABSTRACT:

New lipase (I) from *Aspergillus tubigensis*: (i) retains at least 80% activity after 4 days at 20 deg. C and pH 3.5-8; (ii) retains at least 60 (especially 80)% activity after 1 hour at 60 deg. C in 0.1 M sodium acetate buffer, and (iii) has isoelectric point 3.5-4.5 (preferably 4.0-4.2) as measured by isoelectric focusing. Also new are: (1) recombinant DNA (II) encoding (I), and (2) cells containing (II).

USE - (I) is an improver for breadmaking dough that reduces average pore diameter, and increases pore homogeneity, in the crumb, and increases the gluten index (i.e. improves stability of the gluten network). Cells of (2) are used to produce recombinant (I).

ADVANTAGE - Bread produced from doughs containing (I) have greater mechanical strength, especially sliceability and resistance to physical handling, and the

improved gluten network increases tolerance to variations in fermentation times.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

□ 14. Document ID: WO 9844804 A1, AU 9868206 A, EP 973399 A1, EP 1193314 A1, US 6406723 B1, EP 973399 B1, DE 69806586 E, ES 2178192 T3, US 20030108641 A1

L5: Entry 14 of 37

File: DWPI

Oct 15, 1998

DERWENT-ACC-NO: 1998-568288

DERWENT-WEEK: 200444

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Improving rheological properties of flour dough - by adding glycerol oxidase and optionally lipase, used to increase dough strength, and specific volume and crumb structure of baked products

INVENTOR: MADRID, S M; POULSEN, C H ; RASMUSSEN, P ; SOE, J B ; ZARGAHI, M R

PRIORITY-DATA: 1997DK-0000400 (April 9, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 9844804 A1</u>	October 15, 1998	E	082	A21D008/04
<u>AU 9868206 A</u>	October 30, 1998		000	
<u>EP 973399 A1</u>	January 26, 2000	E	000	
<u>EP 1193314 A1</u>	April 3, 2002	E	000	C12N015/55
<u>US 6406723 B1</u>	June 18, 2002		000	A21D008/04
<u>EP 973399 B1</u>	July 17, 2002	E	000	A21D008/04
<u>DE 69806586 E</u>	August 22, 2002		000	A21D008/04
<u>ES 2178192 T3</u>	December 16, 2002		000	A21D008/04
<u>US 20030108641 A1</u>	June 12, 2003		000	A21D002/00

INT-CL (IPC): A21 D 2/00; A21 D 8/04; A23 L 1/16; C07 K 19/00; C12 N 1/15; C12 N 9/20; C12 N 15/55; C12 N 15/80

ABSTRACTED-PUB-NO: EP 973399B

BASIC-ABSTRACT:

The rheological properties of flour dough, and quality of finished products made from the dough, are improved by adding 10-10000 units of a glycerol oxidase (I)/kg of flour. Also new are: (1) a similar process in which (I) is added together with a lipase (II), and (2) dough improver containing (I) and at least 1 other dough ingredient or additive.

USE - The doughs are particularly used to make bread, noodles and pasta.

ADVANTAGE - Addition of (I) increases the resistance to extension (strength) of the dough, and its effect is significantly increased by (II), which does not itself increase dough strength. (I) and (II) improve crumb structure and specific volume of baked products in a synergistic manner. Noodles and pasta prepared from (I)-treated dough have better colour, consistency and eating quality, including firmness, elasticity and a non-sticky texture.

ABSTRACTED-PUB-NO:

US 6406723B EQUIVALENT-ABSTRACTS:

The rheological properties of flour dough, and quality of finished products made from the dough, are improved by adding 10-10000 units of a glycerol oxidase (I)/kg of flour. Also new are: (1) a similar process in which (I) is added together with a lipase (II), and (2) dough improver containing (I) and at least 1 other dough ingredient or additive.

USE - The doughs are particularly used to make bread, noodles and pasta.

ADVANTAGE - Addition of (I) increases the resistance to extension (strength) of the dough, and its effect is significantly increased by (II), which does not itself increase dough strength. (I) and (II) improve crumb structure and specific volume of baked products in a synergistic manner. Noodles and pasta prepared from (I)-treated dough have better colour, consistency and eating quality, including firmness, elasticity and a non-sticky texture.

The rheological properties of flour dough, and quality of finished products made from the dough, are improved by adding 10-10000 units of a glycerol oxidase (I)/kg of flour. Also new are: (1) a similar process in which (I) is added together with a lipase (II), and (2) dough improver containing (I) and at least 1 other dough ingredient or additive.

USE - The doughs are particularly used to make bread, noodles and pasta.

ADVANTAGE - Addition of (I) increases the resistance to extension (strength) of the dough, and its effect is significantly increased by (II), which does not itself increase dough strength. (I) and (II) improve crumb structure and specific volume of baked products in a synergistic manner. Noodles and pasta prepared from (I)-treated dough have better colour, consistency and eating quality, including firmness, elasticity and a non-sticky texture.

WO 9844804A

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 15. Document ID: AU 759382 B, WO 9838321 A1, AU 9861104 A, EP 1005558 A1, CN 1249003 A, BR 9808654 A, NZ 336563 A, KR 2000075823 A, JP 2001513637 W, US 6524816 B1

L5: Entry 15 of 37

File: DWPI

Apr 10, 2003

DERWENT-ACC-NO: 1998-520761

DERWENT-WEEK: 200337

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New nucleic acid constructs - containing a transcription modulator from an *Aspergillus tubingensis* xylanase A gene to modulate transcription from a promoter

INVENTOR: RASMUSSEN, P

PRIORITY-DATA: 1997GB-0004157 (February 28, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 759382 B</u>	April 10, 2003		000	C12N015/63
<u>WO 9838321 A1</u>	September 3, 1998	E	069	C12N015/63
<u>AU 9861104 A</u>	September 18, 1998		000	C12N015/63
<u>EP 1005558 A1</u>	June 7, 2000	E	000	C12N015/63
<u>CN 1249003 A</u>	March 29, 2000		000	C12N015/63
<u>BR 9808654 A</u>	May 23, 2000		000	C12N015/63

NZ 336563 A	December 22, 2000	000	C12N009/24
KR 2000075823 A	December 26, 2000	000	C12N015/63
JP 2001513637 W	September 4, 2001	070	C12N015/09
US 6524816 B1	February 25, 2003	000	C12P021/00

INT-CL (IPC): C07 H 21/04; C12 N 1/15; C12 N 1/21; C12 N 5/00; C12 N 9/24; C12 N 15/09; C12 N 15/63; C12 N 15/80; C12 P 21/00

ABSTRACTED-PUB-NO: WO 9838321A
BASIC-ABSTRACT:

A nucleic acid construct comprising a promoter which is operatively linked to a NS, characterised in that at least one heterologous copy of the element (I) (see below) has been operatively linked to the promoter; CGGCAGGGTCTC (I). Also claimed are: (1) a host cell transformed with a construct as above; (2) a transgenic organism transformed with a construct as above; (3) a sequence variant of the *Aspergillus tubingensis* xlnB promoter which possess at least 3 copies of the element (I); and (4) a method for modulating the level of transcription of a NS from a promoter, comprising inserting at least one exogenous copy of the element (I) such that it is operably linked to the promoter, and causing the NS to be transcribed from the promoter.

USE - Constructs containing (I) can modulate transcription of a NS from a promoter, in particular they can be used to increase expression. The constructs can be used for the expression of heterologous polypeptides such as polypeptides useful in the foodstuffs, feed and beverage industries, particularly xylanase.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 7 of 7 returned.

☐ 1. Document ID: US 20030116508 A1

Using default format because multiple data bases are involved.

L4: Entry 1 of 7

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030116508

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030116508 A1

TITLE: Method and device for supplying filtering aids and/or process materials during filtration

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ballreich, Gunter	Frickenhhausen		DE	
Lassak, Raimund	Waldstetten		DE	
Rasmussen, Peter	Fredericia		DK	

US-CL-CURRENT: [210/739](#); [210/143](#), [210/193](#), [210/778](#), [210/85](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 2. Document ID: US 6781276 B1

L4: Entry 2 of 7

File: USPT

Aug 24, 2004

US-PAT-NO: 6781276

DOCUMENT-IDENTIFIER: US 6781276 B1

TITLE: Generator for a windmill, stator module for use in such a generator and use of such a generator

DATE-ISSUED: August 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stiesdal; Henrik	Brande			DK
Rasmussen; Peter	Svendborg			DK

US-CL-CURRENT: [310/254](#); [290/44](#), [310/258](#), [310/259](#)

ABSTRACT:

The invention concerns a generator for a windmill. The generator is of the kind being

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.5&ref=4&dbname=PGPB,USPT,USO...> 10/5/04

directly coupled to the main shaft of the wind rotor of the windmill. The generator is a stator consisting of a number of stator modules that are individual and which may be installed, repaired and dismantled individually and independently of each other. This implies that it is very easy and thereby cheaper to mount the mill, especially at sea, as the stator for the generator can be transported in smaller units, which also makes it easier to assemble the stator in the tower top section. By sequent repairs and other maintenance of the generator it is not necessary either to use large cranes, but it is sufficient to use smaller hoisting devices that may be handled by one or two persons.

10 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 3. Document ID: US 6221457 B1

L4: Entry 3 of 7

File: USPT

Apr 24, 2001

US-PAT-NO: 6221457
DOCUMENT-IDENTIFIER: US 6221457 B1

TITLE: Display system for curved surfaces

DATE-ISSUED: April 24, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rasmussen; Peter	Berkeley	CA		

US-CL-CURRENT: 428/99; 40/615, 428/11, 428/13, 428/137, 428/192, 428/542.2, 428/65.1, 428/913.3, 434/131, 434/135, 434/137

ABSTRACT:

A flexible sheet can be stored or patterned while in a flat configuration, and subsequently readily adapted to overlay a curved surface, for example a hemisphere of a sphere. Radial incisions made to the sheet provide a hub and a plurality of substantially triangular gores that adapt the sheet to conform substantially to the curved surface. A patternable transparent cover, adapted to be removably and/or pivotally secured to the hemisphere, closely overlays the sheet to form a covering assembly. Covering assemblies may be placed over one or both hemispheres of a sphere and fixedly or removably joined together.

13 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 4. Document ID: US 4746194 A

L4: Entry 4 of 7

File: USPT

May 24, 1988

US-PAT-NO: 4746194

DOCUMENT-IDENTIFIER: US 4746194 A

TITLE: Method of mounting an end portion of an optical fibre in an optical fibre connector

DATE-ISSUED: May 24, 1988

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Rasmussen; Peter</u>	S-330 33 Hillerstorp			SE

US-CL-CURRENT: 385/80; 385/82, 385/85

ABSTRACT:

In a method for fixing an optical fibre in an optical fibre connector element the fibre is fixed therein by means of centering elements (22) and a curable material (28), for example an adhesive. The centering elements and the curable material are positioned between the envelope of an end portion of the optical fibre (6) and a surface portion (26) of the connector element surrounding said envelope. After the fixing of the fibre end portion in the connector element the end portion of the connector element including the centering elements (22) and the fibre end portion (6) are machined, for example ground, up to a plane (30) which is positioned inside the points of contact between the centering elements (22) and the fibre end portion (6) and between the centering elements (22) and the surface portion (26) of the connector element surrounding the fibre end portion.

3 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 5. Document ID: US 3858332 A

L4: Entry 5 of 7

File: USPT

Jan 7, 1975

US-PAT-NO: 3858332

DOCUMENT-IDENTIFIER: US 3858332 A

TITLE: METHOD AND APPARATUS FOR DEMONSTRATING POLYNOMIAL ALGEBRAIC OPERATIONS

DATE-ISSUED: January 7, 1975

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Rasmussen; Peter</u>	Berkeley	CA	94703	

US-CL-CURRENT: 434/211

ABSTRACT:

An assembly for the demonstration of algebraic or arithmetic operations by the manipulation of a plurality of rectangular elements of different sizes and shapes and characterized by the incommensurability of selected width and length dimensions

thereof, and the distinguishability of opposing faces of the elements to denote positively and negatively oriented elements.

9 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 6. Document ID: WO 147616 A1

L4: Entry 6 of 7

File: EPAB

Jul 5, 2001

PUB-NO: WO000147616A1
DOCUMENT-IDENTIFIER: WO 147616 A1
TITLE: METHOD AND DEVICE FOR SUPPLYING FILTERING AIDS AND/OR PROCESS MATERIALS DURING FILTRATION

PUBN-DATE: July 5, 2001

INVENTOR-INFORMATION:

NAME	COUNTRY
BALLREICH, GUENTER	DE
LASSAK, RAIMUND	DE
RASMUSSEN, PETER	DK

INT-CL (IPC): B01 D 37/04; B01 F 15/04; B01 F 3/12; B01 D 37/02
EUR-CL (EPC): B01F003/12; B01D037/02, B01F015/04

ABSTRACT:

CHG DATE=20010803 STATUS=O>The invention relates to a device for supplying filtering aids and/or process materials during filtration. Such devices are widely used, especially in the beverage industry. The inventive device comprises at least one storage container (5, 6, 7) which contains the filtering aids and/or process materials. The device further comprises elements (25, 26, 27) for the dosed withdrawal from at least one storage container which communicate with a suspension container (28) or a mixing container. The device is also provided with a unit (44) for the dosed withdrawal from the container (28). The actual filtration data are detected by sensors (48, 49) and are transmitted to an electronic control system so that the filtering aids and/or process materials can be withdrawn in a dosed manner.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 7. Document ID: WO 9816748 A1

L4: Entry 7 of 7

File: EPAB

Apr 23, 1998

PUB-NO: WO009816748A1
DOCUMENT-IDENTIFIER: WO 9816748 A1
TITLE: PNEUMATIC CYLINDER ASSEMBLY

PUBN-DATE: April 23, 1998

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.5&ref=4&dbname=PGPB,USPT,USO...> 10/5/04

INVENTOR-INFORMATION:

NAME

RASMUSSEN, PETER

COUNTRY

SE

INT-CL (IPC): F15 B 15/00; B25 J 15/02

EUR-CL (EPC): F15B015/16; B25J018/02

ABSTRACT:

CHG DATE=19990617 STATUS=O>A pneumatic cylinder assembly (1) comprises an outer cylinder element (2), an inner cylinder element (3), which is telescopically displaceable in the axial direction (a) relative to the outer cylinder element, and a piston element (4), which is telescopically displaceable in the axial direction (a) relative to the inner cylinder element (3). The elements (2-4) together define a pressure chamber (6', 11') for extension of the inner cylinder element (3) from the outer cylinder element (2) and of the piston element (4) from the inner cylinder element (3), and pressure chambers (6'', 11'') for retraction of the inner cylinder element (3) into the outer cylinder element (2) and of the piston element (4) into the inner cylinder element (3). At least one non-centrally arranged telescopic tube (23, 24) extends in the axial direction (a) through the cylinder elements (2, 3) and the piston element (4). The tube (23, 24) is adapted to lock the piston element (4) against rotation relative the outer cylinder element (2) and to establish a tight connection between a pressure medium connection (27, 28) at the rear end wall (5) of the outer cylinder element (2) and a pressure medium connection intended for a pneumatic or hydraulic tool, such as a gripping jaw, connected to the piston element (4).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Terms

Documents

Rasmussen-Peter.IN.

7

Display Format:

[Change Format](#)[Previous Page](#)[Next Page](#)[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 7 of 7 returned.

☐ 1. Document ID: BR 200212047 A, WO 2003015812 A2, US 20030157117 A1, EP 1420815 A2, AU 2002325199 A1

Using default format because multiple data bases are involved.

L21: Entry 1 of 7

File: DWPI

Aug 17, 2004

DERWENT-ACC-NO: 2003-312718

DERWENT-WEEK: 200457

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Novel analog of amyloid precursor protein or beta amyloid for treating Alzheimer's disease, has amyloid precursor protein/beta amyloid incorporating B-cell epitope of amyloid protein and foreign T-helper epitope

INVENTOR: DAL DEGAN, F; JENSEN, M R ; KOEFOED, P ; NIELSEN, K G ; RASMUSSEN, P B ; DEGAN, F D

PRIORITY-DATA: 2002US-373027P (April 16, 2002), 2001DK-0001231 (August 20, 2001), 2001US-337543P (October 22, 2001), 2002DK-0000558 (April 16, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>BR 200212047 A</u>	August 17, 2004		000	A61K039/00
<u>WO 2003015812 A2</u>	February 27, 2003	E	122	A61K039/00
<u>US 20030157117 A1</u>	August 21, 2003		000	A61K039/00
<u>EP 1420815 A2</u>	May 26, 2004	E	000	A61K039/00
<u>AU 2002325199 A1</u>	March 3, 2003		000	A61K039/00

INT-CL (IPC): A61 K 39/00; A61 K 39/385; A61 P 25/28; C07 K 14/47; C12 N 9/64

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 2. Document ID: AU 2002233166 A1, WO 200266056 A2, US 20020119162 A1, US 20020187157 A1, EP 1363664 A2

L21: Entry 2 of 7

File: DWPI

Sep 4, 2002

DERWENT-ACC-NO: 2002-706932

DERWENT-WEEK: 200427

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Novel immunogen useful for immunizing an animal, has an activated polyhydroxypolymer backbone to which is attached an antigenic determinant including a B cell epitope and another determinant including a T-helper epitope

INVENTOR: KOEFOED, P; NIELSEN, K G ; JENSEN, M R ; RASMUSSEN, P B

PRIORITY-DATA: 2001US-337543P (October 22, 2001), 2001WO-DK00113 (February 19, 2001), 2001US-0785215 (February 20, 2001), 2001DK-0001231 (August 20, 2001), 2000DK-0000265 (February 21, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2002233166 A1</u>	September 4, 2002		000	A61K039/385
<u>WO 200266056 A2</u>	August 29, 2002	E	052	A61K039/385
<u>US 20020119162 A1</u>	August 29, 2002		000	A61K039/00
<u>US 20020187157 A1</u>	December 12, 2002		000	A61K039/00
<u>EP 1363664 A2</u>	November 26, 2003	E	000	A61K039/385

INT-CL (IPC): A61 K 38/19; A61 K 38/20; A61 K 39/00; A61 K 39/385; A61 K 47/48

ABSTRACTED-PUB-NO: WO 200266056A

BASIC-ABSTRACT:

NOVELTY - An immunogen (I) comprising at least one first antigenic determinant that includes at least one B-cell epitope and/or at least one cytotoxic T lymphocyte (CTL) epitope, and at least one second antigenic determinant that includes a T helper cell epitope (TH epitope), where each of the first and second antigenic determinants are coupled to an activated polyhydroxypolymer carrier, is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for an immunogenic composition (II) for raising an immune response against an antigen in a mammal, including a human, comprising (I), and optionally an adjuvant.

ACTIVITY - None given.

MECHANISM OF ACTION - Vaccine.

Test details are described, but no results are given.

USE - (I) or (II) contained in a virtual lymph node (VLN) device is useful for immunizing an animal, including a human, against an antigen of choice, where the antigen shares the at least one first antigenic determinant with the immuogen (claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference				Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	--------	------	------------

☐ 3. Document ID: US 20030169546 A1, WO 200182439 A1, DK 200000750 A, AU 200152110 A, EP 1290768 A1

L21: Entry 3 of 7

File: DWPI

Sep 11, 2003

DERWENT-ACC-NO: 2002-205747

DERWENT-WEEK: 200367

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Electric distribution circuit supply and protection system with two monitoring circuits detecting error state

INVENTOR: LINDEMANN, S; NIELSEN, K G; NIELSEN, G K

PRIORITY-DATA: 2000DK-0000750 (April 27, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20030169546 A1	September 11, 2003		000	H02H009/00
WO 200182439 A1	November 1, 2001	E	017	H02H003/02
DK 200000750 A	October 28, 2001		000	H02H003/20
AU 200152110 A	November 7, 2001		000	H02H003/02
EP 1290768 A1	March 12, 2003	E	000	H02H003/02

INT-CL (IPC): H02 H 3/02; H02 H 3/20; H02 H 9/00

ABSTRACTED-PUB-NO: WO 200182439A

BASIC-ABSTRACT:

NOVELTY - The supply circuit is formed with at least two independent monitoring circuits performing independent measurements of an error state on the basis of common threshold value generated from the value determined in the circuit. Recording of an error state in the monitoring circuit results in activation of at least one independent current path between the supply potential of the supply circuit and the associated reference value. The electric circuit increases the current through a separator circuit isolating the distribution circuit from the remaining network. The same reference value may be used for several monitoring circuits where the component tolerances are compensated.

USE - For fire protection of electric distribution apparatus.

ADVANTAGE - Protection reliability is increased.

DESCRIPTION OF DRAWING(S) - Drawing shows a block diagram of electronic protection circuit.

Triple protection circuit 201,202,203

Electronic switch 204,205,206

Feedback controlled circuit 208

Reference circuit. 207

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

□ 4. Document ID: CZ 200202748 A3, WO 200162284 A2, AU 200133620 A, NO 200203961 A, EP 1259251 A2, BR 200108566 A, KR 2003001365 A, US 20030086938 A1, HU 200300067 A2, CN 1416350 A, JP 2003523402 W, NZ 521442 A, ZA 200204830 A, SK 200201178 A3

L21: Entry 4 of 7

File: DWPI

Mar 17, 2004

DERWENT-ACC-NO: 2001-589796

DERWENT-WEEK: 200430

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: In vivo down-regulation of amyloid protein for the treatment of Alzheimer's, comprises presenting an amyloidogenic polypeptide or its subsequence and/or at least one analogue of the amyloidogenic polypeptide to the immune system

INVENTOR: BIRK, P; JENSEN, M R ; NIELSEN, K G

PRIORITY-DATA: 2000US-186295P (March 1, 2000), 2000DK-0000265 (February 21, 2000)

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.22&ref=21&dbname=PGPB,USPT,U...> 10/5/04

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
CZ 200202748 A3	March 17, 2004		000	A61K038/17
WO 200162284 A2	August 30, 2001	E	120	A61K039/395
AU 200133620 A	September 3, 2001		000	A61K039/395
NO 200203961 A	August 20, 2002		000	A61K000/00
EP 1259251 A2	November 27, 2002	E	000	A61K038/17
BR 200108566 A	November 19, 2002		000	A61K039/395
KR 2003001365 A	January 6, 2003		000	A61K038/16
US 20030086938 A1	May 8, 2003		000	A61K039/00
HU 200300067 A2	May 28, 2003		000	A61K038/17
CN 1416350 A	May 7, 2003		000	A61K038/17
JP 2003523402 W	August 5, 2003		108	A61K039/00
NZ 521442 A	September 26, 2003		000	A61K039/395
ZA 200204830 A	November 26, 2003		141	A61K000/00
SK 200201178 A3	February 3, 2004		000	A61K039/395

INT-CL (IPC): A61 K 0/00; A61 K 35/12; A61 K 35/66; A61 K 35/76; A61 K 38/00; A61 K 38/16; A61 K 38/17; A61 K 39/00; A61 K 39/39; A61 K 39/395; A61 K 48/00; A61 P 25/28; C07 K 14/435; C07 K 14/47; C07 K 19/00; C12 N 1/15; C12 N 1/19; C12 N 1/21; C12 N 5/10; C12 N 15/09; C12 P 21/02; G01 N 33/53

ABSTRACTED-PUB-NO: WO 200162284A

BASIC-ABSTRACT:

NOVELTY - A method (M1) for in vivo down-regulation of amyloid protein in an animal, including a human, comprising presenting to the animal's immune system an immunogenically effective amount of at least one amyloidogenic polypeptide or its subsequence and/or at least one analogue of the amyloidogenic polypeptide, is new.

DETAILED DESCRIPTION - a method (M1) for in vivo down-regulation of amyloid protein in an animal, including a human, comprising presenting to the animal's immune system an immunogenically effective amount of at least one amyloidogenic polypeptide or its subsequence or at least one analogue of the amyloidogenic polypeptide, is new.

The amyloidogenic polypeptide or its subsequence has been formulated so that immunization of the animal with the amyloidogenic polypeptide or its subsequence induces production of antibodies against the amyloidogenic polypeptide. The analogue of the amyloidogenic polypeptide has at least one modification in the amino acid sequence. Immunization of the animal with the analogue induces production of antibodies against the amyloidogenic polypeptide.

INDEPENDENT CLAIMS are included for the following:

(1) a method (M2) for treating and/or preventing and/or ameliorating Alzheimer's disease or other diseases and conditions characterized by amyloid deposits, comprising down-regulating amyloid according to M1 to such an extent that the total amount of amyloid is decreased or that the rate of amyloid formation is reduced with clinical significance;

(2) an analogue (A1) of an amyloidogenic polypeptide which is derived from an animal amyloidogenic polypeptide where is introduced a modification which has as a result that immunization of the animal with the analogue induces production of antibodies against the amyloidogenic polypeptide;

(3) an immunogenic composition comprising:

(a) an immunogenically effective amount of an amyloidogenic polypeptide autologous in an animal, the amyloidogenic polypeptide being formulated together with an

immunologically acceptable adjuvant so as to break the animal's autotolerance towards the amyloidogenic polypeptide, the composition further comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle; or

(b) an effective amount of A1 the composition further comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle and optionally an adjuvant;

(4) a nucleic acid fragment (N1) which encodes A1;

(5) a vector carrying N1 and capable of autonomous replication;

(6) a transformed cell carrying the vector of (5), such that the transformed cell is capable of replicating N1;

(7) a composition for inducing production of antibodies against an amyloidogenic polypeptide, comprising N1 or the vector of (5);

(8) a stable cell line which carries the vector of (5) and which expresses N1, and which optionally secretes or carries A1 on its surface;

(9) a method for the preparation of the cell of (6), comprising transforming a host cell with N1 or the vector of (6);

(10) a method (M3) for the identification of a modified amyloidogenic polypeptide which is capable of inducing antibodies against unmodified amyloidogenic polypeptide in an animal species where the unmodified amyloidogenic polypeptide is a self-protein; and

(11) a method (M4) for the preparation of an immunogenic composition comprising at least one modified amyloidogenic polypeptide which is capable of inducing antibodies against unmodified amyloidogenic polypeptide in an animal species where the unmodified amyloidogenic polypeptide is a self-protein.

ACTIVITY - Neuroprotective; Nootropic; Immunostimulant; Antidiabetic; Antiparkinsonian; Anticonvulsant.

MECHANISM OF ACTION - Amyloid-Protein-Antagonist; Vaccine; Gene-Therapy.

Mice transgenic for human APP (Alzheimer's precursor protein) were used for the study. These mice, called TgRND8+, express a mutated form of APP that results in high concentration of beta-amyloid-40 and beta-amyloid-42 in the mouse brains (Janus, C. et. al., Nature 408:979-982, (2000))

The mice (8-10 mice per group) were immunized with either beta-amyloid-42 (residues 673-714 of the 770 amino acid sequence defined in the specification, it is synthesized by standard Fmoc strategy) or the hAB43+-34 variant (produced recombinantly) four times at two week intervals. Doses were either 100 mg for beta-amyloid-42 or 50 mg for hAB43+34. Mice were bled at day 43 (after three injections) and after day 52 (after four injections) and the sera were used to determine the level of anti-beta-amyloid-42 specific titres using a direct beta-amyloid-42 ELISA.

The antibody titers obtained when immunizing with the hAB43+-34 beta-amyloid variant are approximately 4 times and 7.5 times higher after 3 and 4 immunizations, respectively, than the titers obtained when using the unaltered wild-type beta-amyloid-42 as an immunogen. This fact is put in perspective, when considering the fact that the amount of variant used for immunization was only 50% of the amount of wild-type sequence used for immunization.

USE - The amyloidogenic polypeptide or its subsequence, and its analogue is useful for the preparation of an immunogenic composition comprising an adjuvant for down-regulating amyloid in an animal. They are also useful in the treatment, prophylaxis or amelioration of Alzheimer's disease or other diseases characterized by amyloid deposits (claimed). They are also useful in the treatment of systemic amyloidosis,

maturity onset diabetes, parkinson's disease, Huntington's disease, fronto-temporal dementia, and prion-related transmissible spongiform encephalopathies.

They are also useful for inducing production of antibodies against an amyloidogenic polypeptide.

Full	Title	Citation	Front	Review	Classification	Data	Reference		Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	----------

□ 5. Document ID: DE 69918146 E, WO 200020027 A2, AU 9958510 A, NO 200101586 A, EP 1117421 A2, CN 1323217 A, KR 2001085894 A, HU 200103976 A2, JP 2002526419 W, CZ 200101049 A3, AU 751709 B, ZA 200102603 A, SK 200100427 A3, NZ 511055 A, EP 1117421 B1, US 20040141958 A1

L21: Entry 5 of 7

File: DWPI

Jul 22, 2004

DERWENT-ACC-NO: 2000-349917

DERWENT-WEEK: 200450

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Inducing immune responses to weakly immunogenic, tumor associated peptide antigens for the treatment of breast and prostate cancer

INVENTOR: DALUM, I; GAUTAM, A ; HAANING, J ; KARLSSON, G ; LEACH, D ; MOURITSEN, S ; NIELSEN, K G ; RASMUSSEN, P B ; STEINAA, L ; RASMUSSEN BIRK, P ; BIRK, P

PRIORITY-DATA: 1998US-105011P (October 20, 1998), 1998DK-0001261 (October 5, 1998), 1998DK-0000012 (October 5, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 69918146 E</u>	July 22, 2004		000	A61K038/17
<u>WO 200020027 A2</u>	April 13, 2000	E	219	A61K039/00
<u>AU 9958510 A</u>	April 26, 2000		000	
<u>NO 200101586 A</u>	May 31, 2001		000	A61K000/00
<u>EP 1117421 A2</u>	July 25, 2001	E	000	A61K038/17
<u>CN 1323217 A</u>	November 21, 2001		000	A61K038/17
<u>KR 2001085894 A</u>	September 7, 2001		000	A61K039/00
<u>HU 200103976 A2</u>	February 28, 2002		000	A61K039/00
<u>JP 2002526419 W</u>	August 20, 2002		200	A61K039/00
<u>CZ 200101049 A3</u>	August 14, 2002		000	A61K039/00
<u>AU 751709 B</u>	August 22, 2002		000	A61K039/00
<u>ZA 200102603 A</u>	December 24, 2002		275	A61K000/00
<u>SK 200100427 A3</u>	February 4, 2003		000	A61K038/17
<u>NZ 511055 A</u>	October 31, 2003		000	A61K039/00
<u>EP 1117421 B1</u>	June 16, 2004	E	000	A61K038/17
<u>US 20040141958 A1</u>	July 22, 2004		000	A61K048/00

, US 20040141958 A1 INT-CL (IPC): A61 K 0/00; A61 K 38/17; A61 K 38/18; A61 K 39/00; A61 K 39/39; A61 K 48/00; A61 P 15/00; A61 P 35/00; C07 K 14/47; C07 K 14/50; C07 K 14/705; C07 K 14/71; C07 K 16/18; C12 N 5/16; C12 N 15/09; C12 N 15/12; C12 N 15/63

ABSTRACTED-PUB-NO: WO 200020027A

BASIC-ABSTRACT:

NOVELTY - A method (I) for inducing immune responses against weakly immunogenic cell-

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.22&ref=21&dbname=PGPB,USPT,U...> 10/5/04

associated peptide antigens (PA) such as those associated with cancers (i.e. self-proteins) (e.g. human PSM (undefined), Her2 and/or fibroblast growth factor (FGF) 8b), is new.

DETAILED DESCRIPTION - A method (I) for inducing an immune responses against weakly immunogenic or non-immunogenic polypeptide antigens (PAs) in animals (including humans), comprising effecting simultaneous presentation by antigen producing cells (APCs) of the animals immune system of:

- (1) at least 1 CTL (cytotoxic T-lymphocyte) group derived from the PA and/or at least 1 B-cell group derived from the cell-associated PA; and
- (2) at least 1 first T helper cell group (TH1 group) which is foreign to the animal.

INDEPENDENT CLAIMS are also included for the following:

(1) a method (II) for the selection of an immunogenic analog of a cell-associated PA that is weakly immunogenic or non-immunogenic which is capable of inducing an immune response in an animal against cell displaying MHC (major histocompatibility complex) Class I (MHC-I) molecules bound to group derived from the cell-associated PA, comprising:

(A) identifying a subsequence of the amino acid sequence of the cell-associated PA which does not contain known or predicted CTL groups;

(B) preparing at least 1 punitively immunogenic analogs of the PA by introducing at least 1 TH group foreign to the animal in a position within the subsequence identified in step (A); and

(C) selecting those analogs from step (B) which are verifiably capable of inducing a CTL response in the animal

(2) a method (III) for the preparation of a cell that produces analogs of cell-associated PAs, comprising introducing a nucleic acid encoding the analog into a vector and transforming a suitable host cell (III) with the vector;

(3) a method (IV) for preparing analogs of cell-associated PAs comprising culturing the transformed host cell (III) under conditions suitable for expression of the protein and recovering the PA analog from the culture;

(4) an analog (V) of human PSM (undefined) that is immunogenic in humans and comprises at least part of all known and predicted CTL and B-cell groups of PSM and includes at least 1 foreign TH group;

(5) an analog (VI) of Her2 that is immunogenic in humans and comprises at least part of all known and predicted CTL and B-cell groups of Her2 and includes at least 1 foreign TH group;

(6) an analog (VII) of human/murine FGF (fibroblast growth factor) 8b that is immunogenic in humans and comprises at least part of all known and predicted CTL and B-cell groups of FGF 8b and includes at least 1 foreign TH group;

(7) compositions comprising (V), (VI) and/or (VII) and an adjuvant;

(8) nucleic acids ((VIII)-(X)) encoding (V), (VI) and/or (VII);

(9) vectors ((XI)-(XIII)) comprising (VIII)-(X) (respectively);

(10) a transformed cell (XIV) comprising (XI)-(XIII);

(11) compositions for inducing production of antibodies against PSM, Her2 and FGF 8b, comprising (VIII)-(X) and/or (XI)-(XIII) and an adjuvant; and

(12) a method for the preparation of the cell (XIV), comprising transforming a host cell with (VIII)-(X) or (XI)-(XIII).

USE - (I) is used to stimulate immune responses to weakly, or non-immunogenic peptide antigens especially self proteins for the treatment of diseases associated with expression of those antigens. If the PA is human PSM (undefined), (I) is used for the treatment of prostate cancer. If the PA is human fibroblast growth factor (FGF) 8b, (I) is used for the treatment of prostate cancer or breast cancer. If the PA is Her2, (I) is used for the treatment of breast cancer (claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

□ 6. Document ID: NZ 509917 A, WO 200005316 A1, AU 9948984 A, EP 1109871 A1, KR 2001072025 A, ZA 200100534 A, JP 2002521651 W, AU 759687 B

L21: Entry 6 of 7

File: DWPI

May 30, 2003

DERWENT-ACC-NO: 2000-182671

DERWENT-WEEK: 200341

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Coating process for solid surfaces that are substantially free of amino, imino or thiol groups involves the application of a water-soluble activated polyhydroxy polymer

INVENTOR: NIELSEN, K G

PRIORITY-DATA: 1998US-094558P (July 29, 1998), 1998DK-0000963 (July 21, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>NZ 509917 A</u>	May 30, 2003		000	C09D201/08
<u>WO 200005316 A1</u>	February 3, 2000	E	045	C09D201/08
<u>AU 9948984 A</u>	February 14, 2000		000	C09D201/08
<u>EP 1109871 A1</u>	June 27, 2001	E	000	C09D201/08
<u>KR 2001072025 A</u>	July 31, 2001		000	C09D201/02
<u>ZA 200100534 A</u>	March 27, 2002		057	C09D000/00
<u>JP 2002521651 W</u>	July 16, 2002		050	G01N033/548
<u>AU 759687 B</u>	April 17, 2003		000	C09D201/08

INT-CL (IPC): A61 K 47/32; A61 K 47/36; A61 K 47/48; C08 J 7/04; C08 L 101:00; C09 D 0/00; C09 D 201/02; C09 D 201/08; G01 N 33/543; G01 N 33/548

ABSTRACTED-PUB-NO: WO 200005316A

BASIC-ABSTRACT:

NOVELTY - The coating of solid surfaces having substantially no amino, imino or thiol groups with a water-soluble activated polyhydroxy polymer is new.

DETAILED DESCRIPTION - A new method for coating a solid surface having substantially no amino, imino or thiol groups with a water-soluble activated polyhydroxy polymer comprises: (a) contacting the surface with an aqueous coating solution of activated polyhydroxy polymer with a pH of 1.5-10 and/or with an ion strength of 0.1-8 to achieve bonding, (b) rinsing the coated surface with a rinse solution, and (c) optionally drying the surface.

An INDEPENDENT CLAIM is made for coated surfaces prepared by the above method.

USE - Coated surfaces are useful for immobilizing a wide variety of molecules including amino acids, 1-30 amino acid oligo-peptides, 1-30 amino acid polypeptides, proteins, immunoglobulins, haptens, enzymes, antibodies, antigens, polysaccharides, 1-20 nucleotide oligonucleotides, 1-20 nucleotide polynucleotides, other biomolecules, microorganisms, prokaryotic cells and, eukaryotic cells. The process is also useful for making, sheets, pellets, films, disks, plates, rings, rods, nets, filters, trays, and especially, beads, sticks, multibladed sticks or micro titer plates e.g. those made from polystyrene.

ADVANTAGE - The process is simple and requires no pretreatment of the solid surface.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 7. Document ID: AU 9455196 A, AU 665702 B

L21: Entry 7 of 7

File: DWPI

May 4, 1995

DERWENT-ACC-NO: 1995-194330

DERWENT-WEEK: 199609

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Compost toilet for domestic use - has waste conduit integrated into toilet pedestal with compost container located below for collection of faecal solids

INVENTOR: NIELSEN, K G ; NIELSEN, N

PRIORITY-DATA: 1993AU-0001860 (October 18, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 9455196 A</u>	May 4, 1995		027	A47K011/00
<u>AU 665702 B</u>	January 11, 1996		000	A47K011/00

INT-CL (IPC): A47 K 11/00

ABSTRACTED-PUB-NO: AU 9455196A

BASIC-ABSTRACT:

The compost toilet includes a toilet pedestal that has a waste delivery conduit extending from it. A compost container is joined in fluid communication with the waste delivery conduit of the toilet pedestal and has an open top. A cover member for the compost container has an air exhaust conduit associated with it. A separating device is located in the compost container for separation of liquid material from solid material.

The toilet has an air exhaust conduit integral with the cover member. The separating device is a partition adapted to allow liquid material to pass through while retaining solid material.

USE/ADVANTAGE - Is simple in construction and is efficient in operation.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Nielsen-K-G.IN.	7

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 8 of 8 returned.

☐ 1. Document ID: US 20040191264 A1

Using default format because multiple data bases are involved.

L19: Entry 1 of 8

File: PGPB

Sep 30, 2004

PGPUB-DOCUMENT-NUMBER: 20040191264

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040191264 A1

TITLE: Synthetic vaccine agents

PUBLICATION-DATE: September 30, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
<u>Nielsen, Klaus Gregorius</u>	Horsholm		DK	
Koefoed, Peter	Horsholm		DK	

US-CL-CURRENT: 424/184.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 2. Document ID: US 20040141958 A1

L19: Entry 2 of 8

File: PGPB

Jul 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040141958

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040141958 A1

TITLE: Novel methods for therapeutic vaccination

PUBLICATION-DATE: July 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Steinaa, Lucilla	Copenhagen V		DK	
Mouritsen, Soren	Birkerod		DK	
Gautam, Anand	Hillerod		DK	
Haaning, Jesper	Birkerod		DK	
Dalum, Iben	Horsholm		DK	
Birk, Peter	Copenhagen O		DK	
Leach, Dana	Hillerod		DK	
<u>Nielsen, Klaus Gregorius</u>	Sorborg		DK	
Karlsson, Gunilla	Copenhagen O		DK	

ABSTRACT:

A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 3. Document ID: US 20030157117 A1

L19: Entry 3 of 8

File: PGPB

Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030157117

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030157117 A1

TITLE: Novel method for down-regulation of amyloid

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rasmussen, Peter Birk	Horsholm		DK	
Jensen, Martin Roland	Horsholm		DK	
Nielsen, Klaus Gregorius	Horsholm		DK	
Koefoed, Peter	Horsholm		DK	
Degan, Florence Dal	Horsholm		DK	

US-CL-CURRENT: 424/185.1; 435/226

ABSTRACT:

Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protein (APP) or beta amyloid (A.beta.). Immunization is preferably effected by administration of analogues of autologous APP or A.beta., said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A.beta. which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against APP or A.beta. and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

☐ 4. Document ID: US 20030086938 A1

L19: Entry 4 of 8

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030086938
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030086938 A1

TITLE: Novel methods for down-regulation of amyloid

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jensen, Martin Roland	Horsholm		DK	
Birk, Peter	Horsholm		DK	
Nielsen, Klaus Gregorius	Horsholm		DK	

US-CL-CURRENT: 424/185.1

ABSTRACT:

Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloidogenic proteins (proteins contributing to formation of amyloid) such as beta amyloid (A.beta.). Immunization is preferably effected by administration of analogues of autologous amyloidogenic polypeptides, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A.beta. which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the majority of A.beta.'s B-cell epitopes. Also disclosed are nucleic acid vaccination against amyloidogenic polypeptides and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic analogues of the amyloidogenic proteins, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

☐ 5. Document ID: US 20020187157 A1

L19: Entry 5 of 8

File: PGPB

Dec 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020187157
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20020187157 A1

TITLE: Novel method for down-regulation of amyloid

PUBLICATION-DATE: December 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jensen, Martin Roland	Holte		DK	
Rasmussen, Peter Birk	Frederiksberg		DK	
Nielsen, Klaus Gregorius	Soborg		DK	

US-CL-CURRENT: 424/185.1; 424/85.1, 424/85.2

ABSTRACT:

A method for in vivo down-regulation of amyloid protein in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunogenically effective amount of at least one amyloidogenic polypeptide or subsequence thereof which has been formulated so that immunization of the animal with the amyloidgenic polypeptide or subsequence thereof induces production of antibodies against the amyloidogenic polypeptide, and/or at least one analogue of the amyloidogenic polypeptide wherein is introduced at least one modification in the amino acid sequence of the amyloidogenic polypeptide which has as a result the immunization of the animal with the analogue induces production of antibodies against the amyloidogenic polypeptide.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 6. Document ID: US 20020119162 A1

L19: Entry 6 of 8

File: PGPB

Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020119162

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020119162 A1

TITLE: Synthetic vaccine agents

PUBLICATION-DATE: August 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Nielsen, Klaus Gregorius	Horsholm		DK	
Koefoed, Peter	Horsholm		DK	

US-CL-CURRENT: 424/185.1

ABSTRACT:

The present invention provides for novel immunogens that are comprised of an activated polyhydroxypolymer backbone to which is attached 2 separate antigenic determinants. The 1st antigenic determinant includes a B-cell or CTL epitope and the 2nd antigenic determinant includes a T-helper epitope. In preferred embodiments, the antigenic determinants are derived from different molecules and species. Exemplary immunogens of the invention are constituted of a linear tresyl-activated dextran backbone to which is coupled B-cell or CTL epitopes of an antigen and to which is also coupled universal T-helper epitopes. Also disclosed are immunogenic compositions comprising the immunogens, methods of immunization and a method for identification of suitable immunogens of the invention.

☐ 7. Document ID: WO 3015812 A2

L19: Entry 7 of 8

File: EPAB

Feb 27, 2003

PUB-NO: WO003015812A2

DOCUMENT-IDENTIFIER: WO 3015812 A2

TITLE: NOVEL METHOD FOR DOWN-REGULATION OF AMYLOID

PUBN-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME

COUNTRY

RASMUSSEN, PETER BIRK

DK

JENSEN, MARTIN ROLAND

DK

NIELSEN, KLAUS GREGORIUS

DK

KOEFOED, PETER

DK

DEGAN, FLORENCE DAL

DZ

INT-CL (IPC): A61 K 39/00; A61 K 39/385; C07 K 14/47; A61 P 25/28

EUR-CL (EPC): A61K039/00

ABSTRACT:

CHG DATE=20030403 STATUS=O>Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protein (APP) or beta amyloid (A beta). Immunization is preferably effected by administration of analogues of autologous APP or A beta , said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A beta which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against APP or A beta and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

☐ 8. Document ID: WO 2066056 A2

L19: Entry 8 of 8

File: EPAB

Aug 29, 2002

PUB-NO: WO002066056A2

DOCUMENT-IDENTIFIER: WO 2066056 A2

TITLE: SYNTHETIC VACCINE AGENTS

PUBN-DATE: August 29, 2002

INVENTOR-INFORMATION:

NAME

COUNTRY

NIELSEN, KLAUS GREGORIUS
KOEFOED, PETER

DK
DK

INT-CL (IPC): A61 K 39/385
EUR-CL (EPC): A61K039/00; A61K039/385

ABSTRACT:

CHG DATE=20031203 STATUS=O>The present invention provides for novel immunogens that are comprised of an activated polyhydroxypolymer backbone to which is attached 2 separate antigenic determinants. The 1st antigenic determinant includes a B-cell or CTL epitope and the 2nd antigenic determinant includes a T-helper epitope. In preferred embodiments, the antigenic determinants are derived from different molecules and species. Exemplary immunogens of the invention are constituted of a linear tresyl-activated dextran backbone to which is coupled B-cell or CTL epitopes of an antigen and to which is also coupled universal T-helper epitopes. Also disclosed are immunogenic compositions comprising the immunogens, methods of immunisation and a method for identification of suitable immunogens of the invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Keywords	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	----------	----------

Clear

Generate Collection

Print

Fwd Refs

Backwd Refs

Generate OACS

Terms

Documents

Nielsen-Klaus-Gregorius.IN.

8

Display Format:

-

Change Format

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 5 of 5 returned.

☐ 1. Document ID: US 6187263 B1

Using default format because multiple data bases are involved.

L7: Entry 1 of 5

File: USPT

Feb 13, 2001

US-PAT-NO: 6187263

DOCUMENT-IDENTIFIER: US 6187263 B1

**** See image for Certificate of Correction ****

TITLE: Method of improving indoor air quality by thermally inactivating fungi on building surfaces

DATE-ISSUED: February 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Nielsen; Klaus	Kokkedal			DK

US-CL-CURRENT: 422/26; 422/38

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 2. Document ID: US 5112756 A

L7: Entry 2 of 5

File: USPT

May 12, 1992

US-PAT-NO: 5112756

DOCUMENT-IDENTIFIER: US 5112756 A

TITLE: Continuous production of bovine Maedi-Visna-like viral antigens in Cf2Th cells

DATE-ISSUED: May 12, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bouillant; Alain M. P.	Aylmer			CA
Nielsen; Klaus	Richmond			CA
Ruckerbauer; Gerda M.	Nepean			CA
Samagh; Bakhshish S.	Nepean			CA
Hare; William C. D.	North Gower			CA

US-CL-CURRENT: 435/235.1; 435/239, 435/350, 435/948

ABSTRACT:

Permanent infection of a cell line such as a canine thymus cell line with a

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.8&ref=7&dbname=PGPB,USPT,USO...> 10/5/04

retrovirus such as equine infectious anemia virus and bovine Maedi-Visna-like virus is now possible. By culturing such an infected cell line under appropriate conditions, it is now possible to produce large quantities of viral antigens on a continuous basis. Such antigens are useful in for diagnostics and research.

7 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 3. Document ID: US 5006463 A

L7: Entry 3 of 5

File: USPT

Apr 9, 1991

US-PAT-NO: 5006463
DOCUMENT-IDENTIFIER: US 5006463 A

TITLE: Immunoassays for discriminating between brucellosis infections and vaccinations

DATE-ISSUED: April 9, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cherwonogrodzky; John W.	Kanata			CA
Duncan; J. Robert	Nepean			CA
Nielsen; Klaus	Richmond			CA
Wright; Peter F.	Richmond			CA
Bundle; David R.	Ottawa			CA
Perry; Malcolm B.	Ottawa			CA

US-CL-CURRENT: 435/7.32; 424/234.1, 424/252.1, 435/101, 435/174, 435/34, 435/810, 435/822, 436/501, 436/518, 436/543, 436/808, 436/809, 436/811, 530/350, 530/387.5, 530/388.4, 530/812, 530/825

ABSTRACT:

A method is disclosed for discriminating between cattle vaccinated against and those infected with Brucella spp. The method involves immunoassay using a purified polysaccharide containing 4,6-dideoxy-4-acylamido-D-mannopyranosyl units obtained from B. abortus or from cross-reacting organisms, and results in improved differentiation between vaccinated and infected animals. Test kits are also disclosed for performing the assay and a process is disclosed for obtaining the O-chain polysaccharides in high purity and yield.

13 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 4. Document ID: WO 9841243 A1

PUB-NO: WO009841243A1

DOCUMENT-IDENTIFIER: WO 9841243 A1

TITLE: METHOD OF THERMALLY REDUCING THE CONTAMINATION WITH PATHOGENIC ORGANISMS IN ANIMAL ENVIRONMENTS

PUBN-DATE: September 24, 1998

INVENTOR-INFORMATION:

NAME

NIELSEN, KLAUS

COUNTRY

DK

INT-CL (IPC): A61 L 2/00

EUR-CL (EPC): A01M021/04; A61L002/07

ABSTRACT:

CHG DATE=19990905 STATUS=O>A method of reducing the contamination with pathogenic organisms associated with a material surface in an animal environment, the method comprising at least partially inactivating said organisms by applying onto said surface thermal energy initially contained in water vapour at a pressure exceeding 1 bar. The thermal energy is applied by releasing pressurized water vapour onto the surface whereby the thermal energy is derived from a transition of the state of the water vapour from the gaseous to the liquid state at a temperature in the range of 90-110 DEG C.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	K00C	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 5. Document ID: EP 715809 A2

L7: Entry 5 of 5

File: EPAB

Jun 12, 1996

PUB-NO: EP000715809A2

DOCUMENT-IDENTIFIER: EP 715809 A2

TITLE: Method of improving indoor air quality by thermally inactivating fungi on building surfaces

PUBN-DATE: June 12, 1996

INVENTOR-INFORMATION:

NAME

NIELSEN, KLAUS

COUNTRY

DK

INT-CL (IPC): A01 M 19/00; A01 M 21/04; E04 B 1/72

EUR-CL (EPC): A01M001/24; A01M019/00

ABSTRACT:

CHG DATE=19990617 STATUS=O> A method of improving the indoor air quality in a building comprising at least partially inactivating fungal mycelia and spores associated with a building material surface by applying onto the surface thermal energy initially contained in water vapour at a pressure exceeding 1 bar, in an amount which is sufficient to at least partially inactivate said fungal mycelia and spores but essentially without causing damages to the surface material.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RWC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Nielsen-Klaus.IN.	5

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 62 of 62 returned.

☐ 1. Document ID: DE 10303828 A1

Using default format because multiple data bases are involved.

L8: Entry 1 of 62

File: DWPI

Aug 19, 2004

DERWENT-ACC-NO: 2004-582034

DERWENT-WEEK: 200457

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Thermostatic radiator valve has thermostat elements that react both to the room temperature and the temperature of the return flow water, with the design of the two thermostat elements being different to reduce valve size

INVENTOR: NIELSEN, K ; SEERUP, J

PRIORITY-DATA: 2003DE-1003828 (January 31, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 10303828 A1	August 19, 2004		006	F16K031/64

INT-CL (IPC): F16 K 31/64; F24 D 19/10; G05 D 23/00

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 2. Document ID: GB 2398117 A, WO 2004057278 A2

L8: Entry 2 of 62

File: DWPI

Aug 11, 2004

DERWENT-ACC-NO: 2004-525501

DERWENT-WEEK: 200452

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Detection apparatus for detecting transmission of catalyst plugs through conduit leading to polymerization reactor, comprises radiation source arranged to direct optical radiation through light path, and optical radiation detector

INVENTOR: NIELSEN, K

PRIORITY-DATA: 2002GB-0030052 (December 23, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
GB 2398117 A	August 11, 2004		000	G01N021/85
WO 2004057278 A2	July 8, 2004	E	031	G01F001/00

INT-CL (IPC): G01 F 1/00; G01 N 21/59; G01 N 21/85

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.9&ref=8&dbname=PGPB,USPT,USO...> 10/5/04

NOVELTY - A detection apparatus comprises an optical radiation source located outside a conduit, a light path through the conduit, and an optical radiation detector. The radiation source is arranged to direct optical radiation through the light path such that it may be detected by the detector.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(a) determining the mass of material transmitted through a conduit by repeatedly detecting intensity of optical radiation reflected from material, detecting the speed of material moving through the conduit, multiplying the intensity and speed values to gain a result curve, integrating the result curve, and multiplying the integral of the result curve by a factor to gain the approximate absolute mass of the material; and

(b) a system for determining the mass of material transmitted through a pipe, comprising a radiation detector for detecting the intensity of optical radiation reflected from the material, a speed detector for detecting the speed at which the material is transmitted, a multiplication unit for multiplying the intensity values and the speed values together to create a result curve, an integration unit for integrating the result curve, a multiplication device for multiplying the integral of the result curve by a factor to gain the mass of the material, and a display device for displaying the result curve and mass values.

USE - The apparatus is used for detecting the transmission of catalyst plugs through a conduit leading to a polymerization reactor. It can be used in association with an apparatus for supplying catalyst plugs to a reactor. It is used to identify abnormal plugs from the output of the detector. It can be used to determine the approximate density of the material from the output of the detector and to determine an indication of mass flow of material based on the measured flow speed and the determined approximate density.

ADVANTAGE - The apparatus enables accurate monitoring of catalyst input into a reactor and consequently allows for a controlled polymerization process.

DESCRIPTION OF DRAWING(S) - The figure is a cross-sectional view of a light intensity detector.

Catalyst-carrying pipe 1

Sight glasses 2, 7

Laser 9

Laser beam 9a

Reflector 20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	KWIC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	-------------

☐ 3. Document ID: AU 2003208312 A1, WO 2003076287 A1

L8: Entry 3 of 62

File: DWPI

Sep 22, 2003

DERWENT-ACC-NO: 2003-833395

DERWENT-WEEK: 200431

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Plastic container, used as packaging, comprises bottom, annular sidewall with annular engagement area, skirt, and flap with different color from skirt

INVENTOR: NIELSEN, K

PRIORITY-DATA: 2002DK-0000359 (March 8, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2003208312 A1</u>	September 22, 2003		000	B65D043/02
<u>WO 2003076287 A1</u>	September 18, 2003	E	015	B65D043/02

INT-CL (IPC): B65 D 43/02; B65 D 43/26; B65 D 55/02

ABSTRACTED-PUB-NO: WO2003076287A

BASIC-ABSTRACT:

NOVELTY - Plastic container, comprises a bottom; an annular sidewall with an annular engagement area; a skirt arranged on the sidewall along the engagement area; and a flap with a different color from that of the skirt.

DETAILED DESCRIPTION - Plastic container (1), comprises a bottom; an annular sidewall (10) with an annular engagement area (15) arranged opposite the bottom and configured for cooperating with a lid; a skirt (20) arranged on the sidewall along the engagement area; and a flap (30) configured for being turnable around a turning connection (8), which is covered by the lid and arranged in proximity of the engagement area, from a first position, in which the flap extends in parallel with or approximately in parallel with the sidewall and upwards to a second position in which the flap is able to lift the lid out of engagement with at least a part of the engagement area. The flap has a different color than that of the skirt.

INDEPENDENT CLAIMS are also included for the following:

(a) an injection molding tool for manufacturing a container as above, defining a mold cavity for forming the container, comprising a first and a second supply conduit for plastics material, where the second supply conduit debouches in the area of the mold cavity in which the flap is formed, and the first and second supply conduits are connected to a source for a respective plastics material; and

(b) a method for manufacturing a container as above using the injection molding tool above, where the flow of plastics material from the respective sources is regulated such that the fronts of the plastics materials meet in proximity of the area.

USE - Useful as a packaging (claimed).

ADVANTAGE - The container allows a consumer to lift off the lid in an easy manner. There is a more clear indication of how the container should be opened. The container can be manufactured in an economically viable manner.

DESCRIPTION OF DRAWING(S) - The figure shows a molded plastics container, seen in an inclined view from above.

Container 1

Turning connection 8

Sidewall 10

Engagement area 15

Skirt 20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 4. Document ID: EP 1456943 A1, WO 2003055059 A1, AU 2002366885 A1

L8: Entry 4 of 62

File: DWPI

Sep 15, 2004

DERWENT-ACC-NO: 2003-559221

DERWENT-WEEK: 200460

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Attenuation control for digital power converter in digital conversion system uses gain control shifting unit to limit attenuation of modulated signal

INVENTOR: NIELSEN, K ; SKOV ANDERSEN, K

PRIORITY-DATA: 2001SE-0004403 (December 21, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1456943 A1	September 15, 2004	E	000	H03F003/217
WO 2003055059 A1	July 3, 2003	E	012	H03F003/217
AU 2002366885 A1	July 9, 2003		000	H03F003/217

INT-CL (IPC): H02 M 1/00; H02 M 1/000; H03 F 1/32; H03 F 1/322; H03 F 3/217

ABSTRACTED-PUB-NO: WO2003055059A

BASIC-ABSTRACT:

NOVELTY - A digital pulse code modulated to pulse width modulated modulator (4) generates a digital input signal and a pulse edge delay error correction control system (5) compensates errors in the power stage, while a gain shift from a feedback unit (8) is applied to control the control system and decrease power supplied to a power supply (6) from a power supply (7) when attenuation of the modulated signal reaches a predefined level.

DETAILED DESCRIPTION - AN INDEPENDENT CLAIM is included for an attenuation control system.

USE - Attenuation control of digital signal in high precision DC-AC power converter such as used in high efficiency audio amplification.

ADVANTAGE - Matches dynamic range of attenuated signal in certain range.

DESCRIPTION OF DRAWING(S) - The drawing shows the system

Modulator 4

Correction control system 5

Power supplies 6,7

Feedback unit 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 5. Document ID: EP 1456944 A1, WO 2003055060 A1, AU 2002366893 A1

L8: Entry 5 of 62

File: DWPI

Sep 15, 2004

DERWENT-ACC-NO: 2003-541904

DERWENT-WEEK: 200460

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Synchronized controlled oscillation modulator for audio amplifier has controlled oscillation modulator and synchronizing oscillator signal generator connected to it

INVENTOR: LIND HANSEN, J; NIELSEN, K

PRIORITY-DATA: 2001SE-0004401 (December 21, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>EP 1456944 A1</u>	September 15, 2004	E	000	H03F003/38
<u>WO 2003055060 A1</u>	July 3, 2003	E	023	H03F003/38
<u>AU 2002366893 A1</u>	July 9, 2003		000	H03F003/38

INT-CL (IPC): H03 F 3/38

ABSTRACTED-PUB-NO: WO2003055060A

BASIC-ABSTRACT:

NOVELTY - The synchronized controlled oscillation modulator includes at least one controlled oscillation modulator (5) and a synchronizing oscillator signal generator (1) connected to the modulator.

USE - For a self-oscillating modulator, especially for precision PWM-based DC-AC conversion systems such as high efficiency audio power amplification and also DC-DC and AC-AC converters.

ADVANTAGE - Improves power conversion in any system.

DESCRIPTION OF DRAWING(S) - The drawing shows a block diagram of the modulator.

Synchronizing oscillator signal generator 1

Controlled oscillation modulator 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 6. Document ID: US 6555774 B1

L8: Entry 6 of 62

File: DWPI

Apr 29, 2003

DERWENT-ACC-NO: 2004-019637

DERWENT-WEEK: 200402

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Lever keyswitch for keyboards, has lever assembly cantilevering button from spine, which has lever and offset piece deflected in opposite angular directions, during pressing of button

INVENTOR: NIELSEN, K

PRIORITY-DATA: 2000US-0628930 (July 28, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6555774 B1	April 29, 2003		008	H01H009/26

INT-CL (IPC): H01 H 9/26

ABSTRACTED-PUB-NO: US 6555774B

BASIC-ABSTRACT:

NOVELTY - A resilient lever assembly cantilevering a button (12d) from a spine (14) attached to an electronic device, has an elongate resilient U-shaped lever (50d) with parallel arms (56d,58d) extended from the spine, and an elongate resilient offset piece (52d) extended from center of the lever to the button. The lever and offset piece are deflected in opposite angular directions during pressing of the button, such that the button movement is linear.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) electronic device; and
- (2) keyswitch assembly.

USE - For electronic devices (claimed) e.g. keyboards, mice, game machines, consumer electronics.

ADVANTAGE - Keyswitch is quickly and easily installed in the electronic device.

DESCRIPTION OF DRAWING(S) - The figure shows a perspective view of lever keyswitch.

lever keyswitch(12d) button 10d

spine 14

lever 50d

offset piece 52d

arms 56d,58d

distal ends 60d,62d

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 7. Document ID: AU 2002344253 A1, WO 200297434 A1, EP 1402257 A1

L8: Entry 7 of 62

File: DWPI

Dec 9, 2002

DERWENT-ACC-NO: 2003-140507

DERWENT-WEEK: 200452

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Diagnosing diabetes in human, by determining presence or level of expression of marker proteins e.g. citrate synthase, fructose-bisphosphate aldolase A, glyceraldehyde-3-phosphate-dehydrogenas- e

INVENTOR: FEY, S J; KARLSEN, A E ; LARSEN, P M ; NERUP, J ; NIELSEN, K ; NERUP, J R

PRIORITY-DATA: 2001DK-0000852 (May 29, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2002344253 A1</u>	December 9, 2002		000	G01N033/50
<u>WO 200297434 A1</u>	December 5, 2002	E	049	G01N033/50
<u>EP 1402257 A1</u>	March 31, 2004	E	000	G01N033/50

INT-CL (IPC): C12 Q 1/68; G01 N 33/50

ABSTRACTED-PUB-NO: WO 200297434A

BASIC-ABSTRACT:

NOVELTY - Diagnosing (M1) diabetes comprising determining expression of any one of 109 marker proteins (MP) (e.g. citrate synthase) given in the specification, in a biological sample, or its derivatives and modified forms having at least 80% homology with MP, where the isoelectric point of MP is determined by isoelectric focusing, and molecular weight is determined on polyacrylamide gel, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

- (1) determining the predisposition in a human for diabetes, by determining the presence or relative level of MP in a biological sample from the human;
- (2) treating diabetes, or preventing or delaying the onset of diabetes in a human, by altering the expression of MP, or administering MP, a nucleotide sequence coding for MP, an antibody for MP, a nucleic acid fragment capable of binding to MP, or a compound capable of binding to MP, to the human;
- (3) determining the likelihood of an agent having a therapeutic effect in the treatment of diabetes, by determining the level of expression of one or more MP, before and after exposing a test model to the agent and comparing the levels;
- (4) determining the effect of a compound in the treatment of diabetes, by determining the level of expression of one or more MP;
- (5) determining the level of effect of a compound used in the treatment of diabetes, by determining the level of expression of one or more MP, before and after exposing a test model to the agent;
- (6) determining the nature or cause of diabetes in a human having or susceptible to the disease, by establishing the level of expression of the MP in relation to a model;
- (7) a nucleic acid fragment (I), where the nucleic acid is DNA, RNA, locked nucleoside analog (LNA) or other derivatives comprising a nucleotide sequence which codes for MP;
- (8) a nucleic acid fragment which hybridizes with (I) or its part;
- (9) an antibody (II), ligand, aptomer, antiomere, peptide, hybrid molecules and other synthetic molecules able to bind to the MP;
- (10) a test kit for diagnosing diabetes or a genetic predisposition for diabetes in a mammal, comprising a binding unit which specifically binds to MP or an antibody for MP, a nucleic acid fragment capable of binding to MP, or a compound capable of binding to MP, to the human, an unit for detecting binding if any, or the level of binding, of the binding unit to at least one of the marker proteins or at least one of the peptides or at least one of the nucleic acid fragments, and an unit for

correlating whether binding if any, or the level of binding, to the binding unit is indicative of the individual mammal having a significantly higher likelihood of having diabetes or a genetic predisposition for having diabetes;

(11) determining the effect of a substance, by using a mammal which has been established to be an individual having a high likelihood of having diabetes or genetic predisposition for having diabetes by (M1), by administering the substance to the individual and determining the effect of the substance;

(12) a pharmaceutical composition comprising a substance which is capable of regulating the expression of a nucleic acid fragment coding for a part of MP, MP, antibody for MP, nucleic acid fragment capable of binding to MP, or a compound capable of binding to MP, to the human;

(13) constructing a cell or a cell line expressing MP, modifications and derivatives of MP, so as to have at least 80% (e.g. 90% or 95%) homology with MP, e.g. by introduction of at least one DNA sequence encoding MP into a cell, such as a self-cell; and

(14) a cell or cell line (III) obtained.

ACTIVITY - Antidiabetic.

No suitable data given.

MECHANISM OF ACTION - None given.

USE - M1 is useful for diagnosing diabetes in humans. (I) and (II) are useful for detecting the presence of the peptide. (I), (II), or nucleic acid fragment capable of binding to MP is useful for treating diabetes, or preventing or delaying the onset of diabetes in a human (claimed). (III) is useful for drug testing or treating a person suffering from diabetes and as a part of pharmaceutical composition.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KOMIC	Draw	Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-------	------	-----

☐ 8. Document ID: US 20040161122 A1, WO 200293973 A1, EP 1391137 A1, KR 2004004607 A, AU 2002302881 A1

L8: Entry 8 of 62

File: DWPI

Aug 19, 2004

DERWENT-ACC-NO: 2003-059094

DERWENT-WEEK: 200455

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Audio signal converter has switching stage and electro-acoustic transducer that are mechanically and electrically integrated into single operational unit

INVENTOR: NIELSEN, K

PRIORITY-DATA: 2001SE-0001720 (May 16, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20040161122 A1</u>	August 19, 2004		000	H04B003/00
<u>WO 200293973 A1</u>	November 21, 2002	E	026	H04R001/00
<u>EP 1391137 A1</u>	February 25, 2004	E	000	H04R001/00
<u>KR 2004004607 A</u>	January 13, 2004		000	H04R003/00
<u>AU 2002302881 A1</u>	November 25, 2002		000	H04R001/00

INT-CL (IPC): H03 M 1/00; H04 B 3/00; H04 R 1/00; H04 R 3/00; H04 R 5/04; H04 R 19/00; H03 M 1/00; H04 R 5:04

ABSTRACTED-PUB-NO: WO 200293973A
BASIC-ABSTRACT:

NOVELTY - An electro-acoustic transducer (19) is directly driven by a pulse train from a switching stage (15), without the need for filtering and outputs audio waves. The switching stage and the transducer are integrated mechanically and electrically into a single operational unit, such that the unit is directly connected to main power supply (12).

USE - Audio signal converter.

ADVANTAGE - Eliminates need for cables and connectors and thus obtains an improved audio conversion with reduced EMI, minimizes high frequency losses and improves mechanical stability and robustness of the audio signal converter, since the switching stage and transducer are mechanically and electrically arranged into the single operational unit.

DESCRIPTION OF DRAWING(S) - The figure shows a schematic view of single stage AC pulse modulated transducer.

Main power supply 12

Switching stage 15

Electro-acoustic transducer 19

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	----------

☐ 9. Document ID: DE 10108520 B4, DE 10108520 A1

L8: Entry 9 of 62

File: DWPI

Jul 8, 2004

DERWENT-ACC-NO: 2002-659004
DERWENT-WEEK: 200445
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Heating valve unit has one stop on stop carrier able to move parallel to axis but not turn in one of two casing parts

INVENTOR: JENSEN, J C; MARKVART, A ; NIELSEN, K

PRIORITY-DATA: 2001DE-1008520 (February 22, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 10108520 B4</u>	July 8, 2004		000	F16K031/60
<u>DE 10108520 A1</u>	September 19, 2002		009	F16K031/60

INT-CL (IPC): F16 K 31/60; F16 K 31/64

ABSTRACTED-PUB-NO: DE 10108520A
BASIC-ABSTRACT:

NOVELTY - The valve unit has two casing parts: a socket (1) and a turning handle (7) screwed into it, turning round an axis (24) between two stops (23, 5) acting with each other so that the handle is not unscrewed from the socket. One of the stops (23)

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.9&ref=8&dbname=PGPB,USPT,USO...> 10/5/04

is mounted on a stop carrier (16) which can be moved parallel to the axis (24), but not turned, in one of the two casing parts.

USE - For temperature setting in heating systems.

ADVANTAGE - Easier to dismantle.

DESCRIPTION OF DRAWING(S) - The drawing shows a sectioned view of the unit in minimum setting.

Socket 1

stops 5, 23

Turning handle 7

Stop carrier 16

Axis 24

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 10. Document ID: AU 2002231611 A1, WO 200264006 A1

L8: Entry 10 of 62

File: DWPI

Aug 28, 2002

DERWENT-ACC-NO: 2002-575792

DERWENT-WEEK: 200427

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Combination of dispensing device and container for batch dispensing granular product such as coffee comprises bottom portion screwed onto container neck and top portion attached to bottom with disc in between to allow dispensing

INVENTOR: NIELSEN, K ; NIELSEN, S E L

PRIORITY-DATA: 2001DK-0001323 (September 11, 2001), 2001DK-0000234 (February 13, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2002231611 A1</u>	August 28, 2002		000	A47J047/04
<u>WO 200264006 A1</u>	August 22, 2002	E	044	A47J047/04

INT-CL (IPC): A47 G 19/34; A47 J 47/04

ABSTRACTED-PUB-NO: WO 200264006A

BASIC-ABSTRACT:

NOVELTY - The combination comprises attachment means for integral or releasable attachment of the dispensing device to the container such that the dispensing device obstructs the dispensing opening in the container. The dispensing device has a bottom (62) screwed to neck of container and a top(63) fixedly attached to bottom with a disc portion(61) in between. The bottom has a plate(64) with an aperture to allow product to flow from container into passage(72) in the disc portion when the disc portion is in a first rotational position. The top has a plate(65) with an aperture to allow product in passage(72) to be dispensed when disc portion is in second rotational position.

USE - Esp. for batch dispensing granular product such as ground coffee, freeze-dried instant coffee, milk powder, sugar, detergent powder and the like.

ADVANTAGE - Provides effective sealing to protect the material from long term contact with atmosphere which will make the granular material cake or dissolve by absorbing moisture and be ruined. Provides precise and uniform batchwise dispensing.

DESCRIPTION OF DRAWING(S) - Shows a schematic view of the device esp. for dispensing hygroscopic granular material

disc portion 61

bottom and top of dispensing device 62,63

plates 64,65

passage 72

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 11. Document ID: DE 10049328 B4, DE 10049328 A1

L8: Entry 11 of 62

File: DWPI

Feb 12, 2004

DERWENT-ACC-NO: 2002-436567

DERWENT-WEEK: 200412

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Versatile, separable valve knob including thermostat, includes supportive surface carried on separately-manufactured base

INVENTOR: KRISTENSEN, P; MOBERG, E ; NIELSEN, K ; PEDERSEN, M

PRIORITY-DATA: 2000DE-1049328 (October 5, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 10049328 B4</u>	February 12, 2004		000	F16K031/64
<u>DE 10049328 A1</u>	May 8, 2002		006	F16K031/64

INT-CL (IPC): F16 K 31/64

ABSTRACTED-PUB-NO: DE 10049328A

BASIC-ABSTRACT:

NOVELTY - A supportive surface (116) is carried by a separately- manufactured base (102). The design enables matching of the knob, which includes the thermostat, with different types of valve.

USE - A separable knob including a thermostat, for a valve.

ADVANTAGE - The force of the compression spring used for restoration, is matched correctly in different cases. The base is a simple adaptor section.

DESCRIPTION OF DRAWING(S) - A vertical cross section through the separated knob and base section is shown.

base 102

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 12. Document ID: US 20040050659 A1, WO 200226598 A2, AU 200191638 A, EP 1332100 A2

L8: Entry 12 of 62

File: DWPI

Mar 18, 2004

DERWENT-ACC-NO: 2002-304813

DERWENT-WEEK: 200421

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Correct article orientation determination method for use on conveyor involves determining if use of tilting device is needed based on the dimensions of the articles

INVENTOR: JENSEN, A M; NIELSEN, K

PRIORITY-DATA: 2000DK-0001424 (September 26, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20040050659 A1	March 18, 2004		000	B65G043/08
WO 200226598 A2	April 4, 2002	E	046	B65G047/24
AU 200191638 A	April 8, 2002		000	B65G047/24
EP 1332100 A2	August 6, 2003	E	000	B65G047/24

INT-CL (IPC): B65 G 43/08; B65 G 47/24

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 13. Document ID: CN 1471758 A, WO 200225357 A2, AU 200216318 A, EP 1323231 A2, KR 2003041991 A, JP 2004510397 W

L8: Entry 13 of 62

File: DWPI

Jan 28, 2004

DERWENT-ACC-NO: 2002-352057

DERWENT-WEEK: 200426

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: A controlled self-oscillation modulator for a switching power conversion system includes a higher order oscillating loop of a forward block with an input voltage and a feedback signal from a load current and voltage feedback block

INVENTOR: NIELSEN, K

PRIORITY-DATA: 2000SE-0003342 (September 19, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
CN 1471758 A	January 28, 2004		000	H03F003/217
WO 200225357 A2	March 28, 2002	E	016	G02F000/00
AU 200216318 A	April 2, 2002		000	G02F000/00

EP 1323231 A2	July 2, 2003	E	000	H03F003/217
KR 2003041991 A	May 27, 2003		000	H03F003/217
JP 2004510397 W	April 2, 2004		030	H02M007/48

INT-CL (IPC): G02 F 0/00; G05 F 1/10; H02 M 3/00; H02 M 7/48; H03 F 1/32; H03 F 3/217

ABSTRACTED-PUB-NO: WO 200225357A
BASIC-ABSTRACT:

NOVELTY - A higher order oscillating loop comprises a forward block (22) receiving an input voltage and a feedback signal from a feedback block (21), and deriving a process error modulating signal to a non-hysteresis comparator referenced to a voltage. The resulting pulse modulated signal is power amplified in a switching power conversion stage to generate a power pulse signal to an inductive load. The measured load current and voltage are connected to the feedback block.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a power conversion system.

USE - The controlled self-oscillation modulator is used for a switching power conversion system.

ADVANTAGE - The modulator provides stable oscillating conditions with improved performance, simple circuitry since no carrier generator is needed, and improved robustness. There is no feedback noise or poor carrier signal.

DESCRIPTION OF DRAWING(S) - The figure shows a block diagram of a controlled self-oscillation modulator.

Feedback block 21

Forward block 22

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 14. Document ID: US 6362702 B1

L8: Entry 14 of 62

File: DWPI

Mar 26, 2002

DERWENT-ACC-NO: 2002-498061
DERWENT-WEEK: 200253
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Controlled self-oscillation modulator for power conversion system, includes feedback and forward units having transfer functions being adapted to generate feedback signal and modulating signal respectively

INVENTOR: FREDERIKSEN, T; NIELSEN, K

PRIORITY-DATA: 2000US-0675647 (September 29, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6362702 B1	March 26, 2002		006	H03C001/00

INT-CL (IPC): H03 C 1/00; H03 C 1/06; H03 F 1/32; H03 F 3/217; H03 F 3/38

ABSTRACTED-PUB-NO: US 6362702B
BASIC-ABSTRACT:

NOVELTY - A feedback unit has a transfer function adapted to generate a feedback signal based on current value measured by a measurement unit. A forward unit has a transfer function adapted to generate a modulating signal based on the feedback signal and an input signal.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for power conversion system.

USE - Controller self-oscillation modulator for switching power conversion systems such as DC-AC conversion system e.g. power amplifiers, DC-DC and AC-AC conversion systems.

ADVANTAGE - Improves load control and eliminates the need of load compensation by measuring the current supplied to the load. Simplifies design, as the current measurement itself implements a transfer function.

DESCRIPTION OF DRAWING(S) - The figure shows a block diagram of controlled self-oscillation modulator.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 15. Document ID: US 6580418 B1, WO 200165329 A1, AU 200138688 A

L8: Entry 15 of 62

File: DWPI

Jun 17, 2003

DERWENT-ACC-NO: 2001-582200
DERWENT-WEEK: 200341
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Haptic feedback joystick for computer software program, applies input motion to control handle, which causes control handle shaft to be pivotly displaced about center point

INVENTOR: GROME, D C; NIELSEN, K T ; GROME, D ; NIELSEN, K

PRIORITY-DATA: 2000US-0515967 (February 29, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 6580418 B1</u>	June 17, 2003		000	G09G005/08
<u>WO 200165329 A1</u>	September 7, 2001	E	053	G05G009/047
<u>AU 200138688 A</u>	September 12, 2001		000	G05G009/047

INT-CL (IPC): G05 G 9/047; G09 G 5/08

ABSTRACTED-PUB-NO: WO 200165329A
BASIC-ABSTRACT:

NOVELTY - An end cap (60) and hemi-spherical shell are coupled to control handle shaft (14) extending from control handle. An input motion applied to the control handle causes handle shaft to be pivotly displaced about center point. Two angular position sensors produce output signal indicating direction and extend of rotation of the control handle.

USE - For controlling machinery, computer software program such as computer games.

ADVANTAGE - If user releases the handle, spring bias force causes the handle to return to centered position about X-axis.

DESCRIPTION OF DRAWING(S) - The figure shows an exploded assembly view of components and sub-assemblies of joystick.

Control handle shaft 14

End cap 60

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 16. Document ID: DK 200001841 A, DK 173737 B, EP 1212933 A2

L8: Entry 16 of 62

File: DWPI

Aug 20, 2001

DERWENT-ACC-NO: 2001-498028

DERWENT-WEEK: 200248

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Agricultural sowing machine, has secondary hoppers arranged to be lifted free of attached sowing unit, each secondary hopper being mounted on vertical axle in order to pivot in horizontal plane in relation to side frame

INVENTOR: KAASTRUP, S; KNUDSEN, M ; NIELSEN, K

PRIORITY-DATA: 2000DK-0001841 (December 7, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DK 200001841 A</u>	August 20, 2001		001	A01C007/00
<u>DK 173737 B</u>	August 20, 2001		000	A01C007/00
<u>EP 1212933 A2</u>	June 12, 2002	E	017	A01C015/00

INT-CL (IPC): A01 B 73/02; A01 C 7/00; A01 C 15/00; B07 B 4/02

ABSTRACTED-PUB-NO: DK 200001841A

BASIC-ABSTRACT:

NOVELTY - The machine comprises a central frame (2) supporting a central hopper (3) and two side frames (4) that each support a secondary hopper (5), which is connected to and filled from the central hopper through an auger conveyor (7), each of the side frames being interchangeable between a working position perpendicular to a transport direction and a transport position where they are parallel with the transport direction. Each secondary hopper has a sowing unit attached and comprising a number of down pipes.

DETAILED DESCRIPTION - The secondary hoppers are arranged to be lifted free of the attached sowing unit, and each secondary hopper is mounted on a vertical axle in order to pivot in a horizontal plane in relation to the side frame. Each side frame is mounted on a horizontal axle in relation to the central frame and comprises a parallelogram in order to pivot in a vertical plane with the hopper maintained in a vertical position.

USE - As a large width sowing machine.

ADVANTAGE - Is mechanically simple and makes possible conversion of the machine from a working position to a transport position simply by using a one double-acting hydraulic cylinder.

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.9&ref=8&dbname=PGPB,USPT,USO...> 10/5/04

DESCRIPTION OF DRAWING(S) - The drawing shows a perspective view of the sowing machine.

Central frame 2

Central hopper 3

Side frames 4

Secondary hopper 5

Auger conveyor 7

ABSTRACTED-PUB-NO:

EP 1212933A EQUIVALENT-ABSTRACTS:

NOVELTY - The machine comprises a central frame (2) supporting a central hopper (3) and two side frames (4) that each support a secondary hopper (5), which is connected to and filled from the central hopper through an auger conveyor (7), each of the side frames being interchangeable between a working position perpendicular to a transport direction and a transport position where they are parallel with the transport direction. Each secondary hopper has a sowing unit attached and comprising a number of down pipes.

DETAILED DESCRIPTION - The secondary hoppers are arranged to be lifted free of the attached sowing unit, and each secondary hopper is mounted on a vertical axle in order to pivot in a horizontal plane in relation to the side frame. Each side frame is mounted on a horizontal axle in relation to the central frame and comprises a parallelogram in order to pivot in a vertical plane with the hopper maintained in a vertical position.

USE - As a large width sowing machine.

ADVANTAGE - Is mechanically simple and makes possible conversion of the machine from a working position to a transport position simply by using a one double-acting hydraulic cylinder.

DESCRIPTION OF DRAWING(S) - The drawing shows a perspective view of the sowing machine.

Central frame 2

Central hopper 3

Side frames 4

Secondary hopper 5

Auger conveyor 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 17. Document ID: DK 200000005 A

L8: Entry 17 of 62

File: DWPI

Jul 6, 2001

DERWENT-ACC-NO: 2001-476873

DERWENT-WEEK: 200152

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Method for controlling heating installation interrupts remote heat water flow through heat exchanger when installation is in no-load condition or there is no heat energy requirement

INVENTOR: FAURSCHOU, J; HOULBERG, S ; NIELSEN, K

PRIORITY-DATA: 2000DK-0000005 (January 5, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DK 200000005 A</u>	July 6, 2001		002	F24D019/10

INT-CL (IPC): F24 D 19/10

ABSTRACTED-PUB-NO: DK 200000005A

BASIC-ABSTRACT:

NOVELTY - The method for controlling a heating installation interrupts remote heat water flow through a heat exchanger when the installation is in a no-load situation or there is no heat energy requirement. It uses a pressure-controlled regulator (19) which has a difference pressure valve with a membrane function, which can possibly be combined with a thermostat control (21).

DETAILED DESCRIPTION - The regulator can control both the primary side outlet pipe (3) and the secondary side inlet pipe (9) to the heat exchanger (4).

USE - For controlling a heating installation.

ADVANTAGE - No-load operation loss is eliminated, with the circulation pump being stopped. It is possible to do without a Summer valve with corresponding manual operation.

DESCRIPTION OF DRAWING(S) - The single figure illustrates the circuit layout.

primary side outlet pipe 3

heat exchanger 4

secondary side inlet pipe 9

pressure-controlled regulator 19

thermostat control 21

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	----------

☐ 18. Document ID: DE 19946797 C1

L8: Entry 18 of 62

File: DWPI

May 31, 2001

DERWENT-ACC-NO: 2001-317977

DERWENT-WEEK: 200134

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Cap for the thermostat valve of a heating radiator has a limit unit to show the max permitted setting of the rotating cap against the housing together with a pointer and a scale

INVENTOR: LARSEN, H E; NIELSEN, K

<http://westbrs.9000/bin/gate.exe?f=TOC&state=7kphob.9&ref=8&dbname=PGPB,USPT,USO...> 10/5/04

PRIORITY-DATA: 1999DE-1046797 (September 29, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 19946797 C1	May 31, 2001		005	F24D019/10

INT-CL (IPC): F16 K 31/64; F16 K 35/10; F24 D 19/10

ABSTRACTED-PUB-NO: DE 19946797C

BASIC-ABSTRACT:

NOVELTY - The cap for a thermostat valve, at a heating radiator, has a limit unit (9,10) with an indicator (17) to show the position at a scale (8) where the rotating grip (2) has the max. permitted rotation in relation to the housing (3). The pointer (19) is between the two sections (9,10) of the limit.

USE - The structure is the cap for a thermostat valve, at a heating radiator, where the rotating cap gives the thermostat setting.

ADVANTAGE - The cap gives a comfortable thermostat operation, with a clear indication of the setting.

DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view of the thermostat valve cap.

rotating grip cap 2

housing 3

scale 8

limit unit 9,10

limit indicator 17

pointer 19

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 19. Document ID: DE 19949136 B4, EP 1103879 A1, DE 19949136 A1, CN 1291689 A, CZ 200003345 A3, RU 2191311 C2, EP 1103879 B1, DE 50000910 G, ES 2186612 T3

L8: Entry 19 of 62

File: DWPI

Feb 12, 2004

DERWENT-ACC-NO: 2001-368993

DERWENT-WEEK: 200412

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Actuation fixture for valve with control circuit controlling heating according to control signal and position signal from position measurement device

INVENTOR: LARSEN, H E; NIELSEN, K; SEERUP, J

PRIORITY-DATA: 1999DE-1049136 (October 12, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 19949136 B4	February 12, 2004		000	F16K031/64

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.9&ref=8&dbname=PGPB,USPT,USO...> 10/5/04

<u>EP 1103879 A1</u>	May 30, 2001	G	007	G05D023/02
<u>DE 19949136 A1</u>	June 7, 2001		000	F16K031/66
<u>CN 1291689 A</u>	April 18, 2001		000	F16K031/66
<u>CZ 200003345 A3</u>	July 11, 2001		000	F16K031/66
<u>RU 2191311 C2</u>	October 20, 2002		000	F16K031/66
<u>EP 1103879 B1</u>	December 11, 2002	G	000	G05D023/02
<u>DE 50000910 G</u>	January 23, 2003		000	G05D023/02
<u>ES 2186612 T3</u>	May 16, 2003		000	G05D023/02

INT-CL (IPC): F16 K 31/00; F16 K 31/64; F16 K 31/66;

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 45 of 45 returned.

☐ 1. Document ID: US 20040175394 A1

Using default format because multiple data bases are involved.

L12: Entry 1 of 45

File: PGPB

Sep 9, 2004

PGPUB-DOCUMENT-NUMBER: 20040175394

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040175394 A1

TITLE: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE

PUBLICATION-DATE: September 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schenk, Dale B.	Burlingame	CA	US	

US-CL-CURRENT: 424/185.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 2. Document ID: US 20040170641 A1

L12: Entry 2 of 45

File: PGPB

Sep 2, 2004

PGPUB-DOCUMENT-NUMBER: 20040170641

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040170641 A1

TITLE: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE

PUBLICATION-DATE: September 2, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schenk, Dale B.	Burlingame	CA	US	

US-CL-CURRENT: 424/184.1

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

☐ 3. Document ID: US 20040166119 A1

L12: Entry 3 of 45

File: PGPB

Aug 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040166119

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040166119 A1

TITLE: Prevention and treatment of amyloidogenic disease

PUBLICATION-DATE: August 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schenk, Dale B.	Burlingame	CA	US	

US-CL-CURRENT: 424/185.1

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

☐ 4. Document ID: US 20040151728 A1

L12: Entry 4 of 45

File: PGPB

Aug 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040151728

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040151728 A1

TITLE: Lectin compositions and methods for modulating an immune response to an antigen

PUBLICATION-DATE: August 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Segal, Andrew H.	Boston	MA	US	
Young, Elihu	Sharon	MA	US	

US-CL-CURRENT: 424/184.1; 424/199.1, 424/200.1, 530/395

ABSTRACT:

The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 5. Document ID: US 20040146521 A1

L12: Entry 5 of 45

File: PGPB

Jul 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040146521

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040146521 A1

TITLE: Prevention and treatment of synucleinopathic disease

PUBLICATION-DATE: July 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schenk, Dale B.	Burlingame	CA	US	
Masliah, Eliezer	San Diego	CA	US	

US-CL-CURRENT: 424/185.1

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 6. Document ID: US 20040141984 A1

L12: Entry 6 of 45

File: PGPB

Jul 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040141984

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040141984 A1

TITLE: Amyloid beta 1-6 antigen arrays

PUBLICATION-DATE: July 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bachmann, Martin F.	Seuzach		CH	
Tissot, Alain	Zurich		CH	
Ortmann, Rainer	Saint Louis		FR	
Luond, Rainer	Therwil		CH	
Staufenbiel, Matthias	Lorrach		DE	
Frey, Peter	Bern		CH	

US-CL-CURRENT: 424/184.1

ABSTRACT:

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A.beta.1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A.beta.1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 7. Document ID: US 20040126357 A1

L12: Entry 7 of 45

File: PGPB

Jul 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040126357

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040126357 A1

TITLE: Lectin compositions and methods for modulating an immune response to an antigen

PUBLICATION-DATE: July 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Segal, Andrew H.	Boston	MA	US	
Young, Elihu	Sharon	MA	US	

US-CL-CURRENT: 424/85.1; 424/185.1, 424/93.2

ABSTRACT:

The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion

polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 8. Document ID: US 20040086516 A1

L12: Entry 8 of 45

File: PGPB

May 6, 2004

PGPUB-DOCUMENT-NUMBER: 20040086516

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040086516 A1

TITLE: Methods

PUBLICATION-DATE: May 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Foxwell, Brian Maurice John	London		GB	
Feldmann, Marc	London		GB	

US-CL-CURRENT: 424/184.1

ABSTRACT:

We describe (1) a method of enhancing antigen presentation, comprising the step of supplying to an antigen presenting cell such as a dendritic cell, or precursor cell, an inhibitor of Toll-related receptor (TRR) signalling and (2) a method of inhibiting antigen presentation, comprising the step of supplying to an antigen presenting cell such as a dendritic cell, or precursor cell, an enhancer of Toll-related receptor (TRR) signalling. The inhibitor of TRR signalling may be a dominant negative mutant of MyD88, for example MyD88lpr.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 9. Document ID: US 20040081657 A1

L12: Entry 9 of 45

File: PGPB

Apr 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040081657

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040081657 A1

TITLE: Prevention and treatment of amyloidogenic disease

PUBLICATION-DATE: April 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schenk, Dale B.	Burlingame	CA	US	

US-CL-CURRENT: 424/185.1; 424/486, 514/54

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.13&ref=12&dbname=PGPB,USPT,U...> 10/5/04

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 10. Document ID: US 20040076633 A1

L12: Entry 10 of 45

File: PGPB

Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040076633

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040076633 A1

TITLE: Use of imidazoquinolinamines as adjuvants in dna vaccination

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Thomsen, Lindy Loise	Hertfordshire		GB	
Tite, John Philip	Stevenage		GB	
Topley, Peter	Hertfordshire		GB	

US-CL-CURRENT: 424/184.1

ABSTRACT:

The present invention relates to the use of a 1H-imidazo[4,5-c]-4-amine derivative as an adjuvant for use with nucleic acid vaccination.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 11. Document ID: US 20040005318 A1

L12: Entry 11 of 45

File: PGPB

Jan 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040005318

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040005318 A1

TITLE: Methods of treatment using CTLA-4 antibodies

PUBLICATION-DATE: January 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Davis, Thomas Andrew	Clarksville	MD	US	

Keler, Tibor P.	Princeton	NJ	US
Graziano, Robert F.	Princeton	NJ	US
Korman, Alan J.	Piedmont	CA	US

US-CL-CURRENT: 424/144.1; 424/185.1

ABSTRACT:

The present invention provides method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 12. Document ID: US 20030232056 A1

L12: Entry 12 of 45

File: PGPB

Dec 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030232056

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030232056 A1

TITLE: Compositions and methods for the therapy and diagnosis of ovarian cancer

PUBLICATION-DATE: December 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fanger, Gary R.	Mill Creek	WA	US	
Fling, Steven P.	Bainbridge Island	WA	US	

US-CL-CURRENT: 424/185.1; 435/320.1, 435/325, 435/6, 435/7.23, 530/350, 536/23.5

ABSTRACT:

Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 13. Document ID: US 20030206918 A1

L12: Entry 13 of 45

File: PGPB

Nov 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030206918

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030206918 A1

TITLE: Compositions and methods for the therapy and diagnosis of ovarian cancer

PUBLICATION-DATE: November 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fanger, Gary R.	Mill Creek	WA	US	
Fling, Steven P.	Bainbridge Island	WA	US	

US-CL-CURRENT: 424/185.1; 435/320.1, 435/325, 435/69.3, 530/350, 536/23.5

ABSTRACT:

Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 14. Document ID: US 20030185840 A1

L12: Entry 14 of 45

File: PGPB

Oct 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030185840

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030185840 A1

TITLE: Induction of tumor immunity by variants of folate binding protein

PUBLICATION-DATE: October 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ioannides, Constantin J.	Houston	TX	US	
Peoples, George E.	Fulton	MD	US	

US-CL-CURRENT: 424/185.1; 435/191

ABSTRACT:

The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 15. Document ID: US 20030161834 A1

L12: Entry 15 of 45

File: PGPB

Aug 28, 2003

PGPUB-DOCUMENT-NUMBER: 20030161834
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030161834 A1

TITLE: Vaccines

PUBLICATION-DATE: August 28, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Friede, Martin	Farnham		GB	
Garcon, Nathalie	Wavre		BE	
Gerard, Catherine Marie Ghislaine	Rhode Saint Genese		BE	
Hermand, Philippe	Court-Saint-Etienne		BE	

US-CL-CURRENT: 424/184.1; 424/186.1, 424/204.1, 424/208.1, 424/226.1, 424/227.1,
424/228.1, 424/229.1, 424/231.1, 424/249.1, 424/258.1, 424/263.1, 424/278.1,
424/283.1, 424/450, 514/25, 514/44

ABSTRACT:

The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 16. Document ID: US 20030157117 A1

L12: Entry 16 of 45

File: PGPB

Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030157117
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030157117 A1

TITLE: Novel method for down-regulation of amyloid

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rasmussen, Peter Birk	Horsholm		DK	
Jensen, Martin Roland	Horsholm		DK	
Nielsen, Klaus Gregorius	Horsholm		DK	
Koefoed, Peter	Horsholm		DK	

US-CL-CURRENT: 424/185.1; 435/226

ABSTRACT:

Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protien (APP) or beta amyloid (A.beta.). Immunization is preferably effected by administration of analogues of autologous APP or A.beta., said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A.beta. which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against APP or A.beta. and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 17. Document ID: US 20030118599 A1

L12: Entry 17 of 45

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030118599

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030118599 A1

TITLE: Compositions and methods for the therapy and diagnosis of lung cancer

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Algate, Paul A.	Issaquah	WA	US	
Lodes, Michael J.	Seattle	WA	US	
Wang, Tongtong	Medina	WA	US	
Fan, Liqun	Bellevue	WA	US	
McNeill, Patricia D.	Federal Way	WA	US	

US-CL-CURRENT: 424/185.1; 435/183, 435/320.1, 435/325, 435/6, 435/69.1, 435/7.23, 536/23.2

ABSTRACT:

Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

☐ 18. Document ID: US 20030086938 A1

L12: Entry 18 of 45

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030086938
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030086938 A1

TITLE: Novel methods for down-regulation of amyloid

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jensen, Martin Roland	Horsholm		DK	
Birk, Peter	Horsholm		DK	
Nielsen, Klaus Gregorius	Horsholm		DK	

US-CL-CURRENT: 424/185.1

ABSTRACT:

Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloidogenic proteins (proteins contributing to formation of amyloid) such as beta amyloid (A.beta.). Immunization is preferably effected by administration of analogues of autologous amyloidogenic polypeptides, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A.beta. which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the majority of A.beta.'s B-cell epitopes. Also disclosed are nucleic acid vaccination against amyloidogenic polypeptides and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic analogues of the amyloidogenic proteins, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

☐ 19. Document ID: US 20030068325 A1

L12: Entry 19 of 45

File: PGPB

Apr 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030068325
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030068325 A1

TITLE: Immunogenic peptide composition for the prevention and treatment of Alzheimers Disease

PUBLICATION-DATE: April 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wang, Chang Yi	Cold Spring Harbor	NY	US	

US-CL-CURRENT: 424/185.1; 435/226

ABSTRACT:

The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of Alzheimer's Disease. More particularly, the peptide immunogen comprises a main functional/regulatory site, an N-terminal fragment of Amyloid .beta. (A.beta.) peptide linked to a helper T cell epitope (Th) having multiple class II MHC binding motifs. The peptide immunogen elicit a site-directed immune response against the main functional/regulatory site of the A.beta. peptide and generate antibodies, which are highly cross-reactive to the soluble A.beta..sub.1-42 peptide and the amyloid plaques formed in the brain of Alzheimer's Disease patients. The antibodies elicited being cross reactive to the soluble A.beta..sub.1-42 peptide, promote fibril disaggregation and inhibit fibrillar aggregation leading to immunoneutralization of the "soluble A.beta.-derived toxins"; and being cross-reactive to the amyloid plaques, accelerate the clearance of these plaques from the brain. Thus, the composition of the invention comprising the peptide immunogen is useful for the prevention and treatment of Alzheimer's Disease.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 20. Document ID: US 20030064072 A9

L12: Entry 20 of 45

File: PGPB

Apr 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030064072

PGPUB-FILING-TYPE: corrected

DOCUMENT-IDENTIFIER: US 20030064072 A9

TITLE: Nucleic acids, proteins and antibodies

PUBLICATION-DATE: April 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 424/184.1; 435/183, 435/320.1, 435/325, 435/6, 435/69.1, 435/7.1, 514/44, 536/23.1

ABSTRACT:

The present invention relates to novel lung cancer related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "lung cancer antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such lung cancer polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the lung, including, but not limited to, the presence of lung cancer and lung cancer metastases. More specifically, isolated lung cancer nucleic acid molecules are provided encoding novel lung cancer polypeptides. Novel lung cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors,

host cells, and recombinant and synthetic methods for producing human lung cancer polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the lung, including lung cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 21. Document ID: US 20030054010 A1

L12: Entry 21 of 45

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054010

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030054010 A1

TITLE: Molecular antigen array

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sebbel, Peter	Zurich		CH	
Dunant, Nicolas	Zurich		CH	
Bachmann, Martin	Winterthur		CH	
Tissot, Alain	Zurich		CH	
Lechner, Franziska	Zurich		CH	
Renner, Wolfgang A.	Zurich		CH	
Hennecke, Frank	Zurich		CH	
Nieba, Lars	Herisau		CH	

US-CL-CURRENT: 424/185.1; 424/186.1, 424/193.1, 424/204.1, 424/93.2, 435/6, 435/91.1

ABSTRACT:

The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. Various embodiments of the invention provide for a core particle that is coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 22. Document ID: US 20030049253 A1

L12: Entry 22 of 45

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049253

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.13&ref=12&dbname=PGPB,USPT,U...> 10/5/04

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030049253 A1

TITLE: Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Frank Q.	Montgomery Village	MD	US	
Chu, Yong-Liang	Rockville	MD	US	
Qiu, Jian-Tai	Rockville	MD	US	

US-CL-CURRENT: 424/144.1; 424/178.1

ABSTRACT:

A method and compositions for modulating an immune system response to an antigen in a mammal are disclosed. The method comprises administering to the mammal a conjugate comprising substantially particle-free hyaluronic acid (HA), or a polymer analogue thereof, covalently linked to a peptide that comprises a T cell epitope, or a plurality of epitopes. Typically, the epitope is defined by a sequence of at least about eight amino acids of the antigen.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 23. Document ID: US 20020187157 A1

L12: Entry 23 of 45

File: PGPB

Dec 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020187157
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020187157 A1

TITLE: Novel method for down-regulation of amyloid

PUBLICATION-DATE: December 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jensen, Martin Roland	Holte		DK	
Rasmussen, Peter Birk	Frederiksberg		DK	
Nielsen, Klaus Gregorius	Soborg		DK	

US-CL-CURRENT: 424/185.1; 424/85.1, 424/85.2

ABSTRACT:

A method for in vivo down-regulation of amyloid protein in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunogenically effective amount of at least one amyloidogenic polypeptide or subsequence thereof which has been formulated so that immunization of the animal with the amyloidgenic polypeptide or subsequence thereof induces production of antibodies against the amyloidogenic polypeptide, and/or at least one

analogue of the amyloidogenic polypeptide wherein is introduced at least one modification in the amino acid sequence of the amyloidogenic polypeptide which has as a result the immunization of the animal with the analogue induces production of antibodies against the amyloidogenic polypeptide.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 24. Document ID: US 20020183499 A1

L12: Entry 24 of 45

File: PGPB

Dec 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020183499
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020183499 A1

TITLE: Compositions and methods for the therapy and diagnosis of lung cancer

PUBLICATION-DATE: December 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lodes, Michael J.	Seattle	WA	US	
Mohamath, Raodoh	Seattle	WA	US	
Henderson, Robert A.	Edmonds	WA	US	
Benson, Darin R.	Seattle	WA	US	
Secrist, Heather	Seattle	WA	US	

US-CL-CURRENT: 536/23.1; 424/184.1, 435/320.1, 435/325, 435/7.23, 530/324, 536/24.3

ABSTRACT:

Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 25. Document ID: US 20020094335 A1

L12: Entry 25 of 45

File: PGPB

Jul 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020094335
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020094335 A1

TITLE: Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

PUBLICATION-DATE: July 18, 2002

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.13&ref=12&dbname=PGPB,USPT,U...> 10/5/04

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chalifour, Robert	Ile Bizard		CA	
Hebert, Lise	Brossard		CA	
Kong, Xianqi	Dollard-des-Oremaux		CA	
Gervais, Francine	Ile Bizard		CA	

US-CL-CURRENT: 424/185.1

ABSTRACT:

The present invention relates to a stereochemically based "non-self" antigen vaccine for the prevention and/or treatment of Alzheimer's and other amyloid related diseases. The present invention provides a vaccine for the prevention and treatment of Alzheimer's and other amyloid related diseases, which overcomes the drawbacks associated with using naturally occurring peptides, proteins or immunogens.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 26. Document ID: US 20020091234 A1

L12: Entry 26 of 45

File: PGPB

Jul 11, 2002

PGPUB-DOCUMENT-NUMBER: 20020091234

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020091234 A1

TITLE: Compositions and methods for enhancing immune responses mediated by antigen-presenting cells

PUBLICATION-DATE: July 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sanderson, Sam D.	Omaha	NE	US	
Hollingsworth, Michael A.	Omaha	NE	US	
Tempero, Richard A.	Omaha	NE	US	

US-CL-CURRENT: 530/328; 424/185.1, 530/327

ABSTRACT:

Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand linked to an immunogen. In particular, these molecular adjuvants are employed in compositions designed to deliver the specific immunogen to antigen presenting cells and simultaneously deliver signals to those cells that produce the desired immune response. Methods are also disclosed for delivery of these molecular adjuvants to patients, resulting in the transduction of activating signals to the targeted antigen presenting cell, thereby enhancing the immune response to the co-delivered immunogen.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 27. Document ID: US 20020044941 A1

L12: Entry 27 of 45

File: PGPB

Apr 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020044941
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020044941 A1

TITLE: Nucleic acids, proteins and antibodies

PUBLICATION-DATE: April 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 424/184.1; 435/183, 435/320.1, 435/325, 435/6, 435/69.1, 435/7.1,
514/44, 536/23.1

ABSTRACT:

The present invention relates to novel lung cancer related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "lung cancer antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such lung cancer polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the lung, including, but not limited to, the presence of lung cancer and lung cancer metastases. More specifically, isolated lung cancer nucleic acid molecules are provided encoding novel lung cancer polypeptides. Novel lung cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human lung cancer polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the lung, including lung cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 28. Document ID: US 6787523 B1

L12: Entry 28 of 45

File: USPT

Sep 7, 2004

US-PAT-NO: 6787523
DOCUMENT-IDENTIFIER: US 6787523 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.13&ref=12&dbname=PGPB,USPT,U...> 10/5/04

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 514/21; 424/1.57, 424/185.1, 424/9.1, 424/9.2, 436/15, 436/507,
436/86, 514/12, 514/2, 530/324

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

24 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 29. Document ID: US 6787144 B1

L12: Entry 29 of 45

File: USPT

Sep 7, 2004

US-PAT-NO: 6787144
DOCUMENT-IDENTIFIER: US 6787144 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/197.11; 424/1.57, 424/185.1, 424/193.1, 424/9.2, 436/86, 514/2,
514/21, 530/324

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

24 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 30. Document ID: US 6787143 B1

US-PAT-NO: 6787143

DOCUMENT-IDENTIFIER: US 6787143 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/193.1; 424/1.57, 424/185.1, 424/197.11, 424/236.1, 424/9.2,
436/86, 514/12, 514/2, 530/324

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

24 Claims, 19 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 31. Document ID: US 6787140 B1

L12: Entry 31 of 45

File: USPT

Sep 7, 2004

US-PAT-NO: 6787140

DOCUMENT-IDENTIFIER: US 6787140 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/185.1; 424/1.57, 424/9.1, 424/9.2, 436/15, 436/507, 436/86,
514/12, 514/2, 514/21, 530/324

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

43 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 32. Document ID: US 6787139 B1

L12: Entry 32 of 45

File: USPT

Sep 7, 2004

US-PAT-NO: 6787139
DOCUMENT-IDENTIFIER: US 6787139 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/185.1; 424/1.57, 424/9.2, 436/86, 514/2, 514/21

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

70 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 33. Document ID: US 6787138 B1

L12: Entry 33 of 45

File: USPT

Sep 7, 2004

US-PAT-NO: 6787138
DOCUMENT-IDENTIFIER: US 6787138 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/185.1; 424/1.57, 424/9.1, 424/9.2, 436/15, 436/507, 436/86,

<http://westbrs.9000/bin/gate.exe?f=TOC&state=7kphob.13&ref=12&dbname=PGPB,USPT,U...> 10/5/04

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

36 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Drawl Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------

☐ 34. Document ID: US 6719978 B2

L12: Entry 34 of 45

File: USPT

Apr 13, 2004

US-PAT-NO: 6719978

DOCUMENT-IDENTIFIER: US 6719978 B2

TITLE: Virus-like particles for the induction of autoantibodies

DATE-ISSUED: April 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schiller; John T.	Silver Spring	MD		
Chackerian; Bryce	Chevy Chase	MD		
Lowy; Douglas R.	Bethesda	MD		

US-CL-CURRENT: 424/199.1; 424/133.1; 424/143.1; 424/144.1; 424/147.1; 424/159.1,
424/184.1; 424/194.1; 424/204.1; 435/174; 435/235.1; 435/472; 530/350

ABSTRACT:

The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the treatment or prevention of human diseases, which involve the onset of B cell tolerance, such as chronic viral infection, chronic inflammatory disease, and neoplasia.

8 Claims, 14 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Drawl Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------

☐ 35. Document ID: US 6706694 B1

US-PAT-NO: 6706694

DOCUMENT-IDENTIFIER: US 6706694 B1

**** See image for Certificate of Correction ****

TITLE: Expression of exogenous polynucleotide sequences in a vertebrate

DATE-ISSUED: March 16, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wolff; Jon A.	Madison	WI		
Duke; David J.	Salem	OR		
Felgner; Philip L.	Rancho Santa Fe	CA		

US-CL-CURRENT: 514/44; 424/130.1, 424/184.1, 435/320.1, 435/325, 435/455

ABSTRACT:

The present invention provides a method for delivering a pharmaceutical polypeptide to the interior of a cardiac cell of a vertebrate in vivo, comprising the step of introducing a preparation comprising a pharmaceutically acceptable injectable carrier and naked polynucleotide operatively coding for the polypeptide into the interstitial space of the heart, whereby the naked polynucleotide is taken up into the interior of the cell and has a pharmacological effect on the vertebrate. In a preferred embodiment wherein the polynucleotide encodes polypeptide immunologically foreign to the vertebrate, the delivery method preferably comprises delivering an immunosuppressive agent to the vertebrate to limit immune responses directed to the polypeptide.

17 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 36. Document ID: US 6605699 B1

L12: Entry 36 of 45

File: USPT

Aug 12, 2003

US-PAT-NO: 6605699

DOCUMENT-IDENTIFIER: US 6605699 B1

TITLE: Galectin-11 polypeptides

DATE-ISSUED: August 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Gentz; Reiner L.	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		
Liu; Fu-Tong	San Diego	CA		

US-CL-CURRENT: 530/350; 424/134.1, 424/184.1, 424/185.1, 424/192.1, 435/69.1,
435/71.1, 530/387.3, 530/395, 530/396

ABSTRACT:

The present invention relates to galectin 11 proteins which are members of the galectin superfamily. In particular, the present invention relates to full-length polypeptides, fragments, and variants of galectin 11.

42 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	----------

☐ 37. Document ID: US'6544518 B1

L12: Entry 37 of 45

File: USPT

Apr 8, 2003

US-PAT-NO: 6544518

DOCUMENT-IDENTIFIER: US 6544518 B1

TITLE: Vaccines

DATE-ISSUED: April 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Friede; Martin	Farnham			GB
Garcon; Nathalie	Wavre			BE
Gerard; Catherine Marie Ghislaine	Rhode Saint Genese			BE
Herland; Philippe	Court-Saint-Etienne			BE

US-CL-CURRENT: 424/184.1; 424/208.1, 424/228.1, 424/229.1, 424/231.1, 424/249.1,
424/278.1, 424/283.1, 514/25

ABSTRACT:

The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.

15 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	----------

☐ 38. Document ID: US 6521776 B2

L12: Entry 38 of 45

File: USPT

Feb 18, 2003

US-PAT-NO: 6521776

DOCUMENT-IDENTIFIER: US 6521776 B2

TITLE: Immunological adjuvant compounds compositions and methods of use thereof

DATE-ISSUED: February 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hawkins; Lynn D.	Concord	MA		
Ishizaka; Sally T.	Weston	MA		
Rose; Jeffrey	Chelmsford	MA		
Yang; Hu	North Andover	MA		

US-CL-CURRENT: 558/159; 424/184.1, 424/278.1

ABSTRACT:

The present invention provides novel compounds that function as immunological adjuvants when co-administered with antigens, including, antigens used as vaccines for any disease or condition amenable to vaccination. The invention also provides adjuvant formulations comprising the novel compounds of the invention and methods for immunizing humans and non-human animals.

16 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 39. Document ID: US 6482411 B1

L12: Entry 39 of 45

File: USPT

Nov 19, 2002

US-PAT-NO: 6482411

DOCUMENT-IDENTIFIER: US 6482411 B1

**** See image for Certificate of Correction ****

TITLE: Methods of reducing bone loss with CD40 ligand

DATE-ISSUED: November 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ahuja; Seema A.	San Antonio	TX		
Bonewald; Lynda F.	San Antonio	TX		

US-CL-CURRENT: 424/185.1; 424/178.1, 424/184.1, 424/192.1, 424/85.1, 514/12, 514/2, 514/8, 514/885, 530/350, 530/351

ABSTRACT:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.13&ref=12&dbname=PGPB,USPT,U...> 10/5/04

Provided are methods and compositions using one or more CD40 agonists, such as CD40 ligands and/or agonistic anti-CD40 antibodies, to reduce or prevent cell death, or apoptosis, in bone cells. Methods of treating or preventing bone loss, including osteoporosis, as well as methods of reducing or eliminating the bone loss associated with steroid administration are particularly provided. Further disclosed are a variety of therapeutic kits and cocktails.

34 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWOC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 40. Document ID: US 6448230 B1

L12: Entry 40 of 45

File: USPT

Sep 10, 2002

US-PAT-NO: 6448230

DOCUMENT-IDENTIFIER: US 6448230 B1

**** See image for Certificate of Correction ****

TITLE: Testis expressed polypeptide

DATE-ISSUED: September 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ruben; Steven M.	Olney	MD		
Rosen; Craig A.	Laytonsville	MD		
Zeng; Zhizhen	Gaithersburg	MD		

US-CL-CURRENT: 514/21; 424/185.1, 424/193.1, 424/194.1, 424/234.1, 514/12, 514/2, 514/44, 530/300, 530/305, 530/324, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

40 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWOC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 41. Document ID: US 6261569 B1

L12: Entry 41 of 45

File: USPT

Jul 17, 2001

US-PAT-NO: 6261569
DOCUMENT-IDENTIFIER: US 6261569 B1

TITLE: Retro-, inverso- and retro-inverso synthetic peptide analogues

DATE-ISSUED: July 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Comis; Alfio	Bossley Park			AU
Tyler; Margaret Isabel	Turramurra			AU
Fischer; Peter	Oslo			NO

US-CL-CURRENT: 424/204.1; 424/184.1, 424/185.1, 424/188.1, 424/190.1, 424/191.1,
424/208.1, 424/225.1, 424/227.1, 424/228.1, 424/236.1, 514/2, 530/300, 530/332,
530/403, 530/806, 530/825, 530/826

ABSTRACT:

Synthetic peptide antigen analogues of native peptide antigens with partial or complete retro, inverso or retro-inverso modifications are provided. When administered as an immunogen to an immunocompetent host the synthetic peptide antigen analogues induce the production of antibodies which recognize the native peptide antigen. Uses of these analogues, vaccines and methods of preparing vaccines comprising these antigen analogues, and antibodies generated using these antigen analogues are also provided.

16 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMK	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 42. Document ID: US 6207644 B1

L12: Entry 42 of 45

File: USPT

Mar 27, 2001

US-PAT-NO: 6207644
DOCUMENT-IDENTIFIER: US 6207644 B1

TITLE: Peptide analogues containing a 7-membered lactam ring

DATE-ISSUED: March 27, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Luke; Richard William Arthur	Macclesfield			GB
Cotton; Ronald	Macclesfield			GB

US-CL-CURRENT: 514/16; 424/185.1, 424/810, 514/17, 514/18, 514/212.01, 530/323,
530/335, 540/485, 540/527

ABSTRACT:

The invention concerns pharmaceutically useful peptide derivatives of the formula

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.13&ref=12&dbname=PGPB,USPT,U...> 10/5/04

(I), P--R.sup.1 --R.sup.2 --R.sup.3 --R.sup.4, in which P, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 have the various meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel peptide derivatives are of value in treating MHC class II dependent T-cell mediated autoimmune or inflammatory diseases, such as rheumatoid arthritis. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds in medical treatment.

12 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 43. Document ID: US 6068844 A

L12: Entry 43 of 45

File: USPT

May 30, 2000

US-PAT-NO: 6068844

DOCUMENT-IDENTIFIER: US 6068844 A

TITLE: Increased resistance to stroke by developing immunologic tolerance to myelin or components thereof

DATE-ISSUED: May 30, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Becker; Kyra J.	Seattle	WA		
Hallenbeck; John M.	Kensington	MD		
McCarron; Richard M.	Kensington	MD		

US-CL-CURRENT: 424/184.1; 424/810, 514/12, 514/2, 530/350

ABSTRACT:

The present invention relates to a method of inducing oral tolerance to ischemic injury which has the objective of minimizing the severity and size of injured regions in the brain that arise as a result of ischemia. The method responds rapidly to the onset of infarction, with treatment that is short in duration. The procedure is specifically focused on the injured area of the infarct by virtue of being targeted immunologically to the ischemic site. The method therefore avoids the possibility of inducing systemic side effects affecting other organs of the patient. The present invention involves administering myelin or a component thereof such as myelin basic protein or proteolipid protein to a subject either orally or by inhalation. The amount administered and the duration of the treatment are effective to minimize the size and severity of the infarct in the brain of the subject. The method is intended for acute conditions related either to an actual recent cerebral ischemic event or to a potential ischemic event that might arise as a result of medical or surgical treatment planned for the subject.

21 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 44. Document ID: US 5843446 A

L12: Entry 44 of 45

File: USPT

Dec 1, 1998

US-PAT-NO: 5843446

DOCUMENT-IDENTIFIER: US 5843446 A

TITLE: Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines

DATE-ISSUED: December 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ladd; Anna Efim	Brooklyn	NY		
Wang; Chang Yi	Cold Spring Harbor	NY		
Zamb; Timothy Joseph	Stony Brook	NY		

US-CL-CURRENT: 424/184.1; 424/185.1, 424/195.11, 424/811

ABSTRACT:

This invention relates to immunogenic luteinizing hormone releasing hormone (LHRH) peptides that lead to suppression of LHRH activity in males or females. These peptides are useful for inducing infertility and for treating prostatic hyperplasia, androgen-dependent carcinoma, prostatic carcinoma and testicular carcinoma in males. In females, the peptides are useful for treating endometriosis, benign uterine tumors, recurrent functional ovarian cysts and (severe) premenstrual syndrome as well as prevention or treatment of estrogen-dependent breast cancer. The subject peptides contain a helper T cell epitope and have LHRH at the C terminus. The helper T cell epitope aids in stimulating the immune response against LHRH. The peptides, optionally contain an invasin domain which acts as a general immune stimulator.

In another aspect this invention relates to immunogenic synthetic peptides having an invasin domain, a helper T cell epitope and a peptide hapten and methods of using these peptides to treat disease or provide protective immunity. The peptide haptens of the invention include LHRH, amylin, gastrin, gastrin releasing peptide, IgE CH4 peptide, Chlamydia MOMP peptides, HIV V3 peptides and Plasmodium berghei.

19 Claims, 39 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 37

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 45. Document ID: US 5759551 A

L12: Entry 45 of 45

File: USPT

Jun 2, 1998

US-PAT-NO: 5759551

DOCUMENT-IDENTIFIER: US 5759551 A

TITLE: Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ladd; Anna Efim	Brooklyn	NY		
Wang; Chang Yi	Cold Spring Harbor	NY		
Zamb; Timothy Joseph	Stony Brook	NY		

US-CL-CURRENT: 424/198.1; 424/185.1, 424/227.1, 514/841, 514/843

ABSTRACT:

This invention relates to immunogenic luteinizing hormone releasing hormone (LHRH) peptides that lead to suppression of LHRH activity in males or females. When male rats are immunized with these peptides, serum testosterone drops and androgen-dependent organs atrophy significantly. These peptides are useful for inducing infertility and for treating prostatic hyperplasia, androgen-dependent carcinoma, prostatic carcinoma and testicular carcinoma in males. In females, the peptides are useful for treating endometriosis, benign uterine tumors, recurrent functional ovarian cysts and (severe) premenstrual syndrome as well as prevention or treatment of estrogen-dependent breast cancer. The subject peptides contain a helper T cell epitope and have LHRH at the C terminus. The helper T cell epitope aids in stimulating the immune response against LHRH. The peptides, optionally contain an invasin domain which acts as a general immune stimulator. In another aspect this invention relates to immunogenic synthetic peptides having an invasin domain, a helper T cell epitope and a peptide hapten and methods of using these peptides to treat disease or provide protective immunity. The peptide haptens of the invention include LHRH, amylin, gastrin, gastrin releasing peptide, IgE CH4 peptide, Chlamydia MOMP peptides, HIV V3 peptides and Plasmodium berghei.

15 Claims, 37 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 37

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	KOMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	----------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms

Documents

L11 AND T helper

45

Display Format: -

Change Format

[Previous Page](#)[Next Page](#)[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 34 of 34 returned.

☐ 1. Document ID: US 20040138096 A1

Using default format because multiple data bases are involved.

L24: Entry 1 of 34

File: PGPB

Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040138096
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040138096 A1

TITLE: Immunoregulator

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Khan, Nisar Ahmed	Rotterdam		NL	
Savelkoul, Hubertus Franciscus Josef	Oud-Beijerland		NL	
Benner, Robbert	Barendrecht		NL	

US-CL-CURRENT: 514/2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 2. Document ID: US 20040058851 A1

L24: Entry 2 of 34

File: PGPB

Mar 25, 2004

PGPUB-DOCUMENT-NUMBER: 20040058851
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040058851 A1

TITLE: Specific autoimmune reactions against isomerised/optically inverted epitopes:
application for diagnosis of autoimmune diseases

PUBLICATION-DATE: March 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cloos, Paul	Kobenhavn		DK	
Christgau, Stephan	Gentofte		DK	

US-CL-CURRENT: 514/2; 435/7.21

ABSTRACT:

Antibodies and T-lymphocytes having immune reactivity with proteins isomerised at an
<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.25&ref=24&dbname=PGPB,USPT,U...> 10/5/04

aspartic acid, asparagine, glutamine or glutamic acid residue are found to be associated with auto-immune conditions involving auto-reactivity to IgG (rheumatoid arthritis) and myelin basic protein (multiple sclerosis). Diagnosis assays for auto-immune reactivity to isomerised protein sequences are described.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 3. Document ID: US 20040005641 A1

L24: Entry 3 of 34

File: PGPB

Jan 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040005641
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040005641 A1

TITLE: Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof

PUBLICATION-DATE: January 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Burnet, Michael	Kusterdingen		DE	
Guse, Jan-Hinrich	Tubingen-Buhl		DE	
Kim, Gene	Tubingen		DE	
Gutke, Hans-Jurgen	Stuttgart		DE	
Beck, Albert	Nehren		DE	
Tsotsou, Georgia	Tubingen		DE	
Droste-Borel, Irina	Tubingen		DE	
Barker, Laurence	Tubingen		DE	
Wolff, Michael	Kusterdingen		DE	

US-CL-CURRENT: 435/7.21; 435/40.5, 514/1

ABSTRACT:

This invention features a method of identifying a compound useful for enhancing efficacy of a therapeutic agent. The method includes incubating a compound in blood cells; separating immune cells from erythrocytic cells; and determining the ratio of the concentration of the compound in the immune cells to the concentration of the compound in the erythrocytic cells; wherein the compound comprises a transportophore and a therapeutic agent, in which the transportophore is covalently bonded to the therapeutic agent via a bond or a linker.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 4. Document ID: US 20040005338 A1

L24: Entry 4 of 34

File: PGPB

Jan 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040005338
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040005338 A1

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.25&ref=24&dbname=PGPB,USPT,U...> 10/5/04

TITLE: Packaged virus-like particles for use as adjuvants: method of preparation and use

PUBLICATION-DATE: January 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bachmann, Martin F.	Seuzach		CH	
Renner, Wolfgang A.	Kilchberg		CH	

US-CL-CURRENT: 424/204.1; 514/2, 514/292, 514/44, 514/54, 514/8

ABSTRACT:

The invention relates to the finding that virus like particles (VLPs) can be loaded and packaged, respectively, with DNA oligonucleotides rich in non-methylated C and G (CpGs). If such CpG-VLPs are mixed with antigens, the immunogenicity of these antigens are dramatically enhanced. In addition, the T cell responses against the antigens are especially directed to the Th1 type. Surprisingly, no covalent linkage of the antigen to the VLP is required; it is sufficient to simply mix the VLPs with the adjuvants for co-administration. In addition, it was found that VLPs did not enhance immune responses unless they were loaded and packaged, respectively, with CpGs. Antigens mixed with CpG-packaged VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 5. Document ID: US 20030171252 A9

L24: Entry 5 of 34

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030171252

PGPUB-FILING-TYPE: corrected

DOCUMENT-IDENTIFIER: US 20030171252 A9

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 514/1; 435/320.1, 435/325, 435/6, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and

therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 6. Document ID: US 20030139364 A1

L24: Entry 6 of 34

File: PGPB

Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030139364

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030139364 A1

TITLE: Methods and products for enhancing immune responses using imidazoquinoline compounds

PUBLICATION-DATE: July 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Krieg, Arthur M.	Wellesley	MA	US	
Schetter, Christian	Hilden	MA	DE	
Bratzler, Robert L.	Concord		US	
Vollmer, Jorg	Dusseldorf		DE	
Jurk, Marion	Dusseldorf		DE	
Bauer, Stefan	Muenchen		DE	

US-CL-CURRENT: 514/44; 435/7.1, 514/171, 514/2, 514/263.38, 514/292

ABSTRACT:

The invention involves administration of an imidazoquinoline agent in combination with another therapeutic agent. The combination of drugs may be administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs. The combinations can be used to enhance ADCC, stimulate immune responses and/or patient and treat certain disorders.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 7. Document ID: US 20030083231 A1

L24: Entry 7 of 34

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030083231

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030083231 A1

TITLE: Blood cell deficiency treatment method

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.25&ref=24&dbname=PGPB,USPT,U...> 10/5/04

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ahlem, Clarence N.	San Diego	CA	US	
Reading, Christopher	San Diego	CA	US	
Frincke, James	San Diego	CA	US	
Stickney, Dwight	Granite Bay	CA	US	
Lardy, Henry A.	Madison	WI	US	
Marwah, Padma	Middleton	WI	US	
Marwah, Ashok	Middleton	WI	US	
Prendergast, Patrick T.	Straffan		IE	

US-CL-CURRENT: 514/2; 514/169, 514/173, 514/26, 514/44, 514/63

ABSTRACT:

The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D- -glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androstane-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 8. Document ID: US 20030082532 A1

L24: Entry 8 of 34

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030082532

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030082532 A1

TITLE: TUMOR NECROSIS FACTOR RECEPTOR RELATED GENE 12 POLYPEPTIDES

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
NI, JIAN	ROCKVILLE	MD	US	
RUBEN, STEVEN M.	OLNEY	MD	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/7.2, 514/2, 530/350, 530/387.9, 536/23.5

ABSTRACT:

The present invention relates to a novel human protein called TNFR Related Gene 12, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.25&ref=24&dbname=PGPB,USPT,U...> 10/5/04

and treating disorders related to this novel human protein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 9. Document ID: US 20030022276 A1

L24: Entry 9 of 34

File: PGPB

Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030022276

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030022276 A1

TITLE: DENDRITIC ENRICHED SECRETED LYMPHOCYTE ACTIVATION MOLECULE

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
YOUNG, PAUL	GAITHERSBURG	MD	US	
RUBEN, STEVEN M.	OLNEY	MD	US	

US-CL-CURRENT: 435/69.1; 424/130.1, 435/320.1, 435/325, 435/7.1, 514/2, 530/350, 536/23.5

ABSTRACT:

The present invention relates to a novel human protein called Dendritic Enriched Secreted Lymphocyte Activation Molecule, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 10. Document ID: US 20020187105 A1

L24: Entry 10 of 34

File: PGPB

Dec 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020187105

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020187105 A1

TITLE: Polymer combinations that result in stabilized aerosols for gene delivery to the lungs

PUBLICATION-DATE: December 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zou, Yiyu	Bronx	NY	US	
Perez-Soler, Roman	New York	NY	US	

ABSTRACT:

The use of non-viral delivery of therapeutically effective compositions through aerosol for therapy or research purpose has been limited by the low efficiency mainly caused by an inefficient delivery system and destruction of formulation (gene and/or delivery system) by aerosol shearing power. This invention develops formulations that are established polymer combination formulations. The formulations are highly efficient in delivering genes in vivo through aerosol and are able to protect the delivered gene from the destruction by aerosol shearing power.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 11. Document ID: US 20020169137 A1

L24: Entry 11 of 34

File: PGPB

Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020169137

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020169137 A1

TITLE: Regulation of amyloid precursor protein expression by modification of ABC transporter expression or activity

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Reiner, Peter B.	Vancouver		CA	
Connop, Bruce P.	Vancouver		CA	
Pollard, Michelle	Vancouver		CA	

US-CL-CURRENT: 514/44; 514/2

ABSTRACT:

The invention relates to the discovery that expression of amyloid precursor protein is regulated by the expression of an ABC transporter. The invention therefore provides methods and compositions for modulating amyloid precursor protein expression in a brain cell, thereby preventing or inhibiting pathological .beta.-amyloid plaque formation in conditions such as Alzheimer's disease.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 12. Document ID: US 20020132753 A1

L24: Entry 12 of 34

File: PGPB

Sep 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020132753

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020132753 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: September 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 514/1; 435/320.1, 435/325, 435/6, 435/69.1, 536/23.1

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 13. Document ID: US 20020086811 A1

L24: Entry 13 of 34

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086811

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020086811 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 514/1; 435/320.1, 435/325, 435/6, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and

therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 14. Document ID: US 20020077270 A1

L24: Entry 14 of 34

File: PGPB

Jun 20, 2002

PGPUB-DOCUMENT-NUMBER: 20020077270

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020077270 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: June 20, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 514/1; 435/320.1, 435/325, 435/6, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 15. Document ID: US 20020061834 A1

L24: Entry 15 of 34

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061834

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061834 A1

TITLE: Human G-protein Chemokine receptor (CCR5) HDGNR10

<http://westbrs.9000/bin/gate.exe?f=TOC&state=7kphob.25&ref=24&dbname=PGPB,USPT,U...> 10/5/04

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Roschke, Viktor	Rockville	MD	US	
Li, Yi	Sunnyvale	CA	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 514/1; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 16. Document ID: US 20020061521 A1

L24: Entry 16 of 34

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061521

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061521 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 435/6; 435/69.1, 514/2, 530/300, 536/23.1

ABSTRACT:

The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular

system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 17. Document ID: US 20020052311 A1

L24: Entry 17 of 34

File: PGPB

May 2, 2002

PGPUB-DOCUMENT-NUMBER: 20020052311

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020052311 A1

TITLE: Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders

PUBLICATION-DATE: May 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Solomon, Beka	Herzlia Pituach		IL	
Frenkel, Dan	Rehovot		IL	

US-CL-CURRENT: 514/2; 424/93.21

ABSTRACT:

A method of immunizing against plaque forming diseases using display technology is provided. The method utilize novel agents, or pharmaceutical compositions for vaccination against plaque forming diseases which rely upon presentation of an antigen or epitope on a display vehicle. The method further includes agents, or pharmaceutical compositions for vaccination against plaque forming diseases, which rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, disaggregation of plaques results from the immunization. The methods of the present invention also generally relates to treating and/or diagnosing neurological diseases and disorders of the central nervous, regardless of whether the disease or disorder is plaque-forming or non-plaque forming.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 18. Document ID: US 20020052308 A1

L24: Entry 18 of 34

File: PGPB

May 2, 2002

PGPUB-DOCUMENT-NUMBER: 20020052308
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020052308 A1

TITLE: Nucleic acids, proteins and antibodies

PUBLICATION-DATE: May 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 514/1; 435/183, 435/320.1, 435/325, 435/6, 435/69.1, 435/7.1, 530/350, 536/23.1

ABSTRACT:

This invention relates to newly identified tissue specific cancer associated polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such tissue specific cancer antigens for detection, prevention and treatment of tissue specific disorders, particularly the presense of cancer. This invention relates to the cancer antigens as well as vectors, host cells, antibodies directed to cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing tissue specific disorders, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

Full	Title	Citation	Front	Review	Classification	Data	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 19. Document ID: US 6787523 B1

L24: Entry 19 of 34

File: USPT

Sep 7, 2004

US-PAT-NO: 6787523

DOCUMENT-IDENTIFIER: US 6787523 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 514/21; 424/1.57, 424/185.1, 424/9.1, 424/9.2, 436/15, 436/507, 436/86, 514/12, 514/2, 530/324

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.25&ref=24&dbname=PGPB,USPT,U...> 10/5/04

diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

24 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 20. Document ID: US 6787144 B1

L24: Entry 20 of 34

File: USPT

Sep 7, 2004

US-PAT-NO: 6787144
DOCUMENT-IDENTIFIER: US 6787144 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/197.11; 424/1.57, 424/185.1, 424/193.1, 424/9.2, 436/86, 514/2,
514/21, 530/324

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

24 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 21. Document ID: US 6787143 B1

L24: Entry 21 of 34

File: USPT

Sep 7, 2004

US-PAT-NO: 6787143
DOCUMENT-IDENTIFIER: US 6787143 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/193.1; 424/1.57, 424/185.1, 424/197.11, 424/236.1, 424/9.2,
436/86, 514/12, 514/2, 530/324

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

24 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 22. Document ID: US 6787140 B1

L24: Entry 22 of 34

File: USPT

Sep 7, 2004

US-PAT-NO: 6787140

DOCUMENT-IDENTIFIER: US 6787140 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/185.1; 424/1.57, 424/9.1, 424/9.2, 436/15, 436/507, 436/86,
514/12, 514/2, 514/21, 530/324

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

43 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 23. Document ID: US 6787139 B1

L24: Entry 23 of 34

File: USPT

Sep 7, 2004

US-PAT-NO: 6787139

DOCUMENT-IDENTIFIER: US 6787139 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/185.1; 424/1.57, 424/9.2, 436/86, 514/2, 514/21

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

70 Claims, 19 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 24. Document ID: US 6787138 B1

L24: Entry 24 of 34

File: USPT

Sep 7, 2004

US-PAT-NO: 6787138

DOCUMENT-IDENTIFIER: US 6787138 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/185.1; 424/1.57, 424/9.1, 424/9.2, 436/15, 436/507, 436/86, 514/12, 514/2, 514/21, 530/324

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.25&ref=24&dbname=PGPB,USPT,U...> 10/5/04

36 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 25. Document ID: US 6605592 B2

L24: Entry 25 of 34

File: USPT

Aug 12, 2003

US-PAT-NO: 6605592
DOCUMENT-IDENTIFIER: US 6605592 B2

TITLE: Protein HOFNF53

DATE-ISSUED: August 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Germantown	MD		
Baker; Kevin P.	Darnestown	MD		
Birse; Charles E.	North Potomac	MD		
Ebner; Reinhard	Gaithersburg	MD		
Fiscella; Michele	Bethesda	MD		
Komatsoulis; George A.	Silver Spring	MD		
LaFleur; David W.	Washington	DC		
Moore; Paul A.	Germantown	MD		
Olsen; Henrik S.	Gaithersburg	MD		
Rosen; Craig A.	Laytonsville	MD		
Ruben; Steven M.	Olney	MD		
Soppet; Daniel R.	Centreville	VA		
Young; Paul E.	Gaithersburg	MD		
Wei; Ping	Brookeville	MD		
Florence; Kimberly A.	Rockville	MD		

US-CL-CURRENT: 514/2, 435/252.3, 435/254.11, 435/320.1, 435/325, 435/471, 435/69.1,
435/71.1, 435/71.2, 514/12, 514/8, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. In particular, the present application relates to a novel human protein, Protein HOFNF53. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

19 Claims, 22 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 22

☐ 26. Document ID: US 6566325 B2

L24: Entry 26 of 34

File: USPT

May 20, 2003

US-PAT-NO: 6566325

DOCUMENT-IDENTIFIER: US 6566325 B2

TITLE: 49 human secreted proteins

DATE-ISSUED: May 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Moore; Paul A.	Germantown	MD		
Ruben; Steven M.	Olney	MD		
Olsen; Henrik S.	Gaithersburg	MD		
Shi; Yanggu	Gaithersburg	MD		
Rosen; Craig A.	Laytonsville	MD		
Florence; Kimberly A.	Rockville	MD		
Soppet; Daniel R.	Centreville	VA		
LaFleur; David W.	Washington	DC		
Endress; Gregory A.	Potomac	MD		
Ebner; Reinhard	Gaithersburg	MD		
Komatsoulis; George	Silver Spring	MD		
Duan; Roxanne D.	Bethesda	MD		

US-CL-CURRENT: 514/2; 530/300, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

52 Claims, 0 Drawing figures

Exemplary Claim Number: 1

☐ 27. Document ID: US 6521412 B1

L24: Entry 27 of 34

File: USPT

Feb 18, 2003

US-PAT-NO: 6521412

DOCUMENT-IDENTIFIER: US 6521412 B1

**** See image for Certificate of Correction ****

TITLE: HsReq*1 and hsReq*2 proteins and use thereof to detect CDK2

DATE-ISSUED: February 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yang; Meijia	East Lyme	CT		
Nandabalan; Krishnan	Guilford	CT		
Schulz; Vincent Peter	Madison	CT		

US-CL-CURRENT: 435/7.1; 435/29, 435/6, 514/12, 514/2, 530/300, 530/350

ABSTRACT:

The present invention relates to complexes of the CDK2 protein with proteins identified as interacting with CDK2 by a modified yeast two hybrid assay system. The proteins identified to interact with CDK2 are cyclin H, cyclin I, ERH, and two gene products, hsReq*-1 and hsReq*-2, which are splice variants of the gene hsReq. Thus, the invention provides complexes of CDK2 and cyclin H, cyclin I, ERH, hsReq*-1, and hsReq*-2, and derivatives, fragments and analogs thereof. The invention also provides nucleic acids encoding the hsReq*-1 and hsReq*-2, and proteins and derivatives, fragments and analogs thereof. Methods of screening the complexes for efficacy in treating and/or preventing certain diseases and disorders, particularly cancer, atherosclerosis and neurodegenerative disease are also provided.

14 Claims, 16 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 16

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 28. Document ID: US 6503184 B1

L24: Entry 28 of 34

File: USPT

Jan 7, 2003

US-PAT-NO: 6503184

DOCUMENT-IDENTIFIER: US 6503184 B1

TITLE: Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2

DATE-ISSUED: January 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Ruben; Steven M.	Olney	MD		

US-CL-CURRENT: 514/12; 514/2

ABSTRACT:

The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding human TR11, TR11SV1, and TR11SV2 receptors. TR11, TR11SV1, and TR11SV2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the

same. The invention further relates to screening methods for identifying agonists and antagonists of TR11, TR11SV1, and TR11SV2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR11, TR11SV1, and TR11SV2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR11, TR11SV1, and TR11SV2 receptors.

28 Claims, 11 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 29. Document ID: US 6482411 B1

L24: Entry 29 of 34

File: USPT

Nov 19, 2002

US-PAT-NO: 6482411

DOCUMENT-IDENTIFIER: US 6482411 B1

**** See image for Certificate of Correction ****

TITLE: Methods of reducing bone loss with CD40 ligand

DATE-ISSUED: November 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ahuja; Seema A.	San Antonio	TX		
Bonewald; Lynda F.	San Antonio	TX		

US-CL-CURRENT: 424/185.1; 424/178.1, 424/184.1, 424/192.1, 424/85.1, 514/12, 514/2, 514/8, 514/885, 530/350, 530/351

ABSTRACT:

Provided are methods and compositions using one or more CD40 agonists, such as CD40 ligands and/or agonistic anti-CD40 antibodies, to reduce or prevent cell death, or apoptosis, in bone cells. Methods of treating or preventing bone loss, including osteoporosis, as well as methods of reducing or eliminating the bone loss associated with steroid administration are particularly provided. Further disclosed are a variety of therapeutic kits and cocktails.

34 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 30. Document ID: US 6448230 B1

L24: Entry 30 of 34

File: USPT

Sep 10, 2002

US-PAT-NO: 6448230

DOCUMENT-IDENTIFIER: US 6448230 B1

TITLE: Testis expressed polypeptide

DATE-ISSUED: September 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ruben; Steven M.	Olney	MD		
Rosen; Craig A.	Laytonsville	MD		
Zeng; Zhizhen	Gaithersburg	MD		

US-CL-CURRENT: 514/21; 424/185.1, 424/193.1, 424/194.1, 424/234.1, 514/12, 514/2,
514/44, 530/300, 530/305, 530/324, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

40 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWOC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 31. Document ID: US 6391589 B1

L24: Entry 31 of 34

File: USPT

May 21, 2002

US-PAT-NO: 6391589

DOCUMENT-IDENTIFIER: US 6391589 B1

TITLE: Human chemokine beta-10 mutant polypeptides

DATE-ISSUED: May 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Olsen; Henrik S.	Gaithersburg	MD		
Li; Haodong	Gaithersburg	MD		
Adams; Mark D.	North Potomac	MD		
Gentz; Solange H. L.	Rockville	MD		
Alderson; Ralph	Gaithersburg	MD		
Li; Yuling	Germantown	MD		
Parmelee; David	Rockville	MD		
White; John R.	Coatsville	PA		
Appelbaum; Edward R.	Blue Bell	PA		

US-CL-CURRENT: 435/69.5; 424/85.1, 435/252.3, 435/254.11, 435/320.1, 435/325,
435/471, 435/71.1, 435/71.2, 514/12, 514/2 , 514/8, 530/324, 536/23.1, 536/23.5

ABSTRACT:

Human chemokine Beta-10 polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.

50 Claims, 21 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 14

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 32. Document ID: US 6261569 B1

L24: Entry 32 of 34

File: USPT

Jul 17, 2001

US-PAT-NO: 6261569
DOCUMENT-IDENTIFIER: US 6261569 B1

TITLE: Retro-, inverso- and retro-inverso synthetic peptide analogues

DATE-ISSUED: July 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Comis; Alfio	Bossley Park			AU
Tyler; Margaret Isabel	Turramurra			AU
Fischer; Peter	Oslo			NO

US-CL-CURRENT: 424/204.1; 424/184.1, 424/185.1, 424/188.1, 424/190.1, 424/191.1,
424/208.1, 424/225.1, 424/227.1, 424/228.1, 424/236.1, 514/2, 530/300, 530/332,
530/403, 530/806, 530/825, 530/826

ABSTRACT:

Synthetic peptide antigen analogues of native peptide antigens with partial or complete retro, inverso or retro-inverso modifications are provided. When administered as an immunogen to an immunocompetent host the synthetic peptide antigen analogues induce the production of antibodies which recognize the native peptide antigen. Uses of these analogues, vaccines and methods of preparing vaccines comprising these antigen analogues, and antibodies generated using these antigen analogues are also provided.

16 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

☐ 33. Document ID: US 6068844 A

L24: Entry 33 of 34

File: USPT

May 30, 2000

US-PAT-NO: 6068844

DOCUMENT-IDENTIFIER: US 6068844 A

TITLE: Increased resistance to stroke by developing immunologic tolerance to myelin or components thereof

DATE-ISSUED: May 30, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Becker; Kyra J.	Seattle	WA		
Hallenbeck; John M.	Kensington	MD		
McCarron; Richard M.	Kensington	MD		

US-CL-CURRENT: 424/184.1; 424/810, 514/12, 514/2, 530/350

ABSTRACT:

The present invention relates to a method of inducing oral tolerance to ischemic injury which has the objective of minimizing the severity and size of injured regions in the brain that arise as a result of ischemia. The method responds rapidly to the onset of infarction, with treatment that is short in duration. The procedure is specifically focused on the injured area of the infarct by virtue of being targeted immunologically to the ischemic site. The method therefore avoids the possibility of inducing systemic side effects affecting other organs of the patient. The present invention involves administering myelin or a component thereof such as myelin basic protein or proteolipid protein to a subject either orally or by inhalation. The amount administered and the duration of the treatment are effective to minimize the size and severity of the infarct in the brain of the subject. The method is intended for acute conditions related either to an actual recent cerebral ischemic event or to a potential ischemic event that might arise as a result of medical or surgical treatment planned for the subject.

21 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

☐ 34. Document ID: US 5851996 A

L24: Entry 34 of 34

File: USPT

Dec 22, 1998

US-PAT-NO: 5851996

DOCUMENT-IDENTIFIER: US 5851996 A

**** See image for Certificate of Correction ****

TITLE: Materials and methods for treatment of plaquing diseases

DATE-ISSUED: December 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kline; Ellis L.	Pendelton	SC		

US-CL-CURRENT: 514/12; 424/206.1, 424/231.1, 514/2, 514/21

ABSTRACT:

Methods and compositions are provided for alleviation of disease states involving plaque formation, such as are manifested in Alzheimer's Disease and other amyloid disorders, and arteriosclerotic disease. Methods for the treatment of herpes virus infections by administration of thimerosal are further provided by the invention.

14 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L23 AND T helper	34

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

Search Forms

Search Results

Help

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

User Searches

Preferences

Logout

Search Results - Record(s) 1 through 100 of 134 returned.

☐ 1. Document ID: US 20040181047 A1

Using default format because multiple data bases are involved.

L27: Entry 1 of 134

File: PGPB

Sep 16, 2004

PGPUB-DOCUMENT-NUMBER: 20040181047

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040181047 A1

TITLE: 33 human secreted proteins

PUBLICATION-DATE: September 16, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Ni, Jian	Rockville	MD	US	
Moore, Paul A.	Germantown	MD	US	
Young, Paul	Gaithersburg	MD	US	
Komatsoulis, George	Silver Spring	MD	US	
Birse, Charles E.	North Potomac	MD	US	

US-CL-CURRENT: 536/23.2; 435/183, 435/320.1, 435/325, 435/69.1, 530/350

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 2. Document ID: US 20040152164 A1

L27: Entry 2 of 134

File: PGPB

Aug 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040152164

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040152164 A1

TITLE: 62 human secreted proteins

PUBLICATION-DATE: August 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Brookeville	MD	US	
Ni, Jian	Germantown	MD	US	
Komatsoulis, George	Silver Spring	MD	US	

http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U... 10/5/04

Rosen, Craig A.	Laytonsville	MD	US
Soppet, Daniel R.	Centreville	VA	US
Shi, Yanggu	Gaithersburg	MD	US
LaFleur, David W.	Washington	DC	US
Olsen, Henrik	Gaithersburg	MD	US
Ebner, Reinhard	Gaithersburg	MD	US
Florence, Kimberly A.	Rockville	MD	US
Moore, Paul A.	North Bethesda	MD	US
Birse, Charles E.	North Potomac	MD	US
Young, Paul	Gaithersburg	MD	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20040146893 A1

L27: Entry 3 of 134

File: PGPB

Jul 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040146893

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040146893 A1

TITLE: 64 human secreted proteins

PUBLICATION-DATE: July 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Brookeville	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Young, Paul E.	Gaithersburg	MD	US	
Greene, John M.	Gaithersburg	MD	US	
Ni, Jian	Germantown	MD	US	
Feng, Ping	Germantown	MD	US	
Florence, Kimberly A.	Rockville	MD	US	
Hu, Jing-Shan	Mountain View	CA	US	
Ferrie, Ann M.	Painted Post	NY	US	
Yu, Guo-Liang	Berkeley	CA	US	
Duan, Roxanne D.	Gaithersburg	MD	US	
Janat, Fouad	Westerly	RI	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 530/388.1, 536/23.5

<http://westbrs.9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 20040142422 A1

L27: Entry 4 of 134

File: PGPB

Jul 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040142422

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040142422 A1

TITLE: Cytokine receptor zcytor17

PUBLICATION-DATE: July 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sprecher, Cindy A.	Seattle	WA	US	
Presnell, Scott R.	Tacoma	WA	US	
Gao, Zeren	Redmond	WA	US	
Whitmore, Theodore E.	Redmond	WA	US	
Kuijper, Joseph L.	Kenmore	WA	US	
Maurer, Mark F.	Seattle	WA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 5. Document ID: US 20040126801 A1

L27: Entry 5 of 134

File: PGPB

Jul 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040126801

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040126801 A1

TITLE: 19 human secreted proteins

PUBLICATION-DATE: July 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fiscella, Michele	Bethesda	MD	US	
Wei, Ping	Agoura Hills	CA	US	
LaFleur, David W.	Washington	DC	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Baker, Kevin P.	Darnestown	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Komatsoulis, George A.	Silver Spring	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Brookeville	MD	US	
Duan, D. Roxanne	Gaithersburg	MD	US	
Young, Paul E.	Gaithersburg	MD	US	
Florence, Kimberly A.	Rockville	MD	US	
Moore, Paul A.	North Bethesda	MD	US	
Birse, Charles E.	North Potomac	MD	US	
Ni, Jian	Germantown	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
Shi, Yanggu	Gaithersburg	MD	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 530/388.1, 536/23.5

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 6. Document ID: US 20040126777 A1

L27: Entry 6 of 134

File: PGPB

Jul 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040126777

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040126777 A1

TITLE: Lp mammalian proteins; related reagents

PUBLICATION-DATE: July 1, 2004

INVENTOR-INFORMATION:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

NAME	CITY	STATE	COUNTRY	RULE-47
Bhatt, Ramesh Rajani	Carmel	IN	US	
Calley, John Nels	Indianapolis	IN	US	
Heuer, Josef Georg	Indianapolis	IN	US	
Keleher, Gerald Patrick	Indianapolis	IN	US	
Lancaster, Joanne Sloan	Indianapolis	IN	US	
Li, Qingqin	Flemington	NJ	US	
Lu, Deshun	Carmel	IN	US	
Mills, Bradley Jay	Fountaintown	IN	US	
Mishra, Santosh Kumar	Singapore	IN	SG	
Perkins, Douglas Raymond	New Palestine	IN	US	
Rowlinson, Scott William	Indianapolis	IN	US	
Smith, Rosamund Carol	Greenfield	IN	US	
Su, Eric Wen	Carmel	IN	US	
Wang, He	Carmel	IN	US	
Zhi, Yu	Indianapolis		US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 530/388.1, 536/23.5

ABSTRACT:

Isolated nucleic acid molecules encoding polypeptides from a human, reagents related thereto (including purified polypeptidespecific antibodies) are provided. Methods of using said reagentsand diagnostic kits are also provided.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 7. Document ID: US 20040091945 A1

L27: Entry 7 of 134

File: PGPB

May 13, 2004

PGPUB-DOCUMENT-NUMBER: 20040091945

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040091945 A1

TITLE: Peptides and methods of screening immunogenic peptide vaccines against Alzheimer's Disease

PUBLICATION-DATE: May 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fitzer-Attas, Cheryl	Rehovot		IL	
Chain, Daniel G.	Jerusalem		IL	

US-CL-CURRENT: 435/7.2; 530/350

ABSTRACT:

The invention is in the field of immunogenicity. In one embodiment, the invention relates to method of identifying T-cell epitopes in amyloid beta peptide or homologue thereof. In another embodiment, the invention relates to a vaccine comprising an

amyloid beta peptide or homologue thereof, whereby the selected peptide is a peptide which lacks certain T-cell epitopes or a peptide which is modified by deleting or modifying amino acids so as to reduce or eliminate the T-cell epitopes. The selected peptides are further assessed for reduced capacity to form fibrils, reduced cytotoxicity, and a reduced ability to induce a cellular autoimmune response. The selected peptides are further assessed for ability to induce a humoral immune response. In another embodiment, the invention relates to a method of predicting the reaction of an individual to a vaccine, which comprises amyloid beta peptide or homologue thereof, based on the HLA haplotype of the subject. In another embodiment, the invention provides a method for matching a vaccine comprising amyloid beta peptide or homologue thereof to an individual, based on the HLA haplotype of that individual. In another embodiment, the invention provides a vaccine comprising an amyloid beta peptide or homologue thereof, whereby the amyloid beta peptide or homologue thereof, lacks the ability to induce a T-cell response

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 8. Document ID: US 20040067518 A1

L27: Entry 8 of 134

File: PGPB

Apr 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040067518
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040067518 A1

TITLE: 36 human secreted proteins

PUBLICATION-DATE: April 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Olsen, Henrik S.	Gaithersburg	MD	US	
Ruben, Steven M.	Brookeville	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Brewer, Laurie A.	St. Paul	MN	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Duan, Roxanne	Bethesda	MD	US	
Florence, Kimberly	Rockville	MD	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to 36 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 9. Document ID: US 20040052816 A1

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

PGPUB-DOCUMENT-NUMBER: 20040052816
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040052816 A1

TITLE: Recombinant protective protein from streptococcus pneumoniae

PUBLICATION-DATE: March 18, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Green, Bruce A.	Pittsford	NY	US	
Masi, Amy W.	Caledonia	NY	US	

US-CL-CURRENT: 424/190.1; 435/252.3, 435/320.1, 435/69.3, 530/350, 536/23.7

ABSTRACT:

The present invention discloses amino acid sequences and nucleic acid sequences relating to a Streptococcus Pneumoniae surface associated Pneumo Protective Protein (PPP) having a molecular weight of about 20 kilo Daltons (kDa). The PPP exhibits the ability to reduce colonization of pneumococcal bacteria. Thus the present invention also pertains to compositions for the treatment and prophylaxis of infection or inflammation associated with bacterial infection.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 10. Document ID: US 20040048304 A1

L27: Entry 10 of 134

File: PGPB

Mar 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040048304
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040048304 A1

TITLE: 95 human secreted proteins

PUBLICATION-DATE: March 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Brookeville	MD	US	
Ni, Jian	Germantown	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Yu, Guo-Liang	Berkeley	CA	US	
Young, Paul	Gaithersburg	MD	US	
Feng, Ping	Germantown	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
Wei, Ying-Fei	Berkeley	CA	US	
Endress, Gregory A.	Florence	MA	US	
Duan, Roxanne	Gaithersburg	MD	US	
Kyaw, Hla	Boonsboro	MD	US	

Ebner, Reinhard	Gaithersburg	MD	US
LaFleur, David W.	Washington	DC	US
Olsen, Henrik	Gaithersburg	MD	US
Shi, Yanggu	Gaithersburg	MD	US
Moore, Paul A.	Germantown	MD	US

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 11. Document ID: US 20040048294 A1

L27: Entry 11 of 134

File: PGPB

Mar 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040048294

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040048294 A1

TITLE: 31 human secreted proteins

PUBLICATION-DATE: March 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Brookeville	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Duan, Roxanne D.	Bethesda	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
LaFleur, David W.	Washington	DC	US	
Young, Paul E.	Gaithersburg	MD	US	
Ni, Jian	Germantown	MD	US	
Komatsoulis, George	Silver Spring	MD	US	
Endress, Gregory A.	Florence	MA	US	
Soppet, Daniel R.	Centreville	VA	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 530/388.25, 536/23.5

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions

related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 12. Document ID: US 20040039156 A1

L27: Entry 12 of 134

File: PGPB

Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040039156
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040039156 A1

TITLE: Lectin compositions and methods for modulating an immune response to an antigen

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Segal, Andrew	Boston	MA	US	
Young, Eli	Sharon	MA	US	

US-CL-CURRENT: 530/300; 424/192.1, 424/204.1, 424/206.1, 424/210.1, 435/6, 435/69.1, 530/350

ABSTRACT:

The present invention relates to a fusion polypeptide comprising at least about 10 contiguous amino acid residues of an influenza virus hemagglutinin and at least about 5 contiguous amino acids of a naturally occurring GM-CSF molecule.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 13. Document ID: US 20040038277 A1

L27: Entry 13 of 134

File: PGPB

Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040038277
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040038277 A1

TITLE: 125 human secreted proteins

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Feng, Ping	Germantown	MD	US	
Ruben, Steven M.	Brookeville	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Olsen, Henrik	Gaithersburg	MD	US	

Ni, Jian	Germantown	MD	US
Wei, Ying-Fei	Berkeley	CA	US
Soppet, Daniel R.	Centreville	VA	US
Moore, Paul A.	Germantown	MD	US
Kyaw, Hla	Boonsboro	MD	US
LaFleur, David W.	Washington	DC	US
Shi, Yanggu	Gaithersburg	MD	US
Janat, Fouad	Westerly	RI	US
Endress, Gregory A.	Florence	MA	US
Carter, Kenneth C.	North Potomac	MD	US
Birse, Charles E.	North Potomac	MD	US

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Desc
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 14. Document ID: US 20040034196 A1

L27: Entry 14 of 134

File: PGPB

Feb 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040034196

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040034196 A1

TITLE: 98 human secreted proteins

PUBLICATION-DATE: February 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Komatsoulis, George A.	Silver Spring	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Brookeville	MD	US	
Duan, D. Roxanne	Bethesda	MD	US	
Moore, Paul A.	Germantown	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
LaFleur, David W.	Washington	DC	US	
Wei, Ying-Fei	Berkeley	CA	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/6, 435/69.1, 530/388.1, 536/23.5

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 15. Document ID: US 20040030115 A1

L27: Entry 15 of 134

File: PGPB

Feb 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040030115
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040030115 A1

TITLE: 31 human secreted proteins

PUBLICATION-DATE: February 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Brookeville	MD	US	
Ferrie, Ann M.	Painted Post	NY	US	
Florence, Charles	Rockville	MD	US	
Young, Paul E.	Gaithersburg	MD	US	
Yu, Guo-Liang	Berkeley	CA	US	
Ni, Jian	Germantown	MD	US	

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/69.1, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 16. Document ID: US 20040023283 A1

L27: Entry 16 of 134

File: PGPB

Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040023283
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040023283 A1

TITLE: 90 human secreted proteins

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Brookeville	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Young, Paul E.	Gaithersburg	MD	US	
Greene, John M.	Gaithersburg	MD	US	
Ferrie, Ann M.	Painted Post	NY	US	
Yu, Guo-Liang	Berkeley	CA	US	
Ni, Jian	Germantown	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Brewer, Laurie	St. Paul	MN	US	
Janat, Fouad	Westerly	RI	US	
Birse, Charles E.	North Potomac	MD	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 17. Document ID: US 20040018969 A1

L27: Entry 17 of 134

File: PGPB

Jan 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040018969

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040018969 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: January 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 514/12; 435/183, 435/320.1, 435/325, 435/6, 435/69.1, 514/44, 530/350, 530/388.1, 536/23.2

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 18. Document ID: US 20040014039 A1

L27: Entry 18 of 134

File: PGPB

Jan 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040014039

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040014039 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: January 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 435/7.1, 514/12, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 19. Document ID: US 20040010132 A1

L27: Entry 19 of 134

File: PGPB

Jan 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040010132
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040010132 A1

TITLE: 53 human secreted proteins

PUBLICATION-DATE: January 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Brewer, Laurie A.	St. Paul	MN	US	
Duan, Roxanne D.	Bethesda	MD	US	
Ruben, Steven M.	Olney	MD	US	
Florence, Kimberly A.	Rockville	MD	US	
Greene, John M.	Gaithersburg	MD	US	
Young, Paul E.	Gaithersburg	MD	US	
Ferrie, Ann M.	Painted Post	NY	US	
Yu, Guo-Liang	Berkeley	CA	US	
Florence, Charles	Rockville	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Olsen, Henrik	Gaithersburg	MD	US	

US-CL-CURRENT: 536/23.2; 435/320.1, 435/325, 435/69.1, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 20. Document ID: US 20040010121 A1

L27: Entry 20 of 134

File: PGPB

Jan 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040010121
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040010121 A1

TITLE: 7 Human ovarian and ovarian cancer associated proteins

PUBLICATION-DATE: January 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Birse, Charles E.	North Potomac	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	

ABSTRACT:

This invention relates to newly identified ovarian or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens", and the use of such ovarian antigens for detecting disorders of the reproductive system, particularly the presence of ovarian cancer and ovarian cancer metastases. This invention relates to ovarian cancer antigens as well as vectors, host cells, antibodies directed to ovarian cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of ovarian cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 21. Document ID: US 20040009491 A1

L27: Entry 21 of 134

File: PGPB

Jan 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040009491

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040009491 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: January 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Birse, Charles E.	North Potomac	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.23, 530/350, 530/388.1, 536/23.2

ABSTRACT:

The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention

further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 22. Document ID: US 20040005579 A1

L27: Entry 22 of 134

File: PGPB

Jan 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040005579

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040005579 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: January 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Birse, Charles E.	North Potomac	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.3, 435/7.23, 514/12, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 23. Document ID: US 20040005577 A1

L27: Entry 23 of 134

File: PGPB

Jan 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040005577

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040005577 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: January 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 24. Document ID: US 20040002134 A1

L27: Entry 24 of 134

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002134
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040002134 A1

TITLE: Novel nucleic acid sequences encoding human KIAA0768 protein-like and human protein PRO228-like polypeptides

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Shimkets, Richard A.	Guilford	CT	US	
Fernandes, Elma R.	Branford	CT	US	
Herrman, John L.	Guilford	CT	US	
Vernet, Corine A.M.	Branford	CT	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

This application is drawn to novel nucleic acid sequences encoding mammalian polypeptides that have sequence similarity to human KIAA0768 protein and human protein PRO228. The nucleic acid sequence is 2862 nucleotides long and contains an open reading frame from nucleotides 508-510 to 2557-9. The novel, encoded polypeptides comprise 683 amino acid residues.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 25. Document ID: US 20040002066 A1

L27: Entry 25 of 134

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002066

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040002066 A1

TITLE: 36 human secreted proteins

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LaFleur, David W.	Washington	DC	US	
Soppet, Daniel R.	Centreville	VA	US	
Olsen, Henrik	Gaithersburg	MD	US	
Ruben, Steven M.	Olney	MD	US	
Ni, Jian	Rockville	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Brewer, Laurie A.	St. Paul	MN	US	
Duan, Roxanne	Bethesda	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 530/388.1, 536/23.5

ABSTRACT:

The present invention relates to 36 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 26. Document ID: US 20030236389 A1

L27: Entry 26 of 134

File: PGPB

Dec 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030236389

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030236389 A1

<http://westbrs.9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

TITLE: Proteins, polynucleotides encoding them and methods of using the same

PUBLICATION-DATE: December 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Shimkets, Richard A.	Guilford	CT	US	
Colman, Steven D.	Guilford	CT	US	
Spytek, Kimberly A.	New Haven	CT	US	
Ballinger, Robert A.	Newington	CT	US	
Guo, Xiaojia (Sasha)	Branford	CT	US	
Tchernev, Velizar T.	Branford	CT	US	
Shenoy, Suresh G.	Branford	CT	US	
Li, Li	Branford	CT	US	
Ellerman, Karen	Branford	CT	US	
Zerhusen, Bryan D.	Branford	CT	US	
Patturajan, Meera	Branford	CT	US	
Casman, Stacie J.	North Haven	CT	US	
Boldog, Ferenc	North Haven	CT	US	
Gusev, Vladimir Y.	Madison	CT	US	
Burgess, Catherine E.	Wethersfield	CT	US	
Edinger, Shlomit R.	New Haven	CT	US	
Gangolli, Esha A.	Madison	CT	US	
Malyankar, Uriel M.	Branford	CT	US	
Gunther, Erik	Branford	CT	US	
Smithson, Glennnda	Guilford	CT	US	
Millet, Isabelle	Milford	CT	US	
Gerlach, Valerie	Branford	CT	US	

US-CL-CURRENT: 530/350

ABSTRACT:

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 27. Document ID: US 20030235829 A1

L27: Entry 27 of 134

File: PGPB

Dec 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030235829

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030235829 A1

TITLE: Nucleic acids, proteins, and antibodies

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

PUBLICATION-DATE: December 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Birse, Charles E.	North Potomac	MD	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 28. Document ID: US 20030232975 A1

L27: Entry 28 of 134

File: PGPB

Dec 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030232975

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030232975 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: December 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 536/23.1; 435/6, 435/7.1, 530/350

ABSTRACT:

The present invention relates to novel endocrine related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "endocrine antigens," and the use of such endocrine antigens for detecting disorders of the endocrine system, particularly the presence of cancers of the endocrine system and endocrine cancer metastases. More specifically, isolated endocrine associated nucleic acid molecules are provided encoding novel endocrine associated polypeptides. Novel

endocrine polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human endocrine associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the endocrine system, including cancers of the endocrine system, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 29. Document ID: US 20030232056 A1

L27: Entry 29 of 134

File: PGPB

Dec 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030232056

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030232056 A1

TITLE: Compositions and methods for the therapy and diagnosis of ovarian cancer

PUBLICATION-DATE: December 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fanger, Gary R.	Mill Creek	WA	US	
Fling, Steven P.	Bainbridge Island	WA	US	

US-CL-CURRENT: 424/185.1; 435/320.1, 435/325, 435/6, 435/7.23, 530/350, 536/23.5

ABSTRACT:

Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 30. Document ID: US 20030220489 A1

L27: Entry 30 of 134

File: PGPB

Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030220489

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030220489 A1

TITLE: 29 human secreted proteins

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Brookeville	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Duan, Roxanne D.	Bethesda	MD	US	
Ni, Jian	Germantown	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
Moore, Paul A.	Germantown	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
LaFleur, David W.	Washington	DC	US	
Olsen, Henrik	Gaithersburg	MD	US	
Birse, Charles E.	North Potomac	MD	US	
Komatsoulis, George A.	Silver Spring	MD	US	

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/6, 435/69.1, 435/7.1, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 31. Document ID: US 20030219758 A1

L27: Entry 31 of 134

File: PGPB

Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219758

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030219758 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 435/7.1, 514/12, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 32. Document ID: US 20030215838 A1

L27: Entry 32 of 134

File: PGPB

Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030215838

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030215838 A1

TITLE: Cytokine receptor zcytor17 multimers

PUBLICATION-DATE: November 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sprecher, Cindy A.	Sierra Vista	AZ	US	
Gao, Zeren	Redmond	WA	US	
Kuijper, Joseph L.	Kenmore	WA	US	
Dasovich, Maria M.	Seattle	WA	US	
Grant, Francis J.	Seattle	WA	US	
Presnell, Scott R.	Tacoma	WA	US	
Whitmore, Theodore E.	Redmond	WA	US	
Hammond, Angela K.	Maple Valley	WA	US	
Novak, Julia E.	Bainbridge Island	WA	US	
Gross, Jane A.	Seattle	WA	US	
Dillon, Stacey R.	Seattle	WA	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 514/12, 530/350, 536/23.5

ABSTRACT:

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 33. Document ID: US 20030211078 A1

L27: Entry 33 of 134

File: PGPB

Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211078
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030211078 A1

TITLE: Pseudo-antibody constructs

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Heavner, George A.	Malvern	PA	US	

US-CL-CURRENT: 424/85.1; 424/130.1, 514/12, 514/54, 525/54.1, 530/350, 530/351,
530/387.1, 536/123

ABSTRACT:

This invention relates to novel pharmaceutically useful compositions that bind to a biological molecule, having improved circulatory half-life, increased avidity, increased affinity, or multifunctionality, and methods of use thereof. The present invention provides a pseudo-antibody comprising an organic moiety covalently coupled to at least two target-binding moieties, wherein the target-binding moieties are selected from the group consisting of a protein, a peptide, a peptidomimetic, and a non-peptide molecule that binds to a specific targeted biological molecule. The pseudo-antibody of the present invention may affect a specific ligand in vitro, in situ and/or in vivo. The pseudo-antibodies of the present invention can be used to measure or effect in an cell, tissue, organ or animal (including humans), to diagnose, monitor, modulate, treat, alleviate, help prevent the incidence of, or reduce the symptoms of, at least one condition.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KNOW	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 34. Document ID: US 20030208044 A1

L27: Entry 34 of 134

File: PGPB

Nov 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030208044
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030208044 A1

TITLE: Galectin 11

PUBLICATION-DATE: November 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ni, Jian	Germantown	MD	US	
Gentz, Reiner L.	Belo Horizonte - Mg	MD	BR	
Rosen, Craig A.	Laytonsville	CA	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 530/388.1, 530/395, 536/23.5

ABSTRACT:

The present invention relates to novel galectin 11 proteins which are members of the galectin superfamily. In particular, isolated nucleic acid molecules are provided encoding the human galectin 11 proteins. Galectin 11 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of galectin 11 activity. Also provided are diagnostic and therapeutic methods.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 35. Document ID: US 20030207285 A1

L27: Entry 35 of 134

File: PGPB

Nov 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030207285

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030207285 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: November 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 36. Document ID: US 20030206918 A1<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

PGPUB-DOCUMENT-NUMBER: 20030206918
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030206918 A1

TITLE: Compositions and methods for the therapy and diagnosis of ovarian cancer

PUBLICATION-DATE: November 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fanger, Gary R.	Mill Creek	WA	US	
Fling, Steven P.	Bainbridge Island	WA	US	

US-CL-CURRENT: 424/185.1; 435/320.1, 435/325, 435/69.3, 530/350, 536/23.5

ABSTRACT:

Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 37. Document ID: US 20030204058 A1

L27: Entry 37 of 134

File: PGPB

Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030204058
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030204058 A1

TITLE: Dendritic enriched secreted lymphocyte activation molecule

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Young, Paul E.	Gaithersburg	MD	US	
Ruben, Steven M.	Brookeville	MD	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 435/7.1, 536/23.5

ABSTRACT:

The present invention relates to a novel human protein called Dendritic Enriched Secreted Lymphocyte Activation Molecule, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and

therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 38. Document ID: US 20030199103 A1

L27: Entry 38 of 134

File: PGPB

Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030199103

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030199103 A1

TITLE: Novel amino acid sequences for human epidermal growth factor-like polypeptides

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Shimkets, Richard A.	West Haven	CT	US	
Fernandes, Elma	Branford	CT	US	
Herrman, John	Guilford	CT	US	
Vernet, Corine	Gainesville	FL	US	

US-CL-CURRENT: 436/518; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

This application is drawn to novel amino acid sequences for mammalian polypeptides that have sequence similarity to a protein fragment of human epidermal growth factor. The polypeptides are novel secreted proteins of approximately 708 amino acids.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 39. Document ID: US 20030190707 A1

L27: Entry 39 of 134

File: PGPB

Oct 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030190707

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030190707 A1

TITLE: 17 human secreted proteins

PUBLICATION-DATE: October 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Komatsoulis, George A.	Silver Spring	MD	US	
Baker, Kevin P.	Darnestown	MD	US	
Birse, Charles E.	North Potomac	MD	US	

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

Soppet, Daniel R.	Centreville	VA	US
Olsen, Henrik S.	Gaithersburg	MD	US
Moore, Paul A.	Germantown	MD	US
Wei, Ping	Brookeville	MD	US
Ebner, Reinhard	Gaithersburg	MD	US
Duan, D. Roxanne	Bethesda	MD	US
Shi, Yanggu	Gaithersburg	MD	US
Choi, Gil H.	Rockville	MD	US
Fiscella, Michele	Bethesda	MD	US
Ni, Jian	Germantown	MD	US
Ruben, Steven M.	Brookeville	MD	US
Barash, Steven C.	Rockville	MD	US

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 40. Document ID: US 20030181692 A1

L27: Entry 40 of 134

File: PGPB

Sep 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030181692

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030181692 A1

TITLE: 207 human secreted proteins

PUBLICATION-DATE: September 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ni, Jian	Germantown	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
LaFleur, David W.	Washington	DC	US	
Moore, Paul A.	Germantown	MD	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
Young, Paul E.	Gaithersburg	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
Florence, Kimberly A.	Rockville	MD	US	
Wei, Ying-Fei	Berkeley	CA	US	

Florence, Charles	Rockville	MD	US
Hu, Jing-Shan	Mountain View	CA	US
Li, Yi	Sunnyvale	CA	US
Kyaw, Hla	Frederick	MD	US
Fischer, Carrie L.	Burke	VA	US
Ferrie, Ann M.	Painted Post	NY	US
Fan, Ping	Potomac	MD	US
Feng, Ping	Gaithersburg	MD	US
Endress, Gregory A.	Florence	MA	US
Dillon, Patrick J.	Carlsbad	CA	US
Carter, Kenneth C.	North Potomac	MD	US
Brewer, Laurie A.	St. Paul	MN	US
Yu, Guo-Liang	Berkeley	CA	US
Zeng, Zhizhen	Lansdale	PA	US
Greene, John M.	Gaithersburg	MD	US

US-CL-CURRENT: 536/23.1; 435/183, 435/320.1, 435/325, 435/69.1, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 41. Document ID: US 20030180784 A1

L27: Entry 41 of 134

File: PGPB

Sep 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030180784

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030180784 A1

TITLE: Novel human Delta3 compositions and therapeutic and diagnostic uses therefor

PUBLICATION-DATE: September 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
McCarthy, Sean A.	San Diego	CA	US	
Gearing, David P.	East Doncaster		AU	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 536/23.5

ABSTRACT:

The invention provides nucleic acids encoding Delta3 proteins. Also provided are derivatives of Delta3 nucleic acids, polypeptides encoded thereby, and antibodies. Delta3 therapeutics, which are either antagonists or agonists of a Delta3 activity

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

and which are capable of modulating the growth and/or differentiation of a cell, e.g., endothelial cell, are also provided herein. Furthermore, methods for treating or preventing diseases associated with an aberrant Delta3 activity and/or associated with abnormal cellular growth and/or differentiation, e.g., neurological disease or vascular disease, such as Agenesis of the Corpus Callosum with Peripheral Neuropathy (ACCPN), as well as diagnostic methods for detecting these diseases are disclosed.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWAC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 42. Document ID: US 20030175858 A1

L27: Entry 42 of 134

File: PGPB

Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030175858

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030175858 A1

TITLE: 186 human secreted proteins

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
Carter, Kenneth C.	North Potomac	MD	US	
Bednarik, Daniel P.	Columbia	MD	US	
Endress, Gregory A.	Florence	MA	US	
Yu, Guo-Liang	Berkeley	CA	US	
Ni, Jian	Germantown	MD	US	
Feng, Ping	Germantown	MD	US	
Young, Paul E.	Gaithersburg	MD	US	
Greene, John M.	Gaithersburg	MD	US	
Ferrie, Ann M.	Painted Post	NY	US	
Duan, D. Roxanne	Bethesda	MD	US	
Hu, Jing-Shan	Mountain View	CA	US	
Florence, Kimberly A.	Rockville	MD	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Fischer, Carrie L.	Burke	VA	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Br�wer, Laurie A.	St. Paul	MN	US	
Moore, Paul A.	Germantown	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
LaFleur, David W.	Washington	DC	US	
Li, Yi	Sunnyvale	CA	US	
Zeng, ZhiZhen	Lansdale	PA	US	
Kyaw, Hla	Frederick	MD	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 435/6, 530/350, 536/23.2

ABSTRACT:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 43. Document ID: US 20030175778 A1

L27: Entry 43 of 134

File: PGPB

Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030175778
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030175778 A1

TITLE: Interferon Receptor HKAEF92

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ni, Jian	Germantown	MD	US	
Ruben, Steven M.	Brookeville	MD	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention relates to a novel Interferon receptor "INFR-HKAEF92" protein which is a member of the Interferon/IL-10 receptor family. In particular, isolated nucleic acid molecules are provided encoding the human INFR-HKAEF92 protein. INFR-HKAEF92 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of INFR-HKAEF92 activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 44. Document ID: US 20030175739 A1

L27: Entry 44 of 134

File: PGPB

Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030175739
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030175739 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 45. Document ID: US 20030166541 A1

L27: Entry 45 of 134

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166541

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030166541 A1

TITLE: 83 human secreted proteins

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Feng, Ping	Germantown	MD	US	
LaFleur, David W.	Washington	DC	US	
Moore, Paul A.	Germantown	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
Kyaw, Hla	Frederick	MD	US	
Li, Yi	Sunnyvale	CA	US	
Zeng, Zhizhen	Lansdale	PA	US	
Carter, Kenneth C.	North Potomac	MD	US	
Endress, Gregory A.	Florence	MA	US	
Wei, Ying-Fei	Berkeley	CA	US	
Fan, Ping	Potomac	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	

US-CL-CURRENT: 514/12; 435/252.3, 435/254.11, 435/320.1, 435/325, 435/6, 435/69.1, 435/7.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 46. Document ID: US 20030157508 A1

L27: Entry 46 of 134

File: PGPB

Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030157508

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030157508 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ebner, Reinhard	Gaithersburg	MD	US	
Ruben, Steven M.	Brookeville	MD	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2**ABSTRACT:**

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 47. Document ID: US 20030153499 A1

L27: Entry 47 of 134

File: PGPB

Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030153499

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030153499 A1

TITLE: Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ni, Jian	Germantown	MD	US	
Ruben, Steven M.	Brookeville	MD	US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding human TR11, TR11SV1, and TR11SV2 receptors. TR11, TR11SV1, and TR11SV2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR11, TR11SV1, and TR11SV2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR11, TR11SV1, and TR11SV2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR11, TR11SV1, and TR11SV2 receptors.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 48. Document ID: US 20030152933 A1

L27: Entry 48 of 134

File: PGPB

Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152933

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030152933 A1

TITLE: Human secreted proteins

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Barash, Steven C.	Rockville	MD	US	
Ni, Jian	Germantown	MD	US	
Ruben, Steven M.	Olney	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 49. Document ID: US 20030134430 A1

L27: Entry 49 of 134

File: PGPB

Jul 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030134430

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030134430 A1

TITLE: Novel amino acid sequences for human caenorhabditis elegans-like protein polypeptides

PUBLICATION-DATE: July 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Shimkets, Richard A.	West Haven	CT	US	
Fernandes, Elma	Branford	CT	US	
Herrman, John	Guilford	CT	US	
Vernet, Corine	Gainesville	FL	US	

US-CL-CURRENT: 436/518; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

This application is drawn to novel amino acid sequences for mammalian polypeptides that have sequence similarity to the fragment F40E10.6 from Caenorhabditis elegans. The polypeptides are novel proteins of approximately 260 amino acids.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 50. Document ID: US 20030129613 A1

L27: Entry 50 of 134

File: PGPB

Jul 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030129613

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030129613 A1

TITLE: Novel human proteins and polynucleotides encoding them

PUBLICATION-DATE: July 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fernandes, Elma R.	Branford	CT	US	
Vernet, Corine A.M.	Branford	CT	US	
Shimkets, Richard A.	Guilford	CT	US	
Anderson, David W.	Branford	CT	US	

Padigaru, Muralidhara	Branford	CT	US
Boldog, Ferenc L.	North Haven	CT	US
Li, Li	Branford	CT	US
Shenoy, Suresh G.	Branford	CT	US
Casman, Stacie J.	North Haven	CT	US
Rastelli, Luca	Guilford	CT	US

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 536/23.5

ABSTRACT:

The present invention provides novel isolated SECX polynucleotides and the membrane-associated or secreted polypeptides encoded by the SECX polynucleotides. Also provided are the antibodies that immunospecifically bind to a SECX polypeptide or any derivative, variant, mutant or fragment of the SECX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the SECX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 51. Document ID: US 20030129192 A1

L27: Entry 51 of 134

File: PGPB

Jul 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030129192

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030129192 A1

TITLE: Compositions and methods for the therapy and diagnosis of ovarian cancer

PUBLICATION-DATE: July 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chenault, Ruth A.	Seattle	WA	US	
Xu, Jiangchun	Bellevue	WA	US	
Fanger, Gary R.	Federal Way	WA	US	
Harlocker, Susan L.			US	
McNeill, Patricia D.			US	

US-CL-CURRENT: 424/155.1; 435/183, 435/320.1, 435/325, 435/6, 435/69.1, 435/7.23, 530/350, 536/23.2

ABSTRACT:

Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

☐ 52. Document ID: US 20030114646 A1

L27: Entry 52 of 134

File: PGPB

Jun 19, 2003

PGPUB-DOCUMENT-NUMBER: 20030114646
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030114646 A1

TITLE: Human cystatin F

PUBLICATION-DATE: June 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Haodong	Gaithersburg	MD	US	
Yu, Guo-Liang	Darnestown	MD	US	
Gentz, Reiner L.	Silver Spring	MD	US	
Ni, Jian	Rockville	MD	US	

US-CL-CURRENT: 530/388.15; 424/130.1, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The invention relates to Cystatin F polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

☐ 53. Document ID: US 20030113840 A1

L27: Entry 53 of 134

File: PGPB

Jun 19, 2003

PGPUB-DOCUMENT-NUMBER: 20030113840
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030113840 A1

TITLE: 25 human secreted proteins

PUBLICATION-DATE: June 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ni, Jian	Germantown	MD	US	
Florence, Kimberly A.	Rockville	MD	US	
Fiscella, Michele	Bethesda	MD	US	

Wei, Ping	Brookeville	MD	US
Baker, Kevin P.	Darnestown	MD	US
Birse, Charles E.	North Potomac	MD	US
Young, Paul E.	Gaithersburg	MD	US
Komatsoulis, George A.	Silver Spring	MD	US
Moore, Paul A.	Germantown	MD	US
Soppet, Daniel R.	Centreville	VA	US

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 54. Document ID: US 20030100051 A1

L27: Entry 54 of 134

File: PGPB

May 29, 2003

PGPUB-DOCUMENT-NUMBER: 20030100051

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030100051 A1

TITLE: 97 human secreted proteins

PUBLICATION-DATE: May 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Florence, Kimberly A.	Rockville	MD	US	
Ni, Jian	Germantown	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Carter, Kenneth C.	North Potomac	MD	US	
Moore, Paul A.	Germantown	MD	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
Young, Paul E.	Gaithersburg	MD	US	
Wei, Ying-Fei	Berkeley	CA	US	
Brewer, Laurie A.	St. Paul	MN	US	
Soppet, Daniel R.	Centreville	VA	US	
LaFleur, David W.	Washington	DC	US	
Endress, Gregory A.	Florence	MA	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Birse, Charles E.	North Potomac	MD	US	

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 55. Document ID: US 20030096339 A1

L27: Entry 55 of 134

File: PGPB

May 22, 2003

PGPUB-DOCUMENT-NUMBER: 20030096339

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030096339 A1

TITLE: Cytokine receptor zcytor17

PUBLICATION-DATE: May 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sprecher, Cindy A.	Seattle	WA	US	
Presnell, Scott R.	Tacoma	WA	US	
Gao, Zeren	Redmond	WA	US	
Whitmore, Theodore E.	Redmond	WA	US	
Kuijper, Joseph L.	Kenmore	WA	US	
Maurer, Mark F.	Seattle	WA	US	

ABSTRACT:

Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 56. Document ID: US 20030087341 A1

L27: Entry 56 of 134

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087341
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030087341 A1

TITLE: 49 human secreted proteins

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Moore, Paul A.	Germantown	MD	US	
Ruben, Steven M.	Olney	MD	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Florence, Kimberly A.	Rockville	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
LaFleur, David W.	Washington	DC	US	
Endress, Gregory A.	Potomac	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Komatsoulis, George	Silver Spring	MD	US	
Duan, Roxanne D.	Bethesda	MD	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 435/6, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 57. Document ID: US 20030082554 A1

L27: Entry 57 of 134

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030082554
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030082554 A1

TITLE: Novel nucleic acid sequences encoding human cell adhesion molecule protein-like polypeptides

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Shimkets, Richard A.	West Haven	CT	US	

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

Fernandes, Elma	Branford	CT	US
Herrman, John	Guilford	CT	US
Vernet, Corine	Gainesville	FL	US

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

This application is drawn to novel nucleic acid sequences encoding mammalian polypeptides that have sequence similarity to a human cell adhesion molecule protein. The nucleic acid sequence is 2116 nucleotides long and contains an open reading frame from nucleotides 517-19 to 1729-31. The novel, encoded polypeptides comprise 404 amino acid residues.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 58. Document ID: US 20030082532 A1

L27: Entry 58 of 134

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030082532

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030082532 A1

TITLE: TUMOR NECROSIS FACTOR RECEPTOR RELATED GENE 12 POLYPEPTIDES

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
NI, JIAN	ROCKVILLE	MD	US	
RUBEN, STEVEN M.	OLNEY	MD	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/7.2, 514/2, 530/350, 530/387.9, 536/23.5

ABSTRACT:

The present invention relates to a novel human protein called TNFR Related Gene 12, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 59. Document ID: US 20030078405 A1

L27: Entry 59 of 134

File: PGPB

Apr 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030078405

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030078405 A1

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

TITLE: 47 human secreted proteins

PUBLICATION-DATE: April 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Endress, Gregory A.	Silver Spring	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
Ni, Jian	Rockville	MD	US	
Duan, Roxanne D.	Bethesda	MD	US	
Moore, Paul A.	Germantown	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
LaFleur, David W.	Washington	DC	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Florence, Kimberly A.	Rockville	MD	US	

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/69.1, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 60. Document ID: US 20030078203 A1

L27: Entry 60 of 134

File: PGPB

Apr 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030078203

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030078203 A1

TITLE: Covalently reactive transition state analogs and methods of use thereof

PUBLICATION-DATE: April 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Paul, Sudhir	Missouri City	TX	US	
Nishiyama, Yasuhiro	Houston	TX	US	

US-CL-CURRENT: 514/12; 424/189.1, 424/190.1, 424/85.1, 424/85.2, 530/350, 530/351

ABSTRACT:

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 61. Document ID: US 20030077706 A1

L27: Entry 61 of 134

File: PGPB

Apr 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030077706
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030077706 A1

TITLE: Mouse cytokine receptor

PUBLICATION-DATE: April 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Presnell, Scott R.	Tacoma	WA	US	
Xu, Wenfeng	Mukilteo	WA	US	
Kindsvogel, Wayne	Seattle	WA	US	
Chen, Zhi	Bellevue	WA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/6, 530/350, 536/23.5

ABSTRACT:

Cytokines and their receptors have proven usefulness in both basic research, animal models, and as therapeutics. The present invention provides a new cytokine receptor designated as "mouse Zcytor16," which can bind and antagonize the IL-TIF cytokine.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 62. Document ID: US 20030069406 A1

L27: Entry 62 of 134

File: PGPB

Apr 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030069406
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030069406 A1

TITLE: 87 human secreted proteins

PUBLICATION-DATE: April 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Young, Paul	Gaithersburg	MD	US	
Greene, John M.	Gaithersburg	MD	US	
Ferrie, Ann M.	Painted Post	NY	US	
Ruben, Steven M.	Olney	MD	US	

Rosen, Craig A.	Laytonsville	MD	US
Duan, Roxanne	Gaithersburg	MD	US
Hu, Jing-Shan	Mountain View	CA	US
Florence, Kimberly	Rockville	MD	US
Olsen, Henrik S.	Gaithersburg	MD	US
Ebner, Reinhard	Gaithersburg	MD	US
Brewer, Laurie A.	St. Paul	MN	US
Moore, Paul A.	Germantown	MD	US
Shi, Yanggu	Gaithersburg	MD	US
Lafleur, David W.	Washington	DC	US
Ni, Jian	Germantown	MD	US

US-CL-CURRENT: 536/23.2; 435/183, 435/320.1, 435/325, 435/6, 435/69.1, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 63. Document ID: US 20030065139 A1

L27: Entry 63 of 134

File: PGPB

Apr 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030065139

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030065139 A1

TITLE: SECRETED PROTEIN HMMBD35

PUBLICATION-DATE: April 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
ROSEN, CRAIG A.	LAYTONSVILLE	MD	US	
WEI, YING-FEI	BERKELEY	CA	US	

US-CL-CURRENT: 530/350; 435/69.1, 530/300

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

☐ 64. Document ID: US 20030054443 A1

L27: Entry 64 of 134

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054443
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030054443 A1

TITLE: 90 human secreted proteins

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Young, Paul E.	Gaithersburg	MD	US	
Greene, John M.	Gaithersburg	MD	US	
Ferrie, Ann M.	Painted Post	NY	US	
Yu, Guo-Liang	Berkeley	CA	US	
Ni, Jian	Germantown	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Brewer, Laurie A.	St. Paul	MN	US	
Janat, Fouad	Westerly	RI	US	
Birse, Charles E.	North Potomac	MD	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 435/6, 435/7.1, 530/350, 536/23.1

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

☐ 65. Document ID: US 20030050442 A1

L27: Entry 65 of 134

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030050442
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030050442 A1

TITLE: 62 human secreted proteins

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Ni, Jian	Germantown	MD	US	
Komatsoulis, George	Silver Spring	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
Shi, Yanggu	Gaithersburg	MD	US	
LaFleur, David W.	Washington	DC	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Florence, Kimberly A.	Rockville	MD	US	
Moore, Paul A.	Germantown	MD	US	
Birse, Charles E.	North Potomac	MD	US	
Young, Paul	Gaithersburg	MD	US	

US-CL-CURRENT: 530/350; 435/183, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 66. Document ID: US 20030050231 A1

L27: Entry 66 of 134

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030050231

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030050231 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 514/12; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

ABSTRACT:

The present invention relates to novel colon related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "colon antigens," and the use of such colon antigens for detecting disorders of the colon, particularly the presence of colon cancer and colon cancer metastases. More specifically, isolated colon associated nucleic acid molecules are provided encoding novel colon associated polypeptides. Novel colon polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human colon associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the colon, including colon cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 67. Document ID: US 20030049618 A1

L27: Entry 67 of 134

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049618

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030049618 A1

TITLE: 186 human secreted proteins

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
Carter, Kenneth C.	North Potomac	MD	US	
Bednarik, Daniel P.	Columbia	MD	US	
Endress, Gregory A.	Florence	MA	US	
Yu, Guo-Liang	Berkeley	CA	US	
Ni, Jian	Germantown	MD	US	
Feng, Ping	Gaithersburg	MD	US	
Young, Paul E.	Gaithersburg	MD	US	
Greene, John M.	Gaithersburg	MD	US	
Ferrie, Ann M.	Painted Post	NY	US	
Duan, D. Roxanne	Bethesda	MD	US	
Hu, Jing-Shan	Mountain View	CA	US	
Florence, Kimberly A.	Rockville	MD	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Fischer, Carrie L.	Burke	VA	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Brewer, Laurie A.	St. Paul	MN	US	

Moore, Paul A.	Germantown	MD	US
Shi, Yanggu	Gaithersburg	MD	US
LaFleur, David W.	Washington	DC	US
Li, Yi	Sunnyvale	CA	US
Zeng, Zhizhen	Lansdale	PA	US
Kyaw, Hla	Frederick	MD	US

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.1

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 68. Document ID: US 20030044907 A1

L27: Entry 68 of 134

File: PGPB

Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030044907

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030044907 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

☐ 69. Document ID: US 20030044905 A1

L27: Entry 69 of 134

File: PGPB

Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030044905
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030044905 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

☐ 70. Document ID: US 20030044904 A1

L27: Entry 70 of 134

File: PGPB

Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030044904
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030044904 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	

Ruben, Steven M.	Olney	MD	US
Barash, Steven C.	Rockville	MD	US

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 71. Document ID: US 20030044890 A1

L27: Entry 71 of 134

File: PGPB

Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030044890

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030044890 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

☐ 72. Document ID: US 20030040088 A1

L27: Entry 72 of 134

File: PGPB

Feb 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030040088
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030040088 A1

TITLE: Secreted protein HT5GJ57

PUBLICATION-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Komatsoulis, George	Silver Spring	MD	US	
Duan, Roxanne D.	Bethesda	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Moore, Paul A.	Germantown	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
LaFleur, David W.	Washington	DC	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Brewer, Laurie A.	St. Paul	MN	US	
Florence, Kimberly A.	Rockville	MD	US	
Young, Paul E.	Gaithersburg	MD	US	
Mucenski, Michael	Cincinnati	OH	US	
Endress, Gregory A.	Florence	MA	US	
Soppet, Daniel R.	Centreville	VA	US	

US-CL-CURRENT: 435/183; 435/320.1, 435/325, 435/6, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

☐ 73. Document ID: US 20030036505 A1

L27: Entry 73 of 134

File: PGPB

Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036505
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030036505 A1

TITLE: Signal transduction pathway component polynucleotides, polypeptides, antibodies and methods based thereon

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Barash, Steven C.	Rockville	MD	US	
Ni, Jian	Germantown	MD	US	
Ruben, Steven M.	Olney	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Young, Paul E.	Berkeley	CA	US	
Rohrschneider, Larry R.	Seattle	WA	US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/6, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to newly identified human polynucleotides and the polypeptides encoded by these polynucleotides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human antigens. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human antigens.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 74. Document ID: US 20030036181 A1

L27: Entry 74 of 134

File: PGPB

Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036181

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030036181 A1

TITLE: Peptide extended glycosylated polypeptides

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Okkels, Jens Sigurd	Vedbaek		DK	
Jensen, Anne Dam	Copenhagen		DK	
van den Hazel, Bart	Copenhagen		DK	

US-CL-CURRENT: 435/184; 435/183, 530/322, 530/350, 530/351, 530/388.1, 530/397

ABSTRACT:

Glycosylated polypeptides comprising the primary structure NH.sub.2--X--Pp--COOH, wherein X is a peptide addition comprising or contributing to a glycosylation site, and Pp is a polypeptide of interest or comprising the primary structure NH.sub.2-P.sub.x--X--P.sub.y-COOH, wherein P.sub.x is an N-terminal part of a polypeptide Pp of interest, P.sub.y is a C-terminal part of said polypeptide Pp, and X is a peptide addition comprising or contributing to a glycosylation site are provided. The

glycosylated polypeptides possess improved properties as compared to the polypeptide of interest.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 75. Document ID: US 20030027776 A1

L27: Entry 75 of 134

File: PGPB

Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027776
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027776 A1

TITLE: 29 human cancer associated proteins

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roschke, Viktor	Rockville	MD	US	

US-CL-CURRENT: 514/44; 435/320.1, 435/325, 435/6, 435/69.1, 435/7.23, 530/350,
536/23.1

ABSTRACT:

This invention relates to newly identified cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cancer antigens", or alternatively "cancer related proteins", and the use of such cancer antigens for detecting disorders related to the tissues where these cancer antigens are expressed, particularly the presence of cancer and cancer metastases. This invention relates to cancer antigens as well as vectors, host cells, antibodies directed to cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the tissues where these cancer antigens are expressed, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 76. Document ID: US 20030027297 A1

L27: Entry 76 of 134

File: PGPB

Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027297
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027297 A1

TITLE: 19 human secreted proteins

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fiscella, Michele	Bethesda	MD	US	
Wei, Ping	Brookeville	MD	US	
LaFleur, David W.	Washington	DC	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Baker, Kevin P.	Darnestown	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Komatsoulis, George A.	Silver Spring	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Duan, Roxanne D.	Bethesda	MD	US	
Young, Paul E.	Gaithersburg	MD	US	
Florence, Kimberly A.	Rockville	MD	US	
Moore, Paul A.	Germantown	MD	US	
Birse, Charles E.	North Potomac	MD	US	
Ni, Jian	Rockville	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
Shi, Yanggu	Gaithersburg	MD	US	

US-CL-CURRENT: 435/183; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	K00C	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 77. Document ID: US 20030022277 A1

L27: Entry 77 of 134

File: PGPB

Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030022277

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030022277 A1

TITLE: HUMAN NEUROPEPTIDE RECEPTOR

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
SOPPET, DANIEL R.	CENTREVILLE	VA	US	
LI, YI	SUNNYVALE	CA	US	
ROSEN, CRAIG A.	LAYTONSVILLE	MD	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/6, 435/7.1, 530/350, 536/23.5<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

ABSTRACT:

The present invention relates to a novel human protein called human neuropeptide receptor, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 78. Document ID: US 20030022276 A1

L27: Entry 78 of 134

File: PGPB

Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030022276
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030022276 A1

TITLE: DENDRITIC ENRICHED SECRETED LYMPHOCYTE ACTIVATION MOLECULE

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
YOUNG, PAUL	GAITHERSBURG	MD	US	
RUBEN, STEVEN M.	OLNEY	MD	US	

US-CL-CURRENT: 435/69.1; 424/130.1, 435/320.1, 435/325, 435/7.1, 514/2, 530/350, 536/23.5

ABSTRACT:

The present invention relates to a novel human protein called Dendritic Enriched Secreted Lymphocyte Activation Molecule, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 79. Document ID: US 20030018180 A1

L27: Entry 79 of 134

File: PGPB

Jan 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030018180
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030018180 A1

TITLE: Secreted protein HFEAF41

PUBLICATION-DATE: January 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Young, Paul	Gaithersburg	MD	US	
Greene, John M.	Gaithersburg	MD	US	
Ferrie, Ann M.	Painted Post	NY	US	
Ruben, Steven M.	Olney	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Duan, Roxanne	Bethesda	MD	US	
Hu, Jing-Shan	Mountain View	CA	US	
Florence, Kimberly	Rockville	MD	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Brewer, Lauie A.	St. Paul	MN	US	
Moore, Paul A.	Germantown	MD	US	
Shi, Yanggu	Gaithersburg	VA	US	
Lafleur, David W.	Washington	DC	US	
Ni, Jian	Germantown	MD	US	

US-CL-CURRENT: 536/23.2; 435/183, 435/320.1, 435/325, 435/69.1, 530/350

ABSTRACT:

The present invention relates to 87 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 80. Document ID: US 20030013649 A1

L27: Entry 80 of 134

File: PGPB

Jan 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030013649

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030013649 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: January 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/6, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 81. Document ID: US 20030004324 A1

L27: Entry 81 of 134

File: PGPB

Jan 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030004324

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030004324 A1

TITLE: 31 human secreted proteins

PUBLICATION-DATE: January 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Ferrie, Ann M.	Tewksbury	MA	US	
Florence, Charles	Rockville	MD	US	
Young, Paul E.	Gaithersburg	MD	US	
Yu, Guo-Liang	Berkeley	CA	US	
Ni, Jian	Rockville	MD	US	

US-CL-CURRENT: 536/23.1; 435/183, 435/320.1, 435/325, 435/6, 435/69.1, 435/7.1, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 82. Document ID: US 20030003462 A1

L27: Entry 82 of 134

File: PGPB

Jan 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030003462
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030003462 A1

TITLE: Novel human interleukin-like proteins and polynucleotides encoding them

PUBLICATION-DATE: January 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fernandes, Elma	Branford	CT	US	
Vernet, Corine	Gainesville	FL	US	
Shimkets, Richard A.	West Haven	CT	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.2, 530/350, 536/23.5

ABSTRACT:

The present invention provides novel isolated SECX polynucleotides and the membrane-associated or secreted polypeptides encoded by the SECX polynucleotides. Also provided are the antibodies that immunospecifically bind to a SECX polypeptide or any derivative, variant, mutant or fragment of the SECX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the SECX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 83. Document ID: US 20020193305 A1

L27: Entry 83 of 134

File: PGPB

Dec 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020193305
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020193305 A1

TITLE: Cytokine receptor common gamma chain like

PUBLICATION-DATE: December 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Moore, Paul A.	Germantown	MD	US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to a novel human gene encoding a polypeptide which is a member of the Cytokine Receptor family. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named Cytokine

Receptor Common Gamma Chain Like, or "CRGCL." This invention also relates to CRGCL polypeptides, as well as vectors, host cells, antibodies directed to CRGCL polypeptides, and the recombinant methods for producing the same. Also provided are diagnostic methods for detecting disorders related to the immune system, and therapeutic methods for treating diagnosing, detecting, and/or preventing such disorders. The invention further relates to screening methods for identifying agonists and antagonists of CRGCL activity.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 84. Document ID: US 20020168711 A1

L27: Entry 84 of 134

File: PGPB

Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020168711
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020168711 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.1

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 85. Document ID: US 20020165137 A1

L27: Entry 85 of 134

File: PGPB

Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020165137
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020165137 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Birse, Charles E.	North Potomac	MD	US	

US-CL-CURRENT: 514/12; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 86. Document ID: US 20020164685 A1

L27: Entry 86 of 134

File: PGPB

Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020164685

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020164685 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.1

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides

and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 87. Document ID: US 20020151681 A1

L27: Entry 87 of 134

File: PGPB

Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020151681
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020151681 A1

TITLE: Nucleic acids, proteins and antibodies

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.3, 536/23.5

ABSTRACT:

This invention relates to newly identified prostate or prostate cancer related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "prostate cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, and to antibodies that immunospecifically bind these polypeptides, as well as the use of such prostate cancer polynucleotides, antigens, and antibodies for detection, prevention, prognosis, and treatment of disorders of the reproductive system, particularly disorders of the prostate, including, but not limited to, the presence of prostate cancer and prostate cancer metastases. More specifically, isolated prostate cancer nucleic acid molecules are provided encoding novel prostate cancer polypeptides. Novel prostate cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human prostate cancer polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the prostate, including prostate cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 88. Document ID: US 20020151479 A1

L27: Entry 88 of 134

File: PGPB

Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020151479
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020151479 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 89. Document ID: US 20020147140 A1

L27: Entry 89 of 134

File: PGPB

Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020147140
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020147140 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 514/12; 435/183, 435/320.1, 435/325, 435/6, 435/69.1, 530/350,

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

ABSTRACT:

The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 90. Document ID: US 20020120103 A1

L27: Entry 90 of 134

File: PGPB

Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020120103

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020120103 A1

TITLE: 17 human secreted proteins

PUBLICATION-DATE: August 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Komatsoulis, George A.	Silver Spring	MD	US	
Baker, Kevin P.	Darnestown	MD	US	
Birse, Charles E.	North Potomac	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Moore, Paul A.	Germantown	MD	US	
Wei, Ping	Brookeville	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Duan, D. Roxanne	Bethesda	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
Choi, Gil H.	Rockville	MD	US	
Fiscella, Michele	Bethesda	MD	US	
Ni, Jian	Germantown	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 91. Document ID: US 20020103335 A1

L27: Entry 91 of 134

File: PGPB

Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020103335
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020103335 A1

TITLE: PEPTIDE DERIVATIVES

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
OLDHAM, KEITH	MACCLESFIELD		GB	
EDWARDS, PHILIP NEIL	MACCLESFIELD		GB	
LUKE, RICHARD WILLIAM ARTHUR	MACCLESFIELD		GB	
COTTON, RONALD	MACCLESFIELD		GB	

US-CL-CURRENT: 530/300; 435/7.1

ABSTRACT:

The invention concerns pharmaceutically useful peptide derivatives of the formula (I), P-AA 1 -AA 2 -AA 3 -AA 4 -AA 5 -AA 6 -AA 7 -AA 8 -Q, in which P, AA 1, AA 2, AA 3, AA 4, AA 5, AA 6, AA 7, AA 8, and Q have the various meanings defined herein and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel peptide derivatives are of value in treating MHC class II dependent T-cell mediated autoimmune or inflammatory diseases, such as rheumatoid arthritis. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds in medical treatment.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 92. Document ID: US 20020102638 A1

L27: Entry 92 of 134

File: PGPB

Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020102638
PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020102638 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.1

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 93. Document ID: US 20020102604 A1

L27: Entry 93 of 134

File: PGPB

Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020102604

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020102604 A1

TITLE: Full-length human cDNAs encoding potentially secreted proteins

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Milne Edwards, Jean-Baptiste Dumas	Paris		FR	
Bougueleret, Lydie	Petit Lancy		CH	
Jobert, Severin	Paris		FR	

US-CL-CURRENT: 435/7.1; 530/350, 536/23.1

ABSTRACT:

The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7kphob.28&ref=27&dbname=PGPB,USPT,U...> 10/5/04

addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 94. Document ID: US 20020098541 A1

L27: Entry 94 of 134

File: PGPB

Jul 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020098541

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020098541 A1

TITLE: TNFR related gene 12

PUBLICATION-DATE: July 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ni, Jian	Germantown	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/6, 530/350, 536/23.5

ABSTRACT:

The present invention relates to a novel human protein called TNFR Related Gene 12, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 95. Document ID: US 20020081659 A1

L27: Entry 95 of 134

File: PGPB

Jun 27, 2002

PGPUB-DOCUMENT-NUMBER: 20020081659

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020081659 A1

TITLE: Nucleic acids, proteins and antibodies

PUBLICATION-DATE: June 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	

ABSTRACT:

The present invention relates to novel pancreatic related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "pancreatic antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such pancreatic polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the pancreas, including, but not limited to, the presence of pancreatic cancer and pancreatic cancer metastases. More specifically, isolated pancreatic nucleic acid molecules are provided encoding novel pancreatic polypeptides. Novel pancreatic polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human pancreatic polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the pancreas, including pancreatic cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 96. Document ID: US 20020077287 A1

L27: Entry 96 of 134

File: PGPB

Jun 20, 2002

PGPUB-DOCUMENT-NUMBER: 20020077287

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020077287 A1

TITLE: 28 human secreted proteins

PUBLICATION-DATE: June 20, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Li, Yi	Sunnyvale	CA	US	
Zeng, Zhizhen	Lansdale	PA	US	
Kyaw, Hla	Frederick	MD	US	
Fischer, Carrie L.	Burke	VA	US	
Li, Haodong	Gaithersburg	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
Gentz, Reiner L.	Rockville	MD	US	
Wei, Ying-Fei	Berkeley	CA	US	
Moore, Paul A.	Germantown	MD	US	
Young, Paul E.	Gaithersburg	MD	US	
Greene, John M.	Gaithersburg	MD	US	
Ferrie, Ann M.	Tewksbury	MA	US	

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KOMIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-------	------------

☐ 97. Document ID: US 20020076756 A1

L27: Entry 97 of 134

File: PGPB

Jun 20, 2002

PGPUB-DOCUMENT-NUMBER: 20020076756

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020076756 A1

TITLE: 28 human secreted proteins

PUBLICATION-DATE: June 20, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Li, Yi	Sunnyvale	CA	US	
Zeng, ZhiZhen	Lansdale	PA	US	
Kyaw, Hla	Frederick	MD	US	
Fischer, Carrie L.	Burke	VA	US	
Li, Haodong	Gaithersburg	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
Gentz, Reiner L.	Rockville	MD	US	
Wei, Ying-Fei	Berkeley	CA	US	
Moore, Paul A.	Germantown	MD	US	
Young, Paul E.	Gaithersburg	MD	US	
Greene, John M.	Gaithersburg	MD	US	
Ferrie, Ann M.	Painted Post	NY	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

☐ 98. Document ID: US 20020061834 A1

L27: Entry 98 of 134

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061834
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020061834 A1

TITLE: Human G-protein Chemokine receptor (CCR5) HDGNR10

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Roschke, Viktor	Rockville	MD	US	
Li, Yi	Sunnyvale	CA	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 514/1; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies.

☐ 99. Document ID: US 20020061521 A1

L27: Entry 99 of 134

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061521
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020061521 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	

Ruben, Steven M.	Olney	MD	US
Barash, Steven C.	Rockville	MD	US

US-CL-CURRENT: 435/6; 435/69.1, 514/2, 530/300, 536/23.1

ABSTRACT:

The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 100. Document ID: US 20020052308 A1

L27: Entry 100 of 134

File: PGPB

May 2, 2002

PGPUB-DOCUMENT-NUMBER: 20020052308

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020052308 A1

TITLE: Nucleic acids, proteins and antibodies

PUBLICATION-DATE: May 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 514/1; 435/183, 435/320.1, 435/325, 435/6, 435/69.1, 435/7.1, 530/350, 536/23.1

ABSTRACT:

This invention relates to newly identified tissue specific cancer associated polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such tissue specific cancer antigens for detection, prevention and treatment of tissue specific disorders, particularly the presense of cancer. This invention

relates to the cancer antigens as well as vectors, host cells, antibodies directed to cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing tissue specific disorders, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L26 AND T helper	134

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

☐ 101. Document ID: US 20020026040 A1

Using default format because multiple data bases are involved.

L27: Entry 101 of 134

File: PGPB

Feb 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020026040

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020026040 A1

TITLE: 49 human secreted proteins

PUBLICATION-DATE: February 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Moore, Paul A.	Germantown	MD	US	
Ruben, Steven M.	Olney	MD	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Florence, Kimberly A.	Rockville	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
LaFleur, David W.	Washington	DC	US	
Endress, Gregory A.	Potomac	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Komatsoulis, George	Silver Spring	MD	US	
Duan, Roxanne D.	Bethesda	MD	US	

US-CL-CURRENT: 536/23.1; 435/6, 530/300

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 102. Document ID: US 20020012966 A1

L27: Entry 102 of 134

File: PGPB

Jan 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020012966

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020012966 A1

TITLE: 18 Human secreted proteins

PUBLICATION-DATE: January 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Shi, Yanggu	Gaithersburg	MD	US	
Young, Paul E.	Gaithersburg	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Soppet, Daniel R.	Centreville	VA	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/325, 530/350, 536/23.1

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 103. Document ID: US 20020012669 A1

L27: Entry 103 of 134

File: PGPB

Jan 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020012669

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020012669 A1

TITLE: Human cytokine receptor

PUBLICATION-DATE: January 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Presnell, Scott R	Tacoma	WA	US	
Xu, Wenfeng	Mukilteo	WA	US	
Kindsvogel, Wayne	Seattle	WA	US	
Chen, Zhi	Seattle	WA	US	

US-CL-CURRENT: 424/192.1; 435/252.1, 435/254.1, 435/255.1, 435/317.1, 435/326, 435/348, 435/410, 435/6, 435/69.1, 435/7.1, 514/12, 530/350, 530/387.2, 530/387.3, 530/388.1, 530/389.1, 530/391.1, 536/23.5

ABSTRACT:

Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as "Zcytor16."

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 104. Document ID: US 20020004491 A1

L27: Entry 104 of 134

File: PGPB

Jan 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020004491
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020004491 A1

TITLE: Compositions and methods for the therapy and diagnosis of ovarian cancer

PUBLICATION-DATE: January 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Xu, Jiangchun	Bellevue	WA	US	
Stolk, John A.	Bothell	WA	US	
Algate, Paul A.	Issaquah	WA	US	
Fling, Steven P.	Bainbridge Island	WA	US	

US-CL-CURRENT: 514/44; 424/155.1, 435/183, 435/325, 435/69.1, 514/12, 530/350, 530/387.1, 536/23.1

ABSTRACT:

Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 105. Document ID: US 20010021700 A1

L27: Entry 105 of 134

File: PGPB

Sep 13, 2001

PGPUB-DOCUMENT-NUMBER: 20010021700
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010021700 A1

TITLE: 49 human secreted proteins

PUBLICATION-DATE: September 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Moore, Paul A.	Germantown	MD	US	
Ruben, Steven M.	Oley	MD	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Florence, Kimberly A.	Rockville	MD	US	

Soppet, Daniel R.	Centreville	VA	US
Lafleur, David W.	Washington	DC	US
Endress, Gregory A.	Potomac	MD	US
Ebner, Reinhard	Gaithersburg	MD	US
Komatsoulis, George	Silver Spring	MD	US
Duan, Roxanne D.	Bethesda	MD	US

US-CL-CURRENT: 514/44; 435/320.1, 435/325, 435/69.1, 435/69.7, 435/7.1, 514/12,
530/350, 530/388.2, 536/23.5

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 106. Document ID: US 20010012889 A1

L27: Entry 106 of 134

File: PGPB

Aug 9, 2001

PGPUB-DOCUMENT-NUMBER: 20010012889

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010012889 A1

TITLE: 36 human secreted proteins

PUBLICATION-DATE: August 9, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LaFleur, David W.	Washington	DC	US	
Soppet, Daniel R.	Centreville	VA	US	
Olsen, Henrik	Gaithersburg	MD	US	
Ruben, Steven M.	Olney	MD	US	
Ni, Jian	Rockville	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Brewer, Laurie A.	St. Paul	MN	US	
Duan, Roxanne	Bethesda	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	

US-CL-CURRENT: 536/23.1; 435/325, 435/6, 435/69.1, 435/7.1, 530/300, 530/387.1

ABSTRACT:

The present invention relates to 36 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic

methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 107. Document ID: US 6787637 B1

L27: Entry 107 of 134

File: USPT

Sep 7, 2004

US-PAT-NO: 6787637

DOCUMENT-IDENTIFIER: US 6787637 B1

TITLE: N-Terminal amyloid-.beta. antibodies

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 530/387.1; 424/130.1, 530/300, 530/350

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred including N-terminal fragments of A.beta. and antibodies binding to the same.

7 Claims, 25 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 18

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 108. Document ID: US 6761888 B1

L27: Entry 108 of 134

File: USPT

Jul 13, 2004

US-PAT-NO: 6761888

DOCUMENT-IDENTIFIER: US 6761888 B1

TITLE: Passive immunization treatment of Alzheimer's disease

DATE-ISSUED: July 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/130.1; 530/300, 530/350, 530/387.1

http://westbrs:9000/bin/cgi-bin/accum_query.pl

10/5/04

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A.beta. and antibodies binding to the same.

36 Claims, 25 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 109. Document ID: US 6759508 B2

L27: Entry 109 of 134

File: USPT

Jul 6, 2004

US-PAT-NO: 6759508
DOCUMENT-IDENTIFIER: US 6759508 B2

TITLE: Compositions and methods for the therapy and diagnosis of lung cancer

DATE-ISSUED: July 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lodes; Michael J.	Seattle	WA		
Mohamath; Raodoh	Seattle	WA		
Henderson; Robert A.	Edmonds	WA		
Benson; Darin R.	Seattle	WA		
Secrist; Heather	Seattle	WA		

US-CL-CURRENT: 530/324; 530/326, 530/350

ABSTRACT:

Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

8 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 110. Document ID: US 6750324 B1

L27: Entry 110 of 134

File: USPT

Jun 15, 2004

http://westbrs:9000/bin/cgi-bin/accum_query.pl

10/5/04

US-PAT-NO: 6750324
DOCUMENT-IDENTIFIER: US 6750324 B1

TITLE: Humanized and chimeric N-terminal amyloid beta-antibodies

DATE-ISSUED: June 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		
Bard; Frederique	Pacifica	CA		
Yednock; Theodore	Forest Knolls	CA		

US-CL-CURRENT: 530/387.1; 424/130.1, 530/300, 530/350

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A.beta. and antibodies binding to the same.

12 Claims, 25 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 111. Document ID: US 6743427 B1

L27: Entry 111 of 134

File: USPT

Jun 1, 2004

US-PAT-NO: 6743427
DOCUMENT-IDENTIFIER: US 6743427 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: June 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/130.1; 530/300, 530/350, 530/387.1

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A.beta. and antibodies binding to the same.

19 Claims, 0 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 112. Document ID: US 6719978 B2

L27: Entry 112 of 134

File: USPT

Apr 13, 2004

US-PAT-NO: 6719978
DOCUMENT-IDENTIFIER: US 6719978 B2

TITLE: Virus-like particles for the induction of autoantibodies

DATE-ISSUED: April 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schiller; John T.	Silver Spring	MD		
Chackerian; Bryce	Chevy Chase	MD		
Lowy; Douglas R.	Bethesda	MD		

US-CL-CURRENT: 424/199.1; 424/133.1, 424/143.1, 424/144.1, 424/147.1, 424/159.1,
424/184.1, 424/194.1, 424/204.1, 435/174, 435/235.1, 435/472, 530/350

ABSTRACT:

The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the treatment or prevention of human diseases, which involve the onset of B cell tolerance, such as chronic viral infection, chronic inflammatory disease, and neoplasia.

8 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 113. Document ID: US 6713450 B2

L27: Entry 113 of 134

File: USPT

Mar 30, 2004

US-PAT-NO: 6713450
DOCUMENT-IDENTIFIER: US 6713450 B2

TITLE: Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid .beta. for induction of an immune response to amyloid .beta. and amyloid deposits

DATE-ISSUED: March 30, 2004

http://westbrs.9000/bin/cgi-bin/accum_query.pl

10/5/04

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Frangione; Blas	New York	NY		
Wisniewski; Thomas	Staten Island	NY		
Sigurdsson; Einar M.	New York	NY		

US-CL-CURRENT: 514/12; 424/198.1, 530/300

ABSTRACT:

The present invention relates to synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid .beta. which can be used alone or conjugated to an immunostimulatory molecule in an immunizing composition for inducing an immune response to amyloid .beta. peptides and amyloid deposits.

30 Claims, 13 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 114. Document ID: US 6632920 B1

L27: Entry 114 of 134

File: USPT

Oct 14, 2003

US-PAT-NO: 6632920

DOCUMENT-IDENTIFIER: US 6632920 B1

**** See image for Certificate of Correction ****

TITLE: 36 human secreted proteins

DATE-ISSUED: October 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Olsen; Henrik S.	Gaithersburg	MD		
Ruben; Steven M.	Olney	MD		
Rosen; Craig A.	Laytonsville	MD		
Brewer; Laurie A.	St. Paul	MN		
Ebner; Reinhard	Gaithersburg	MD		
Duan; Roxanne	Bethesda	MD		
Florence; Kimberly	Rockville	MD		

US-CL-CURRENT: 530/300; 435/69.1, 530/324

ABSTRACT:

The present invention relates to 36 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

42 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KIMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 115. Document ID: US 6620912 B2

L27: Entry 115 of 134

File: USPT

Sep 16, 2003

US-PAT-NO: 6620912

DOCUMENT-IDENTIFIER: US 6620912 B2

TITLE: Dendritic enriched secreted lymphocyte activation molecule

DATE-ISSUED: September 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Young; Paul E.	Gaithersburg	MD		
Ruben; Steven M.	Olney	MD		

US-CL-CURRENT: 530/350; 435/320.1, 435/471, 435/69.1, 435/71.1, 536/23.5

ABSTRACT:

The present invention relates to a novel human protein called Dendritic Enriched Secreted Lymphocyte Activation Molecule, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

95 Claims, 6 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KIMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 116. Document ID: US 6605699 B1

L27: Entry 116 of 134

File: USPT

Aug 12, 2003

US-PAT-NO: 6605699

DOCUMENT-IDENTIFIER: US 6605699 B1

TITLE: Galectin-11 polypeptides

DATE-ISSUED: August 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Gentz; Reiner L.	Rockville	MD		

http://westbrs:9000/bin/cgi-bin/accum_query.pl

10/5/04

Rosen; Craig A. Laytonsville MD
Liu; Fu-Tong San Diego CA

US-CL-CURRENT: 530/350; 424/134.1, 424/184.1, 424/185.1, 424/192.1, 435/69.1,
435/71.1, 530/387.3, 530/395, 530/396

ABSTRACT:

The present invention relates to galectin 11 proteins which are members of the galectin superfamily. In particular, the present invention relates to full-length polypeptides, fragments, and variants of galectin 11.

42 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

Full	Title	Cite	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 117. Document ID: US 6605592 B2

L27: Entry 117 of 134

File: USPT

Aug 12, 2003

US-PAT-NO: 6605592
DOCUMENT-IDENTIFIER: US 6605592 B2

TITLE: Protein HOFNF53

DATE-ISSUED: August 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Germantown	MD		
Baker; Kevin P.	Darnestown	MD		
Birse; Charles E.	North Potomac	MD		
Ebner; Reinhard	Gaithersburg	MD		
Fiscella; Michele	Bethesda	MD		
Komatsoulis; George A.	Silver Spring	MD		
LaFleur; David W.	Washington	DC		
Moore; Paul A.	Germantown	MD		
Olsen; Henrik S.	Gaithersburg	MD		
Rosen; Craig A.	Laytonsville	MD		
Ruben; Steven M.	Olney	MD		
Soppet; Daniel R.	Centreville	VA		
Young; Paul E.	Gaithersburg	MD		
Wei; Ping	Brookeville	MD		
Florence; Kimberly A.	Rockville	MD		

US-CL-CURRENT: 514/2; 435/252.3, 435/254.11, 435/320.1, 435/325, 435/471, 435/69.1,
435/71.1, 435/71.2, 514/12, 514/8, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic

acids containing the coding regions of the genes encoding such proteins. In particular, the present application relates to a novel human protein, Protein HOFNF53. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

19 Claims, 22 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 22

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KWC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 118. Document ID: US 6605441 B1

L27: Entry 118 of 134

File: USPT

Aug 12, 2003

US-PAT-NO: 6605441
DOCUMENT-IDENTIFIER: US 6605441 B1

TITLE: Antibodies against fibroblast growth factor 11

DATE-ISSUED: August 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alderson; Ralph	Gaithersburg	MD		
Melder; Robert J.	Boyds	MD		
Duan; Roxanne D.	Bethesda	MD		
Rosen; Craig A.	Laytonsville	MD		
Hu; Jing-Shan	Mountain View	CA		

US-CL-CURRENT: 435/7.1; 435/7.21, 435/7.23, 435/7.5, 435/7.72, 435/7.9, 530/300,
530/350

ABSTRACT:

The present invention relates to a novel human protein called Fibroblast Growth Factor 11, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

104 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KWC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 119. Document ID: US 6593112 B1

L27: Entry 119 of 134

File: USPT

Jul 15, 2003

US-PAT-NO: 6593112
DOCUMENT-IDENTIFIER: US 6593112 B1

TITLE: Polynucleotides encoding fibroblast growth factor 15

DATE-ISSUED: July 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Greene; John M.	Gaithersburg	MD		
Rosen; Craig A.	Laytonsville	MD		
Alderson; Ralph	Gaithersburg	MD		
Melder; Robert J.	Gaithersburg	MD		
Duan; D. Roxanne	Bethesda	MD		

US-CL-CURRENT: 435/69.4; 435/243, 435/320.1, 435/325, 435/69.7, 514/44, 530/300,
530/399, 536/23.1, 536/23.5

ABSTRACT:

The present invention relates to a novel human protein called Fibroblast Growth Factor 15, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein.

67 Claims, 20 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 20

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 120. Document ID: US 6566325 B2

L27: Entry 120 of 134

File: USPT

May 20, 2003

US-PAT-NO: 6566325
DOCUMENT-IDENTIFIER: US 6566325 B2

TITLE: 49 human secreted proteins

DATE-ISSUED: May 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Moore; Paul A.	Germantown	MD		
Ruben; Steven M.	Olney	MD		
Olsen; Henrik S.	Gaithersburg	MD		
Shi; Yanggu	Gaithersburg	MD		
Rosen; Craig A.	Laytonsville	MD		
Florence; Kimberly A.	Rockville	MD		
Soppet; Daniel R.	Centreville	VA		
LaFleur; David W.	Washington	DC		
Endress; Gregory A.	Potomac	MD		

Ebner; Reinhard	Gaithersburg	MD
Komatsoulis; George	Silver Spring	MD
Duan; Roxanne D.	Bethesda	MD

US-CL-CURRENT: 514/2; 530/300, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

52 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 121. Document ID: US 6534631 B1

L27: Entry 121 of 134

File: USPT

Mar 18, 2003

US-PAT-NO: 6534631
DOCUMENT-IDENTIFIER: US 6534631 B1

TITLE: Secreted protein HT5GJ57

DATE-ISSUED: March 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ruben; Steven M.	Olney	MD		
Komatsoulis; George	Silver Spring	MD		
Duan; Roxanne D.	Bethesda	MD		
Rosen; Craig A.	Laytonsville	MD		
Moore; Paul A.	Germantown	MD		
Shi; Yanggu	Gaithersburg	MD		
LaFleur; David W.	Washington	DC		
Ebner; Reinhard	Gaithersburg	MD		
Olsen; Henrik	Gaithersburg	MD		
Brewer; Laurie A.	St. Paul	MN		
Florence; Kimberly A.	Rockville	MD		
Young; Paul	Gaithersburg	MD		
Mucenski; Michael	Cincinnati	OH		
Endress; Gregory A.	Potomac	MD		
Soppet; Daniel R.	Centreville	VA		

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 530/300, 536/23.1, 536/24.1

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

12 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 122. Document ID: US 6525174 B1

L27: Entry 122 of 134

File: USPT

Feb 25, 2003

US-PAT-NO: 6525174

DOCUMENT-IDENTIFIER: US 6525174 B1

TITLE: Precerebellin-like protein

DATE-ISSUED: February 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Young; Paul	Gaithersburg	MD		
Greene; John M.	Gaithersburg	MD		
Ferrie; Ann M.	Tewksbury	MA		
Ruben; Steven M.	Olney	MD		
Rosen; Craig A.	Laytonsville	MD		
Hu; Jing-Shan	Sunnyvale	CA		
Olsen; Henrik S.	Gaithersburg	MD		
Ebner; Reinhard	Gaithersburg	MD		
Brewer; Laurie A.	St. Paul	MN		
Moore; Paul A.	Germantown	MD		
Shi; Yanggu	Gaithersburg	MD		
Florence; Charles	Rockville	MD		
Florence; Kimberly	Rockville	MD		
Lafleur; David W.	Washington	DC		
Ni; Jian	Rockville	MD		
Fan; Ping	Gaithersburg	MD		
Wei; Ying-Fei	Berkeley	CA		
Fischer; Carrie L.	Burke	VA		
Soppet; Daniel R.	Centreville	VA		
Li; Yi	Sunnyvale	CA		
Zeng; Zhizhen	Gaithersburg	MD		
Kyaw; Hla	Frederick	MD		
Yu; Guo-Liang	Berkeley	CA		
Feng; Ping	Gaithersburg	MD		
Dillon; Patrick J.	Carlsbad	CA		
Endress; Gregory A.	Potomac	MD		

US-CL-CURRENT: 530/350; 435/69.1

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

19 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Cita	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 123. Document ID: US 6521412 B1

L27: Entry 123 of 134

File: USPT

Feb 18, 2003

US-PAT-NO: 6521412

DOCUMENT-IDENTIFIER: US 6521412 B1

**** See image for Certificate of Correction ****

TITLE: HsReq*1 and hsReq*2 proteins and use thereof to detect CDK2

DATE-ISSUED: February 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yang; Meijia	East Lyme	CT		
Nandabalan; Krishnan	Guilford	CT		
Schulz; Vincent Peter	Madison	CT		

US-CL-CURRENT: 435/7.1; 435/29, 435/6, 514/12, 514/2, 530/300, 530/350

ABSTRACT:

The present invention relates to complexes of the CDK2 protein with proteins identified as interacting with CDK2 by a modified yeast two hybrid assay system. The proteins identified to interact with CDK2 are cyclin H, cyclin I, ERH, and two gene products, hsReq*-1 and hsReq*-2, which are splice variants of the gene hsReq. Thus, the invention provides complexes of CDK2 and cyclin H, cyclin I, ERH, hsReq*-1, and hsReq*-2, and derivatives, fragments and analogs thereof. The invention also provides nucleic acids encoding the hsReq*-1 and hsReq*-2, and proteins and derivatives, fragments and analogs thereof. Methods of screening the complexes for efficacy in treating and/or preventing certain diseases and disorders, particularly cancer, atherosclerosis and neurodegenerative disease are also provided.

14 Claims, 16 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 16

☐ 124. Document ID: US 6509173 B1

L27: Entry 124 of 134

File: USPT

Jan 21, 2003

US-PAT-NO: 6509173

DOCUMENT-IDENTIFIER: US 6509173 B1

TITLE: Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2

DATE-ISSUED: January 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Ruben; Steven M.	Olney	MD		

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/395, 530/300, 530/350, 530/395,
536/1.11, 536/18.7, 536/22.1, 536/23.1 , 536/23.5

ABSTRACT:

The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding human TR11, TR11SV1, and TR11SV2 receptors. TR11, TR11SV1, and TR11SV2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR11, TR11SV1, and TR11SV2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR11, TR11SV1, and TR11SV2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR11, TR11SV1, and TR11SV2 receptors.

41 Claims, 11 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

☐ 125. Document ID: US 6482411 B1

L27: Entry 125 of 134

File: USPT

Nov 19, 2002

US-PAT-NO: 6482411

DOCUMENT-IDENTIFIER: US 6482411 B1

**** See image for Certificate of Correction ****

TITLE: Methods of reducing bone loss with CD40 ligand

DATE-ISSUED: November 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
------	------	-------	----------	---------

Ahuja; Seema A. San Antonio TX
Bonewald; Lynda F. San Antonio TX

US-CL-CURRENT: 424/185.1, 424/178.1, 424/184.1, 424/192.1, 424/85.1, 514/12, 514/2,
514/8, 514/885, 530/350, 530/351

ABSTRACT:

Provided are methods and compositions using one or more CD40 agonists, such as CD40 ligands and/or agonistic anti-CD40 antibodies, to reduce or prevent cell death, or apoptosis, in bone cells. Methods of treating or preventing bone loss, including osteoporosis, as well as methods of reducing or eliminating the bone loss associated with steroid administration are particularly provided. Further disclosed are a variety of therapeutic kits and cocktails.

34 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 126. Document ID: US 6476195 B1

L27: Entry 126 of 134

File: USPT

Nov 5, 2002

US-PAT-NO: 6476195

DOCUMENT-IDENTIFIER: US 6476195 B1

TITLE: Secreted protein HNFGE20

DATE-ISSUED: November 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Komatsoulis; George	Silver Spring	MD		
Rosen; Craig A.	Laytonsville	MD		
Ruben; Steven M.	Olney	MD		
Duan; Roxanne D.	Bethesda	MD		
Moore; Paul A.	Germantown	MD		
Shi; Yanggu	Gaithersburg	MD		
LaFleur; David W.	Washington	DC		
Wei; Ying-Fei	Berkeley	CA		
Ni; Jian	Rockville	MD		
Florence; Kimberly A.	Rockville	MD		
Young; Paul	Gaithersburg	MD		
Brewer; Laurie A.	St. Paul	MN		
Soppet; Daniel R.	Centreville	VA		
Endress; Gregory A.	Potomac	MD		
Ebner; Reinhard	Gaithersburg	MD		
Olsen; Henrik	Gaithersburg	MD		
Mucenski; Michael	Cincinnati	OH		

US-CL-CURRENT: 530/350; 435/6, 435/7.1, 536/23.1

http://westbrs:9000/bin/cgi-bin/accum_query.pl

10/5/04

ABSTRACT:

The present invention relates to novel human secreted protein (HNFGF20). Polypeptides of the invention are useful in diagnosis and treatment of disorders affecting the immune system.

36 Claims, 3 Drawing figures
Exemplary Claim Number: 1,7
Number of Drawing Sheets: 3

Full	Title	Cite	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 127. Document ID: US 6475753 B1

L27: Entry 127 of 134

File: USPT

Nov 5, 2002

US-PAT-NO: 6475753

DOCUMENT-IDENTIFIER: US 6475753 B1

TITLE: 94 Human Secreted Proteins

DATE-ISSUED: November 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ruben; Steven M.	Olney	MD		
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		
Wei; Ying-Fei	Berkeley	CA		
Young; Paul	Gaithersburg	MD		
Florence; Kimberly	Rockville	MD		
Soppet; Daniel R.	Centreville	VA		
Brewer; Laurie A.	St. Paul	MN		
Endress; Gregory A.	Potomac	MD		
Carter; Kenneth C.	Potomac	MD		
Mucenski; Michael	Cincinnati	OH		
Ebner; Reinhard	Gaithersburg	MD		
Lafleur; David W.	Washington	DC		
Olsen; Henrik	Gaithersburg	MD		
Shi; Yanggu	Gaithersburg	MD		
Moore; Paul A.	Germantown	MD		
Komatsoulis; George	Silver Spring	MD		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 435/471, 435/69.4, 435/71.1,
530/350, 536/23.5

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

37 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 128. Document ID: US 6448230 B1

L27: Entry 128 of 134

File: USPT

Sep 10, 2002

US-PAT-NO: 6448230

DOCUMENT-IDENTIFIER: US 6448230 B1

**** See image for Certificate of Correction ****

TITLE: Testis expressed polypeptide

DATE-ISSUED: September 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ruben; Steven M.	Olney	MD		
Rosen; Craig A.	Laytonsville	MD		
Zeng; Zhizhen	Gaithersburg	MD		

US-CL-CURRENT: 514/21, 424/185.1, 424/193.1, 424/194.1, 424/234.1, 514/12, 514/2,
514/44, 530/300, 530/305, 530/324, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

40 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 129. Document ID: US 6433145 B1

L27: Entry 129 of 134

File: USPT

Aug 13, 2002

US-PAT-NO: 6433145

DOCUMENT-IDENTIFIER: US 6433145 B1

**** See image for Certificate of Correction ****

TITLE: Keratinocyte derived interferon

DATE-ISSUED: August 13, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
LaFleur; David W.	Washington	DC		
Moore; Paul A.	Germantown	MD		
Ruben; Steven M.	Olney	MD		

US-CL-CURRENT: 530/351; 424/85.4; 435/7.1, 530/350

ABSTRACT:

The present invention relates to a novel KDI protein which is a member of the interferon family. In particular, isolated nucleic acid molecules are provided encoding a human interferon polypeptide, called "KDI". KDI polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of KDI activity. Also provided are therapeutic methods for treating immune system-related disorders.

92 Claims, 9 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

Full	Title	Cite	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 130. Document ID: US 6372473 B1

L27: Entry 130 of 134

File: USPT

Apr 16, 2002

US-PAT-NO: 6372473

DOCUMENT-IDENTIFIER: US 6372473 B1

TITLE: Tissue plasminogen activator-like protease

DATE-ISSUED: April 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Moore; Paul A.	Germantown	MD		
Ruben; Steven M.	Olney	MD		
Ebner; Reinhard	Gaithersburg	MD		

US-CL-CURRENT: 435/212; 435/217, 530/327, 530/328, 530/350, 530/827, 530/828

ABSTRACT:

The present invention relates to a novel t-PALP protein which is a member of the serine protease family. In particular, isolated nucleic acid molecules are provided encoding the human t-PALP protein. t-PALP polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of t-PALP activity. Also provided are diagnostic methods for detecting circulatory system-related disorders and therapeutic methods for treating circulatory system-related disorders.

77 Claims, 8 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 8

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KOMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 131. Document ID: US 6261569 B1

L27: Entry 131 of 134

File: USPT

Jul 17, 2001

US-PAT-NO: 6261569
DOCUMENT-IDENTIFIER: US 6261569 B1

TITLE: Retro-, inverso- and retro-inverso synthetic peptide analogues

DATE-ISSUED: July 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Comis; Alfio	Bossley Park			AU
Tyler; Margaret Isabel	Turramurra			AU
Fischer; Peter	Oslo			NO

US-CL-CURRENT: 424/204.1; 424/184.1, 424/185.1, 424/188.1, 424/190.1, 424/191.1,
424/208.1, 424/225.1, 424/227.1, 424/228.1, 424/236.1, 514/2, 530/300, 530/332,
530/403, 530/806, 530/825, 530/826

ABSTRACT:

Synthetic peptide antigen analogues of native peptide antigens with partial or complete retro, inverso or retro-inverso modifications are provided. When administered as an immunogen to an immunocompetent host the synthetic peptide antigen analogues induce the production of antibodies which recognize the native peptide antigen. Uses of these analogues, vaccines and methods of preparing vaccines comprising these antigen analogues, and antibodies generated using these antigen analogues are also provided.

16 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KOMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 132. Document ID: US 6068844 A

L27: Entry 132 of 134

File: USPT

May 30, 2000

US-PAT-NO: 6068844
DOCUMENT-IDENTIFIER: US 6068844 A

TITLE: Increased resistance to stroke by developing immunologic tolerance to myelin or components thereof

DATE-ISSUED: May 30, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Becker; Kyra J.	Seattle	WA		
Hallenbeck; John M.	Kensington	MD		
McCarron; Richard M.	Kensington	MD		

US-CL-CURRENT: 424/184.1; 424/810, 514/12, 514/2, 530/350

ABSTRACT:

The present invention relates to a method of inducing oral tolerance to ischemic injury which has the objective of minimizing the severity and size of injured regions in the brain that arise as a result of ischemia. The method responds rapidly to the onset of infarction, with treatment that is short in duration. The procedure is specifically focused on the injured area of the infarct by virtue of being targeted immunologically to the ischemic site. The method therefore avoids the possibility of inducing systemic side effects affecting other organs of the patient. The present invention involves administering myelin or a component thereof such as myelin basic protein or proteolipid protein to a subject either orally or by inhalation. The amount administered and the duration of the treatment are effective to minimize the size and severity of the infarct in the brain of the subject. The method is intended for acute conditions related either to an actual recent cerebral ischemic event or to a potential ischemic event that might arise as a result of medical or surgical treatment planned for the subject.

21 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Cite	Front	Review	Classification	Date	Reference				Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--	--------	------	------------

☐ 133. Document ID: US 6066617 A

L27: Entry 133 of 134

File: USPT

May 23, 2000

US-PAT-NO: 6066617

DOCUMENT-IDENTIFIER: US 6066617 A

TITLE: Human cystatin F

DATE-ISSUED: May 23, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Li; Haodong	Gaithersburg	MD		
Yu; Guo-Liang	Darnestown	MD		
Gentz; Reiner L.	Silver Spring	MD		
Ni; Jian	Rockville	MD		

US-CL-CURRENT: 514/12; 530/350

ABSTRACT:

The invention relates to Cystatin F polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the

polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

58 Claims, 6 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Cita	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 134. Document ID: US 5986055 A

L27: Entry 134 of 134

File: USPT

Nov 16, 1999

US-PAT-NO: 5986055

DOCUMENT-IDENTIFIER: US 5986055 A

TITLE: CDK2 interactions

DATE-ISSUED: November 16, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yang; Meijia	East Lyme	CT		
Nandabalan; Krishnan	Guilford	CT		
Schultz; Vincent Peter	Madison	CT		

US-CL-CURRENT: 530/350; 530/300

ABSTRACT:

The present invention relates to complexes of the CDK2 protein with proteins identified as interacting with CDK2 by a modified yeast two hybrid assay system. The proteins identified to interact with CDK2 are cyclin H, cyclin I, ERH, and two gene products, hsReq*-1 and hsReq*-2, which are splice variants of the gene hsReq. Thus, the invention provides complexes of CDK2 and cyclin H, cyclin I, ERH, hsReq*-1, and hsReq*-2, and derivatives, fragments and analogs thereof. The invention also provides nucleic acids encoding the hsReq*-1 and hsReq*-2, and proteins and derivatives, fragments and analogs thereof. Methods of screening the complexes for efficacy in treating and/or preventing certain diseases and disorders, particularly cancer, atherosclerosis and neurodegenerative disease are also provided.

8 Claims, 9 Drawing figures

Exemplary Claim Number: 3


Number of Drawing Sheets: 16

Full	Title	Cita	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--------	------	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
-------	-----------

Display Format: -**Change Format**[Previous Page](#)[Next Page](#)[Go to Doc#](#)



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for APP AND T helper Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 20 Sort Send to Text

About Entrez

Items 1 - 6 of 6

One

Text Version

1: [Suh YH, Choi W, Kim SH, Kim JS, Rhi BY, Chong YH, Woo JI, Lee KW.](#) Related Articles, 1

Expression of Alzheimer's amyloid precursor protein in human lymphocyte.
Arch Gerontol Geriatr. 1997 Jan-Feb;24(1):1-7.
PMID: 15374130 [PubMed - in process]

2: [Petrushina I, Tran M, Sadzikava N, Ghochikyan A, Vasilevko V, Agadjanyan MG, Cribbs DH.](#) Related Articles, 1

Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice.
Neurosci Lett. 2003 Feb 20;338(1):5-8.
PMID: 12565127 [PubMed - indexed for MEDLINE]

3: [Town T, Vendrame M, Patel A, Poetter D, DelleDonne A, Mori T, Smeed R, Crawford F, Klein T, Tan J, Mullan M.](#) Related Articles, 1

Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42).
J Neuroimmunol. 2002 Nov;132(1-2):49-59.
PMID: 12417433 [PubMed - indexed for MEDLINE]

4: [Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P.](#) Related Articles, 1

Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals.
Exp Gerontol. 2002 Jul;37(7):943-8.
PMID: 12086704 [PubMed - indexed for MEDLINE]

5: [Dickey CA, Morgan DG, Kudchodkar S, Weiner DB, Bai Y, Cao C, Gordon MN, Ugen KE.](#) Related Articles, 1

Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide.
DNA Cell Biol. 2001 Nov;20(11):723-9.
PMID: 11788050 [PubMed - indexed for MEDLINE]

6: [Enwonwu CO.](#) Related Articles, 1

Cellular and molecular effects of malnutrition and their relevance to periodontal diseases.
J Clin Periodontol. 1994 Nov;21(10):643-57. Review.
PMID: 7531721 [PubMed - indexed for MEDLINE]

Display Summary Show: 20 Sort Send to Text


[Write to the Help Desk](#)

[NCBI | NLM | NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement | Freedom of Information Act | Disclaimer](#)

Oct 4 2004 14:25:05



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for Abeta AND T helper Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 20 Sort Send to Text

About Entrez

Items 1 - 10 of 10

One

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: [Karkos J.](#)

[Related Articles, 1](#)

[Immunotherapy of Alzheimer's disease. Results of experimental investigation and treatment of perspectives]

Fortschr Neurol Psychiatr. 2004 Apr;72(4):204-19. Review. German.

PMID: 15095177 [PubMed - indexed for MEDLINE]

☐ 2: [Lemos MP, Esquivel F, Scott P, Laufer TM.](#)

[Related Articles, 1](#)

MHC class II expression restricted to CD8alpha+ and CD11b+ dendritic cells sufficient for control of Leishmania major.

J Exp Med. 2004 Mar 1;199(5):725-30.

PMID: 14993255 [PubMed - indexed for MEDLINE]

☐ 3: [Petrushina I, Tran M, Sadzikava N, Ghochikyan A, Vasilevko V, Agadjanyan MG, Cribbs DH.](#)

[Related Articles, 1](#)

Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice.

Neurosci Lett. 2003 Feb 20;338(1):5-8.

PMID: 12565127 [PubMed - indexed for MEDLINE]

☐ 4: [Town T, Vendrame M, Patel A, Poetter D, DelleDonne A, Mori T, Smeed R, Crawford F, Klein T, Tan J, Mullan M.](#)

[Related Articles, 1](#)

Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42).

J Neuroimmunol. 2002 Nov;132(1-2):49-59.

PMID: 12417433 [PubMed - indexed for MEDLINE]

☐ 5: [Munch G, Robinson SR.](#)

[Related Articles, 1](#)

Potential neurotoxic inflammatory responses to Abeta vaccination in humans.

J Neural Transm. 2002 Jul;109(7-8):1081-7. Review.

PMID: 12111445 [PubMed - indexed for MEDLINE]

☐ 6: [Dickey CA, Morgan DG, Kudchodkar S, Weiner DB, Bai Y, Cao C, Gordon MN, Ugen KE.](#)

[Related Articles, 1](#)

Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide.

DNA Cell Biol. 2001 Nov;20(11):723-9.

PMID: 11788050 [PubMed - indexed for MEDLINE]

☐ 7: [Pan CH, Chen HW, Huang HW, Tao MH.](#)

[Related Articles, 1](#)

Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses.

J Virol. 2001 Dec;75(23):11457-63.

PMID: 11689627 [PubMed - indexed for MEDLINE]

☐ 8: [Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M.](#)

[Related Articles, 1](#)

Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42.

Neurosci Lett. 2001 Jul 13;307(2):101-4.

PMID: 11427310 [PubMed - indexed for MEDLINE]

☐ **9:** [Riberdy JM, Mostaghel E, Doyle C.](#)[Related Articles, I](#)**Disruption of the CD4-major histocompatibility complex class II interaction blocks the development of CD4(+) T cells in vivo.**

Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4493-8.

PMID: 9539765 [PubMed - indexed for MEDLINE]

☐ **10:** [Vidovic D, Boulanger N, Kuye O, Toral J, Ito K, Guenot J, Bluethmann H, Nagy ZA.](#)[Related Articles, I](#)**The helper T-cell repertoire of mice expressing class II major histocompatibility complex beta chains in the absence of alpha chains.**


Immunogenetics. 1997;45(5):325-35.

PMID: 9038105 [PubMed - indexed for MEDLINE]

Display	Summary	Show:	20	Sort	Send to	Text
---------	---------	-------	----	------	---------	------

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Oct 4 2004 14:25:05



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books

Search PubMed for Amyloid precursor protein AND T helper Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Items 1 - 6 of 6

One

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Suh YH, Choi W, Kim SH, Kim JS, Rhi BY, Chong YH, Woo JI, Lee KW. Related Articles, 1

Expression of Alzheimer's amyloid precursor protein in human lymphocyte.
Arch Gerontol Geriatr. 1997 Jan-Feb;24(1):1-7.
PMID: 15374130 [PubMed - in process]

2: Petrushina I, Tran M, Sadzikava N, Ghochikyan A, Vasilevko V, Agadjanyan MG, Cribbs DH. Related Articles, 1

Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice.
Neurosci Lett. 2003 Feb 20;338(1):5-8.
PMID: 12565127 [PubMed - indexed for MEDLINE]

3: Munch G, Robinson SR. Related Articles, 1

Potential neurotoxic inflammatory responses to Abeta vaccination in humans.
J Neural Transm. 2002 Jul;109(7-8):1081-7. Review.
PMID: 12111445 [PubMed - indexed for MEDLINE]

4: Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Related Articles, 1

Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals.
Exp Gerontol. 2002 Jul;37(7):943-8.
PMID: 12086704 [PubMed - indexed for MEDLINE]

5: Dickey CA, Morgan DG, Kudchodkar S, Weiner DB, Bai Y, Cao C, Gordon MN, Ugen KE. Related Articles, 1

Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide.
DNA Cell Biol. 2001 Nov;20(11):723-9.
PMID: 11788050 [PubMed - indexed for MEDLINE]

6: Katunuma N, Kido H. Related Articles, 1

Recent advances in research on tryptases and endogenous tryptase inhibitors.
Monogr Allergy. 1990;27:51-66. Review. No abstract available.
PMID: 2150689 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text


Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Oct 4 2004 14:25:05



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books

Search PubMed for Amyloid beta AND T helper Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Items 1 - 12 of 12

One

Text Version

1: [Suh YH, Choi W, Kim SH, Kim JS, Rhi BY, Chong YH, Woo JI, Lee KW](#) Related Articles, 1

Expression of Alzheimer's amyloid precursor protein in human lymphocyte.
Arch Gerontol Geriatr. 1997 Jan-Feb;24(1):1-7.
PMID: 15374130 [PubMed - in process]

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

2: [Karkos J](#) Related Articles, 1

[Immunotherapy of Alzheimer's disease. Results of experimental investigation and treatment of perspectives]
Fortschr Neurol Psychiatr. 2004 Apr;72(4):204-19. Review. German.
PMID: 15095177 [PubMed - indexed for MEDLINE]

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

3: [Petrushina I, Tran M, Sadzikava N, Ghochikyan A, Vasilevko V, Agadjanyan MG, Cribbs DH](#) Related Articles, 1

Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice.
Neurosci Lett. 2003 Feb 20;338(1):5-8.
PMID: 12565127 [PubMed - indexed for MEDLINE]

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

4: [Town T, Vendrame M, Patel A, Poetter D, DelleDonne A, Mori T, Smeed R, Crawford F, Klein T, Tan J, Mullan M](#) Related Articles, 1

Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42).
J Neuroimmunol. 2002 Nov;132(1-2):49-59.
PMID: 12417433 [PubMed - indexed for MEDLINE]

5: [Munch G, Robinson SR](#) Related Articles, 1

Potential neurotoxic inflammatory responses to Abeta vaccination in humans.
J Neural Transm. 2002 Jul;109(7-8):1081-7. Review.
PMID: 12111445 [PubMed - indexed for MEDLINE]

6: [Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P](#) Related Articles, 1


Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals.
Exp Gerontol. 2002 Jul;37(7):943-8.
PMID: 12086704 [PubMed - indexed for MEDLINE]

7: [Dickey CA, Morgan DG, Kudchodkar S, Weiner DB, Bai Y, Cao C, Gordon MN, Ugen KE](#) Related Articles, 1

Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide.
DNA Cell Biol. 2001 Nov;20(11):723-9.
PMID: 11788050 [PubMed - indexed for MEDLINE]

8: [Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M](#) Related Articles, 1

Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42.
Neurosci Lett. 2001 Jul 13;307(2):101-4.
PMID: 11427310 [PubMed - indexed for MEDLINE]


 **9:** [Doffinger R, Klein TC, Pepys MB, Casanova JL, Kyewski BA](#) [Related Articles, I](#)



The MHC class II-restricted T cell response of C57BL/6 mice to human C-reactive protein: homology to self and the selection of T cell epitopes and T cell receptors.

Mol Immunol. 1997 Feb;34(2):115-24.

PMID: 9188844 [PubMed - indexed for MEDLINE]

 **10:** [Boraschi D, Villa L, Volpini G, Bossu P, Censini S, Ghiara P, Scapigliati G, Nencioni L, Bartalini M, Matteucci G](#) [Related Articles, I](#)



Differential activity of interleukin 1 alpha and interleukin 1 beta in the stimulation of the immune response in vivo.

Eur J Immunol. 1990 Feb;20(2):317-21.

PMID: 2311646 [PubMed - indexed for MEDLINE]

 **11:** [Katunuma N](#) [Related Articles, I](#)



New biological functions of intracellular proteases and their endogenous inhibitors as bioreactants.

Adv Enzyme Regul. 1990;30:377-92. Review.

PMID: 2206023 [PubMed - indexed for MEDLINE]

 **12:** [Katunuma N, Kido H](#) [Related Articles, I](#)



Recent advances in research on tryptases and endogenous tryptase inhibitors.

Monogr Allergy. 1990;27:51-66. Review. No abstract available.

PMID: 2150689 [PubMed - indexed for MEDLINE]

Display **Summary** **Show:** **500** **Sort** **Send to** **Text**


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Oct 4 2004 14:25:05



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books

Search PubMed for beta-amyloid AND T helper Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Items 1 - 6 of 6

One

Text Version

1: Sub YH, Choi W, Kim SH, Kim JS, Rhi BY, Chong YH, Woo JI, Lee KW. Related Articles, 1

Expression of Alzheimer's amyloid precursor protein in human lymphocyte.
Arch Gerontol Geriatr. 1997 Jan-Feb;24(1):1-7.
PMID: 15374130 [PubMed - in process]

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

2: Karkos J. Related Articles, 1

[Immunotherapy of Alzheimer's disease. Results of experimental investigation and treatment of perspectives]
Fortschr Neurol Psychiatr. 2004 Apr;72(4):204-19. Review. German.
PMID: 15095177 [PubMed - indexed for MEDLINE]

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

3: Petrushina I, Tran M, Sadzikava N, Ghochikyan A, Vasilevko V, Agadjanyan MG, Cribbs DH. Related Articles, 1

Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice.
Neurosci Lett. 2003 Feb 20;338(1):5-8.
PMID: 12565127 [PubMed - indexed for MEDLINE]

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

4: Town T, Vendrame M, Patel A, Poetter D, DelleDonne A, Mori T, Smeed R, Crawford F, Klein T, Tan J, Mullan M. Related Articles, 1

Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42).
J Neuroimmunol. 2002 Nov;132(1-2):49-59.
PMID: 12417433 [PubMed - indexed for MEDLINE]

5: Dickey CA, Morgan DG, Kudchodkar S, Weiner DB, Bai Y, Cao C, Gordon MN, Ugen KE. Related Articles, 1

Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide.
DNA Cell Biol. 2001 Nov;20(11):723-9.
PMID: 11788050 [PubMed - indexed for MEDLINE]

6: Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M. Related Articles, 1

Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42.
Neurosci Lett. 2001 Jul 13;307(2):101-4.
PMID: 11427310 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text


Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Oct 4 2004 14:25:05



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for amyloid AND T helper Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Items 1 - 24 of 24

One

Text Version

1: [Suh YH, Choi W, Kim SH, Kim JS, Rhi BY, Chong YH, Woo JI, Lee KW](#) Related Articles, I

Expression of Alzheimer's amyloid precursor protein in human lymphocyte.
Arch Gerontol Geriatr. 1997 Jan-Feb;24(1):1-7.
PMID: 15374130 [PubMed - in process]

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

2: [Karkos J](#) Related Articles, I

[Immunotherapy of Alzheimer's disease. Results of experimental investigation and treatment of perspectives]
Fortschr Neurol Psychiatr. 2004 Apr;72(4):204-19. Review. German.
PMID: 15095177 [PubMed - indexed for MEDLINE]

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

3: [Petrushina I, Tran M, Sadzikava N, Ghochikyan A, Vasilevko V, Agadjanyan MG, Cribbs DH](#) Related Articles, I

Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice.
Neurosci Lett. 2003 Feb 20;338(1):5-8.
PMID: 12565127 [PubMed - indexed for MEDLINE]

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

4: [Maury CP, Tiitinen S, Laiho K, Kaarela K, Liljestrom M](#) Related Articles, I

Raised circulating interleukin-18 levels in reactive AA-amyloidosis.
Amyloid. 2002 Jun;9(2):141-4.
PMID: 12440487 [PubMed - indexed for MEDLINE]

5: [Town T, Vendrame M, Patel A, Poetter D, DelleDonne A, Mori T, Smeed R, Crawford F, Klein T, Tan J, Mullan M](#) Related Articles, I

Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42).
J Neuroimmunol. 2002 Nov;132(1-2):49-59.
PMID: 12417433 [PubMed - indexed for MEDLINE]

6: [Munch G, Robinson SR](#) Related Articles, I


Potential neurotoxic inflammatory responses to Abeta vaccination in humans.
J Neural Transm. 2002 Jul;109(7-8):1081-7. Review.
PMID: 12111445 [PubMed - indexed for MEDLINE]

7: [Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P](#) Related Articles, I


Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals.
Exp Gerontol. 2002 Jul;37(7):943-8.
PMID: 12086704 [PubMed - indexed for MEDLINE]

8: [Dickey CA, Morgan DG, Kudchodkar S, Weiner DB, Bai Y, Cao C, Gordon MN, Ugen KE](#) Related Articles, I

Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide.
DNA Cell Biol. 2001 Nov;20(11):723-9.
PMID: 11788050 [PubMed - indexed for MEDLINE]


 **9:** [Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M.](#)

[Related Articles](#), [1](#)


 **Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42.**

Neurosci Lett. 2001 Jul 13;307(2):101-4.

PMID: 11427310 [PubMed - indexed for MEDLINE]


 **10:** [Zekarias B, Landman WJ, Tooten PC, Gruys E.](#)

[Related Articles](#), [1](#)


 **Leukocyte responses in two breeds of layer chicken that differ in susceptibility to induced amyloid arthropathy.**

Vet Immunol Immunopathol. 2000 Nov 23;77(1-2):55-69.

PMID: 11068066 [PubMed - indexed for MEDLINE]


 **11:** [Taylor-Robinson AW.](#)

[Related Articles](#), [1](#)


 **Increased production of acute-phase proteins corresponds to the peak parasitaemia of primary malaria infection.**

Parasitol Int. 2000 Feb;48(4):297-301.

PMID: 10725693 [PubMed - indexed for MEDLINE]


 **12:** [Kirkley SA, Cowles J, Pellegrini VD, Harris CM, Boyd AD, Blumberg N.](#)

[Related Articles](#), [1](#)


 **Blood transfusion and total joint replacement surgery: T helper 2 (TH2) cytokine secretion and clinical outcome.**

Transfus Med. 1998 Sep;8(3):195-204.

PMID: 9800291 [PubMed - indexed for MEDLINE]


 **13:** [Doffinger R, Klein TC, Pepys MB, Casanova JL, Kyewski BA.](#)

[Related Articles](#), [1](#)


 **The MHC class II-restricted T cell response of C57BL/6 mice to human C-reactive protein: homology to self and the selection of T cell epitopes and T cell receptors.**

Mol Immunol. 1997 Feb;34(2):115-24.

PMID: 9188844 [PubMed - indexed for MEDLINE]


 **14:** [Hosono M, Hanada K, Toichi E, Naiki H, Higuchi K, Hosokawa T.](#)

[Related Articles](#), [1](#)


 **Immune abnormality in relation to nonimmune diseases in SAM mice.**

Exp Gerontol. 1997 Jan-Apr;32(1-2):181-95. Review.

PMID: 9088915 [PubMed - indexed for MEDLINE]

 **15:** [Perfetti V, Bellotti V, Maggi A, Arbustini E, De Benedetti F, Paulli M, Marinone MG, Merlini G.](#)

[Related Articles](#), [1](#)


 **Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease.**

Am J Hematol. 1994 Jul;46(3):189-93.

PMID: 7910717 [PubMed - indexed for MEDLINE]


 **16:** [Pouget J, Pellissier JF, Azulay JP, Vallat JM, Visy JM, Serratrice G.](#)

[Related Articles](#), [1](#)


 **[Non hypertrophic amyloid myopathy with muscular inflammation in plasma cell dyscrasia]**

Rev Neurol (Paris). 1992;148(3):200-6. Review. French.

PMID: 1604134 [PubMed - indexed for MEDLINE]

 **17:** [Boraschi D, Villa L, Volpini G, Bossu P, Censini S, Ghiara P, Scapigliati G, Nencioni L, Bartalini M, Matteucci G.](#)

[Related Articles](#), [1](#)














 **Differential activity of interleukin 1 alpha and interleukin 1 beta in the stimulation of the immune response in vivo.**

Eur J Immunol. 1990 Feb;20(2):317-21.

PMID: 2311646 [PubMed - indexed for MEDLINE]

 **18:** [Katunuma N.](#)

[Related Articles](#), [1](#)

-  **New biological functions of intracellular proteases and their endogenous inhibitors as bioreactants.**
Adv Enzyme Regul. 1990;30:377-92. Review.
PMID: 2206023 [PubMed - indexed for MEDLINE]
-  **19:** [Katunuma N, Kido H.](#) Related Articles, 1
 **Recent advances in research on tryptases and endogenous tryptase inhibitors.**
Monogr Allergy. 1990;27:51-66. Review. No abstract available.
PMID: 2150689 [PubMed - indexed for MEDLINE]
-  **20:** [Morgan JE, McCaul DS, Rodriguez FH, Abernathy DA, deShazo RD, Banks DE.](#) Related Articles, 1
 **Pulmonary immunologic features of alveolar septal amyloidosis associated with multiple myeloma.**
Chest. 1987 Oct;92(4):704-8.
PMID: 3115688 [PubMed - indexed for MEDLINE]
-  **21:** [Fontana A, Bodmer S, Frei K.](#) Related Articles, 1
 **[Interleukin 1]**
Schweiz Med Wochenschr. 1985 Oct 12;115(41):1424-8. Review. German.
PMID: 2416045 [PubMed - indexed for MEDLINE]
-  **22:** [Verea HR, Dominguez L, Montero C, Martin MT, Masa JF, Amigo J, Fontan JM.](#) Related Articles, 1
 **[Common-variable hypogammaglobulinemia with reactive amyloidosis. A case with a deficiency of T4+ cells]**
Med Clin (Barc). 1985 Jun 8;85(2):66-9. Spanish. No abstract available.
PMID: 3160898 [PubMed - indexed for MEDLINE]
-  **23:** [Rodeck U, Kuwert E, Ohnhaus E.](#) Related Articles, 1
 **[Regulatory T-lymphocytes in the immune deficiency syndrome]**
Monatsschr Kinderheilkd. 1984 Apr;132(4):238-9. German.
PMID: 6610109 [PubMed - indexed for MEDLINE]
-  **24:** [Oppenheim JJ, Stadler BM, Siraganian RP, Mage M, Mathieson B.](#) Related Articles, 1
 **Lymphokines: their role in lymphocyte responses. Properties of interleukin 1**
Fed Proc. 1982 Feb;41(2):257-62.
PMID: 6800841 [PubMed - indexed for MEDLINE]

Display **Summary** Show: **500** Sort **Send to** **Text**

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
 Department of Health & Human Services
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Oct 4 2004 14:23:05

Duration and Specificity of Humoral Immune Responses in Mice Vaccinated with the Alzheimer's Disease-Associated β -Amyloid 1-42 Peptide

CHAD A. DICKEY,^{1,2} DAVID G. MORGAN,^{1,2} SAGAR KUDCHODKAR,³ DAVID B. WEINER,³
YUN BAI,⁴ CHUANHAI CAO,⁴ MARCIA N. GORDON,^{1,2} and KENNETH E. UGEN⁴

ABSTRACT

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by overproduction of β -amyloid ($A\beta$), which is formed from amyloid precursor protein (APP), with the subsequent pathologic deposition of $A\beta$ in regions of the brain important for memory and cognition. Recently, vaccination of murine models of AD that exhibit $A\beta$ deposition has halted or delayed the usual progression of the pathology of AD. Our group has demonstrated that vaccination of a doubly transgenic mouse model (expressing mutant APP and presenilin-1) with the $A\beta$ 1-42 peptide protects these mice from the memory deficits they would ordinarily develop. This report further characterizes the $A\beta$ 1-42 peptide vaccine in mice. Anti- $A\beta$ response time course analysis indicated that at least three vaccinations (each 100 μ g) were necessary to elicit a significant anti- $A\beta$ titer. Subsequent vaccinations resulted in half-maximal antibody titers of at least 10,000, and these titers were maintained for at least 5 months after the final boost. Peptide binding competition studies indicated that the highest humoral responses are generated against the N terminus of the $A\beta$ peptide. Also, measurement of specific murine Ig isotypes in $A\beta$ -vaccinated mice demonstrated a predominant IgG₁ and IgG_{2b} response, suggesting a type 2 (Th2) T-helper cell immune response, which drives humoral immunity. Finally, lymphocyte proliferation assay experiments using $A\beta$ peptides and splenocytes from vaccinated mice demonstrated that the vaccine specifically stimulates T-cell epitopes present within the $A\beta$ peptide.

INTRODUCTION


IT IS ESTIMATED that during the next 50 years, the number of cases of Alzheimer's disease (AD) in the US will increase from 4 million to 10 million or more, underscoring the pressing need for the development of novel effective therapies to combat this devastating disease. In AD, β -amyloid ($A\beta$) from the amyloid precursor protein (APP) is overproduced and deposited in extracellular plaques within the cerebral cortex and hippocampus, resulting in neurodegeneration with associated memory loss (Hardy, 1997; Selkoe, 2000). Recently, transgenic murine models have been utilized for vaccine studies with the $A\beta$ 1-42 peptide. In a landmark paper published in 1999, Schenk *et al.* reported that vaccination of an APP transgenic mouse model with the $A\beta$ peptide resulted in a significant reduction

in cerebral $A\beta$ deposits. In a subsequent experiment, those investigators showed that the passive transfer of anti- $A\beta$ antibodies (polyclonal or monoclonal) mediated the beneficial effect of vaccination as judged by a decrease in $A\beta$ burden (Bard *et al.*, 2000). Further studies by Basksai *et al.* demonstrated through multiphoton imaging that local application of $A\beta$ antibody to the brains of live PDAPP mice resulted in clearance of cerebral $A\beta$ plaques (Basksai *et al.*, 2001). Other important work in the area of immune responses against $A\beta$ is that from Solomon's group in Tel Aviv. Her laboratory showed that vaccination of mice with engineered filamentous phage that express the $A\beta$ 3-6 epitope (EFRH) resulted in anti- $A\beta$ antibodies of significant titer (Frenkel *et al.*, 2000). Previously, Solomon's laboratory demonstrated that monoclonal antibodies that recognize the amino region of $A\beta$ could prevent the for-

¹Alzheimer's Research Laboratory and ²Department of Pharmacology, University of South Florida, Tampa, Florida.

³Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

⁴Department of Medical Microbiology and Immunology, University of South Florida.



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for [] Go Clear

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Sort Send to Text

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health


Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: DNA Cell Biol. 2001 Nov;20(11):723-9.

Related Articles,



Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid peptide.

Dickey CA, Morgan DG, Kudchodkar S, Weiner DB, Bai Y, Cao C, Gordon MN, Ugen KE.

Alzheimer's Research Laboratory, University of South Florida, Tampa, Florida 33612, USA.

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by overproduction of beta-amyloid (Abeta), which is formed from amyloid precursor protein (APP), with the subsequent pathologic deposition of Abeta in regions of the brain important for memory and cognition. Recently, vaccination of murine models of AD that exhibit Abeta deposition has halted or delayed the usual progression of the pathology of AD. Our group has demonstrated that vaccination of a doubly transgenic mouse model (expressing mutant APP and presenilin-1) with the Abeta 1-42 peptide protects these mice from the memory deficits they would ordinarily develop. This report further characterizes the Abeta 1-42 peptide vaccine in mice. Anti-Abeta response time course analysis indicated that at least three vaccinations (each 100 microg) were necessary to elicit a significant anti-Abeta titer. Subsequent vaccinations resulted in half-maximal antibody titers of at least 10,000, and these titers were maintained for at least 5 months after the first boost. Peptide binding competition studies indicated that the highest humoral responses are generated against the N terminus of the Abeta peptide. Also, measurement of specific murine Ig isotypes in Abeta-vaccinated mice demonstrated a predominant IgG(1) and IgG(2b) response, suggesting a type 2 (Th2) T-helper cell immune response, which drives humoral immunity. Finally, lymphocyte proliferation assay experiments using Abeta peptides and splenocytes from vaccinated mice demonstrated that the vaccine specifically stimulates T-cell epitopes present within the Abeta peptide.

PMID: 11788050 [PubMed - indexed for MEDLINE]


Display Abstract Show: 20 Sort Send to Text

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for amyloid AND epitope AND T cell Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Items 1 - 9 of 9

One

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Seabrook TJ, Iglesias M, Bloom JK, Spooner ET, Lemere CA.

Related Articles, i



Differences in the immune response to long term Abeta vaccination in C57BL and B6D2F1 mice.

Vaccine. 2004 Sep 28;22(29-30):4075-83.

PMID: 15364459 [PubMed - in process]

2: Seabrook TJ, Bloom JK, Iglesias M, Spooner ET, Walsh DM, Lemere CA.

Related Articles, i



Species-specific immune response to immunization with human versus rodent beta peptide.

Neurobiol Aging. 2004 Oct;25(9):1141-51.

PMID: 15312960 [PubMed - in process]

3: Monsonego A, Zota V, Karni A, Krieger JL, Bar-Or A, Bitan G, Budson

Related Articles, i

AE, Sperling R, Selkoe DJ, Weiner HL.



Increased T cell reactivity to amyloid beta protein in older humans and patient with Alzheimer disease.

J Clin Invest. 2003 Aug;112(3):415-22.

PMID: 12897209 [PubMed - indexed for MEDLINE]

4: Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava

Related Articles, i

N, Babikyan D, Kessler P, Kieber-Emmons T, Cotman CW, Agadjanyan MG.



Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid.

Int Immunol. 2003 Apr;15(4):505-14.

PMID: 12663680 [PubMed - indexed for MEDLINE]

5: Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL.

Related Articles, i



Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10273-8. Epub 2001 Aug 21.

PMID: 11517335 [PubMed - indexed for MEDLINE]

6: Mancardi G, Hart BA, Capello E, Brok HP, Ben-Nun A, Roccatagliata L,

Related Articles, i

Giunti D, Gazzola P, Dono M, Kerlero de Rosbo N, Colombo M, Uccelli A.



Restricted immune responses lead to CNS demyelination and axonal damage.

J Neuroimmunol. 2000 Jul 24;107(2):178-83. Review.

PMID: 10854654 [PubMed - indexed for MEDLINE]

7: Doffinger R, Klein TC, Pepys MB, Casanova JL, Kyewski BA.

Related Articles, i



The MHC class II-restricted T cell response of C57BL/6 mice to human C-reactive protein: homology to self and the selection of T cell epitopes and T cell receptors.

Mol Immunol. 1997 Feb;34(2):115-24.

PMID: 9188844 [PubMed - indexed for MEDLINE]

☐ **8:** [Fontana A, Bodmer S, Frei K.](#)

[Related Articles, 1](#)



[Interleukin 1]

Schweiz Med Wochenschr. 1985 Oct 12;115(41):1424-8. Review. German.

PMID: 2416045 [PubMed - indexed for MEDLINE]

☐ **9:** [Scheinberg MA.](#)

[Related Articles, 1](#)



Immunology of amyloid disease: a review.

Semin Arthritis Rheum. 1977 Nov;7(2):133-40. Review. No abstract available.

PMID: 73225 [PubMed - indexed for MEDLINE]

Display	Summary	Show: 500	Sort	Send to	Text
---------	---------	-----------	------	---------	------


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Oct 4 2004 14:25:05



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for amyloid AND T cell Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Items 1 - 197 of 197

One

Text Version

☐ 1: [Sub YH, Choi W, Kim SH, Kim JS, Rhi BY, Chong YH, Woo JI, Lee KW](#)

Related Articles, 1



Expression of Alzheimer's amyloid precursor protein in human lymphocyte.
Arch Gerontol Geriatr. 1997 Jan-Feb;24(1):1-7.
PMID: 15374130 [PubMed - in process]

☐ 2: [Dalakas MC](#)

Related Articles, 1



Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis.
Curr Opin Neurol. 2004 Oct;17(5):561-567.
PMID: 15367860 [PubMed - as supplied by publisher]

☐ 3: [Seabrook TJ, Iglesias M, Bloom JK, Spooner ET, Lemere CA](#)

Related Articles, 1



Differences in the immune response to long term Abeta vaccination in C57BL and B6D2F1 mice.
Vaccine. 2004 Sep 28;22(29-30):4075-83.
PMID: 15364459 [PubMed - in process]

☐ 4: [Lee EO, Shin YJ, Chong YH](#)

Related Articles, 1



Mechanisms involved in prostaglandin E2-mediated neuroprotection against TNF-alpha: possible involvement of multiple signal transduction and beta-catenin/T-cell factor.
J Neuroimmunol. 2004 Oct;155(1-2):21-31.
PMID: 15342193 [PubMed - in process]

☐ 5: [van Rossum AP, Fazzini F, Limburg PC, Manfredi AA, Rovere-Querini P, Mantovani A, Kallenberg CG](#)

Related Articles, 1



The prototypic tissue pentraxin PTX3, in contrast to the short pentraxin serum amyloid P, inhibits phagocytosis of late apoptotic neutrophils by macrophages.
Arthritis Rheum. 2004 Aug;50(8):2667-74.
PMID: 15334483 [PubMed - indexed for MEDLINE]

☐ 6: [Seabrook TJ, Bloom JK, Iglesias M, Spooner ET, Walsh DM, Lemere CA](#)

Related Articles, 1



Species-specific immune response to immunization with human versus rodent beta peptide.
Neurobiol Aging. 2004 Oct;25(9):1141-51.
PMID: 15312960 [PubMed - in process]

☐ 7: [Sigurdsson EM, Knudsen E, Asuni A, Fitzner-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T](#)








Related Articles, 1

























An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.
J Neurosci. 2004 Jul 14;24(28):6277-82.
PMID: 15254082 [PubMed - in process]

☐ 8: [Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, Selkoe DJ, Palmour RM, Ervin FR](#)

Related Articles, 1

-  Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet.
Am J Pathol. 2004 Jul;165(1):283-97.
PMID: 15215183 [PubMed - indexed for MEDLINE]
-  **9:** Nissinen R, Leirisalo-Repo M, Peltomaa R, Palosuo T, Vaarala O. Related Articles, 1
 Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis.
Ann Rheum Dis. 2004 Jun;63(6):681-7.
PMID: 15140775 [PubMed - indexed for MEDLINE]
-  **10:** Karkos J. Related Articles, 1
 [Immunotherapy of Alzheimer's disease. Results of experimental investigation and treatment of perspectives]
Fortschr Neurol Psychiatr. 2004 Apr;72(4):204-19. Review. German.
PMID: 15095177 [PubMed - indexed for MEDLINE]
-  **11:** Mochida S, Yoshimoto T, Mimura S, Inao M, Matsui A, Ohno A, Koh H, Saitoh E, Nagoshi S, Fujiwara K. Related Articles, 1
 Transgenic mice expressing osteopontin in hepatocytes as a model of autoimmune hepatitis.
Biochem Biophys Res Commun. 2004 Apr 23;317(1):114-20.
PMID: 15047155 [PubMed - indexed for MEDLINE]
-  **12:** Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Related Articles, 1
 Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease.
Brain Pathol. 2004 Jan;14(1):11-20.
PMID: 14997933 [PubMed - indexed for MEDLINE]
-  **13:** Kawabe S, Abe T, Kawamura H, Gejyo F, Abo T. Related Articles, 1
 Generation of B220low B cells and production of autoantibodies in mice with experimental amyloidosis: association of primordial T cells with this phenomenon.
Clin Exp Immunol. 2004 Feb;135(2):200-8.
PMID: 14738446 [PubMed - indexed for MEDLINE]
-  **14:** Baril L, Nicolas L, Croisile B, Crozier P, Hessler C, Sassolas A, McCormick JB, Trannoy E. Related Articles, 1
 Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects.
Neurosci Lett. 2004 Jan 30;355(3):226-30.
PMID: 14732472 [PubMed - indexed for MEDLINE]
-  **15:** Schindowski K, Kratzsch T, Peters J, Steiner B, Leutner S, Touchet N, Maurer K, Czech C, Pradier L, Frolich L, Muller WE, Eckert A. Related Articles, 1
 Impact of aging: sporadic, and genetic risk factors on vulnerability to apoptosis in Alzheimer's disease.
Neuromolecular Med. 2003;4(3):161-78.
PMID: 14716024 [PubMed - indexed for MEDLINE]
-  **16:** Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA, Parker EM. Related Articles, 1
 Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation.
J Biol Chem. 2004 Mar 26;279(13):12876-82. Epub 2004 Jan 06.
PMID: 14709552 [PubMed - indexed for MEDLINE]

-  **17:** Rosen P, Thompson S, Glass D. Related Articles, 1
 **Non-HLA gene polymorphisms in juvenile rheumatoid arthritis.**
 Clin Exp Rheumatol. 2003 Sep-Oct;21(5):650-6. Review.
 PMID: 14611119 [PubMed - indexed for MEDLINE]
-  **18:** McGeer PL, McGeer EG. Related Articles, 1
 **Innate immunity, local inflammation, and degenerative disease.**
 Sci Aging Knowledge Environ. 2002 Jul 24;2002(29):re3. Print 2002 Jul 24. Review.
 PMID: 14602998 [PubMed - indexed for MEDLINE]
-  **19:** Monsonogo A, Weiner HL. Related Articles, 1
 **Immunotherapeutic approaches to Alzheimer's disease.**
 Science. 2003 Oct 31;302(5646):834-8. Review.
 PMID: 14593170 [PubMed - indexed for MEDLINE]
-  **20:** Kojouharova MS, Tsacheva IG, Tchorbadijeva ML, Reid KB, Kishore U. Related Articles, 1
 **Localization of ligand-binding sites on human C1q globular head region using recombinant globular head fragments and single-chain antibodies.**
 Biochim Biophys Acta. 2003 Nov 3;1652(1):64-74.
 PMID: 14580997 [PubMed - indexed for MEDLINE]
-  **21:** Li B, Ryder J, Su Y, Zhou Y, Liu F, Ni B. Related Articles, 1
 **FRAT1 peptide decreases Abeta production in swAPP(751) cells.**
 FEBS Lett. 2003 Oct 23;553(3):347-50.
 PMID: 14572648 [PubMed - indexed for MEDLINE]
-  **22:** Lolli F, Mazzanti B, Rovero P, Papini AM. Related Articles, 1
 **Synthetic peptides in the diagnosis of neurological diseases.**
 Curr Protein Pept Sci. 2003 Aug;4(4):277-84. Review.
 PMID: 14529534 [PubMed - indexed for MEDLINE]
-  **23:** Dalakas MC, Hohlfeld R. Related Articles, 1
 **Polymyositis and dermatomyositis.**
 Lancet. 2003 Sep 20;362(9388):971-82. Review.
 PMID: 14511932 [PubMed - indexed for MEDLINE]
-  **24:** Monsonogo A, Imitola J, Zota V, Oida T, Weiner HL. Related Articles, 1
 **Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid beta peptide presentation to Th1 cells.**
 J Immunol. 2003 Sep 1;171(5):2216-24. Erratum in: J Immunol. 2004 Jan 1;172(1):717.
 PMID: 12928365 [PubMed - indexed for MEDLINE]
-  **25:** Rothkrantz-Kos S, van Diejen-Visser MP, Mulder PG, Drent M. Related Articles, 1
 **Potential usefulness of inflammatory markers to monitor respiratory function impairment in sarcoidosis.**
 Clin Chem. 2003 Sep;49(9):1510-7.
 PMID: 12928233 [PubMed - indexed for MEDLINE]
-  **26:** Das P, Chapoval S, Howard V, David CS, Golde TE. Related Articles, 1
 **Immune responses against Abeta1-42 in HLA class II transgenic mice: implications for Abeta1-42 immune-mediated therapies.**
 Neurobiol Aging. 2003 Nov;24(7):969-76.
 PMID: 12928057 [PubMed - indexed for MEDLINE]
-  **27:** Monsonogo A, Zota V, Karni A, Krieger JL, Bar-Or A, Bitan G, Budson AE, Sperling R, Selkoe DJ, Weiner HL. Related Articles, 1
 **Increased T cell reactivity to amyloid beta protein in older humans and patients**